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Background: Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD)
frequently persist into adolescence and young adulthood. However, there are few clinical services
that support those with these disorders through adulthood.
Objective: Our aim was to determine if clinical services meet the needs of people with ASD and ADHD,
who are ‘at transition’ from childhood to adulthood.
Design: A longitudinal study of individuals with ASD and ADHD, the impact of services and treatments.
Methods: Our research methods included (1) interviewing > 180 affected individuals (and their families)
with a confirmed diagnosis of ASD and/or ADHD, (2) screening for ASD and ADHD in approximately
1600 patients and (3) surveying general practitioner prescribing to 5651 ASD individuals across the UK.
In addition, we tested the effectiveness of (1) new ASD diagnostic interview measures in 169 twins,
145 familes and 150 non-twins, (2) a magnetic resonance imaging-based diagnostic aid in 40 ASD individuals,
(3) psychological treatments in 46 ASD individuals and (4) the feasability of e-learning in 28 clinicians.
Setting: NHS clinical services and prisons.
Participants: Focus – young people with ASD and ADHD as they ‘transition’ from childhood and
adolescence into early adulthood.
Interventions: Testing the utility of diagnostic measures and services, web-based learning interventions,
pharmacological prescribing and cognitive–behavioural treatments.
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Main outcome measures: Symptom severity, service provision and met/unmet need.
Results: People with ASD and ADHD have very significant unmet needs as they transition through
adolescence and young adulthood. A major contributor to this is the presence of associated mental health
symptoms. However, these are mostly undiagnosed (and untreated) by clinical services. Furthermore, the
largest determinant of service provision was age and not severity of symptoms. We provide new tools to
help diagnose both the core disorders and their associated symptoms. We also provide proof of concept
for the effectiveness of simple psychological interventions to treat obsessional symptoms, the potential to
run treatment trials in prisons and training interventions.
Limitations: Our findings only apply to clinical service settings.
Conclusions: As individuals ‘transition’ their contact with treatment and support services reduces
significantly. Needs-led services are required, which can both identify individuals with the ‘core symptoms’
of ASD and ADHD and treat their residual symptoms and associated conditions.
Future work: To test our new diagnostic measures and treatment approaches in larger controlled trials.
Trial registration: Current Controlled Trials ISRCTN87114880.
Funding: The National Institute for Health Research Programme Grants for Applied Research programme.
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Plain English summary
Our aim was to determine if clinical services meet the needs of people with attention deficithyperactivity disorder (ADHD) and autism spectrum disorder (ASD) who are ‘at transition’ from
childhood to adulthood and those of their carers; and to identify how improvements could be made. We
asked four research questions:
1. What are the needs of affected individuals and their carers?
2. Are people with ADHD and ASD recognised and treated?
3. Can we improve the identification of ADHD and ASD?
4. Can we improve the treatment of ADHD and ASD?
We found the following answers.
People with ASD and ADHD have significant needs as they move through adolescence and young
adulthood. A major contributor to these is the presence of associated mental health symptoms (e.g.
depression and anxiety), which are mostly undiagnosed (and untreated). As affected individuals age,
there are less likely to be seen by services. Carer burden may be approximately the same as looking after
somebody with a traumatic brain injury or dementia. New changes to the ways people are diagnosed
suggest that many individuals will be excluded from services.
Clinical services have a high prevalence of people with ASD and ADHD. However, only a minority of
affected individuals are recognised, or treated, by the services they are in touch with. This may
reflect a lack of both techniques to identify people with these conditions and staff knowledge.
Our research identified new tools to diagnose the core disorders associated with ADHD and ASD and their
associated symptoms and suggests that simple psychological interventions to treat obsessional symptoms
may be beneficial. We also found that treatment trials could potentially be run in prisons and that
web-based training interventions are useful to clinicians.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxv

Scientific summary
Background
Autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) both frequently persist
into adolescence and young adulthood. However, there are few clinical services that support those with
these disorders through adulthood. Research into the needs of young adults with an ASD or ADHD (and
their carers) is important in order to design effective care programmes, but little is known about the service
use and needs of these groups as they reach adolescence and transition to adulthood.
Research questions
1. What are the needs of affected individuals and their carers and are these met by health services?
2. Are people with ADHD and ASD already in contact with clinical services recognised and treated by
the services?
3. Can we improve the diagnosis of ADHD and ASD by clinical services?
4. Can we improve the treatment of ADHD and ASD by clinical services?
Methods
The research comprised findings from four different work packages within this study over 5 years, from
2009 to 2013.
We (1) interviewed > 180 affected individuals (and their families) with a confirmed diagnosis of ASD and/or
ADHD, (2) screened for ASD and ADHD in approximately 1600 patients currently in receipt of clinical services
in community medical (general practice) and mental health services (including general adult, forensic and
prison settings) and (3) surveyed general practitioner (GP) prescribing to 5651 ASD individuals across the
UK (as prescribing in ADHD has already been reported). Finally, we tested the effectiveness of (1) new ASD
diagnostic interview measures in 169 twins, 145 families and 150 non-twins, (2) a magnetic resonance
imaging-based diagnostic aid in 40 ASD individuals, (3) psychological treatements in 46 ASD individuals
and (4) the feasability of e-learning in 28 clinicians.
Results
The needs of affected individuals and their carers
Young people with ASD and ADHD have very significant needs as they transition through adolescence
and young adulthood. A major contributor to this is associated mental health symptoms and/or ongoing
educational and other functional impairments related to the ‘core disorder’. However, the additional/residual
mental health problems (e.g. depression and anxiety) in ASD and ADHD are mostly undiagnosed (and
untreated) by clinical services. Furthermore, the largest determinant of service provision is age and not
severity of symptoms (e.g. in ADHD each 1-year increase in a young person’s age reduces the odds of being
seen by services by 38%). This leads to a carer burden that is similar to looking after somebody with a
traumatic brain injury or dementia.
Implications
Needs-led services are required that can both identify individuals with the ‘core symptoms’ of ASD and
ADHD and treat their residual symptoms and associated conditions such anxiety and depression.
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Are people with ADHD and ASD already in contact with clinical services recognised
and treated?
Clinical services have a relatively high prevalence of people with ASD and ADHD, but these people are
mainly unrecognised. Furthermore, these (unrecognised) individuals are functionally more impaired, have a
higher rate of suicide attempts and spend longer periods in seclusion.
Overall, costs for both disorders are mainly borne by education and social care services – with much less
accounted for by physical (and especially mental) health services. Finally, as individuals with ADHD and
ASD grew older, mental health service costs reduce very significantly.
Implications
As individuals ‘transition’, their contact with treatment and support services reduces significantly.
It is essential to increase diagnostic awareness and service provision.
Can we aid the diagnosis of ADHD and ASD by clinical services?
We took the pragmatic decision to adapt existing instruments (rather than developing completely new
ones). In addition, relatively easy-to-use instruments for screening/diagnosing ADHD already exist. Hence,
as a first step, we focused on ASD by testing the utility of the Development and Well-Being Assessment
(DAWBA) and Strengths and Difficulties Questionnaire (SDQ) for diagnosing the core disorder and for
identifying associated mental health symptoms, respectively.
The DAWBA performed well in our study of children and it has the potential to be a useful tool in
community settings. In addition, the SDQ is a valid way to screen for comorbid anxiety disorders,
depression and ADHD in adults with ASD.
In the next study, we explored the effect that changes to clinical diagnostic practice [as recommended in
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)] would have on affected
individuals. We found that DSM-V is a relatively insensitive measure of ASD in young adults compared
with alternatives that are currently used in the UK [such as International Classification of Diseases,
Tenth Edition (ICD-10)]. This is noteworthy as ICD-10 is about to be revised – and if similar approaches
are adopted in International Classification of Diseases, Eleventh Edition, to those now used in DSM-V, or
if DSM-V is adopted in the UK as a service ‘gatekeeper’, then many affected individuals with ASD could be
excluded from services.
We therefore next determined if, in young adults, we could establish proof of concept that new advances
in brain imaging provide objective measures that may help categorise young adults with ASD and/or
ADHD. We could correctly classify 85% of all cases overall at a sensitivity and specificity as high as 90%
and 80%, respectively.
Implications
Interview-based tools can help to diagnose the core disorder and associated symptoms in ASD; and there
is proof of concept for the potential utility of brain biomarkers to help aid classification of ASD and ADHD
in young adults.
Can we improve the treatment of ADHD and ASD?
In other parts of this programme, we found very high rates of associated mental health symptoms in
people with ASD (e.g. depression and anxiety). However, relatively few individuals had been diagnosed
with these symptoms by their GPs, and although approximately one-third of individuals with ASD received
at least one psychotropic drug prescription, these were mostly for stimulants, antiepileptic drugs and mood
stabilisers, and antipsychotics. Furthermore, as people aged prescribing rates for risperidone remained high
(whereas others decreased).
SCIENTIFIC SUMMARY
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Our pilot study on the effectiveness of cognitive–behavioural therapy (CBT) treatment was comparable to
clinical trials of obsessive–compulsive disorder (OCD) in people without ASD. Unexpectedly, however,
anxiety management (AM) training was also effective in bringing about a reduction in OCD symptoms.
Implications
1. Those who are prescribed antipsychotics are (relatively) unlikely to be taken off them.
2. People with ASD and ADHD are often not prescribed appropriate medications to treat common mental
health symptoms.
3. AM training may allow more people to be treated (and at lower cost) for OCD in ASD, as it can be
provided more simply and with a lower degree of staff expertise, than CBT.
Conclusions
As individuals ‘transition’ their contact with treatment and support services reduces significantly. Needs-led
services are required, which can both identify individuals with the ‘core symptoms’ of ASD and ADHD and
treat their residual symptoms and associated conditions.
Future work
To test our new diagnostic measures and treatment approaches in larger controlled trials.
Trial registration
This trial is registered as ISRCTN87114880.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
We need to develop better services and treatments for people with attention deficit hyperactivitydisorder (ADHD) and autism spectrum disorder (ASD) who are ‘in transition’ from childhood
to adulthood.
People with ADHD have serious deficits in attention and are hyperactive. In contrast, those with ASD
(autism, ‘atypical’ autism and Asperger syndrome) have stereotyped and obsessional behaviours and severe
abnormalities in socioemotional behaviour and communication. They are different disorders, but have a lot
in common. Thus, we studied them together.
Both ADHD and ASD are neurodevelopmental disorders (NDs) that have lifelong effects. They are of great
public concern, much more common than previously thought, very frequently co-occur in the same person
and are associated with serious comorbid mental health problems [e.g. drug abuse, anxiety, depression,
learning disability (LD) and obsessive–compulsive disorder (OCD)]. This has a large social impact (e.g. the
individual lifetime cost for ASD exceeds £2.4M and is significantly increased by comorbid LD).
People with ADHD and ASD have particular problems during the transition from children to adult services.
Many ‘drop out’ and go untreated. In addition, few adult services are skilled in managing them, those
already in these services are often misdiagnosed and inappropriately treated, and LD people are frequently
excluded. This probably has an impact on the clinical outcome and costs – as treatment of the core
disorders during childhood greatly reduces comorbidity. However, it is unknown (1) if this is true in young
adults or those with LD and (2) if beneficial treatments developed in the general psychiatric population for
the comorbid problems frequently found in ASD and ADHD are transferable to, and cost-effective, in these
groups [e.g. cognitive–behavioural therapy (CBT) for OCD].
Government policy calls for evidence-based practice, needs-led services and National Institute for Health
and Care Excellence (NICE) guidelines that stress psychological treatments. We have previously published
instruments, which measure health needs, costs and consumption and gold standard research diagnostic
tools. In addition, we carried out pilot studies in the treatment of comorbid disorders using both
pharmacological approaches and CBT.
We therefore extended our work in two phases with the themes: (1) more effective services and
(2) better treatments.
We used the following research questions to guide our work:
1. What are the needs of affected individuals and their carers and are these met by health services?
2. Are people with ADHD and ASD already in contact with clinical services recognised and treated by
the services?
3. Can we improve the diagnosis of ADHD and ASD by clinical services?
4. Can we improve the treatment of ADHD and ASD by clinical services?
We included people with ADHD and/or ASD between the ages of 16 and 25 years during the ‘transition’
from child to adult services and those with a LD. In phase 1 (years 1–3) we worked to improve case
identification and management. In phase 2 (years 3–5) we tested if effective treatments developed in the
general population reduce comorbidity.
To develop more effective services we (1) developed simple protocols for case identification, (2) ascertained
why people ‘drop out’ of services during the ‘transition’ and the consequences of that and (3) determined
what interventions help adult services better identify, and meet the needs, of these people.
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In this second part, we attempted to reduce disease burden by better use of current pharmacological and
psychological treatments, and helping people who are often excluded. The drug studies initially focused
on ADHD, as effective medications already existed that can be rapidly tested. In contrast, psychological
interventions were aimed at common comorbid symptoms (OCD) in ASD.
We have constructed this report in five sections to match our programme design. In Section 1
(see Chapters 2–6), we present the patient and family perspective, and in Section 2 (see Chapters 7–13)
we provide the service perspective. The third section (see Chapters 14–18) focuses on improving outcomes
through better diagnosis, whereas the fourth section (see Chapters 19–23) focuses on improving outcomes
through intervention. Section 5 (see Chapters 24 and 25) concludes the report by presenting our
conclusions, recommendations for future research and examples of the impact of our work.
Within this report, some chapters or parts thereof have been previously published in the following papers:
l Kooij et al.1
l Huntley et al.2
l McEwen et al.3
l Ecker et al.4
l Lai et al.5
l Murray et al.6
Patient and public involvement
Our team involved users, carers and their representatives as co-applicants.
They identified the service and treatment priorities we addressed. In addition, they helped design this study
and took an active part in carrying out the research. For example, we employed affected individuals as
researchers. Furthermore, their representatives monitored our progress by serving on our Study Steering
Board.
Dissemination materials and training packages have been prepared in collaboration with users and carers.
INTRODUCTION
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Section 1 Patient and family perspective
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Chapter 2 Needs at the transition from child to
adult services in ADHD and ASD: an overview of
rationale and shared methods
Overall aims and objectives
Our aim was to investigate service use and needs among people with ADHD and ASD at the transition
from adolescence to young adulthood (from ages 14 to 24 years). We wished to further understand
(1) the demographic and medical correlates (e.g. age and comorbid conditions) of service use, (2) if current
services are meeting the needs of young people with ADHD and ASD and (3) to what extent, and at what
cost, family members of affected young people are able to meet these needs.
Background
Neurodevelopmental disorders such as ASD and ADHD are of increasing concern given their high cost to
health services, individuals and families. For example, recent estimates suggest that the cost to the UK
economy of supporting children with an ASD is approximately £2.7B (US$4.4B) each year and the cost of
supporting adults is much higher (US$40.4B each year).7 Moreover, although ASD and ADHD are often
thought of as childhood disorders, both can persist into adolescence and young adulthood. Approximately
96% of those diagnosed with an ASD as children still warrant diagnosis in young adulthood.8 The figure is
lower for ADHD, with persistence rates estimated between 15% and 65%, depending on the diagnostic
criteria used.9
Not only do young people (adolescents and young adults) with these disorders continue to experience
symptoms, they also retain significant impairments. For example, most young people with an ASD show
continued impairments in daily living skills, communication, social interaction, employment and education.10–13
Young adults with ADHD tend to achieve greater independence than their peers with ASDs, but are still more
likely than the general population to be unemployed,14 experience more frequent job losses,14,15 underachieve
in education,16 experience instability in emotional relationships16,17 and display antisocial behaviours.18–20
Even though symptoms and impairments continue among young people with ASD and ADHD, few services
exist to support those with these disorders through adulthood.21–23 Additionally, as these conditions have been
found to be underdiagnosed among young adults,24,25 many are likely to remain solely reliant on family and
friends for assistance. Thus, the situation for most young people with an ASD or ADHD is that they continue
to experience symptoms and impairment, but have limited support from services and so rely on families.
Although many studies have investigated service use and needs of children with developmental disorders
(e.g. ASD), to date little is known about the service use and needs of these groups as they reach
adolescence and transition to adulthood. Nonetheless, concern has been expressed in the UK parliament
about the perceived failure to provide effective transitioning because of:
l inconsistency of referral and treatment criteria
l poor communication between services
l lack of continuity
l conflict between the ‘child/family’ approaches of paediatric mental health services and the individual
approach of adult mental health services
l the disengagement of young adults who drop out of the health-care system.26
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In summary, there is the perception that there are significant problems in the provision of services for
‘youngsters’ as they transition into young adulthood. However, the evidence to help inform the debate is
lacking. Hence, research into the needs of young adults with ASD or ADHD and their carers is important in
order to design and implement appropriate and effective care programmes and support for carers as well
as young adults with this disorder. This first section of our work therefore investigated the following in both
ASD and ADHD: (1) service use, met and unmet needs, (2) the role of family members in meeting needs,
(3) changes over time in service use and needs and (4) the consequences of these changes for the young
person’s and the nominated family member’s well-being. Our approach was to use a core set of measures
for both disorders when possible, but to use more appropriate disorder-specific measures when prudent.
Methods used that were common to both ADHD and ASD
We conducted an observational study based on face-to-face interviews and self-completion questionnaires
with young people with ADHD and an ASD and their parents (usually mothers) at yearly intervals. The ADHD
study was a 3-year prospective study; the ASD group was followed for 2 years [this difference in follow-up
time arose owing to delay from Research Ethics Committees (RECs), resource constraints and time limits for
the programme set by the National Institute for Health Research (NIHR); for further details, please see
Obstacles and solutions]. The study collected information on health service use, needs and social/
demographic and health information relating to participants and their family member at the time of the
interview. For the ADHD study, self-completion questionnaires were also administered to adolescents/young
adults to obtain information regarding drug and alcohol use and problems with the police. Differences in the
study design between the ADHD and ASD groups are highlighted in the sections that follow.
Study site
Data collection largely took place in participants’ homes or at the Institute of Psychiatry (IoP). Most
participants were from Greater London; the remainder were spread throughout England, extending
from Cornwall to Lincolnshire in the north-east.
Sample
Our study included 183 families consisting of young people aged 14–24 years (n = 82 with ADHD and
n = 101 with ASD) and their parents. More detailed information on sample sizes is provided in Tables 1
and 4. Families were recruited through their children’s childhood clinical diagnoses of ADHD or an ASD
from Child and Adolescent Mental Health Services (CAMHS) and adult clinics, charities and research
databases that form part of our clinical research networks. Clinical diagnosis of autism was confirmed in
all cases using the Autism Diagnostic Interview – Revised27 (ADI-R) and ADHD (combined type) was defined
using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria. As
participants in the ADHD group were originally recruited for the International Multi-Centre ADHD Genetics
(IMAGE) programme, they were excluded if they had been diagnosed with autism, epilepsy, general
learning difficulties, brain disorders and any genetic or medical disorder associated with externalising
behaviours that might mimic ADHD based on both history and clinical assessment.
Recruitment for the ADHD sample began on 1 April 2009 and ended on 23 February 2011, for the ASD
sample it began on 7 June 2010 and ended on 20 October 2011. Both studies received REC approval from
the London – Camberwell St. Giles REC (previously known as the Joint South London and Maudsley and
the IoP REC, South East London REC 4). The ASD REC reference is 04/H0807/71 and the ADHD REC
reference is 08/H0807/68.
Instruments common to both ADHD and ASD studies
The instruments common to both studies are described below. Those used only in either the ADHD or the
ASD elements of the project are described in the relevant disorder-specific section (see Chapters 2 and 3).
The level of need of the young person was captured using the Camberwell Assessment of Need for Adults
with Developmental and Intellectual Disabilities (CANDID).28 CANDID assesses needs across 25 domains,
including social, physical, mental health, self-care and practical needs. For each domain, the young person
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TABLE 1 Descriptive characteristics of ADHD study sample and variables (n= 82)
Variable % Mean (SD) Range Missing (n)
YP age (years) 17.50 (2.30) 14–21 0
YP male 89 0
YP white or white British 100 0
YP education
Full time 57 0
Part time 7 0
Not in education 34 0
PR education
Low 63 2
High 37 2
YP accommodation
Family home 87 0
Other 13 0
YP residing in Greater London 56 0
YP DIVA above cut-off point (> 6) 73 2
YP CIS-R 7.90 (6.50) 0–29 1
YP CIS-R above cut-off point (> 12) 27 1
YP impairments 4.46 (2.72) 0–10 3
YP total needs (parent report) 5.05 (3.43) 0–25 0
Met (parent report) 2.58 (2.30) 0–25 0
Unmet (parent report) 2.48 (2.51) 0–25
YP AUDIT-C 4.99 (3.89) 0–12 6
YP AUDIT-C above cut-off point (> 4) 65 0–12 6
YP drug use in past month 24 7
YP drug use ever 48 7
YP problems with police in past 12 months 25 7
YP exclusion from school 50 0
YP not in contact with services 41 0
YP in contact with services
Children’s service 33 0
Adult service 10 0
ADHD service all ages 16 0
Childhood
CD 37 2
AUDIT-C, Alcohol Use Disorders Identification Test Consumption; CD, conduct disorder; CIS-R, Clinical Interview Schedule –
Revised; DIVA, Diagnostic Interview for ADHD in Adults; PR, parent report; SD, standard deviation; YP, young person.
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and the parent were asked whether or not there was a significant need (coded as 1). If so, further questions
were asked to ascertain if sufficient formal and/or informal support was being received. If adequate support
was received, the need was classified as ‘met’ (regardless of whether or not it was met by formal or informal
carers); if insufficient support was received the need was classified as ‘unmet’. Both met and unmet need
scores were calculated by summing the number of domains where each was recorded. A total needs score
(range 0–25) was calculated by summing the met and unmet need scores.28
We adapted a brief series of questions on drug use from the Office for National Statistics (ONS) survey
Mental Health of Children and Young People in Great Britain, 2004 Report.29 Young people were asked
to self-rate the frequency and nature of drug use from a range of drugs including cannabis, cocaine and
heroin. For each individual drug, a question was asked regarding whether or not the participant had ever
used this drug, even if just once. If the young person answered yes to this first opening question, two
more questions were asked: (1) at what age the young person had first used this drug and (2) whether or
not the young person had used this drug in the past month.
Alcohol use was assessed using the Alcohol Use Disorders Identification Test Consumption (AUDIT-C),
a brief and validated three-question screen that can help identify hazardous and harmful drinking.30 The
AUDIT-C is an abbreviated version of the 10-question Alcohol Use Disorders Identification Test (AUDIT);
the only screening instrument of hazardous alcohol use specifically designed for international use that is
consistent with International Classification of Diseases, Tenth Edition (ICD-10), definitions of alcohol
dependence and harmful alcohol use. Higher scores indicate greater likelihood of hazardous and harmful
drinking and may reflect greater severity of alcohol problems and dependence, as well as a greater need
for more intensive treatment.
Problems with police were examined through a series of questions based on those in the background
information questionnaire used in the adult ADHD service at the Maudsley Hospital (adapted for this
study). All participants were asked whether or not they had been in trouble with the police in the past
12 months. Those who answered yes were asked a brief series of questions regarding the nature and
frequency of these problems (e.g. frequency of custodial sentences, times spent in a prison cell,
appearances in court).
Caregiver burden was measured using the 12-item Zarit Burden Interview.31 This captures the psychological
and social impact of caring and asks respondents to rate the extent to which they agree or disagree with
statements regarding their feelings about the results of caring on a five-point scale, with possible responses
ranging from 0 (‘never’) to 4 (‘nearly always’). A total score (0–48) was calculated by summing the scores
for each question.31
We used a modified version of the Client Service Receipt Inventory (CSRI) to capture service use.32 In
particular, participants were asked to state whether or not they were under the formal care of child or
adult health services, with those answering yes recorded as currently being in touch with services (coded
as 1). The CSRI was completed jointly by the parent and young person (where they took part).
Obstacles and solutions
Our main obstacles related to five main factors:
1. delays with REC approval and the need to submit separate ethics applications for both groups
2. reaching young people
3. attrition, a problem common to all longitudinal studies but of particular concern for the ADHD group
4. the online completion of the Development and Well-Being Assessment (DAWBA) by parents of the
ASD group
5. the lack of detail on prescribing patterns in an epidemiological sample that could be accessed in the
time scale of this programme.
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First, approval of the ASD research project for the purposes of the Mental Capacity Act 200533 led to
significant delays due to the higher prevalence of LDs. As there is currently no standardised or accepted
protocol for assessing whether or not a person lacks capacity to consent to take part in research it was
necessary to develop a protocol for assessing capacity for this research project. Thus, a mental capacity
assessment was adapted from one used in an earlier project under the same NIHR programme grant
(REC 09/H0807/72). As this took some time to develop and to be approved by the local REC, the ASD
study began 1 year after the ADHD study. This meant that ASD participants were followed for only 2 years
(instead of 3 years, as for ADHD participants).
Second, our original design for the ADHD sample was based on contacting parents (as participants were
contacted as children we only had contact details for parents). However, we soon amended the research
design to be more inclusive in approach to young people, rather than approaching only via parents. To this
effect, initial letters of invitation were sent both to parents and the adolescents/young adults at their
parents’ homes.
Third, in order to reduce attrition (and non-response), especially among those with ADHD, we implemented
a variety of measures. As participants were initially recruited through the IMAGE sample, the newsletter was
revived and sent on an occasional basis to participants with summaries of the research and key findings
(this has been led by Professor Asherson and his colleagues).
Fourth, we encountered difficulties in getting parents to complete the online DAWBA for their children
with an ASD. This is because this online assessment is relatively time-consuming. We adopted several
solutions to address this issue. Our researchers repeatedly contacted those with incomplete DAWBAs,
reminding them of the need to provide this information. Furthermore, our researchers offered to assist
parents in completing the forms. Finally, we offered parents a gift voucher of £20 in order to compensate
them better for time taken to complete the DAWBAs.
Furthermore, we were concerned by the lack of accurate prescribing data and an epidemiological sample
that we could access – as this raises issues about the generalisability of our results. Hence, we developed a
collaboration with Professor Ian Wong (who was then at the School of Pharmacy) to examine medication
use in a nationally representative data set based on general practitioner (GP) records: The Health
Improvement Network (THIN). The data for young people with ADHD have already been published and so
we examined psychotropic drug prescribing and neuropsychiatric comorbidities among 0- to 24-year-olds
with ASD between 1992 and 2008 in a nationally representative primary care database. Further details
outlining the rationale for this component and our results are provided later in this report (see Chapter 20).
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Chapter 3 Needs in ADHD at the ‘transition’
Study design
For the ADHD study three separate face-to-face interviews were administered and one self-completion
questionnaire. The young person’s questionnaire consisted of:
l a needs assessment based on the CANDID (i.e. a standardised needs-assessment instrument that
assesses need in 25 life domains described above, see Chapter 2)
l the Clinical Interview Schedule – Revised (CIS-R; a rating scale of comorbid psychological symptoms
used in the ONS Psychiatric Morbidity surveys)
l background information (e.g. current employment situation and educational circumstances).
Self-administered questionnaires gathered information from ADHD adolescents/young adults on:
l the Barkley Adult ADHD Rating Scale – IV (BAARS-IV; i.e. questions about attention and activity levels
over the past 6 months)
l the Center for Neurologic Study – Liability Scale (CNS-LS), a self-reported measure of the occurrence of
moods in the past month and in the past 5 years
l the AUDIT-C, a widely used self-reported measure of alcohol use described above (see Chapter 2)
l a brief series of questions on drug use and police contact (e.g. if any problem with police in the past
12 months and number of formal police cautions and times spent in police cell and youth custody).
Parents were asked to:
l complete the same questions about the their child’s level of symptoms or problems that co-occur with
ADHD using the BAARS-IV
l complete the same questions about their child’s needs using the CANDID
l assess the impact of their child’s condition on their own employment situation and physical,
psychological and social well-being
l answer questions about the frequency and type of services they used
l complete a widely used measure of carer burden (an abbreviated version of the Zarit Burden Interview)
l provide background information (e.g. marital and tenure status, living arrangements).
A joint interview with both the young person and their parent consisted of:
l the Diagnostic Interview for ADHD in Adults (DIVA) (this was conducted in the first year only)
l the CSRI adapted for this clinical group asking information about the young person’s frequency
and type of service use in the past 3 months, contact with transition teams and their experiences
(and satisfaction) of transitioning from child to adult services (described in Chapter 2).
Each of the instruments specific to the ADHD study is described in more detail below.
Instruments specific to ADHD study
We used the DIVA,34 a diagnostic interview measure for adults with ADHD, recommended by the
European ADHD Consensus Group,1 to measure current inattentive and hyperactive/impulsive symptoms
(that is in the past 6 months). Using the DIVA, three subtypes of ADHD can be identified: predominantly
inattentive, predominantly hyperactive–impulsive and combined inattentive and hyperactive–impulsive.34
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Given that there is currently no measure of ADHD symptoms and impairments that is validated for use
across the whole age range used in this study (i.e. 14–21 years), the DIVA was chosen for several reasons.
First, despite being a relatively new measure, it was used in preference to existing published diagnostic
interviews such as the Conners’ Adult ADHD Diagnostic Interview for DSM-IV (CAADID),35 because it is
briefer, permitted greater freedom in responses and is used increasingly throughout Europe. Second,
compared with the CAADID, which has items that are similar to the DIVA, the DIVA is also publicly
available. Third, the items in the DIVA were considered to be more realistic for the diagnostic assessment
of ADHD in adults by the European ADHD Consensus Group.1 Finally, it was judged important to keep the
outcome data the same across the whole sample, rather than choose one measure for adolescents and
one for adults.
We also used the BAARS-IV (informant version),36 a standardised and widely used rating scale for the
assessment, diagnosis and monitoring of treatment of ADHD in adults. It assesses 18 symptom items from
the diagnostic criteria for ADHD in the DSM-IV and 10 items relating to impairment across different areas
of functioning. The informant is asked to rate the frequency and severity of impairments with scores on a
four-point scale ranging from 0 to 3 capturing the severity and frequency of the behaviours representing
‘0, not at all or rarely’; ‘1, sometimes’; ‘2, often’; and ‘3, very often’. Although both parent and young
person ratings of impairments were obtained only the parent ratings are used here.
Psychiatric-associated conditions were assessed using the CIS-R.37 It is a standardised, valid and reliable
structured diagnostic instrument used for rating psychiatric symptoms across 14 domains (e.g. anxiety,
depression), and is widely used in both clinical and the general populations.37 Scores on each section
can range from 0 to 4 (0–5 for the section on depressive ideas), with a total score ranging from 0 to 57.
A total score of ≥ 12 is regarded as clinically significant.37
Results
So far, our study of the ADHD group has focused on addressing the service use (and needs) of this clinical
group at the transition to adolescence and young adulthood (that is ages 14–24 years). In addition, we
explored the experiences of health-care transition (i.e. the process of moving from child to adult health
services) from the young person’s and parents’ perspective.
Our framework for understanding service use among this clinical group was the Andersen–Newman
Behavioural Model Of Health Service Use.38–40 It is an established framework widely used by health
economists, psychologists and medical sociologists to explain patterns of service utilisation among diverse
populations.41,42 The model organises service use into predisposing, enabling and need categories, whereby
use of services is conceptualised as a function of predisposing (such as the person’s age), enabling (such as
parental education) and need factors (such as ADHD symptoms, impairments, psychiatric comorbidities,
needs and caregiver burden).
Sample characteristics
We included 82 individuals with ADHD. The average age of ADHD group was 17.5 years (see Table 1),
and most were male (89%), still living at home (87%), unmarried (96%) and still in education (66%). Half
reported having been excluded from school. Thirty-seven per cent of parents reported having achieved an
educational level higher than A level (Advanced level).
The majority (73%) still met DSM-IV criteria for ADHD. Overall, there was no significant difference
between the younger (14–17 years) and the older (18–21 years) age groups in the percentage who met
DSM-IV diagnostic criteria for ADHD (χ2 = 0.108; p = 0.742). However, a higher percentage of the younger
group met criteria for combined ADHD (41% vs. 24%), whereas the predominantly inattentive subtype
was more common in older individuals (44% vs. 24%) (Figure 1).
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In addition, nearly two-thirds scored above the cut-off score on the AUDIT, suggesting high levels of
alcohol consumption. Forty-eight per cent had used illegal drugs at some point and close to one in four
had used drugs in the past month. Finally, 25% reported having been in trouble with the police within
the past year.
Impairments
In both age groups nearly all were impaired in at least one life activity (Figure 2). Overall, around two-thirds
of parents reported significant impairments in their child’s management of daily responsibilities (68%),
home life (67%), educational activities (62%) and money (61%); half of parents reported impairments
among their children related to work (49%). There were no significant differences in percentages of
impairments reported between the two age groups apart from in social interactions – where parents
reported more impairments among those in the 14–17 years age group in comparison with those aged
18–21 years [χ2 = 10.48, degrees of freedom (df) = 3; p = 0.013]. In summary, impairments were not
restricted to younger individuals with ADHD – both groups demonstrated marked impairments.
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Associated psychiatric symptoms
Twenty-seven per cent scored above the cut-off score (> 12) on the CIS-R, indicating the likelihood of
comorbid psychopathology. For example, over one-third of participants reported significant levels of
fatigue and irritability and around one-quarter reported significant anxieties (Figure 3). There was no
significant difference between the two age groups in the prevalence of associated mental health
difficulties – including neurotic symptoms (t = –0.452, df = 79; p = 0.652).
Needs
Parents reported that their child had a mean number of five needs (on average 2.58 of which were met
and 2.48 of which were unmet; see Table 1). There was no significant difference between the younger
and older age groups in the mean number of reported needs (5.25 vs. 4.89, t = 0.47; p = 0.64), met needs
(2.78 vs. 2.41, t = 0.71; p = 0.48), or unmet needs (2.47 vs. 2.48, t = –0.01; p = 0.99). There was also no
significant difference by age group in the percentages who reported needs within individual domains.
The only exception being in the social contact domain, with parents of young people aged 14–17 years
reporting more needs than parents of young people aged 18–21 years (χ2 = 6.20, df= 1; p = 0.01) (Figure 4).
Most of the help received towards meeting these needs came from family or friends rather than from formal
services (Figure 5). Overall, formal services provided little or no help towards needs other than those linked
to the participant’s physical health, whereas families or friends or young people provided most of the help
towards meeting young people’s needs. For example, whereas 88% of participants received some help from
family and friends towards their reported need in the safety to others domain, only 12% reported receiving
some help from formal services towards this reducing this need.
Service use
Despite a high prevalence of associated mental health symptoms, 41% of the sample reported that they
were no longer in contact with services. Thirty-three per cent of the sample were in contact with children’s
services and 16% reported regularly attending an ADHD service without age boundaries (that is one
specialising in the management of children, adolescents and adults with neurodevelopmental difficulties).
Only eight (10%) of the participants were seen by adult services (Table 2).
Those more likely to be in contact with services were younger, reported more impairments and higher
parent–carer burden (Table 3 shows the results of the logistic regression model used to analyse correlates
of service use). The key outcome measure was whether or not the participant reported being currently
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seen by child, adult or tertiary services. The predictors captured predisposing (young person’s age), enabling
(parental education) and need factors [ADHD symptoms, impairments, psychiatric comorbidities, parental
caregiver burden and childhood conduct disorder (CD)]. Needs were not included in the model given their
significant association with impairment (r = 0.51, df = 79; p < 0.01). Age was the only significant correlate
of service use [odds ratio (OR) 0.62, 95% confidence interval (CI) 0.46 to 0.83; p = 0.001], with a 1-year
increase in the young person’s age reducing the odds of being seen by services by 38%. None of the other
factors considered was significantly correlated with service use. The proportion of variance explained by the
models was 0.24 using Cox and Snell R2 and 0.38 using Nagelkerke R2, indicating that between 24% and
38% of the variance is explained by this model. In summary, we found that in ADHD age (and not level of
impairment) determines the chance of being seen by services.
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Health-care transition
As reported above, only 10% (n = 8) of participants reported having experienced a transfer to adult care.
However, among this group, seven (≈85%) families reported not having received a written transition plan
as recommended in clinical guidelines, and approximately 75% had not been spoken to by a professional
about the move from child to adult services (and even the 25% who had said that this occurred reported
that it been only a brief conversation). Around half of young people reported that they needed more help
during the transition process to help them prepare for the move to adult services. Young people reported
TABLE 2 Key characteristics associated with service use, ADHD group (n= 82)
Variable
In contact with servicesa
Significance testYes No
Predisposing
YP age 16.9 (2.1) 18.4 (2.3) df= 79, t = –3.32**
Enabling
PR (parent) education
Low 27 (57) 21 (44) df= 1, χ2= 0.041
High 17 (59) 12 (41)
Need
YP DIVA above cut-off point (> 6) 35 (61) 22 (39) df= 1, χ2= 0.849
YP impairments 5 (2.8) 3.7 (2.5) df= 76, t = 2.12*
YP CIS-R 8.8 (6.8) 6.8 (5.9) df= 79, t = 1.39
YP total needs 5.5 (3.8) 4.4 (2.9) df= 79, t = 1.43
YP childhood CD 17 (57) 13 (43) df= 1, χ2= 0.048
PR carer burden 19.7 (10.6) 15.4 (6.8) df= 79, t = 2.07*
*p< 0.05, **p< 0.01.
CD, conduct disorder; PR, parent report; SD, standard deviation; YP, young person.
a Mean (SD) or n (%) as appropriate.
TABLE 3 Multivariate binary logistic regression model for service use (n= 72)
χ2 6.95*
Cox and Snell R2 0.24
Nagelkerke R2 0.38
Predictor β OR
Age –0.476 0.62**
Parent education 0.821 2.27
Has ADHD 0.304 1.36
Impairment 0.221 1.28
Psychiatric comorbidity 0.057 1.06
Carer burden 0.017 1.02
Childhood CD –0.064 0.938
*p< 0.05, **p< 0.01.
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a need for more information to help them plan for the future (47%), someone to show them which
services are available as they grow up (51%) and someone to explain the transition process to them
(49%). In addition, around 70% of parents reported that their child needed more help in relation to
information about future options (72%), having someone to talk to about transition (70%) and having
someone to explain the transition process to them (69%). In addition, the majority (57%) of the those few
young people and parents who had received some help in terms of transition reported that their transition
had been poorly managed, with two-thirds reporting that they would have wanted more emotional and
practical support.
Discussion
Our data indicate that two-thirds of adolescents and young adults with a childhood diagnosis of ADHD
continue to meet DSM-IV diagnostic criteria at follow-up. Many also present with associated psychiatric
symptoms and impairments – as well as a wide range of health and social needs. Furthermore, there was
no significant age-related difference in the overall prevalence of ADHD symptoms, impairments, psychiatric
comorbidity or needs. Despite the continuing burden of symptoms and needs, reported service use
decreased significantly with increasing age. For instance, a young person with a childhood diagnosis of
ADHD reported 38% lower odds of service use at age 18 years than at age 17 years (irrespective of the
severity of ADHD symptoms, impairments, comorbidities, carer burden or diagnosis of CD in childhood).
This finding stresses the need for improving access to and/or use of health services among adolescents and
young adults with ADHD.
In contrast, we found that most help towards meeting needs for adolescents and young adults came from
friends and family rather than services (and families reported being provided with little or no help for the
majority of domains). In addition, even where services were reported to have been involved, these were
mainly targeted towards meeting the physical – rather than mental health or social – needs of this group.
Finally, we found considerable problems in health-care provision among this group that were specifically
related to health-care transition. Only 10% of the sample had been transferred to adult services. Around
half of all young people (and two-thirds of all parents) reported a need for more support from services in
(1) accessing information regarding which services are available when they grow up, (2) the co-ordination
of transition planning and (3) having someone to talk to about their practical as well as emotional needs.43
Strengths and weaknesses
To our knowledge, this is the first analysis of needs and services use among those diagnosed with ADHD
in childhood who are now at transition to adolescence and young adulthood. A key strength of our study
includes the use of face-to-face interviews with both young people and their parents using reliable
diagnostic and outcome measures. Moreover, our use of separate face-to-face interviews with young
people and their parents enabled us to gain a more comprehensive picture of the wide range of needs
among this group and to gauge the extent to which these needs are currently being met by services and
family or friends. Another key strength of our study lies in our consideration of multiple potential factors
that may correlate with service use among this group. This allowed us to better quantify the relative, and
independent, contribution of factors that influence service use among this clinical group. Finally, our
exploration of young people’s and their parents’ experiences of health-care transition, enabled us to
identify key areas where improvements are necessary in health-care delivery. These are required from the
perspective of both the affected person and their carers (e.g. a lack of access to sufficient information,
problems with co-ordinating transition and lack of sufficient attention to the individual needs of young
people and parents).
However, this was not an epidemiologically based sample and so our findings may not generalise.
Nonetheless, we suggest that it is likely that the situation may be even worse in the general population,
as our sample included individuals who had been in prior research studies of ADHD, and given that our
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sample had been in contact with CAMHS in childhood. Previous contact with such services may also have
resulted in a bias towards presenting with higher levels of psychological problems at follow-up (e.g. in
comparison with those in contact only with paediatric services in childhood). Nevertheless, rates of
psychiatric comorbidity in our study are consistent with those reported in previous studies of ADHD.44–48
Furthermore, as only those with a childhood intelligence quotient (IQ) of > 70 were included (with two
exceptions), it is possible that our findings represent an underestimate of needs among those with
intellectual disabilities. Likewise, as this study involved participants who were mostly males and from a
Caucasian background it is not possible to say how representative the current findings are for women and
those of ethnic minorities. Finally, due to our sample size we were likely underpowered to show significant
effects of some of the predictor variables.
Conclusions
At transition, adolescents and young adults with ADHD represent a vulnerable group who are likely to
have continuing needs that are currently poorly met by services. Key to improving transitional care are the
health-care professionals and commissioners who design and run services. Without wider organisational
support transitional health care is unlikely to become fully integrated into health services. Our initial results
confirm Kennedy’s49 suggestion that changes could be made in policy, funding and training to enable the
flexibility and continuity needed to put the young person at the centre of care. This comes at a cost.
However, set against the considerable costs to the individual, family and society that are associated with
untreated ADHD, there are clear clinical, ethical and financial arguments that suggest that investment in
transition would realise long-term gains.
Key messages
Age, rather than symptom severity, level of impairment or comorbidities, is the strongest correlate of service
use in ADHD (with younger people being more likely to receive treatments).
Young people with a childhood diagnosis of ADHD at transition to adolescence and young adulthood suffer
from persistent ADHD. In addition, they experience ongoing impairments and psychiatric comorbid symptoms.
This leads to a wide range of health and social needs that would benefit from evidence-based treatment.
Most needs among adolescents and young adults with a childhood diagnosis of ADHD and their parents are
poorly met by services. Most of the help received comes from families or friends.
Young people with a childhood diagnosis of ADHD and their parents report considerable unmet needs in
health-care transition.
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Chapter 4 Needs in ASD at the ‘transition’
Methods
As with the ADHD group, face-to-face interviews were conducted at yearly intervals with the ASD group.
However, this study took place over a 2- rather than a 3-year period. In contrast to the ADHD study (see
Chapter 3), interviews were largely undertaken with the parent and (whenever possible) with the young
person themselves (we took parental advice into account on how best to manage the interviews in order
not to cause any undue distress).
Thus, the first part of the parent interview consisted of a series of questions about their child (including
the CANDID, their child’s alcohol and drug use and police contact if any). The second part collected
information on the impact of their child’s disorder on their own situation and the final part, conducted
when possible together with their child, asked questions about their child’s service use and transitions.
When possible, the adolescent/young adult version of the ASD questionnaire consisted of questions on
level of need, mood, drug and alcohol use and police contact. With few differences, we collected the
same information for both young people and parents in the ASD group as we did for the ADHD group
(e.g. the CANDID, the CSRI). The measures unique to the ASD group are briefly discussed below
(i.e. those assessing ASD symptoms and associated comorbid psychiatric conditions). We included 101
individuals with ASD.
ASD-specific instruments
Current severity of ASD symptoms were captured using the Autism Quotient (AQ) – informant version.50
It contains 50 items covering five different areas: social skills, attention switching, attention to detail,
communication and imagination. For each question respondents report whether they ‘slightly agree’,
‘definitely agree’, ‘slightly disagree’ or ‘definitely disagree’ that a described behaviour is exhibited. Each
question is scored 1 if the respondent reports the autistic symptom (by either ‘definitely’ or ‘slightly’
endorsing the symptom) and 0 if not. A total score (0–50) is calculated by summing the scores for each
question. Scores over a cut-off point of 32 are indicative of an ASD.50
Information on psychological co-occurring mental health symptoms was assessed using the DAWBA.51
We did not use the CIS-R (as we did in the ADHD study) because there is no informant version of this
instrument. The DAWBA assesses psychiatric symptoms and their impact across a number of domains
through structured and open-ended questions, which cover the criteria required for a diagnosis according
to both DSM-IV and ICD-10 criteria. The domains assessed were specific phobia, social phobia, panic,
agoraphobia, OCD, generalised anxiety, depression, deliberate self-harm, impulsivity/hyperactivity and
tics/Tourette syndrome. The DAWBA was completed online (www.dawba.net) by parents and young
people when possible. Two trained raters (both psychiatrists) reviewed each case and produced consensus
diagnoses based on the information provided by both parent and young person (where available). All
conditions were rated according to ICD-10 criteria except ADHD, which was rated using DSM-IV criteria
(as ADHD is not covered by ICD-10). An additional variable was derived from this measure stating whether
or not the young person met criteria for one or more comorbid conditions [e.g. ADHD, Generalised
Anxiety Disorder (GAD)].
Mental capacity issues
The ASD (but not ADHD) sample included individuals with intellectual disability (ID). Given the nature
of the research, some of those who were eligible to participate lacked capacity to consent. We are aware
that the baseline position is that capacity to consent is assumed unless there is reason to suppose otherwise.
However, some neurological, psychological and/or behavioural markers may suggest lack of capacity for
some things at some times. We also recognise that capacity is fluid in time and with respect to subject.
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Indicators of potential lack of capacity include (but are not restricted to) the diagnosis of a LD, an IQ of
< 70, significant deficits in adaptive functioning or other signs or symptoms of mental disorder that might
compromise capacity to give informed consent. This was of particular concern for the ASD group as we did
not exclude participants who had a LD (as was the case for the ADHD group, see above). All individuals
with capacity gave informed consent.
Where there were doubts about the capacity of a young adult to give consent the study introduced an
easy-read version of the information sheet and a capacity assessment was carried out by a trained
researcher. The capacity assessment tool addressed the following questions, which are based on the
principles outlined in Section 3 (1) of the Mental Capacity Act 2005:33
l Can the person understand the information relevant to the decision?
l Can the person retain that information?
l Can the person use or weigh that information as part of the process of making the decision?
l Can the person communicate his/her decision (whether by talking, using sign language or any other means)?
When it was established that the participant did not have capacity, but showed willingness to take part in
the study, a relative or close friend (other than the carer) was approached to act as a personal consultee.
The role of the consultee is to consider what the wishes and feelings of the participant would be if they
had capacity, and if they judge that the person would want to take part, to consent on their behalf. We
did our best to ensure that the consultee had no conflict of interest. If there were concerns about a
conflict of interest then the parent was asked to contact the research team, at which stage a member of
the research team spoke to them about the possibility of finding an alternative personal consultee.
The researchers who interviewed the ASD participants all received training from Dr Dene Robertson
(consultant psychiatrist at the Mental Impairment and Evaluation Service, Bethlem Hospital) in assessing
mental capacity to consent. In addition, they also undertook additional training; for example, they
attended short courses on the Mental Health Act 200533 and Deprivation of Liberty Safeguards awareness
training, as well as training on protection of vulnerable adults and the Protection of Children Act 1978.52
When possible, the researchers conducted assessments in collaboration with a member of the health-care
team, known to the potential participant, with experience in assessing mental capacity.
Results
Service use (and needs) among those with an ASD in adolescence and young adulthood
As with the ADHD group, our focus so far has been on addressing the first research question, the
correlates of service use. In addition, similar to ADHD, there is a lack of adult services for those with an
ASD [and in particular among those with high-functioning autism (HFA) who have ongoing needs and
functional impairments]. Appropriate and effective planning of care programmes requires knowledge of
the needs of this population (and their carers).
Consequently, our aim was to investigate needs and correlates of service use (e.g. medical and
demographic) among those diagnosed with ASD in adolescence and young adulthood (aged 14–24 years),
to help identify how they are supported while they move from adolescence to young adulthood.
Similar to the analysis of the ADHD group, we used the Andersen–Newman Behavioural Model of Health
Service (see Chapter 3, Results) to investigate the correlates of health service use among young people
with an ASD.
ASD sample characteristics
Similar to the ADHD sample the young people were predominantly male (92%) and still living at home
(87%). Seventy-three per cent met criteria on the DAWBA for an associated psychiatric condition and
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13% had a clinically defined LD. Most of the total sample were still in education (77%) and had received a
statement of special educational needs (70%); 40% had been excluded from school at some point in their
education. Parental education was assessed and 60% reported a high level of achievement – that is they
had received A-level qualifications or above.
Service and medication use
Fifty-six per cent of participants (Table 4) reported currently being in contact with child (33%), adult (22%)
or tertiary services (1%). The services most commonly seen in the past 3 months were a GP (used by 43%
of participants), psychiatrist (26%), key worker (22%) or psychologist (17%). Those who stated they were
TABLE 4 Descriptive characteristics of ASD sample (n= 101)
Variable % Mean (SD) Range Missing, n
YP age (years) 17.67 (2.9) 14–24 0
YP male 92 0
YP education
Full time 70 0
Part time 07
Not in education 23
YP employed (of those not in education) 35 0
Parental education
Low 41 0
High 59
YP ethnicity 1
White 85
Black/Asian/other 14
YP accommodation
Family home 87 1
Other 12
YP symptoms
YP AQ symptoms 35.85 (5.74) 22–46 1
YP met criteria on DAWBA for one or more psychiatric condition 73 12
YP LD 13 3
YP needs
Total needs (parent rated) 9.58 (3.64) 0–18 0
Unmet needs (parent rated) 3.25 (2.88) 0–11
Met needs (parent rated) 6.34 (2.72) 0–12
YP service use
Children’s services 33 0
Adults 22
Tertiary 1
None/do not know 45
SD, standard deviation; YP, young person.
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in contact with child, adult or tertiary services were significantly more likely than those who were not in
contact with formal services to report having seen a psychiatrist (χ2 = 3.66; p = 0.001) or a mental health
key worker in the past 3 months (χ2 = 7.92; p = 0.005).
Thirty-eight per cent of participants were currently taking at least one prescribed medication (Table 5).
The most common prescribed medication was for ADHD (taken by 9% of participants), followed by
antidepressants (8%) and sleep medication (8%). On average participants were prescribed 0.64 medications.
Psychiatric associated symptoms
Figure 6 shows the number of ASD participants who also met criteria on the DAWBA for common
psychiatric conditions. Figure 6 shows, for those who met the criteria for each condition, the numbers who
TABLE 5 Percentage of sample prescribed medication by type of medication (n= 93)a
Participant information % Mean (SD) Range
Currently using medication 38
Number of medications prescribed 0.64 (0.48) 0–4
Type of medication used
ADHD 9
Antidepressant 8
Sleep medication 8
Antihistamine 7
Respiratory 5
Epilepsy 3
Beta-blockers 3
Antipsychotic 2
SD, standard deviation.
a Note, eight participants were missing medication details.
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were in touch with services; had saw a psychiatrist, psychiatric nurse, psychologist or counsellor in the past
3 months; and whose parents reported that their children had previously received a clinical diagnosis for
an associated psychiatric disorder. Results show that 43% of the sample met clinical research diagnostic
criteria for ADHD (38/89), 33% for GAD (29/89), 19% for a specific phobia (17/89) and 20% for tic/
Tourette syndrome (18/89). In addition, a large proportion met criteria for more than one mental health
problem. For instance, nearly half (47%) of participants met criteria for two or more co-occurring mental
health disorders. However, relatively few of the parents whose children met the criteria for a co-occurring
mental health disorder reported having previously been told that their child had a clinical diagnosis of the
disorder. The most common additional diagnoses that parents had been made aware of are ADHD [36%
(14/39)], agoraphobia [11% (1/9)], OCD [14% (1/7)] and tic/Tourette syndrome [6% (1/18)]. Young people
with an ASD who met criteria on the DAWBA for at least one psychiatric disorder were more likely than
those who did not to be in touch with services (χ2 = 10.67; p = 0.001). However, of those who currently
met criteria for at least one additional psychiatric condition, one-third stated that they were not currently
being seen by any services and over half had not seen any psychological or psychiatric services in the past
3 months (see Figure 6).
Need
Parents reported that their child had a mean number of 10 needs (on average six of which were met and
three of which were unmet; see Table 4).
Figure 7 shows the needs most commonly reported by parents and the number of participants who were
receiving help from family or services. Eighty-three per cent of parents reported that their child had a need
relating to exploitation risk, 73% reported a need related to food, 72% reported a need related to money
budgeting and 63% reported social needs. Few of the young people were receiving help for these needs
from services; in contrast, almost all were receiving some help for them from friends or families.
As expected, younger people with an ASD with higher levels of need were more likely to be in contact
with services than those who were not [mean 10.54, standard deviation (SD) 3.60, in contact vs. mean
8.14, SD 3.57, not in contact, t = –3.13; p = 0.002].
Correlates of service use
Table 6 shows the results of the logistic regression model used to analyse correlates of service use. The
dependent variable was whether or not the participant stated that they were currently being seen by child,
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adult or tertiary health-care services. The predictors captured predisposing (young person’s age), enabling
(parental education) and need factors (that is the level of ASD symptomology, total level of need, whether
or not they met criteria on the DAWBA for any associated psychiatric conditions and the presence of a LD).
The only significant correlate of service use was whether or not the young person met criteria on the
DAWBA for one or more psychiatric conditions. For instance, the odds of young people with an ASD and
an associated psychiatric condition being in touch with services are four times higher than for those
without such a condition. The proportion of variance explained by the model was 0.18 using Cox and Snell
R2 and 0.24 using Nagelkerke R2, indicating that between 18% and 24% of the variance in service use is
explained by this model.
Service use, diagnosis and treatment of comorbid psychiatric conditions
Table 7 examines the relationship between being in touch with services and diagnosis and treatment (in
terms of reporting any psychiatric input in the past 3 months and receiving relevant medications), for the
two most prevalent psychiatric symptoms (ADHD and GAD). We would expect that those who met criteria
for a psychiatric condition and who were in touch with services would be more likely to report having
received a clinical diagnosis and treatment. However, we found no such relationship (albeit with one
exception). Among those with an ASD meeting DAWBA criteria for an anxiety disorder, 98% (43/44)
reported that they had not been informed of (or diagnosed with) this additional problem by any service,
52% (23/44) had received no psychiatric input in the past 3 months and 86% (38/44) reported that they
were receiving no relevant medication for anxiety. Only for those with an ASD who met criteria for ADHD
was being in touch with services significantly associated with receiving psychiatric input in the past 3 months
(see Table 7). However, even among this group, 65% (22/34) reported not having received a clinical
diagnosis and 85% (29/34) were not being prescribed relevant medication.
Discussion
We found that young adults with an ASD have a high burden of associated psychiatric symptoms,
including ADHD, and this is one of the main drivers of their service use. Even so, 45% were not using any
services. In addition, among those who were, most of their parents reported that their children had not
been clinically diagnosed or treated for the mental health problem(s) that (we detected) they suffered
from. Among our sample, we found that, of those participants reaching DAWBA criteria for GAD and who
were in touch with services, no parents had reported that their child had received a formal clinical
diagnosis. Eighty-one per cent did not report any relevant medication use for their children. Close to half
(49%) reported that their child had no psychiatric input in the past 3 months. Similarly, 85% of those with
both ASD and ADHD were untreated.
TABLE 6 Multivariate logistic regression model of significant independent variables and service use (‘are you
currently in touch with any services’) (n= 88)
Predictor β SE OR Significance
PR education (0 = high) 0.774 0.522 2.168 0.145
YP age –0.090 0.085 0.914 0.289
YP autism symptoms (AQ) 0.002 0.044 0.998 0.973
YP total need (parent rated) 0.124 074 1.132 0.095
YP met criteria on DAWBA for any condition 1.353 0.587 3.870 0.021
SE, standard error; YP, young person.
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TABLE 7 Diagnosis and treatment of ADHD and GAD for those in contact with services and those with no contact (excluding participants who stated ‘don’t know’ on the
service use question) (n= 81)
DAWBA condition
In touch with
services
Reporting diagnosis
Fisher’s
exact
Any psychiatric input in
past 3 months
Fisher’s
exact test
Reporting relevant
medication
χ2
Row total for
number meeting
DAWBA criteriaYes No Yes No Yes No
ADHD Yes 10, 38.5% 16, 61.5% 14, 53.8% 12, 41.2% 4, 18.5% 22, 81.5% 26
No 2, 25.0% 6, 75.0% 0, 0.0% 8, 100.0% 1, 12.5% 7, 87.5% 8
Total 12, 35.3% 22, 64.7% p= 0.68 14, 41.2% 20, 58.8% p = 0.01 5, 14.7% 29, 85.3% p= 1.00 34
GAD Yes 0, 0.0% 32, 100.0% 17, 53.1% 15, 46.9% 6, 18.8% 26, 81.2% 32
No 1, 8.3% 11, 91.7% 4, 33.3% 8, 66.7% 1, 8.3% 11, 91.7% 12
Total 1, 2.3% 43, 97.7% p= 0.27 21, 47.7% 23, 52.3% p = 0.32 7, 15.9% 38, 84.1% p= 0.65 44
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In addition, we found a very high level of need among this group – and these were more likely to be met
by family and friends rather than by services. These needs mainly pertained to core daily living activities
and independence and are highlighted in the recent NICE guidelines for adults as important to preparing
adults on the spectrum as they transition into adulthood.53
Our findings support those from a recent study highlighting the lack of treatment and services for adults
living with severe and enduring mental health difficulties, including depressive and anxiety disorders and
ADHD (URL: http://cep.lse.ac.uk/pubs/download/special/cepsp26.pdf). The report concludes that living with
a mental illness such as GAD can be even more debilitating than most chronic physical conditions even
though three-quarters get no treatment (URL: http://cep.lse.ac.uk). Thus, our findings highlight the need
for better recognition, referral and treatment of psychiatric comorbid conditions among young people with
an ASD.
There are few recognised ASD-specific treatments. However, there are a number of effective treatments
for ADHD, GAD and depression that have been developed in the general population. In addition, there is
recognised success in treating some of the associated psychiatric conditions in developmental disorders.
For example, the effective use of optimal dosing of methylphenidate (Concerta XL®; Janssen-Cilag Ltd,
High Wycombe, UK) in children with hyperkinetic disorder and ID, ASD54 and for higher-functioning ASD.55
Yet, despite this, we found very few affected individuals reported that they had been diagnosed or were
being treated.
Strengths and weaknesses
This study has a number of limitations. First, the sex balance is not representative of the ASD population as
> 90% of our sample is male, compared with a sex ratio of approximately 4 : 1 typically found by others.
Second, our sample included relatively high-functioning individuals compared with the ASD samples
investigated in other studies. For example, approximately 15% of our sample was diagnosed with a LD
compared with a prevalence of 56% in a population cohort of children.56 Even so, there is increasing
recognition that many individuals with an ASD do not have an ID, but still report high prevalence of
functional impairments, psychological comorbid disorders and needs.57,58 Finally, this initial report is from a
cross-sectional study and is therefore able to examine associations of need and service use at only one
point in time and so causality cannot be inferred.
Nevertheless, this study has significant strengths in comparison with earlier research. Our study is one of
the few to focus on adolescents and young adults with an ASD – whereas most studies concentrate on
children.59,60 In addition, our diagnostic assessment, the ADI-R, is a widely recognised and well-validated
informant-based (so-called ‘gold standard’) measure of ASD and so the sample contains ‘true’ cases.
Our study has shown a high prevalence of unrecognised psychiatric associated conditions and needs
among adolescents and young adults with an ASD. Many of the young people in this clinical group have
needs that are met not by services but largely by family and friends. Moreover, our findings show that only
severity of psychiatric conditions is associated with service use, and not ASD symptomology. Even those
young people with an ASD who met criteria for an additional psychiatric condition and were in touch with
services are no more likely to report appropriate diagnosis and treatment. Yet, further research is required
into the appropriate use, efficacy and long-term safety of antipsychotics and stimulants in the autistic
population before moving towards standardised pharmacological treatments (see Chapter 19). Too few
services are ‘autism focused’ and geared towards programmes to help those with an ASD to maintain
independence and sustain employment.61 Our data suggest that needs-led services are required which can
meet the complexities of ASD, including the core symptoms (e.g. difficulties with reciprocal social
interaction and communication, repetitive behaviours and interests), but which can also diagnose and treat
severe associated conditions such as ADHD, anxiety and depression, and thus reduce both the challenges
facing the young person and the burden they place on caregivers.
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Key messages
Despite a high prevalence of associated psychiatric symptoms, many adolescents and young adults with an ASD
are not being helped by services.
Our findings suggest that needs-led services are required to meet the complexities associated with
lifelong disorders.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27

Chapter 5 Carer burden as people with ASD and
ADHD ‘transition’ into adolescence and adulthood in
the UK
Background
Here we address the third research question – that is to define the relationship between symptomology,
need and service use among people with ADHD or an ASD at transition to adolescence and young
adulthood and carer burden. Previous research focused largely on burden to carers of young children with
ASD; few studies used adult samples.
The few available studies in ASD reported high levels of caregiver stress and burden; this was greater than
in parents caring for adults with other disabilities such as fragile X syndrome and Down syndrome.62,63
However, to our knowledge, no studies compared levels of burden for ADHD and ASD.
Methods
We used a modified stress appraisal model64 to examine correlates of burden. The model includes the
following components as potential correlates of caregiver burden: (1) family background characteristics
(parental education), (2) primary stressors (ADHD or ASD symptoms, a LD and measures of psychiatric
comorbidities), (3) a primary appraisal (a measure of need) and (4) resources (use of services). This model
was based on the stress appraisal model65 incorporating the two main theories regarding caregiver burden:
the appraisal model66 and the stress process model.67 Yates and colleagues’ stress-appraisal model65
consisted of five components: (1) primary stressors (e.g. level and type of disability), (2) primary appraisal
(the caregiver’s subjective appraisal of care need), (3) resources (individual and societal resources that may
affect the stressor such as the level of formal help), (4) secondary appraisal (often measured as caregiver
burden) and (5) outcome (psychological well-being). Casado and Sacco64 altered this model by adding a
family background component from Pearlin and colleagues’67 stress process model (family sociodemographic
background) and by conceptualising caregiver burden as an outcome. Thus, we propose that family
background, the young person’s level of symptoms and psychological comorbidities, and parental
perceptions regarding the need for care and resources lead to perceptions of burden.
Results
Sample characteristics
We included 89 individuals with ASD and 81 individuals with ADHD. Young people in the two groups
were similar in age, sex (≈90% male), education (≈70% in education) and accommodation (≈90% lived
at home) (Table 8). Caregiver sociodemographic characteristics in the two groups were also broadly similar
(see Table 8). All of the caregivers were either a biological or an adoptive parent. Caregivers from the two
samples showed similar sex and marital status distributions (72% of ASD caregivers were married vs. 78%
of ADHD caregivers, χ2 = 0.77; p = 0.38). In addition, around 35% of parents in both groups provided care
for someone else aside from their child with ASD/ADHD (χ2 = 0.28; p = 0.60). Caregivers from the two
samples were also comparable in terms of age (ASD mean 49 years, SD 6 years vs. ADHD mean 48 years,
SD 5 years, t = 1.65; p = 0.10). There were, however, significant differences in occupation of the two
caregiver groups: parents of ASD were in higher occupational groups (managerial/professional and
associate professional/administrative) (55% ASD vs. 42% ADHD, χ2 = 12.54; p = 0.01).
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Caregiver burden and study variables
Caregiver burden was high in both68,69 groups, but it was significantly higher in ASD than ADHD (ASD mean
22.66, SD 8.84 vs. ADHD mean 17.80, SD 9.18, t = 3.52; p = 0.001). Family background (parental education)
was significantly different, with 62% of parents in the ASD group being in the highest educational category,
compared with 35% in ADHD (χ2 = 12.58; p < 0.001). Primary stressors (i.e. symptoms, LDs and psychiatric
comorbidities) also showed significant differences between the two groups. The mean current severity of
ASD as measured by AQ score for the ASD group was 36 (SD 6), with 73% of this group showing AQ scores
above the suggested cut-off point of 32. The mean BAARS-IV current symptom score for the ADHD group
was 10.63 (SD 4.73). Using a cut-off point of > 5 on the BAARS-IV current symptom score, 58% met
TABLE 8 Descriptive characteristics of study sample and variables ASD (n= 89) and ADHD (n= 81)
Variable
ASD ADHD
Significance test% Mean (SD) Range % Mean (SD) Range
YP age (years) 17.57 (2.87) 14–24 17.47 (2.28) 14–22 df = 168, t = 0.26
YP male 92 89 df = 1, χ2 = 0.52
PR age (years) 49.02 (5.89) 38–64 47.60 (5.44) 36–59 df = 167, t = 1.65
PR female 93 96 df = 1, χ2 = 0.33
YP education df = 2, χ2 = 1.67
Full time 67 57
Part time 8 9
Not in education 25 35
PR education df = 1, χ2 = 12.58***
Low 38 65
High 62 35
YP accommodation df = 1, χ2 = 0.19
Family home 90 88
Other 10 12
YP symptoms
YP AQ symptoms 35.56 (5.54) 22–46
YP ADHD symptoms 10.63 (4.73) 0–18
YP LD 15 0
YP SDQ total 20.51 (7.04) 4–36
YP CIS-R 7.85 (6.34) 0–29
YP needs
YP total needs 9.90 (3.55) 0–18 5.01 (3.12) 0–14 df = 168, t = 9.51***
Met 6.58 (2.72) 0–12 2.60 (2.31) 0–11 df = 167.26, t = 10.31***
Unmet 3.31 (2.89) 0–11 2.41 (2.23) 0–9 df = 163.70, t = 2.30*
Service contact and needs
YP In contact with services 58 56 df = 1, χ2 = 0.14
Zarit Burden Interview 22.66 (8.84) 4–41 17.80 (9.18) 0–38 df = 168, t = 3.52**
*p< 0.05, **p< 0.01, *** p< 0.001.
PR, parent; SDQ, Strengths and Difficulties Questionnaire; YP, young person.
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threshold for inattentiveness, 42% for hyperactivity and 36% for combined ADHD. Fifteen per cent of the
ASD group had been previously diagnosed with a LD, compared with none of the ADHD group. In terms of
psychiatric comorbidities, the mean Strengths and Difficulties Questionnaire (SDQ) score for the ASD group
was 21 (SD 7), with 70% scoring in the abnormal range (> 16). Fifty-five per cent of the autism group also
scored in the abnormal range on the hyperactivity subscale of the SDQ (> 6). The mean CIS-R score for the
ADHD group was 8 (SD 6), with 27% per cent of the ADHD group scoring ≥ 12, indicating the presence of a
common mental disorder.
Need, our measure of primary appraisal, also showed significant differences between the two groups, with
the needs of those with an ASD (as rated by caregivers) being significantly higher (ASD mean 9.90, SD
3.55, vs. ADHD mean 5.01, SD 3.12, t = 9.51; p < 0.001). We used service use to conceptualise resources.
There was little difference in this indicator between the two groups; 58% of the ASD group and 56% of
the ADHD group were currently being seen by health services.
Tables 9–11 present the sequential multiple regression models used to examine the correlates of caregiver
burden. Separate models were produced for each condition, as well as a model combining both conditions.
Variables representing family background characteristics (parental education) were first entered into the
model, followed by those capturing primary stressors (symptoms, a LD for ASD and psychiatric comorbidities),
primary appraisal (need) and resources (use of services). For both samples, caregiver-rated need was a
significant correlate of burden even after other factors were controlled for (see Tables 9–11). In addition,
once need was controlled for, severity of disorder symptoms was no longer a significant predictor of burden
for ASD, but remained significant for ADHD (see Table 10, model 3). Conversely, although psychiatric
comorbidities were a significant predictor of burden for ASD, they were not for ADHD. Given that
approximately half of the ASD group also met the threshold on the SDQ hyperactivity scale, we also
investigated whether or not ADHD symptomology was associated with burden for the ASD group. When
the SDQ hyperactivity subscale was included as a separate variable in the model (along with a variable
comprising the total score from the other three subscales), the hyperactivity subscale was not significantly
associated with burden.
TABLE 9 Linear regression model for predictors of caregiver burden (ASD, n= 89)
Model 1 Model 2 Model 3 Model 4
Adjusted R2 0.01 0.28 0.35 0.34
F change 0.49 9.56*** 10.37*** 8.61***
ASD β β β β β β β β
Correlates (reference groups)
Family background
Parent education (high) –1.36 –0.08 –2.64 –0.15 –2.31 –0.13 –2.44 –0.14
Primary stressor
LD 0.36 0.01 –1.01 –0.04 –0.99 –0.04
ASD symptoms 0.03 0.02 –0.00 –0.00 –0.00 –0.00
Psychiatric comorbidities 0.70*** 0.56 0.52*** 0.41 0.51*** 0.41
Primary appraisal
Need 0.77** 0.31 0.74** 0.30
Resources
Service use (no service use) 0.86 0.05
**p < 0.01, ***p < 0.001.
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TABLE 10 Linear regression model for predictors of caregiver burden (ADHD, n= 81)
Model 1 Model 2 Model 3 Model 4
Adjusted R2 –0.01 0.16 0.23 0.23
F change 0.20 5.99** 6.97*** 5.75***
ADHD β β β β β β β β
Correlates (reference group)
Family background
Parent education (high) –0.30 –0.02 0.29 0.02 –0.26 –0.01 –0.13 –0.01
Primary stressor
ADHD symptoms 0.69** 0.36 0.48* 0.25 0.44* 0.23
Psychiatric comorbidities 0.34* 0.24 0.29* 0.20 0.28 0.19
Primary appraisal
Need 0.90** 0.31 0.88** 0.30
Resources
Service use (no service use) 1.78 0.10
*p< 0.05, **p< 0.01, ***p< 0.001.
TABLE 11 Linear regression model for predictors of caregiver burden (ASD and ADHD, n= 170)
Model 1 Model 2 Model 3 Model 4
Adjusted R2 0.01 0.15 0.29 0.29
F change 2.23 6.79*** 12.25*** 10.87***
ASD and ADHD β β β β β β β β
Correlates (reference group)
Family background
Parent education (high) –2.12 –0.12 –0.14 –0.01 –0.64 0.03 –0.72 0.04
Primary stressor
ASD (ADHD) 2.44 0.13 –1.95 –0.11 –1.72 –0.09
LD 0.05 0.00 –1.77 –0.05 –1.73 –0.05
SDQ > 16/CIS-R > 11
(16/11 or less)
4.87** 0.26 3.16* 0.17 3.15* 0.17
AQ > 32/BAARS-IV inattention/
hyperactivity > 5 (32/5 or less)
3.50* 0.18 2.28 0.11 2.15 0.11
Primary appraisal
Need 1.10*** 0.49 1.04*** 0.46
Resources
Service use (no service use) 1.81 0.10
*p< 0.05, **p< 0.01, ***p< 0.001.
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In the combined model need and comorbid psychopathology were significant predictors of burden,
whereas having a diagnosis of either an ASD or ADHD was not (see Table 11). The models show 34%
of the variance in caregiver burden among those caring for a young person with an ASD (see Table 9) in
comparison with 23% in the ADHD group (see Table 10). Further models were run for both disorders using
the young person’s assessment of their needs; however, no relationship was found with parental burden.
In order to further explore the relationship between need and burden the models above were run with
unmet and met need instead of total need (not shown). The results showed that only unmet need was
significantly associated with caregiver burden. The models using unmet need instead of total need
accounted for 42% of the variance in burden for the ASD group and 26% for the ADHD group. To
investigate these results further, additional bivariate correlations were calculated between individual
CANDID items and caregiver burden. Table 12 shows the individual domains of unmet needs, which were
significantly correlated with burden in the two groups. Unmet needs, related to depression/anxiety,
inappropriate behaviour, exploitation risk, aggression/violence and daytime activities, were significantly
correlated with burden for both samples. Specific to the ASD sample were significant correlations between
burden and unmet needs relating to social relationships, mental health problems, safety of self and
communication.
TABLE 12 Significant correlations between items rated by parent as an unmet need and caregiver burden
(ASD n= 89 and ADHD n= 81)
CANDID item of unmet need
Correlation with Zarit
Burden Interview (r) % of sample reporting unmet need
ASD
Depression/anxiety 0.38** 37
Exploitation risk 0.36** 20
Major mental health problems 0.35** 11
Social relationships 0.35** 43
Inappropriate behaviour 0.33** 25
Daytime activities 0.31** 25
Safety of self 0.29** 10
Communication 0.28** 21
Sexual expression 0.27* 3
Aggression/violence 0.24* 14
Substance misuse 0.22* 1
ADHD
Exploitation risk 0.32** 14
Aggression/violence 0.29** 14
Inappropriate behaviour 0.28* 30
Depression/anxiety 0.27* 11
Daytime activities 0.25* 20
*p < 0.05, **p< 0.01.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
Discussion
We explored (for the first time) the levels, and correlates, of burden among parents caring for a young
person with ASD or ADHD at transition from adolescence and young adulthood; and the relationship
between caregiver perceptions of their child’s need (met and unmet) and their own burden. Caregivers in
both groups had very high levels of burden that equate to those caring for individuals with very serious
medical disorders, and there was preliminary evidence that burden was significantly higher in the ASD
group. For example, level of burden among caregivers of young people with an ASD was comparable to
that among caregivers of those with acquired brain injury, and levels of burden among caregivers of those
with ADHD were comparable to those seen in the caregivers of people with dementia.70
Similar to previous studies, we found that current severity of symptomology of the core disorder is
associated with caregiver burden for ADHD but not in ASD32,71 once other potentially relevant factors are
controlled for. Contrary to some prior work,72 comorbid psychiatric symptoms were significantly associated
with caregiver burden among the ASD group but not among the ADHD group. Previous studies have also
found that the presence of physical health problems is associated with higher levels of burden.69,73 To
examine this we explored correlations between the CANDID item assessing physical health needs and
caregiver burden; however, no association was found. Similarly, there was no relationship between
presence of a LD and caregiver burden.69,72 Given the fact that few specific autism services (especially for
those who are high functioning) are available, our finding that burden is significantly associated with
comorbid psychiatric symptoms and needs in the ASD group suggests that autism-specific services
targeting multiple conditions may be beneficial in reducing disease burden.
For both disorders, level of unmet need was a significant predictor of burden even after other potential
contributing factors (e.g. symptomology) were taken into account. This suggests that it is not just family
background factors and primary stressors that contribute to caregiver burden among those caring for a
young person with ASD/ADHD, but also the caregiver’s appraisal of the level of unmet need. Unmet needs
significantly correlated with burden for both disorders were depression and anxiety, exploitation risk,
inappropriate behaviour and aggression/violence. Specific to ASD were significant associations between
burden and unmet needs concerning social contact, major mental health problems, appropriate daytime
activities, safety of self and communication. Our results suggest that targeted interventions to meet the needs
of young people with ASD and ADHD in these domains may also act to reduce caregiver burden. However,
it is important to note that burden was associated with parental perceptions of unmet need, not the affected
young person’s perceptions of their own unmet needs. This suggests the need for a holistic approach to
assessment and treatment of young people; it may be important to consider not only their own assessment of
needs, but also their parents’ perceptions of needs, as this is significantly associated with caregiver burden.
Strengths and weaknesses
This study has a number of limitations. First, we did not have a direct measure of maladaptive behaviour,
although it is likely that the measures used (e.g. of need and psychiatric comorbidities) also captured
behavioural difficulties. Second, our ASD sample appears to be higher functioning than the ASD
populations that have been investigated in other studies. For example, approximately 15% of our sample
was diagnosed with a LD, in comparison with a prevalence of 56% found by others in a population cohort
of children.7 In addition, there is increasing recognition that many individuals with ASD do not have ID.
Even so, caregivers of these higher-functioning individuals still describe a very significant level of burden.
Hence, public health policies should not assume that relatively higher-functioning ASD individuals and their
caregivers do not also have significant (and unmet) needs. Third, the sex balance of the young people in
both the ASD and ADHD samples was not representative of the respective populations. A male to female
ratio of 3.3 : 1 was reported in a study of children with ASD62 and a male to female ratio of 1.6 : 1 was
reported in a study of adults with ADHD.63
By contrast, our samples had ratios of approximately 9 : 1 (male : female). In addition, almost all caregivers
in the study were mothers. Given that studies in ASD and ADHD have found having a male child to be
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associated with higher levels of burden,68,69 and that levels of burden have been reported to be higher in
mothers than in fathers,74 our results may overestimate the level of burden in this population. Fourth,
although a measure of ADHD symptomology was included for the ASD sample (the hyperactivity/inattention
subscale of the SDQ), no corresponding measure of ASD symptomology was included for the ADHD sample.
Although the ADHD sample was screened for ASD in childhood, mild autism traits could still have been
present; however, we were unable to consider the effect of these traits on caregiver burden. Fifth, this initial
study was cross-sectional and is therefore able to examine associations of need and caregiver burden at only
one point in time. Future longitudinal research is required to determine whether or not input from formal
services significantly reduces parental burden. Sixth, there was some reduction in sample size due to missing
data. As the CIS-R in the ADHD group was taken from the young person’s interview, analyses focused on
those families with both a parent and young person interview (i.e. out of 86 paired interviews, 81 contained
complete information). For the ASD group, analyses focused on the parent interviews as these contained the
necessary measures. The sample size for this group dropped from 101 to 89, largely as a result of missing
data on the SDQ. Seventh, differences in the relationship between comorbidities and caregiver burden in the
two groups may be due to differences in the way that this information was collected: through self-reports in
the ADHD group using the CIS-R and through informant reports in the ASD group using the SDQ. Finally, our
initial analyses were cross-sectional – but we need to also examine change. As all data have now been
collected, our future focus will be examining changes over time as outlined in research questions 2 and 3.
Thus, we will investigate how needs and associated comorbidities have changed over time in this clinical
group and examine the demographic and medical factors associated with this change. Our final analysis,
which has not yet begun, will be to examine the main family carer’s role in meeting needs and how this has
changed over time and whether or not this is related to changes in service use. We will assess correlates
associated with this change and the consequences of changes in the family carer’s role for their own well-being.
Conclusions
This part of our study has shown that caregivers of adolescents and young adults with ASD and ADHD
experience very high levels of burden (likened to caregivers of those with acquired brain injury and people
with dementia). Many of the young people have needs that are currently unmet by services and the level
of unmet need is significantly associated with caregiver burden. These high levels of burden are likely to
affect the parents’ health75 and their ability to continue providing care. Interventions to screen for and
target depression/anxiety, exploitation risk, inappropriate behaviour and aggression could help reduce
burden on caregivers of young people with ASD and ADHD. Interventions to improve the young people’s
communication and social relationships, to provide appropriate daytime activities and to treat mental
health problems could also act to alleviate burden on caregivers of those with ASD.
Key messages
Caregivers of young people with an ASD and ADHD have very high (and frequently unrecognised) levels of
burden. In ASD this is comparable to that reported in people caring for those with a brain injury.
Psychiatric comorbidities (but not severity of core disorder) are significant sources of this burden in ASD,
whereas the opposite is true in ADHD.
In both groups caregiver burden is mainly explained by the affected person’s unmet need, yet there are
effective (but unused) treatment interventions available for these needs.
Specific interventions, using currently available treatments, that target unmet needs of young people with ASD
and ADHD may reduce caregiver burden.
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Chapter 6 Six-year follow-up study of combined-
type ADHD from childhood to young adulthood:
predictors of functional impairment and comorbid
symptoms
Background
In the previous chapters, we reported that individuals with ASD and ADHD who are ‘transitioning’ into
young adulthood have high rates of (frequently undiagnosed) co-occurring mental health problems – and
that the needs arising from these were not being met by clinical services. In addition, they were associated
with significant impact on school/higher education, social performance and carer burden. However, the
determinants of these outcomes are unknown. We present, and discuss, our initial findings for ADHD.
There is considerable evidence that the presence of ADHD in childhood is associated with a range of poor
outcomes in adulthood, including poorer academic achievement,76 impaired occupational functioning77 and
higher risk of criminality,78 substance abuse,79 interpersonal difficulties80 and psychiatric comorbidity,46
particularly antisocial, addiction, mood and anxiety disorders. However, relatively little is known about
which childhood and adulthood factors are predictive of poor outcomes. In particular, whether the
negative outcomes are linked to earlier ADHD during childhood or current levels of ADHD symptoms
reflecting persistence of the disorder, which may therefore be amenable to treatments targeted at ADHD.
It is well established that the hyperactive–impulsive symptoms tend to decline with increasing age, whereas
the inattentive symptoms tend to persist and cause the greatest problems to young adults.81 However, when
hyperactive–impulsive symptoms do persist into adulthood they may be particularly impairing (e.g. patients
with ADHD and addiction2 or forensic problems20). Meta-analysis of follow-up studies concluded that,
although 15% of subjects diagnosed with ADHD during childhood retained the full diagnostic criteria at
age 25 years (syndromatic persistence), an additional 50% met criteria for ADHD in partial remission,
meaning that they remained impaired by persistent levels of ADHD symptoms, although subthreshold to the
diagnostic criteria (symptomatic persistence).9 We therefore see that ADHD persists to different degrees, with
some individuals meeting full criteria as adults, some in partial remission and some showing full recovery.
Previous investigators have investigated predictors of comorbid outcomes. A 5-year follow-up study of girls
with ADHD concluded that it was the persistence of ADHD symptoms that predicted the occurrence of
later psychiatric comorbidities, behavioural problems and functional impairments in adolescents and young
adults.82 Another study found that it was the persistence of ADHD symptoms in adolescence that was a
predictor of antisocial and drug abuse disorders, although in adults these problems appeared to be
independent of the persistence of ADHD symptoms.83 A more recent longer-term follow-up study found
that persistence of ADHD was the main predictor of impairments later in life, that could not be accounted
for by other comorbid psychopathologies.84 These earlier studies therefore point towards the persistence of
ADHD as a predictor of current impairments and co-occurring behavioural problems such as antisocial
behaviour and drug abuse.
To date the reported follow-up studies are predominantly from the USA and most have used broad criteria
for ADHD, including all the clinical subtypes. This may have led to relatively low estimates of the persistence
rate for the diagnosis and a different pattern of comorbidities. Furthermore, differences in patterns of
referral and diagnostic rates between Europe and the USA might reflect overall less impaired groups in the
US studies compared with typical ADHD cases seen in child and adolescent clinics in the UK. We therefore
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set out to follow up a well-defined group of children from UK clinics who all met strict criteria for DSM-IV
combined-type ADHD at initial assessment. Here we evaluate the range of outcomes and provide an initial
evaluation of the predictors of comorbid outcomes in late adolescence and early adulthood.
We hypothesised that:
1. We would see high rates of persistence due to the selection of combined-type cases, with high levels of
both inattentive and hyperactive–impulsive symptoms.
2. The persistent ADHD group would have a significantly higher rate of mental health problems and
poorer psychosocial outcomes than population norms.
3. Severity of ADHD at follow-up would be the main predictor of comorbid mental health and
behavioural problems.
Method
Sample
Participants were recruited from the IMAGE study,85 a genetic study of ADHD carried out by researchers at
the IoP between June 2003 and January 2006. Families were originally recruited to the IMAGE study by
referral from child and adolescent clinics in south-east England on the basis that they had received a
clinical diagnosis of combined-type ADHD (as defined in the DSM-IV) and had at least one surviving
biological sibling aged 5–17 years. Both participants and their siblings were included in the IMAGE study
if they were between the ages of 5 and 17 years, had an IQ of ≥ 70, were of European or Caucasian
descent and had at least one biological parent willing to provide DNA samples. Participants were excluded
from the IMAGE study if they had been diagnosed with autism, epilepsy, an IQ of < 70, brain disorders
and/or any genetic or medical disorder associated with externalising behaviours that might mimic ADHD
based on both history and clinical assessment.
To compare mental health outcomes with population norms, comparison data were acquired from the
Adult Psychiatric Morbidity Study (APMS).86 Data were included from 411 participants aged 16–23 years
who did not meet criteria for ADHD.
Baseline measures
Parent Account of Childhood Symptoms
Parent Account of Childhood Symptoms (PACS) is a semistructured, standardised, investigator-based
interview developed as an instrument to provide an objective measure of children’s behaviour.87 A trained
interviewer administered PACS with parents, who were asked for detailed descriptions of the child’s typical
behaviour in a range of specified situations. Interviewers then made their own ratings on the basis of a
formal training and written definitions of the behaviours to be rated, on a four-point scale of severity and
frequency in the previous week and previous year. Inter-rater reliability was high, with product–moment
correlations for pairs of interviewers ranging from 0.79 to 0.96.
Parent Account of Childhood Symptoms includes several subscales. The hyperactivity subscale is made
up of attention span (time spent on a single activity, rated separately for four different kinds of activity);
restlessness (moving about during the same activities); fidgetiness (movements of parts of the body during
the same activities); and activity level (rated for structured situations such as mealtimes and car journeys).
The defiance subscale is composed of items concerning temper tantrums, lying, stealing, defiance,
disobedience, truancy and destructiveness. The emotional disorder subscale is made up of items of misery,
worrying, fears and somatic symptoms that describe overt emotional stress rather than inferences concerning
the emotional basis of symptoms. The comorbid and other problems section elicits symptoms of ASDs,
attachment disorders, manic episode, substance abuse, psychotic symptoms, obsessive–compulsive
symptoms and other specific developmental disorder and neurological conditions.
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The Long Version of Conners’ Parent Rating Scale
The Long Version of Conners’ Parent Rating Scale consists of 80 items in total, each scored on a Likert
scale from 0 to 3. In this scale, 0 represents ‘not true at all (never, seldom)’, 1 represents ‘just a little true
(occasionally)’, 2 represents ‘pretty much true (often, quite a bit)’ and 3 represents ‘very much true (very
often, very frequent)’.88
The 80 items yield 14 subscales (from ‘A’ to ‘N’), derived from the published algorithms in the manual.
These subscales were constructed based on their factorial validity derived from community samples. The
14 subscales are A, ‘oppositional’ (10 items); B, cognitive problems/inattention (12 items); C, hyperactivity
(nine items); D, anxious/shy (eight items); E, perfectionism (seven items); F, social problems (five items);
G, psychosomatic (six items); H, ADHD index (12 items); I, Conners’ Global Index: restless-impulsive
(7 items); J, Conners’ Global Index: emotional lability (three items); K, Conners’ Global Index: total
(10 items); L, DSM-IV symptoms subscales: inattention (nine items); M, DSM-IV symptoms subscales:
hyperactive–impulsive (9items); and N, DSM-IV symptoms subscales: total (18 items).
Intelligence quotient
Probands and siblings were screened for global learning difficulties with pro-rated full-scale IQ scores
derived from four subtests of the Wechsler Intelligence Scale for Children:89 picture completion, block
design, similarities and vocabulary. Individuals with a pro-rated IQ of < 70 were excluded from this analysis.
DSM-IV diagnoses at initial assessment
A standardised algorithm for PACS was applied to all raw PACS data to yield diagnoses based on operational
DSM-IV criteria for ADHD. Age adjustment for symptom threshold is built into the PACS algorithm. Situational
pervasiveness is captured by the different situations investigated within the PACS interview as well as the
presence of at least one symptom in each domain reported by teachers using the Conners’ ADHD subscale.
Low teacher ratings for ADHD probands can occur when children are stably maintained on medication at
school and, for this reason, situational pervasiveness is also captured in the PACS interview.
Follow-up procedure
Participants were recruited for the present study if they were aged between 14 and 24 years by 1 March 2009.
Parents and young people were initially contacted by letter and followed up by telephone. Participants were
interviewed either at our research offices or at the participant’s home. Of the original IMAGE sample of 204
families, 118 ADHD probands and their parents were successfully followed up. Mean follow-up duration was
6 (range 3–8) years.
Follow-up measures
ADHD symptoms and diagnostic status
The DIVA was used to assess ADHD symptoms at follow-up.34 DIVA investigates the DSM-IV criteria of
ADHD as well as impairment in five areas of functioning. Although the DIVA is a new measure, it is being
widely adopted across Europe for both clinic and research investigations of ADHD in adults. DIVA follows
a similar approach with the same enquiries about the DSM-IV symptom items as the more established
CAADID.90 In comparison, it provides more realistic examples of symptoms for the diagnostic assessment of
ADHD in adults and has a more detailed impairment section.1
Functional Impairment
The informant version of the ADHD rating scale for adults36 was also used to measure functional
impairment of ADHD symptoms at follow-up. It is a widely used rating scale for the assessment, diagnosis
and monitoring of treatment of ADHD in adults. It assesses the same 18 symptom items from the
diagnostic criteria for ADHD in the DSM-IV and contains an additional 10 questions assessing impairment
across different areas of functioning, including home life, occupation, social interactions, education,
driving, money management, leisure time and routine daily responsibilities. Functional impairment scores
were calculated by taking the average score for each participant from the 10 impairment questions.
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Psychiatric associated symptoms
The CIS-R was used to assess psychiatric comorbidities.37 It is a standardised, valid and reliable structured
diagnostic instrument used for rating psychiatric symptoms across 14 domains (e.g. anxiety, depression),
and has been widely used in both clinical and general population surveys.86,91 The minimum score on each
section is zero when the symptoms were either not present in the past week or were present only in mild
degree. Symptoms are regarded as severe when the score is ≥ 2 with a maximum score on each section
being 4 (5 for the section on depressive ideas). A total score of ≥ 12 is regarded as a clinically significant
indicator of general mental health problems.37
Emotional lability
The auxiliary subscale from the CNS-LS92 was used to measure labile frustration, anger and impatience. It
has been validated with patients with amyotrophic lateral sclerosis92 and Pseudobulbar affect.93 Emotional
lability measured with this scale has also been found to be increased in non-comorbid adults with ADHD
and to be an independent predictor of impairment.94 Participants rate the extent to which eight statements
apply over the past month. Each statement is rated from 1 to 5, giving a range of 8–40.
Drug and alcohol use and police contact
Drug use was assessed through a series of questions adapted from the ONS survey Mental Health of
Children and Young People in Great Britain, 2004 Report.29 These questions were comparable to questions
on drug use used in the APMS 2007.86 Young people were asked to self-rate the frequency and nature of
drug use from a range of drugs such as cannabis, cocaine and heroin. For each drug, participants were
asked whether or not they had used the drug within their lifetime and within the past month.
Alcohol use was assessed using the AUDIT-C,30 a brief and validated three-question screen that can help
identify hazardous and harmful drinking. A score of ≥ 5 indicates hazardous alcohol use.
Problems with police were examined through a series of questions based on those in the background
information questionnaire used in the adult ADHD service at the Maudsley Hospital (adapted for this
study). All participants were asked whether or not they had been in trouble with the police in the past
12 months.
Analyses
Descriptive statistics were produced for the sample at baseline and follow-up. To examine the persistence
of ADHD, participants were classified into two groups using DIVA scores:
1. persistent ADHD, which included combined type (six or more inattentive and six or more hyperactive/
impulsive symptoms), inattentive subtype (six or more inattentive symptoms and fewer than six
hyperactive symptoms), and hyperactive–impulsive subtype (six or more hyperactive/impulsive symptoms
and fewer than six inattentive symptoms)
2. subthreshold ADHD, which included partial remission (four or five inattentive or hyperactive/impulsive
symptoms) and full remission (fewer than four inattentive and hyperactive symptoms).
To investigate the outcomes of persistent ADHD, comparisons were made between participants with
persistent ADHD, subthreshold ADHD and the comparison sample from the APMS 2007 study. Comparison
data from the APMS study were available for psychiatric comorbidity, drug and alcohol use. To explore
correlates of these outcomes, multiple linear regression and logistic regression models were produced for
each outcome, including both childhood and adult characteristics as predictors. All analyses were conducted
in IBM SPSS Statistics for Windows version 20 (IBM Corporation, Armonk, NY, USA).
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Results
Sample characteristics
We included 118 individuals with ADHD. The average age of the ADHD group at follow-up was 17.5 years
(Table 13); most were males (89%) and still living at home (88%). Fifty-three per cent had used illegal drugs
in their lifetime, 20% had used drugs in the past month and 22% had been in trouble with the police
within the past year. Over half of the sample met the cut-off score on the AUDIT, suggesting high levels of
alcohol consumption. Twenty-seven per cent exceeded the cut-off score on the CIS-R, which is indicative of
comorbid psychopathology (see Table 13). Over half of the sample were in full-time education and 12%
were in full-time employment. As expected, the proportion of the sample in education decreases with age
and the percentage in employment increases with age. However, 46% of those aged 19–23 years reported
being unemployed (Table 14).
Persistence of ADHD at follow-up
At follow-up, 80% of the sample met full diagnostic criteria for DSM-IV ADHD: combined-type ADHD
(37%), inattentive subtype (36%) and hyperactive–impulsive subtype (7%). Of the group who did not
meet full DSM-IV criteria for ADHD, 15% were in partial remission (subthreshold ADHD), with only 5% in
total remission (Tables 15 and 16). Age at follow-up was unrelated to the number of inattentive (r = –0.6;
p = 0.54) or number of hyperactive symptoms (r = –0.12; p = 0.21) (Figure 8).
TABLE 13 Descriptive characteristics of study sample and variables at follow-up (n= 118)
Variable %
Mean (SD) or
percentage of sample Range Data available, n (%)
Current
Age 17.55 (2.40) 14–23 117 (99)
Male 89 89% 118 (100)
Parent education 74 (63)
Low 64 64%
High 37 37%
CIS-R mean 7.69 (6.63) 0–29 114 (97)
CIS-R above cut-off score (> 11) 27 114 (97)
Mood 18.58 (9.51) 8–40 104 (91)
BAARS-IV score 1.48 (0.61) 0–2.78 107 (91)
AUDIT-C 4.72 (3.72) 0–12 99 (84)
AUDIT-C above cut-off point (> 4) 54 54% 99 (84)
Drug use in past month 20 20% 108 (92)
Drug use ever 53 53% 98 (84)
Recent police contact? 22 22% 101 (86)
Childhood
IQ 101.14 (15.78) 117 (99)
At least one psychiatric condition on PACS 84% 118 (100)
Taking medication 87% 118 (100)
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
Psychiatric comorbidity at follow-up
Significant differences were detected between persistent ADHD, subthreshold ADHD and normative
groups in the rate of co-occurring mental health problems as assessed by scores on the CIS-R (F = 8.95;
p < 0.001). Total scores on this measure were significantly higher in the persistent ADHD group than in the
normative sample, indicating higher rates of comorbidity than in the non-ADHD control sample. No other
group differences were present (Figure 9). The CIS-R contains some domains (memory and concentration)
that overlap with ADHD diagnostic criteria. These analyses were therefore repeated with the memory and
concentration items excluded, with no overall change in the finding for higher CIS-R scores in the ADHD
TABLE 14 Employment, education and residential status by age (n= 75)
Participant information All ages
Age range (years)
14–15 (n= 21) 16–18 (n= 26) 19–23 (n= 28)
Education (%)
Full time 55 90 65 21
Part time 9 5 12 11
Not in education 34 5 23 68
Employment (%)
Full time 12 0 4 21
Part time 25 19 31 25
Not in employment 63 81 65 46
Not in education or full-time employment 16 3 15 27
Accommodation (%)
At home 88 100 92 75
Not at home 12 0 8 25
TABLE 15 Percentage of sample meeting criteria for different ADHD subtypes at follow-up
Participant information DIVA (%) (n= 106)
Persistent ADHD 80
Combined type 37
Inattentive subtype 36
Hyperactive subtype 7
Remitted ADHD 20
Partial remission 15
No ADHD 5
TABLE 16 Mean scores on ADHD ratings scales at childhood and follow-up
Rating scale Childhood, mean (SD) Adulthood, mean (SD) t-value/p-value
PACS/DIVA inattentive (n= 108) 8.31 (0.89) 6.62 (2.19) t(107) = –7.36; p< 0.001
PACS/DIVA hyperactive (n= 106) 8.25 (0.92) 5.23 (2.42) t(105) = –13.14; p< 0.001
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group. We conducted further analyses by defining cases as above or below the recognised cut-off score
of 32 on the CIS-R. There was a significant difference between the three groups [χ2(2) = 10.24; p = 0.06],
with 17% of the control group above the threshold for other mental health disorders, compared with
40% of the ADHD persistent group. Thus, these results indicate that the individuals with persistent ADHD
may be more at risk of psychiatric comorbidity compared with both the subthreshold ADHD group and the
general population control sample. The subthreshold and control samples had similar rates of other mental
health problems.
Next, we explored scores on the individual domains of the CIS-R to examine differences in the type of
mental health symptoms between the three groups. The persistent ADHD group had significantly higher
scores than both the subthreshold ADHD and normative group in the ‘fatigue’ and ‘concentration/memory’
domains and significantly higher scores than the normative group in the ‘anger’ domain. No differences
were found in any other clinical domains reflecting a wider range of mental health problems (Figure 10).
Drug use and police contact
The persistent ADHD group showed significantly higher rates of lifetime drug use [χ2(2) = 24.26; p < 0.001]
relative to the normative group, but not the subthreshold ADHD group (Figure 11). Both the persistent and
subthreshold ADHD groups showed significantly higher rates of police contact than the normative group,
but no differences were found between the two ADHD groups [χ2(2) = 0.03; p = 8.72]. No differences were
detected between any of the three groups in dangerous alcohol use [χ2(2) = 0.11; p = 0.95].
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Emotional lability
Normative data were not available for measures of emotional lability or functional impairment, so
comparisons were made only between the persistent and subthreshold ADHD groups. Significant
differences between the two groups were observed on the emotional lability scale, with the persistent
ADHD group scoring higher levels of emotional instability [t(41.10) = –3.93; p < 0.001]. Functional impairment
did not differ between the two groups [t(93) = –1.84; p < 0.07].
Predictors of outcome
To explore which child and adulthood characteristics were associated with outcomes, multiple regression
and logistic regression models were produced for the main outcome variables. Predictor variables
investigated included the number of adult and childhood ADHD symptoms (derived from DIVA and PACS
interviews), age, IQ and sex. Emotional lability scores and a variable indicating whether or not they
exceeded the cut-off point on the CIS-R were entered for the models for which those variables were not
the dependent variable. Childhood medication status and the presence of a comorbid oppositional defiant
disorder and CD in childhood were included in preliminary models but were not found to be significantly
associated with any outcome measure, so were excluded from the final analysis.
Tables 17–20 list the findings from regression models investigating predictors of comorbid symptoms,
behavioural problems and impairment scores. The main findings were as follows:
l Total functional impairments as rated by informants on the BAARS-IV impairments scale at follow-up
was significantly associated with childhood inattentive symptoms and sex (see Table 17). None of the
follow-up measures showed any association with impairment.
l Using a binary variable stating whether or not they met threshold scores for comorbid symptoms on
the CIS-R (> 11) as the dependent variable, current level of hyperactive–impulsive symptoms, age, sex
and emotional lability were all significant predictors (see Table 18). None of the childhood measures of
ADHD showed any association with the adult comorbidity scores.
l Emotional lability was associated with current comorbidity scores. Childhood characteristics did not
predict current emotional lability (see Table 19).
l Table 20 shows the findings from a linear regression model for alcohol use. Being of male sex was
significantly associated with increased alcohol use, but none of the clinical characteristics was significant.
l The remaining models examined predictors of drug use and police contact. In both models, the only
significant predictor was the child’s age; none of the measures of adult or childhood ADHD symptom
severity predicted current drug use and police contact.
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Discussion
We report on the first UK follow-up study of a cohort diagnosed with combined-type ADHD in childhood.
The current study had three aims: (1) to describe the rates of persistence of ADHD, (2) to investigate
differences in outcome between those with persistent and subthreshold ADHD and compare these to
population norms and (3) to explore whether childhood predictors or current symptomology predict
follow-up impairment and comorbid outcomes.
Regarding the first aim, we found very high levels of persistence, with 76% of the sample still meeting full
criteria for DSM-IV ADHD. This is much higher than the 15% reported from a meta-analysis of follow-up
TABLE 17 Linear regression model for impairment (dependent variable = BAARS-IV impairment score; n= 87)
Adjusted R2 0.20
F change 3.41***
Predictor of impairment β β
Adult inattentive symptoms (DIVA) 0.06 0.03
Adult hyperactive symptoms (DIVA) 0.04 0.03
Childhood inattentive symptoms (PACS) 0.20 0.14***
Childhood hyperactive symptoms (PACS) –0.11 –0.07
Age 0.00 0.03
Childhood IQ –0.00 –0.00
Above CIS-R cut-off point –0.02 –0.16
Sex (0 =male) 0.52 0.16***
Mood lability 0.00 0.01
***p< 0.001.
TABLE 18 Multivariate binary logistic regression model for psychiatric comorbidity (dependent variable = above
CIS-R cut-off point; n= 96)
χ2 25.70***
Cox and Snell R2 0.24
Nagelkerke R2 0.35
Predictor β OR
Adult inattentive symptoms (DIVA) –0.24 0.79
Adult hyperactive symptoms (DIVA) 0.36 1.43*
Childhood inattentive symptoms (PACS) –0.15 0.86
Childhood hyperactive symptoms (PACS) 0.13 1.14
Age 0.25 1.28*
IQ 0.01 1.00
Sex (0 =male) 1.71 5.55*
Mood lability 0.07 1.07*
*p< 0.05, ***p< 0.001.
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samples in available data sets in 2006.9 There are likely to be several reasons for this finding. First, in
general, the sample was recruited from child and adolescent clinics in south-east England. The diagnostic
rates for ADHD are far lower in the UK than in the USA, where the previous outcomes studies were
completed. This is likely to be reflected in a greater severity in the ADHD cases in the UK, where
recommended criteria include impairments of at least moderate severity.95 Second, our sample all had
combined subtype ADHD when they first came into the study; selecting for a sample with a greater level
of ADHD symptoms compared with broader criteria applied in other follow-up studies.
Furthermore, our sample covered a wide age span (from 14 to 23 years) at follow-up and the high rate of
ADHD could be explained by the average age of 17 years in this sample. In previous meta-analysis the rate
of 15% with the full diagnosis was estimated for age 25 years. To investigate this further we divided the
sample into adolescents (aged 14–17 years) and young adults (aged 18–23 years) and found that 76% still
TABLE 19 Linear regression model for mood (dependent variable = CNS-LS score past month; n= 97)
Adjusted R2 0.17
F change 3.40**
Predictor β β
Adult inattentive symptoms (DIVA) 0.74 0.44
Adult hyperactive symptoms (DIVA) 0.69 0.18
Childhood inattentive symptoms (PACS) –1.36 –0.13
Childhood hyperactive symptoms (PACS) 0.58 0.06
Age 0.08 0.02
IQ –0.10 –0.17
Above CIS-R cut-off point 5.18 0.24*
Sex 0.45 0.02
*p < 0.05, **p< 0.01.
TABLE 20 Linear regression model for alcohol use (dependent variable =AUDIT-C score; n= 93)
Adjusted R2 0.12
F change 2.27*
Predictor β β
Adult inattentive symptoms (DIVA) 4.77 0.10
Adult hyperactive symptoms (DIVA) –6.49 –0.15
Childhood inattentive symptoms (PACS) –12.77 –0.10
Childhood hyperactive symptoms (PACS) 12.18 0.11
Age –7.12 –0.16
IQ 1.20 0.18
Above CIS-R cut-off point –8.29 –0.03
Sex –103.71 –0.30**
Mood lability –0.07 –0.01
*p < 0.05, **p< 0.01.
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met ADHD criteria in the younger group, compared with 83% in the older group. This finding might seem
unexpected with a higher rate among the older participants, but is likely to be explained by the selection
for combined-type ADHD. This clinical subtype reflects a more severe condition when present in older
patients than in younger patients, as the same clinical criteria with the same high symptom threshold are
used and some of the younger group will no longer meet combined-type criteria by the time they are
adolescents. Combined subtype ADHD has previously been linked to higher rates of persistence in
adulthood in an epidemiological study.96
The other key observation is the change in clinical subtypes, in which around 36% of the combined-type
probands progressed to the inattentive subtype at outcome. This is to be expected and is consistent with
previous data supporting the change in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-V), in which the clinical subtypes are viewed as developmentally unstable and the previous subtypes
are now referred to as clinical presentations. Overall, we can see that there is a very high rate of
persistence of ADHD beyond the age of 17 years in a UK sample of children with combined-type ADHD.
This is in stark contrast to service development in the UK, which continues to lag behind the clinical needs
of this patient group (see Chapter 3 for discussion of the unmet needs of this clinical group).
For our second aim, we found significantly higher rates of comorbid symptoms among participants with
persistent ADHD as compared with both subthreshold ADHD and the general population sample. When
this was analysed in detail, the symptoms/syndromes that were increased in the ADHD group included
fatigue, concentration/memory and anger, as well as behavioural problems of using drugs and increased
police contact. However, increased rates of potential comorbidities such as anxiety and depression were
not seen in the patient group at follow-up. The profile of symptoms detected by the CIS-R screen for
mental health problems (fatigue, concentration, memory, anger), is most likely to reflect persistence of the
core syndrome of ADHD, as both concentration and memory problems are part of diagnostic criteria for
ADHD. In this study, we found that emotional lability (related to anger) and current hyperactive–impulsive
symptoms were the main predictors of these symptoms. This is consistent with our previous analysis of a
sample of adults with ADHD carefully selected for no other mental health problems who reported increased
rates of fatigue, anger and irritability.94 It therefore seems that in this patient group the development of
co-occurring mental health disorders, such as anxiety and depression, is not a common outcome compared
with population norms, despite the increase in ‘comorbidity’ scores from the CIS-R. Rather, the symptoms
detected on this appear to be closely related to the core disorder of ADHD in adolescents and young adults.
Similar conclusions were reached in a comparable follow-up study from Mannuzza and colleagues83 in
the USA.
The reasons for the low rate of comorbid conditions may be related to this being a clinical follow-up
sample, in which most of the participants were actively engaged in treatment programmes as children. In
contrast, higher rates of comorbid conditions are reported in cross-sectional studies with mainly untreated
ADHD cases (e.g. Fayyad and colleagues97), or in clinic surveys of adult patients, many of whom were not
previously treated for ADHD.94 Further studies are needed to clarify this point, but overall it seems that
when children with ADHD are engaged in treatment programmes they report low levels of newly
developing adult-onset disorders compared with patients who were untreated during childhood.
In contrast, our study found higher rates of behavioural comorbidities. Both drug use and police contact
were found at higher rates than among population norms, reflecting the development of behavioural
problems throughout development and into young adult life in young people with ADHD. However, this
was equally true for both the persistent and subthreshold groups and, therefore, seems to be related to
the childhood diagnosis of ADHD rather than the current clinical status. Similarly, we did not detect
differences in ratings of functional impairments between the persistent and non-persistent ADHD groups,
which were related to the severity of inattentive symptoms during childhood. Similar observations were
made by Mannuzza and colleagues78,83 in some (but not all) of the studies in the USA. Overall, although it
is clear that children with ADHD are at risk from the development of problem behaviours, such as drug use
and antisocial or criminal behaviour, the predictors remain to some extent uncertain, with discrepancies
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across different studies.78 Nevertheless, our findings do emphasise the importance of the severity of ADHD
in childhood and the long-term impact on behavioural and functional outcomes in young adults.
This suggestion is supported by a recent epidemiological survey from Sweden that points towards not only
a higher risk of criminal behaviour among those with a diagnosis of ADHD, but also the effects of medical
treatment [with stimulants or atomoxetine (Strattera®; Eli Lilly and Company, Indianapolis, IN, USA)] on
reductions in rates of criminal convictions.98 Furthermore, in our ongoing study of young ADHD prisoners
aged 18–24 years (see Section 5), we can see the ways in which both current and past ADHD affect
behaviour. We find high rates of school expulsions, low educational achievement and conduct problems
among prisoners with ADHD during their childhood, as well as persistent problems with inattention and
impulsivity related more directly to current behavioural problems such as inability to retain themselves in
employment and aggressive outbursts.
Further studies are needed to clarify the impact of treating ADHD in older adolescents and young adults
on drug use and criminal behaviour, as well as the impact of medical treatment on functional outcomes.
The finding of a mixed impact of both present and past ADHD on different aspects of outcomes supports
the multimodal approach recommended by NICE, that include symptom control with medication, alongside
psychological treatments such as CBT to improve the longer-term negative consequences of childhood ADHD.99
Strengths and weaknesses
In drawing conclusions from this study, we need to consider several limitations. First, different interview
measures were used to assess ADHD in childhood and at follow-up. However, both of these measures are
based on the DSM-IV and are recommended for use in the respective age bands as diagnostic instruments.
Second, all of our ADHD sample was in touch with services at baseline and had combined-type ADHD.
Hence, our ADHD sample is not representative of the broader spectrum of ADHD cases, although in most
clinical settings around two-thirds of ADHD cases meet criteria for the combined subtype. The relatively
homogeneous sample does, however, bring advantages by reducing clinical heterogeneity and focusing on
what are widely considered the most impaired group of children with ADHD. Further work could usefully
be completed in the UK to follow groups of children (and girls) with predominantly inattentive symptoms,
where outcomes may potentially differ. Finally, due to our relatively small sample size, we were unable to
examine separately participants with partially remitted or completely remitted ADHD. Indeed, this problem
arose from the very high rate of persistence for the full diagnosis of ADHD that we saw in this sample at
follow-up.
Conclusions
Our preliminary analysis demonstrates the poor psychosocial outcomes during the transition years to young
adulthood of children who had been previously diagnosed with combined-type ADHD and been in contact
with services during childhood. Our work suggests that, as young adults, those patients with persistent
ADHD do not have high rates of comorbid psychiatric disorders, but nevertheless suffer from educational
and other functional impairments and display symptoms closely linked to ADHD such as fatigue and
feelings of irritability or anger. Even when ADHD symptoms decline to subthreshold levels, we still see
problems that require continued treatment. Similarly, we also found that high rates of drug use and recent
police contact were related to the severity of ADHD in childhood and were seen in both the persistent and
non-persistent ADHD groups. Taken together, our results suggest the importance of continuing services for
ADHD throughout the transitional years and into adulthood. Future work needs to clarify the impact of
different forms of medical and psychological treatments on the various clinical, functional and behavioural
impairments seen in children with ADHD when they enter the adult years.
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Section 2 Service perspective
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Chapter 7 Outline of our work plan
In the previous section (see Section 1), we asked people with ADHD and ASD (and their families) abouttheir needs. We found that many had residual impairments related to the core disorder together with
associated mental health symptoms (most of which they were unaware of and/or were untreated). We also
found that the main determinant of service provision was age (and not level of need). This led to concern
that ASD and ADHD may be over-represented (but unrecognised) in particular parts of the NHS – and
perhaps also in prison populations. However, we did not have the perspective of clinical services in our
other work streams.
The main aim of this part of the programme, therefore, was to estimate the proportion of ADHD and ASD
cases within GP and adult mental health/prison services that are currently unrecognised and untreated.
This was achieved by screening adults who attended primary care physicians in the community and adult
mental health and forensic/prison services run by one organisation (The South London and Maudsley NHS
Trust). As a pragmatic step, we targeted individuals/clinics that were likely to have high rates of ADHD
and ASD.
In addition, due to the relatively poor understanding of the rates of ADHD and ASD in forensic settings
and the response to treatment in these settings, we:
l surveyed rates of ADHD and ASD in NHS forensic inpatient units run by one NHS provider (and provide
an initial more detailed analysis of ADHD data)
l carried out a search of electronic databases to identify the literature on ASD in prisons
l carried out two pilot (proof of concept) studies on current rates of disorder (and associated mental
health symptoms) in two different prison settings (one for young prisoners and the other for adults);
in this section we report the findings from our analyses of ADHD.
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Chapter 8 ASD and ADHD in general practitioner,
NHS hospital and prison settings: a general overview
Background
As ADHD and ASD have only recently been recognised in the UK as adult mental health disorders, little is
known about the rate of recognition of ADHD and ASD among people already presenting to adult mental
health services with co-occurring conditions such as anxiety, depression, personality disorder (PD) and
addictions, as well as criminal behaviour. We therefore wished to clarify the extent to which ADHD and
ASD goes undiagnosed and untreated within adult mental health and forensic services and whether or not
this leads to inappropriate or poorly targeted treatments.
Attention deficit hyperactivity disorder has an estimated prevalence during childhood in the UK of 3.6%.100
Longitudinal follow-up studies find that around two-thirds of those affected continue to be impaired by
ADHD symptoms in adulthood, with an estimated worldwide prevalence for the disorder in adults of
around 2.5%.101 Despite the high rate of ADHD in adults, the disorder remains underdiagnosed and
undertreated beyond the adolescent years.102 This is a particular issue for adult mental health because
ADHD symptoms not only lead to impairments in academic, occupational and social functioning, but are
also associated with the development of comorbid disorders, including anxiety, depression, PD, antisocial
behaviour and substance use disorders (SUDs).97,103–105
This also suggests that individuals with ADHD may be over-represented in forensic mental health and
prison settings. For instance, it has been reported that the prison population106 may have a 3- to 10-fold
increase in ADHD (calculated using 4% community prevalence). Despite this, only one study has reported
rates of ADHD symptoms in forensic mental health settings and this study, which focused solely on
patients with a primary diagnosis of PD, reported that one-third screened positive.107 This raises the
question of whether or not people diagnosed with such conditions may in some cases have undiagnosed
and untreated ADHD and whether or not treatment of underlying ADHD may lead to improvements in
their comorbid disorder(s).
People with ASD also have high rates of co-existing psychiatric disorders. In young children, our research
shows that 90% of 4- to 8-year-olds with ASD have at least one psychiatric disorder that impairs their ability
to function in everyday life.108 Even in older children the rate of impairment is 70%.58,109 The most common
disorders in children with ASD include anxiety, oppositional defiant disorder and ADHD. In adult life,
psychiatric disorders are also reported to occur in the majority of people with ASD. For instance, we found
that as part of this programme (see Chapter 4), adults with ASD are especially affected by anxiety disorders,
OCD and depression. These associated difficulties are long lasting,54 affect quality of life and (as noted in
Chapter 5) are associated with significantly increased carer burden.57 It has been suggested that some
individuals with ASD are at increased risk of offending behaviour (but this is based on limited data). In
addition, it is unknown how many people within general practice and mental health (and forensic) services
have unrecognised ASD.
Hence, it is important to understand how frequently within adult medical and psychiatric (including prison)
services ADHD and ASD are currently unrecognised and untreated. Furthermore, within a prison setting,
it is important to know if rates of ASD and ADHD are similar in the different prison systems which detain
younger and older individuals. Given the known population prevalence of the disorders it is expected that
at least 1% of young adult patients within GP clinics will have ADHD or ASD, but that the proportion will
be higher (unknown) among ‘attenders’ in adult psychiatric and forensic services.
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Methods
We conducted a survey of adult patients attending primary and secondary mental health care services for
adults. Patients were screened using rating scales, followed by diagnostic assessments with recognised
diagnostic instruments used in both clinical and research practice. We further collected data on impairment
and, when possible, on the health service costs related to the care of the identified cases with ADHD
and ASD.
Study sites
Patients in the following local primary, forensic and adult mental health services were screened and assessed:
l primary care patients currently being treated for other common mental health disorders, mainly anxiety
and depression
l patients in the anxiety disorders unit at the Bethlem Hospital, which is an inpatient facility for the
treatment of severe anxiety disorders
l patients in the secure forensic psychiatry inpatient units at Broadmoor Hospital, River House and
Bethlem Hospital, which are ‘prison hospitals’ caring for two main groups of patients: around
two-thirds with a primary diagnosis of severe mental illness (usually schizophrenia) and one-third
with a primary diagnosis of severe and dangerous PD
l patients in addiction inpatient facilities at the Bethlem Hospital and Maudsley Hospital and a
community outpatient drug treatment service
l sentenced young male prisoners aged 18–25 years, held at Her Majesty’s Prison (HMP) Isis
(south London)
l sentenced adult male prisoners aged 25–65 years, held at HMP Brixton (south London).
Sample
We screened 1604 individuals for ADHD/ASD: 253 individuals from primary care, 153 individuals from hospital
anxiety services, 159 individuals from hospital forensic services and 226 individuals from hospital addiction
services. Within the prison settings we investigated the rates of ADHD in 592 young people aged 18–25 years
and 221 older prisoners aged 25–65 years. As the study of young prisoners was completed as part of a clinical
trial of stimulants for ADHD and related behaviours (see Results and discussion), we were unable to complete
Autism Diagnostic Observation Schedule (ADOS) interviews in addition to ADHD interviews, because of the
already complex protocol and constraints on interview time as advised by the prison.
Diagnosing ADHD
Participants completed the DSM-IV 18-item self-report screening questionnaires for current and childhood
ADHD symptoms using either the BAARS-IV44 or, in primary care, the Adult ADHD Self-Report Scale.110,111
Positive screening for ADHD consisted of six or more ADHD symptoms during childhood, plus four or
more symptoms during adulthood. Participants who screened positive in the first stage were invited to a
diagnostic interview.
Research diagnosis of ADHD was established using the DIVA,71 conducted by trained research assistants
(RAs). Consultant psychiatrists experienced in the diagnosis of ADHD further reviewed the cases. The DIVA
interview systematically evaluates each of the DSM-IV symptom items for both current and childhood
symptoms and asks additional questions to establish impairment from ADHD symptoms (impairment
criteria), in two or more settings (pervasiveness criteria) and the age at onset of symptoms (age at onset
criteria). The diagnostic algorithm for ADHD used the following criteria: (1) six or more ADHD symptoms in
either domain from retrospective childhood rating scales, (2) four or more ADHD symptoms from either
domain from current ADHD symptom rating scales and (3) research diagnosis of DSM-IV ADHD following
application of diagnostic interview for DSM-IV ADHD.
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Diagnosing ASD
In the screening step, the AQ was used to screen for ASD.50 Participants with above threshold AQ scores
(> 31) were invited to complete the Autism Diagnostic Observation Schedule – Generic (ADOS-G).27 The
ADOS-G algorithm scores participants as below threshold, autism spectrum or autism. The ADOS-G is a
structured play and conversational interview that includes a series of social presses and other opportunities
to elicit symptoms of ASD. Thirty-one accompanying ratings are divided between the domains of social
interaction, communication, imagination/creativity, stereotyped behaviours and restricted interests.
According to the coding algorithm, scores in the domains of social interaction, communication and the
sum of these two, contribute to the ADOS-G classification of ‘below threshold’ (≤ 6), ‘autism spectrum’
(≥ 7), or ‘autism’ (≥ 10).
Results and discussion
Overview of findings for ADHD
In total, we screened 1468 participants for ADHD from adult mental health and prison mental health
services (Table 21). Across all the participants, we estimated an overall prevalence of ADHD of 15.1%,
which is around a three- to fivefold increase compared with the population rate of 2.5–4.3%. However,
there were marked differences depending on the clinical group being evaluated. The highest rate of ADHD
was seen among prison inmates (20.8% for older prisoners; 16.9% for younger prisoners), followed by
primary care mental health patients (11.6%), addiction patients (11.7%), forensic psychiatry patients
(7.3%) and anxiety disorder patients (6.1%).
The higher rate of ADHD in the older prisoners is not significantly greater than the rate estimated for the
younger prisoners.
The rates in the forensic psychiatry unit appear to be only slightly raised above that in the general
population; however, further analysis found that this depended on the primary diagnosis. No cases of
ADHD were identified among 81 patients diagnosed with a severe mental illness (schizophrenia in most
cases), whereas the estimate was 23.5% among the smaller group of 52 forensic patients with a primary
TABLE 21 Summary of the number of participants screened for ADHD and ASD, the number of screen-positive
cases and the numbers who completed diagnostic assessments and met diagnostic criteria
Service
Total screened n= 1604
Primary
care
Anxiety
disorders unit
Prison (aged
18–25 years)
Prison (aged
26–65 years)
Forensic
psychiatry unit
Addiction
treatment unit
ADHD ASD ADHD ASD ADHD ASD ADHD ASD ADHD ASD ADHD ASD
Screeners
completed (n)
250 249 122 101 592 n/a 221 221 129 158 154a 113
Positive
screeners (n)
50 77 15 30 129 n/a 60 39 43 43 32 4
Assessments
completed (n)
31 62 8 18 71 n/a 60 39 24 24 16 3
Met research
criteria (n)
18 4 4 3 55 n/a 46 12 15 15 9 1
Estimated
prevalence (%)
11.6 2.0 6.1 5.0 16.9 n/a 20.8 5.4 7.3 17.0 11.7 1.2
n/a, not applicable.
a For addiction sample total of 226 screened. 154 reported here where we had repeated screening after detox.
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diagnosis of severe and dangerous PD. When the criteria were broadened to include those with high levels
of ADHD symptoms (four or more symptoms in either domain) persisting from childhood and still causing
impairment (ADHD in partial remission), the prevalence within this subgroup was 35.3%.
The increased rate of ADHD in the primary care setting is particularly interesting, as we screened only
patients who were currently being treated for common mental health conditions, such as anxiety and
depression. This contrasted with the lower rate of ADHD in the specialist anxiety disorder unit, which
consisted of patients with a sufficiently severe form of anxiety of OCD to require inpatient treatment.
For the addiction inpatient unit, when patients were entering detoxification programmes, we noted a
significant decline in the numbers screening positive for ADHD within 1 week of their admission to the
unit. Current ADHD scores dropped significantly between screening assessment session 1 (T1) and
screening assessment session 2 (T2) ratings (1 week part) with a mean change of 8.6. We found that
52% of participants with T1 and T2 data had a clinically meaningful reduction of ≥ 8 points on the
self-completed ADHD rating scales, which is equivalent to a one-level drop in the Clinical Global Impression
(CGI) scale.112 This finding means that care must be taken when evaluating the level of ADHD symptoms
in patients actively addicted to drugs and/or alcohol.
Across the entire set of clinic samples, none of the 90 cases identified as currently meeting diagnostic
criteria for ADHD was currently recognised as having ADHD or being treated for the disorder. A small
number had been diagnosed during childhood, and this was particularly notable among the young prison
study group, who were all aged between 18 and 25 years. None of the cases of ADHD identified in the
other services had received a diagnosis during childhood.
Overall, these data find high rates of undiagnosed and untreated ADHD in adult mental health and
forensic services, particular among young male prisoners (even though they are routinely screened for
other mental health conditions), among the subgroup of male forensic psychiatry patients with a primary
diagnosis of severe and dangerous PD, among patients with an addiction disorder and among primary care
patients being treated for other common mental health conditions.
A total of 842 participants completed screening for ASD; we did not screen for ASD in young offenders
as there were local concerns (expressed by the prison) about the inclusion of the necessary additional
screening and diagnostic steps in this population. We were, however, able to carry complete screening in
an adult category C prison (Brixton).
An overall rate of ASD was estimated to be 5.5%, which is around eightfold higher than the general
population prevalence of 0.6%. However, obtaining accurate diagnoses of ASD was difficult because of
the limited access to parent reports of early childhood and developmental onset and course. This was a
particular concern within the forensic psychiatry group, in which there was an estimated 17% of patients
with ASD according to the ADOS-G assessment, which evaluates current autistic-like behaviours. Many of
these patients had a primary diagnosis of schizophrenia and it is possible that ADOS-G scores are explained
by the schizophrenic disorders and not autism. Further investigation would require autism diagnostic
interviews to be completed with the parents of the forensic psychiatry cases, which was not possible owing
to the low rate of agreement to contact families within this patient group. Higher rates were also found in
the older adult prisoners (5.4%) and the specialist anxiety unit (5%), but only a relatively small increase in
rates within primary care (2.0%) and the addiction service (1.2%). The association of severe anxiety
disorders with ASD is interesting because it suggests that in at least some cases ASD may be an important
risk factor, leading to sustained difficulties in controlling high levels of anxiety. The rate of ASD was higher
in the anxiety unit than within the primary care setting, suggesting that the link is with severe anxiety that
has not responded to other forms of treatment, rather than the more common forms of anxiety seen in
general practice. ASD, as well as ADHD, appears to be linked to criminal behaviour, leading to incarceration
in either forensic psychiatry or prison settings.
ASD AND ADHD IN GENERAL PRACTITIONER, NHS HOSPITAL AND PRISON SETTINGS: A GENERAL OVERVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
In addition to providing an overview of the findings in the section above, we have completed further,
more detailed ,analyses of the forensic psychiatry and addiction subpopulations. Here we not only focus
on the prevalence of undiagnosed ADHD and ASD, but also start to map out the associated impairments.
We have mainly focused on the analysis of impairment data in the ADHD data.
Key messages
Overall prevalence of ADHD in the adult mental health services investigated was 13.4%, three- to fivefold
higher than the population prevalence.
Overall prevalence of ASD in the adult mental health services investigated was 5.3%, approximately fivefold
higher than the population prevalence.
ADHD cases are overall more impaired than non-ADHD patients in the clinical settings investigated.
None of the 113 participants with ADHD or ASD identified in this study had been recognised by the services as
having ADHD or ASD and none had been referred for, or were in receipt of, appropriate treatment for these
disorders.
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Chapter 9 Detailed analysis of the different
clinical settings: preliminary results on ADHD and
ASD in primary care
The primary care study was completed during May 2013. Here we present preliminary findings from thispart of the programme.
Background
The population prevalence of adult ADHD is estimated at 2.5–4.4%101,113 and of ASD at 0.6–1%.114 We
know from experience within our specialist services and the literature that both ADHD and ASD are
commonly associated with additional mental health problems, including depression, anxiety and substance
misuse problems. We therefore expected that many primary care service users offered mental health
interventions may have undiagnosed ADHD and/or ASD. Identifying such cases would contribute to service
development through the identification of comorbidities that might otherwise be missed and that may
have important treatment implications. Hence, we also undertook a preliminary, qualitative, ‘scoping’ pilot
study to investigate how treatment is received by affected individuals.
Methods
Recruitment of participants
General practitioner surgeries for recruitment were identified in the local area by the Primary Care
Research Network (URL: www.nihr.ac.uk/research-and-impact/nihr-clinical-research-network-portfolio/),
and approached by the research team to take part. In accordance with Primary Care Research Network
standards, the surgeries/GPs were paid a fee for participating in the study and a ‘per-head’ cost for each
participant recruited to the study. Eligible participants included primary care patients aged > 18 years
receiving a mental health intervention, including prescription of selective serotonin reuptake inhibitor
medication and/or referral to Improving Access to Psychological Therapies services. A list of eligible patients
was generated from the surgeries’ computerised databases. These lists were checked by GPs themselves to
exclude any patients inappropriate to approach. Researchers prepared invitation letters to post to potential
participants. These were signed by the GP before posting on paper or electronically. The letter included
information on the study and consent forms to allow participants to opt in. The consent form included
permission for researchers to notify GPs of the outcome of their patients’ participation. Inclusion criteria
included all patients with non-psychotic disorders attending the clinic. Exclusion criteria for most settings
will include major mental disorders such as schizophrenia, bipolar I disorder and dementia. Inclusion/
exclusion criteria may differ between units.
Results and discussion
Within the primary care setting, we screened 252 cases and identified 18 cases with ADHD and four cases
with ASD. The estimated prevalence rates were 11.6% for ADHD and 2% for ASD, which are around
three to four times and twice the population average, respectively. Within the primary care population, we
compared the DIVA-positive cases (n = 15) with the ADHD screen-negative cases (n = 39). Individuals with
ADHD scored higher in all seven of the impairment domains on the Weiss Functional Impairment Rating
Scale (WFIRS); however, only risk and total scores showed significantly more impairment in the ADHD
groups than in the ADHD screen-negative patients (Table 22).
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None of the cases was currently identified as suffering from either ADHD or ASD and they were being
treated for other conditions. We have yet to analyse all the comorbidity data, but in most of the cases we
felt that the individuals were being given treatment for other conditions rather than targeting the NDs that
underlined their condition.
ADHD treatment outcome in primary care (qualitative feasibility/pilot study)
From the primary care sample, 15 patients were started on treatment for ADHD. We took baseline
measures and after 6 months reviewed their progress. We are currently completing this stage of the
project; however, all patients reported improvements in symptoms of ADHD and associated impairments.
We conducted review meetings with the patients on ADHD medication. During the meetings some
interesting comments were made about the effect of medication and the treatment process. Patient LL
(60-year-old female) reported being able to ‘cope with things better’ and can ‘sit still and watch full
programme on TV’, which she had never been able to do before starting medication. Overall, she felt her
quality of life had greatly improved. Patient AW (57-year-old male) reported feeling ‘much better’ on
medication as it helps get his ‘head together’ and he was getting many more things done. Patient KC
(28-year-old female) reported that the medication made her feel ‘more functional’. Medication ‘helped
50% and the rest was just having the diagnosis as it did wonders for my self-esteem . . . used to be down
on myself but now I know there is a reason behind how I am’. Others all reported finding the treatment
and improved understanding of their condition an enormous help, with some praising the team for finding
solutions to long-standing difficulties. For example, one man often had arguments with his daughter who
was also diagnosed and treated for ADHD. He now found that his behaviour was much better controlled
and he had time to stop and think rather than starting a shouting match with his daughter.
ASD in primary care
One of the most striking findings within the primary care sample was the high rate of false positives.
A total of 62 out of 77 patients who were AQ positive had a further ASD assessment (ADOS-G). Only
four cases were above threshold (6.45%) and 58 cases were below threshold (93.6%). This suggests that
the AQ may not be an effective screening measure in individuals with associated mental health conditions
such as generalised anxiety or depression. However, it is important to note the lack of information on
developmental history within the primary care sample. The mean age of individuals who were AQ positive
was 43 (range 20.6–65.1, SD 11.6) years and many individuals were unable to provide informants to
complete the ADI-R assessing key behaviours during early development. Without this essential information
it is hard to be say definitively whether the individuals who scored above threshold on the ADOS-G
actually had ASD and/or the ADOS-G failed to identify some cases.
TABLE 22 Comparing WFIRS scores between ADHD DIVA-positive patients and ADHD screen-negative patients
WFIRS item Screener negative (n= 27–39),a mean (SD) DIVA positive (n= 12–15),a mean (SD) t-test
Family 6.65 (5.43) 7.38 (3.75) –0.45
Work 8.30 (5.58) 10.83 (5.27) –1.33
Life skills 12.92 (7.99) 17.73 (8.75) –1.93
Self-concept 11.18 (4.19) 12.73 (2.60) –1.34
Social 10.49 (5.50) 10.67 (7.45) –1.00
Risk 4.95 (5.24) 10.07 (6.48) –2.90**
Total score 51.64 (25.27) 66.40 (19.52) –2.04*
*p< 0.05, **p< 0.01.
a n values varied between WFIRS items (e.g. some people did not work and could not answer the ‘work’ items).
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Analysis of impairment data revealed that patients who screened positive for ASD had significantly greater
social impairments than ASD-negative individuals. There were no other significant group differences on the
remaining five scales of the WFIRS (Table 23).
When analysis was repeated using a continuous approach, there was a significant positive correlation
between AQ total and family (r = 0.28; p = 0.03) and social (r = 0.31; p = 0.01) impairment scores on the
WFIRS. The results indicate a significant association between a higher number of autistic traits and greater
self-reported impairment in family and social domains (Figure 12). There were no significant differences
between ASD screen-positive and ASD screen-negative individuals on the Pittsburgh Sleep Quality Index
scale, measuring sleep impairments, or on the Affective Lability Scale, measuring affective liability.
It was not possible to compare those above and below the threshold for ASD due to the large difference
in numbers in each group (4 vs. 172).
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FIGURE 12 Scatterplot displaying the relationship between AQ total score and self-report family impairment
on WFIRS.
TABLE 23 Impairment scores from the WFIRS, comparing ASD screen-positive patients and ASD screen-negative
patients
WFIRS item
ASD screener negative vs. ASD screener positive
ASD screener negative (n= 12), mean (SD) ASD screener positive (n= 56), mean (SD) t-test
Total 58.33 (20.09) 56.15 (24.36) 0.77
Family 5.20 (2.57) 7.31 (5.22) –1.25
Work 8.60 (6.02) 9.49 (6.28) –0.40
Life skills 18.17 (6.34) 14.70 (8.49) 1.34
Self-concept 10.58 (4.06) 11.60 (3.97) –0.80
Social 7.50 (6.87) 11.61 (5.97) –2.10*
Risk 10.42 (8.31) 5.87 (5.34) 2.39**
*p < 0.05, **p≤ 0.01.
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Analysis of impairments in populations
Further analyses on impairments have yet to be completed.
Key messages
Current screening tools for ASD recommended in NICE guidelines have very high rates of false positives.
ADHD is approximately four times more common in vulnerable people within general practices than in the
general population.
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Chapter 10 Detailed analysis of the different
clinical settings: addiction services
Background
There are relatively few accounts of an increase in drug or alcohol addiction among people with ASDs.
In contrast, a bidirectional association of ADHD with addiction disorders is well recognised, with increased
rates of SUD within ADHD populations and increased rates of ADHD within SUD populations.115–117
Previous studies of ADHD in the USA and Europe estimate very high prevalence rates for lifetime SUD of
up to 58%.118 These studies found that alcohol and cannabis are the most frequently abused substances,116
followed by cocaine and amphetamines.119
There are potentially methodological issues that may inflate prevalence rates, indicated by the wide range
in reported prevalence rates for ADHD in SUD populations of around 10–55%.120,121 Challenges to the
correct identification of ADHD in SUD settings include high dropout rates between screening and
assessment stages and the potential overlap of symptoms between the two disorders,122 including
intoxication and withdrawal states119 and the long-term effects of chronic drug use on brain function123–125
that could mimic ADHD. Retrospective recall of childhood ADHD symptoms is particularly challenging in
SUD populations due to impaired memory and the often complex histories with adverse psychosocial risk
factors for the development of behavioural problems. Informant reports are often not available in SUD
populations because relationships with informants are frequently strained,119 and for this reason most
studies depend on self-report. When evaluating ADHD, few papers report the time since last substance
use, although delayed screening until 3 weeks of abstinence has been reported.126
Our study addresses some of these concerns by implementing a systematic screening protocol for ADHD
in London SUD clinics, with the aim of estimating the rate of undiagnosed and untreated ADHD within
SUD patients; and evaluating whether or not those with comorbid ADHD and SUD experience greater
impairment, in terms of comorbid diagnoses, previous convictions or suicide attempts, than those with
SUD alone. We also screened for ASD but found low levels in this population (see Results).
Methods
Participants
Sample characteristics are listed in Table 24. Participants (n = 226) were recruited from two inpatient
alcohol and drug detoxification and stabilisation units in south-east London. Consecutive admissions to the
inpatient units were invited to take part in the study over an 18- (clinic 1) or 11-month (clinic 2) period. Of
these, 74% had previously attended a detoxification treatment programme. One participant already had a
current adult diagnosis of ADHD and two had a recorded childhood diagnosis of ADHD. We excluded
individuals with a history of current or recent psychosis (n = 4), current serious physical illness (n = 3),
insufficient understanding of English to give informed consent (n = 6) and lack of capacity to consent
(n = 2). Overall, 51% of patients approached agreed to participate. Study participants received no payment
for participation.
Study procedures
The study of people undergoing inpatient detoxification included two screening stages using ADHD rating
scale data, followed by formal evaluation of the diagnosis of ADHD using a semistructured interview for
DSM-IV ADHD. By including two screening steps (T1 and T2) we were able to evaluate the difference
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between the level of ADHD symptoms on admission (T1) and 1 week later (T2), when they had been
detoxified or stabilised on treatments such as methadone.
Screening assessment session 1 (T1) took place soon after admission (mean 5 days, SD 4 days). The second
screening assessment session (T2) was completed as close as possible to 7 days after the T1 assessment
(mean 8 days, SD 6 days). During the T1 session, patients completed current and childhood symptom
checklists for DSM-IV ADHD; however, during the T2 session patients completed current symptoms only,
as it was assumed that only the report of current levels of symptoms would be affected by state of
detoxification and current drug use and needed to be measured at both time points. In addition, whenever
possible, we obtained contact details from informants for childhood and current ADHD symptoms who
were asked to complete an informant version of the screening questionnaire. Current informant ratings
were obtained for 72 participants and childhood ratings for 48 participants. The self-rated screening
data were used to allocate participants into a screen-positive group and a screen-negative group for ADHD.
Participants screening positive for ADHD were invited to complete a research diagnostic interview
assessment. Participants who failed to attend the diagnostic interview were offered up to three further
appointments. Following three missed appointments, a final letter invited participants to contact the
research team to reschedule an appointment before the assessment was recorded as ‘missing’.
Results
All 226 patients completed T1 screening questionnaires, of whom 69% completed T2 ratings. Reasons for
missing T2 screeners included early self-discharge or disciplinary discharge (n = 23), refusal to take further
part in the study (n = 15) and repeatedly missing T2 appointments (n = 32).
Childhood ADHD screeners
Mean total childhood ADHD symptom scores were highest in the group treated for drug dependency
(mean 29, SD 14), followed by the combined drug and alcohol group (mean 24, SD 15) and the alcohol
dependency group (mean 17, SD 14). A one-way analysis of variance (ANOVA) showed significant effects
of primary diagnosis (drug vs. alcohol vs. combined) on childhood screener total score (p < 0.001). Planned
contrasts showed significantly higher ratings of ADHD symptoms for drug than for alcohol participants
(p < 0.001), but not between drug and combined drug and alcohol groups (p = 0.12).
T1 compared with T2 ratings
These data are summarised in Table 25. Current ADHD scores dropped significantly between T1 and T2
ratings, with a mean change of 8.6. We found that 52% of participants with T1 and T2 data had a
clinically meaningful reduction of ≥ 8 points on the self-completed ADHD rating scales, which is equivalent
to a one-level drop in the CGI scale.112
TABLE 24 Sample characteristics
Total sample size, n 226
Male sex, n (%) 173 (76.5)
Mean agea in years (SD) 39.0 (10.3)
Ethnicity,a n (%) 183 (81.0) white European
Alcohol dependence,a n (%) 112 (49.6)
Drug dependence,a n (%) 29 (12.8)
Alcohol and drug dependence,a n (%) 85 (37.6)
a Background information available for 100% inpatient and 50% community participants.
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There is a significant reduction in ADHD symptoms following 1 week or more of treatment in the addiction
units. A 2 × 3 mixed model factorial ANOVA on the time (T1 vs. T2) and primary diagnosis (drug vs. alcohol
vs. combined drug and alcohol) found a significant main effect of time (p < 0.001), indicating that self-rated
ADHD symptom scores are influenced by the detoxification treatment process and/or withdrawal states
following admission. A significant effect of primary diagnosis was also found (p < 0.001), but no significant
interaction between time and primary diagnosis (p = 0.34). Between-subjects contrasts showed significant
differences for ADHD ratings between the alcohol and combined drug and alcohol groups (p < 0.001), but
not between drug and combined (p = 0.28) or alcohol and drug (p = 0.11), indicating higher levels of ADHD
symptoms at T1 and T2 among those with drug abuse compared with those with alcohol abuse alone.
Estimated prevalence of ADHD
There was an estimated prevalence rate for ADHD of 12.2%. Of these, 73% met criteria for the combined
subtype, 18% for the hyperactive–impulsive subtype and 9% for the inattentive subtype. The prevalence
was calculated using the proportion of participants completing each step that did and did not fulfil ADHD
screening and assessment criteria. This in turn allowed us to calculate an estimated prevalence rate of positive
screens at each stage, which is not affected by attrition rates between screening and assessment stages.
To evaluate whether or not rates of ADHD might differ in the groups that screened positive for ADHD
at T1 and T2, but did (or did not) attend for diagnostic interviews, we compared the attendees to the
non-attendees. The participants who attended the diagnostic assessments showed no significant differences
from those that did not at T1. However, they had significantly higher score for inattentive (but not
hyperactive–impulsive) symptoms at T2 (6.1 vs. 4.3; p = 0.025), suggesting that the prevalence estimate
based on available data might be slightly inflated.
Broader definitions of ADHD
Broadening the diagnostic threshold, based on the DIVA (diagnostic interview), had only a small impact
on the prevalence estimate. For example, reducing the threshold for diagnosing ADHD from six or more
symptoms in childhood to four or more increased the overall prevalence estimate only to 14.4%. In addition,
no additional cases were identified by decreasing the threshold for current symptoms to four or more.
Informant rating scales
Sixty-four per cent of participants provided contact details for informants of their current behaviour and
43% for childhood behaviour. In addition, 50% of both sets of contacts returned screening questionnaires.
Informant ratings of current ADHD symptoms correlated moderately with self-reported symptoms and were
similar to the equivalent correlations in the control sample (r = 0.47; p < 0.001). However, the participants
with positive screens for ADHD agreed far more strongly with their informants than those who did not
screen positive for ADHD (correlations 0.62 to 0.66). Correlations between childhood self and informant
ratings were similar to those for current behaviour, but were non-significant. Overall, participants and
informants were concordant for the 4+ screening criteria in 64% of cases at T1 and in 50% of cases at
T2 and 81% were concordant for the childhood 6+ criteria (Table 26).
TABLE 25 Mean (SD) ADHD screening scores for retrospective ratings from childhood and current symptoms at
T1 and T2 in the total inpatient sample
ADHD screening score Childhood T1 T2
Mean change
T1 vs. T2
Paired t-value
(T1 vs. T2 change)
Total score/54 21.09 (SD 15.0) 23.03 (SD 12.5) 14.65 (SD 12.1) –8.6 (SD 9.1) 11.92**
Inattentive symptoms/9 3.51 (SD 3.2) 3.59 (SD 2.9) 1.83 (SD 2.5) –1.80 (SD 2.2) 10.21**
Hyperactive/impulsive
symptoms/9
3.29 (SD 3.0) 3.46 (SD 2.6) 2.30 (SD 2.6) –1.23 (SD 2.1) 7.40**
**p < 0.001.
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Impairment and substance use
As expected, the SUD sample rated themselves as significantly more impaired than controls (p < 0.05).
Among the individuals with SUD there was a significant positive relationship between self-rated
impairment and the severity of ADHD symptoms in childhood and at both T1 and T2 (respectively,
r = 0.52, p < 0.001; r = 0.73, p < 0.001; r = 0.51, p < 0.001). Furthermore, impairment was significantly
negatively correlated with change scores between T1 and T2 (r = –0.23; p < 0.01), indicating that
participants with greater impairment at T1 showed a smaller drop in ADHD symptoms between T1 and T2.
Finally, within the SUD population we compared the diagnosed ADHD cases with the non-ADHD cases.
Those with ADHD had significantly higher rates of self-reported impairments and were significantly more
likely to have reported using cocaine or amphetamines (Table 27), consumed more units of alcohol per day
and had more prior suicide attempts. In addition, they had a trend towards higher rates of depression,
previous convictions and previous drug or alcohol dependency treatment (see Table 27).
ASD
Only four participants out of 113 who completed the AQ were above the threshold and, of these, only
one met criteria for possible ASD. As the rates of ASD in this population, based initially on self-report data,
appear to be very low, we did not pursue this line of investigation further. Future studies should consider
informant reports of autistic behaviours at the screening stage, to exclude the possibility of low reporting
of ASD behaviours using self-report questionnaires.
TABLE 26 Correlations between self and informant reports
T1 T2
Self-report: current behaviour informant report
All participants, n= 72 0.372** 0.375*
Positive ADHD screeners [childhood 6+ and T1 and T2 (if applicable) 4+], n= 16 0.617* 0.654*
Negative ADHD screeners, n= 56 0.258 0.169
Childhood screener: childhood behaviour informant report
All participants, n= 47 0.391**
Positive ADHD screeners (childhood 6+), n= 20 0.231
Negative ADHD screeners, n= 27 0.293
*p< 0.05, **p< 0.01.
TABLE 27 Drug use (past or current) in ADHD vs. non-ADHD groups
Heroin Amphetamine Crack cocaine Cocaine Marijuana
ADHD (n = 11), % 45.5 63.7 18.2 54.6 36.4
Non-ADHD (n= 182), % 29.7 6.6 29.1 11.0 15.4
Likelihood ratio 1.141 21.289 0.663 11.361 2.685
p-value 0.285 < 0.001** 0.416 0.001** 0.101
**p < 0.01.
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Discussion
Our main finding was that the estimated prevalence of undiagnosed ADHD within SUD clinic populations’
in south London is around 12%. This is of importance as we also found evidence that those individuals
with both SUD and ADHD had significantly higher self-rated impairments across several domains of daily
life; and higher rates of substance abuse and alcohol consumption, suicide attempts and depression,
recorded in their case notes. Taken together, these two findings highlight the negative impact of ADHD
on the individual and the increased burden they most probably place on services. When considering the
generalisability of these findings, a limitation of this study is the focus on inpatient detoxification units in
London. Further work is therefore required to evaluate rates and impact of ADHD among outpatient SUD
populations and other national and international regions.
Impairments associated with comorbid ADHD and substance use disorder
The finding of higher levels of impairment among ADHD cases within the SUD sample appears to be
robust, as we found indicators of impairment from both self-report and more objective (case note)
measures. Appropriate assessment and management of ADHD in SUD patients would therefore seem to
be potentially important to improve the general level of functional impairments, particularly given our
finding that ADHD is associated with increased frequency of suicide attempts and depression. Whether or
not treating ADHD in the context of SUD improves depression has yet to be adequately studied; however,
we know that in people with ADHD symptoms such as mood instability and low self-esteem respond well
to treatments for ADHD.127–130
Another finding was that the ADHD group had significantly higher use of stimulants, such as cocaine and
amphetamine (although not crack cocaine). One possible (but untested) explanation for this, given that
stimulants are routinely used to treat ADHD in the general population, is that people with ADHD are using
stimulants as a form of self-treatment. However, an additional mechanism could be that people with
ADHD have a preference for drugs that are more ‘stimulating’, especially when injected or taken at high
dose. Further work is needed to address this issue.
Definition of ADHD and methodological issues
Our work attempted to address, as best we could, the inevitable methodological difficulties that might
impact on accurate estimation of prevalence rates for ADHD within people with SUD. These include the
potential for unreliable information from self-report questionnaires, difficulties with retrospective recall of
childhood symptoms and the direct impact of drug and alcohol intoxication and withdrawal states on
ADHD-like symptoms. We therefore attempted to measure ADHD symptoms before and after detoxification,
included independent informant ratings whenever possible, compared these with population control data
and completed research diagnostic interviews. One additional confounder might arise if the study participants
considered a positive diagnosis of ADHD as a way to obtain stimulant medication. However, the study was
not linked directly to the treatment of ADHD, and expectations for treatment with stimulants are currently
low in the UK, because in most cases ADHD in adults goes unrecognised and untreated.102
Based on the percentage of patients who screened positive for ADHD in childhood and adulthood and the
proportion of those interviewed, we estimated an overall rate of ADHD of around 12% in our sample,
much higher than the equivalent estimated worldwide prevalence of around 2.5–3.4% in non-SUD
populations.97,101,113 Using slightly broader criteria for ADHD to reflect different approaches to the diagnosis
of adult ADHD being taken by different investigators and clinicians, we found the estimated prevalence in
our sample increased to a maximum of 15%. Overall, the estimated prevalence of ADHD in our sample is
far higher than population rates, yet lower than those cited in some previous studies of ADHD in SUD
populations. There are several potential reasons for these differences in the findings from this and
previous studies.
One potential reason was our stringent application of the DSM-IV criteria, which might have led to an
underestimate of the true rate of ADHD in the SUD population for several reasons. First, the inherent
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problem in collecting childhood data retrospectively might mean that some participants who met current
criteria for ADHD may have been unable to recall sufficient examples of childhood symptoms. We recorded
‘unknown’ ratings in the diagnostic interview assessments if participants could not provide sufficient
information to conclude that a symptom was present or absent and found that on average 15% of
childhood symptoms could not be scored. Second, DSM-IV criteria only require that ‘some’ symptoms and
impairments were present during early childhood and do not specifically require six or more symptoms
from childhood so long as the symptom count criteria are currently met as an adult. Nevertheless, we
decided to take the more stringent approach because of the lack of prospective data from childhood and
to guard against inclusion of ADHD-like syndromes that might arise as a result of chronic drug abuse in
the absence of an underlying ADHD diagnosis. Finally, we know that the current DSM-IV criteria are not
adjusted to take into account age-related changes in the development of ADHD, and there is evidence
that four or more symptoms in adults, rather than the current six or more symptoms, is sufficient. Indeed,
this change is being considered for the fifth revision of the DSM that is currently in preparation.102,131,132
However, taking all of these alternative thresholds into account had only a minor impact on our estimate
of the prevalence of ADHD in the SUD population.
The impact of drug detoxification on ADHD symptoms
We investigated the impact of drug intoxication and/or the detoxification process by evaluating self-rated
ADHD symptom scores a few days after admission to the detoxification unit and 1 week later, when the
participants were detoxified or stabilised on long-term medication and no longer in a withdrawal state.
We found significant decreases in ADHD symptoms of around 8 points (15% of the total score), which is a
clinically significant reduction in ADHD symptoms and comparable to a one-level drop of the CGI scale.112
In terms of our screening criteria, this led to 40% of patients no longer meeting screening criteria for
ADHD at T2 compared with T1. Hence, prior studies may have reported a higher prevalence than we
found due to the confounding effect of drug use and/or withdrawal symptoms. Other researchers have
noted mood disturbances during alcohol detoxification133 and it is therefore possible that ADHD-like
symptoms are also part of the withdrawal syndrome. Despite this, we found that in 60% of cases
self-rated ADHD symptoms remained clinically significant following completion of the detoxification
process. One implication is that, although the withdrawal process may impact on the level of ADHD
symptoms (and this should be taken into account when evaluating ADHD in SUD patients), there remain a
significant number of individuals with clinically significant symptoms of ADHD – and these require treatment.
Clinical implications
Our findings suggest that clinical evaluations for ADHD are probably best completed once detoxification
or stabilisation for drug or alcohol dependency has been completed. However, this suggestion may be
difficult to implement in community patients. Furthermore, once diagnosis of ADHD has been established
it will be important to offer treatment. However, use of some pharmacological treatments (such as
stimulants) is complex in those with a current SUD. Nevertheless, therapeutic nihilism is not an option, as
treatment of underlying ADHD may be important to the success of drug treatment programmes for some
individuals. It might be advisable to use the more stringent screening criteria of six or more symptoms in
either domain to identify those that need full clinical evaluation for ADHD, or to recognise the need for
detailed ADHD assessment in a higher proportion of cases. Moreover, it may be more appropriate to use
non-stimulant medications, such as atomoxetine, as a first-line treatment. Further work is required to
address this issue and the potential for using CBT-based therapies for ADHD in this complex population.
Obtaining informant data on ADHD symptoms for childhood and for current symptoms proved difficult
in this population. The reasons for this were not investigated here, but probably reflect the often poor
relationships that many SUD patients have with their family and friends. Therefore, in clinical practice it
will also often be the case that the diagnostic assessment of ADHD will depend on self-report alone.
We were able to investigate the validity of these self-reported data by comparison of self-report with
informant-reported data in a subset of our sample and a comparison control sample. This investigation
revealed moderate correlations between raters which were similar to that seen in non-SUD control
populations. For the most impaired subgroup, however, who were screening positive for ADHD based on
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their self-report, there was a far higher correlation with informant report for current ADHD ratings of
around 0.62–0.65. We therefore suggest that, although discrepancies between raters exist for ADHD
rating scales, this does not appear to be different for SUD compared with control populations.
Furthermore, ratings showed moderately high levels of agreement for the group of patients with ADHD.
Previous research has shown that in general people with ADHD tend to rate their symptoms lower than
informants,134 perhaps reflecting difficulties in self-evaluation of ADHD symptoms. Our research does not
support this finding within the SUD population investigated here. When we completed diagnostic
interviews with 26 people who screened positive for ADHD on the basis of their self-rated symptoms, we
found that only 61% met full criteria for ADHD. The clinical implication of this finding is that the diagnosis
of ADHD in patients with SUD should depend not solely on rating scale data, but rather on more objective
examples of symptoms characteristic of ADHD, as applied here using the DIVA interview. Rating scales are
a valuable tool for screening for ADHD, but should not be used as a replacement for a full diagnostic
assessment by clinical interview. Furthermore, although informant reports are helpful in supporting the
diagnosis, the moderately high correlations with self-report suggest that in most cases self-report alone
should be sufficient. For inpatient SUD units it should also be feasible to observe patients for level of
restlessness, problems with self-organisation, inattentiveness, impulsive responses and poor emotional
regulation, which are characteristic of ADHD in adults.
Conclusions
This study applied stringent ADHD diagnostic criteria, necessary to avoid mistaking withdrawal states and
other mental health problems for ADHD. This resulted in identification of a relatively small ADHD group
compared with other studies relying only on self-report screening questionnaires. Despite this, our findings
confirm high rates of ADHD within SUD populations that are approximately fivefold higher than general
population rates. Furthermore, SUD patients with high levels of ADHD were functionally more impaired
(including a higher rate of suicide attempts). This study highlights the importance of identifying the
subgroup of people with both SUD and ADHD. Further studies are required to evaluate the effectiveness
of targeted treatments for ADHD within SUD patient populations.
Key messages
ADHD in people with SUDs is approximately fivefold more common than in the general population.
People with ADHD and SUDs are more functionally impaired and have a higher rate of suicide attempts.
Screening for ADHD may be better undertaken after, and not before, detoxification.
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Chapter 11 Detailed analysis of the different
clinical settings: forensic psychiatry – rates of ADHD
in NHS medium-secure forensic units
Methods
Participants
Adult patients participated in the study from both high- and medium-security establishments in the Greater
London area. Three hundred and forty-one mentally disordered offenders, all of whom were detained under
the UKMental Health Act 2007,135 were resident at these two secure services [241 (71%) at the high-secure
service and 100 (29%) at the medium-secure service]. The majority of patients in these settings have a primary
diagnosis of either serious mental illness (SMI; e.g. schizophrenia, schizoaffective disorder, bipolar disorder)
or PD. Exclusion criteria included age > 65 years and those patients who were too mentally unstable to
participate, had severe cognitive deficits due to neurological illness or head injury, posed a risk of violence to the
researcher and/or who lacked capacity to consent to participate in the study. Of the 341 patients, 93 (27.3%)
were identified as ineligible to participate; 68 (20%) did not meet study criteria and a further 25 (7%) were on
trial leave or discharged prior to the assessment. Of the 68 patients who did not meet exclusion criteria, 28
lacked capacity to consent and 40 were mentally unstable. Thus, a total of 248 patients were eligible to take
part in the study. From this sample of 248 patients, a further 115 (46%) patients refused to participate in the
research. Hence, 133 participated in the study [92 (69.2%) from the high-secure psychiatric service and 41
(30.8%) from the regional medium-secure service].
Assessment procedure
The study took place over a 16-month period. An information sheet describing the study and specifying
inclusion and exclusion criteria was sent to clinical teams. Patients meeting these criteria were referred to
the researchers, who subsequently approached the patients to explain the study and obtain informed
consent. Once consent had been given, patients met with a RA to complete screening measures for
ADHD and data were extracted from the clinical records. Four patients in the SMI category consented to
participate in the study and met with researchers, but did not consent for their records to be accessed.
Hence, there were missing data for these participants.
If a patient screened positive on the BAARS-IV scales (self-rated scales for current and retrospective ADHD
symptoms), they were invited to participate in a diagnostic interview. These interviews were administered
by a RA who had received training, including observation of these assessments by qualified staff in a
clinical setting; specific training by qualified and experienced clinicians who routinely administer the
interviews; and practice ratings of recorded clinical interviews to a point of reliability and convergence of
ratings. For patients who were positive on the clinical diagnostic interview for ADHD, an informant
interview was conducted with the patient’s primary nurse to supplement information from the self-report
interview. Once completed, materials for each case were reviewed by a consultant psychiatrist (PA) from
the Maudsley Hospital Adult ADHD service.
Behavioural function
Critical incidents were obtained from clinical records recorded by staff over the previous 12-month period.
The data were grouped based on harmful impact on others: (1) ‘no harm incidents’ including security issues,
verbal aggression and physical injury not requiring treatment or (2) ‘harmful incidents’, classified as any
physical injury requiring further assessment or treatment. There were no critical incidents involving grievous
bodily harm or homicide during the 12-month period. Seclusion data were obtained from clinical records
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recorded by staff over the previous 12-month period and categorised by number of episodes and duration of
time in seclusion.
Results
Comorbid diagnoses
All participants had a DSM-IV primary diagnosis of SMI (n = 81, 60.90%) or PD (n = 52, 39.10%).
Four patients in the SMI category denied us access to records so we were unable to specify their primary
diagnosis, offence history, ethnicity, age, critical incidents, episodes and duration of seclusion. The SMI
category consisted of patients with a primary diagnosis of psychotic (n = 71, 92.21%) or bipolar disorders
(n = 6, 7.79%). The PD category consisted of patients with a primary diagnosis of borderline (n = 24,
46.15%), antisocial (n = 23, 44.23%), schizoid (n = 3, 5.77%), narcissistic (n = 1, 1.92%) or histrionic
(n = 1, 1.92%) PD. In common with all forensic mental health settings, there were high rates of
comorbidity within the sample; however, only six patients had a history of ADHD recorded in their records
(three in the SMI category and three in the PD group), and none had a current diagnosis or was receiving
medication for ADHD at the time.
Age, ethnicity and history of offences
Most SMI patients were male (n = 79, 97.53%), with ethnicity classified as white (n = 39, 50.65%), black
(n = 32, 41.56%), Asian (n = 2, 2.60%) or mixed race (n = 4; 5.19%). In the PD category, all patients were
male (n = 52), with 47 (90.38%) classified as white, two (3.85%) as black, one (1.92%) as Asian and two
(3.85%) as mixed race. Participants were aged between 19.3 and 64.3 years with no significant difference
in age between the SMI (mean 37.10 years, SD 10.69 years) and PD categories (mean 40.26 years, SD
11.19 years) [t(129) = –1.62; p = 0.11]. Nearly all the participants had a history of violence (n = 96, 74.42%)
and/or sexual violence (n = 26, 20.16%). Other offences (n = 7, 5.43%) included arson, burglary and
driving offences.
Prevalence estimates
One hundred and thirty-three patients completed the ADHD child and current screeners (SMI, n = 81;
PD, n = 52). Compared with patients in the SMI group, in the PD group patients had significantly higher
BAARS-IV current total scores [SMI: mean 12.00, SD 9.93; PD: mean 15.92, SD 15.92, t(133) = –2.11; p = 0.04]
and childhood scores [SMI: mean 16.59, SD 13.89; PD: mean 27.41, SD 15.07, t(133) = –2.11; p = 0.00].
Twenty-six patients (19.55%) screened positive for ADHD on the BAARS-IV scales and were offered a
clinical diagnostic interview. Seven (8.64%) patients had a primary diagnosis of SMI and 19 (36.53%) had
a primary diagnosis of PD. Three patients refused further assessment with a clinical diagnostic interview;
thus, 23 of the screen-positive participants completed a DIVA (SMI, n = 6; PD, n = 17). Following the
DIVA assessment, four participants (23.52%) in the PD category showed persistent ‘syndromatic’ ADHD
(one with hyperactive–impulsive type and three with combined type). When applying the more relaxed
‘symptomatic’ criteria, six participants (35.29%) in the PD group had persisting symptoms (three
hyperactive–impulsive type and three combined type). Of the six participants in the SMI category who
screened positive, none met criteria for either ‘syndromatic’ or ‘symptomatic’ ADHD. Hence, subsequent
analysis was conducted on only the PD group.
Self-rated impairments
The forensic patients who met clinical and symptomatic criteria for ADHD (n = 6) and those who screened
positive for ADHD (n = 19) rated themselves as significantly more impaired than forensic psychiatry patients
who screened negative for ADHD, with a large effect size for all items except for money management
(Table 28). Significant positive correlations were also seen between ADHD symptom scores (in adulthood
and childhood) and all domains of self-reported impairment (Table 29).
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Critical incidents and seclusion
Critical incident and seclusion data taken from prison records did not show a significant difference (albeit
we found trend to higher rates in ADHD cases; p = 0.07). This perhaps reflects the serious nature of the
comorbid disorders and behavioural problems, other than those related to ADHD, in this high-risk population
and the small sample of identified ADHD cases. Using the broader category of screen-positive cases, there
was a significant increase in hours spent in seclusion compared with the screen-negative group (see Table 28).
Discussion
We set out to investigate rates of ADHD in mentally disordered offenders and quantify functional outcomes
for these patients in institutional settings. In the SMI group, seven patients scored above threshold on the
ADHD screeners, but none fulfilled criteria for ADHD on further assessment. In the PD group, 19 patients
screened positive for ADHD. Out of 17 screen-positive PD patients interviewed with the DIVA, six were
categorised as having ADHD. This gives an overall estimated prevalence of 8.6% for syndromatic ADHD
and 12.9% for symptomatic ADHD, which is two to four times higher than the DSM-IV rate of ADHD
TABLE 28 Barkley Adult ADHD Rating Scale – IV impairment scores, critical incidents and seclusion data, comparing
PD patients screening negative for ADHD with positive screening ADHD patients and DIVA-positive patients
Item
ADHD-negative screener vs. ADHD-positive screener
ADHD-negative screener vs.
DIVA-positive screener
ADHD-negative
screener
(n= 25–30),
mean (SD)
ADHD-positive
screener
(n= 11–19),
mean (SD)
Mann–Whitney
U-test, z-value
(Cohen’s d)
DIVA-positive
screener (n= 6),
mean (SD)
Mann–Whitney
U-test, z-value
(Cohen’s d)
BAARS-IV impairment scores
Total impairment
score
7.17 (6.07) 17.67 (7.30) –3.62*** (1.6) 20.33 (6.86) –3.16*** (2.0)
Home life 0.36 (0.68) 1.47 (1.23) 3.17*** (1.1) 1.67 (1.37) –2.51* (1.2)
Work 0.60 (0.81) 1.38 (0.81) –3.15*** (1.0) 1.83 (0.41) –3.29*** (1.9)
Social interactions 0.90 (0.66) 1.95 (1.03) –3.55*** (1.2) 2.67 (0.52) –3.86*** (2.9)
Community activities 0.89 (0.92) 2.06 (0.77) –3.68*** (1.4) 2.33 (0.82) –2.91*** (1.7)
Education 1.04 (1.06) 2.11 (1.10) –2.97*** (1.0) 2.50 (0.84) –2.70*** (1.5)
Relationships 0.73 (1.04) 1.75 (1.39) –2.32* (0.8) 2.40 (1.34) –2.37* (1.4)
Money management 0.55 (0.87) 1.26 (1.10) –2.51*** (0.7) 1.33 (1.37) –1.59 (0.7)
Driving 0.24 (0.44) 1.45 (1.29) –2.91*** (1.3) 2.00 (1.23) –3.14*** (1.9)
Leisure activities 0.53 (0.63) 1.74 (1.15) –3.62*** (1.3) 2.33 (0.82) –3.65*** (2.5)
Daily responsibilities 0.53 (0.68) 1.68 (0.89) –4.08*** (1.5) 2.00 (0.63) –3.48*** (2.2)
Critical incidents and seclusions
Total critical incidents 2.36 (3.60) 5.50 (6.56) –1.46 (0.6) 4.83 (5.71) –1.15 (0.5)
‘No harm’ incidents 2.24 (3.55) 5.11 (6.08) –1.55 (0.6) 4.50 (5.61) –1.16 (0.5)
‘Harm’ incidents 0.12 (0.42) 0.39 (0.85) –1.34 (0.4) 0.33 (0.82) –0.63 (0.7)
Episodes of seclusion 0.09 (0.29) 0.72 (1.71) –1.87 (0.5) 1.50 (2.81) –1.81 (0.7)
Hours in seclusion 1.0 (5.22) 106 (348.39) –1.90* (0.4) 305.83 (583.50) –1.81 (0.7)
*p < 0.05, ***p< 0.001.
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(estimated from previous studies to lie in the region of 2.5–4.3% in the adult population97,101,113). Despite
the high level of ADHD in the PD group, none of the patients were recognised as having ADHD at the time
of the research assessments.
The absence of ADHD within the SMI group suggests that there is no particular association among
offenders between ADHD and psychotic disorders, mainly schizophrenia in this sample. This finding
suggests that a detailed diagnostic assessment of ADHD should be able to distinguish between ADHD and
schizophrenia in most cases and that schizophrenia does not usually generate an ADHD-like syndrome. If
this finding generalises to non-forensic psychiatric populations, it increases the likelihood that when ADHD
symptoms and impairments are seen in someone with a history of psychosis, they probably reflect two
independent co-occurring conditions. Further research is needed to clarify this question.
The screening rate of 36.5% for ADHD in the PD group is consistent with previous reports in a PD
population.107 The screening approach applied in this study had moderate sensitivity within the PD group,
whereas it seemed to be less helpful within the SMI population, among which none of the screen-positive
participants met clinical criteria for ADHD.
A second aim of the study was to determine the functional impairment of patients with comorbid ADHD
compared with their non-ADHD-detained peers in a forensic setting. Overall, significantly greater
impairment was reported across all personal, social and occupational domains among the PD and ADHD
TABLE 29 Correlations for the PD patients between screener scores, BAARS-IV impairment data, critical incidents
and seclusion data
BAARS-IV symptoms scales scores
Child (n= 35–48) Adult (n= 36–49)
Total impairment score 0.56*** 0.66***
Home life 0.63*** 0.53***
Work 0.47*** 0.52***
Social interactions 0.55*** 0.57***
Community activities 0.56*** 0.58***
Education 0.50*** 0.45***
Relationships 0.38* 0.61***
Money management 0.47*** 0.33*
Driving 0.65*** 0.47***
Leisure activities 0.47*** 0.62***
Daily responsibilities 0.63*** 0.64***
Critical incidents and seclusions
n= 51 n= 51
Total critical incidents 0.23 0.20
‘No harm’ incidents 0.25 0.19
‘Harm’ incidents 0.26 0.27
Episodes of seclusion 0.14 0.14
Hours in seclusion 0.15 0.15
*p< 0.05, ***p< 0.001.
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group compared with those without ADHD, mostly with large effect sizes. ADHD symptoms, both
childhood and current, were positively correlated with self-rated impairment.
More specifically, significant differences between groups were found for self-rated impairment across
all domains with the exception of money management, which most likely reflects the fact that this
environment provides little opportunity for self-management of financial affairs. For the same reasons,
patients omitted to complete items on the BAARS-IV impairment scales (e.g. many patients did not attend
educational and/or occupational activities). There was wide variation in frequency of incidents, episodes
and hours of seclusion. Nevertheless, there was a trend among the comorbid ADHD and PD patients to
have a higher number of seclusion interventions and to spend more time in seclusion than their peers.
These findings suggest that the staff were more likely to use seclusion to manage PD and ADHD patients
than their non-ADHD peers and that the former require more hours in seclusion once this intervention has
been applied. This may indicate that, once aroused, individuals with ADHD look agitated and take longer
to calm down. This is supported by the finding that level of observed agitation and younger age have
been found to be significant predictors of the use of seclusion on psychiatric wards.136 Further studies are
required to establish whether or not treatment of ADHD in these patients will lead to a change in behaviour
reflected in a reduction of hours in seclusion.
There was no significant difference between groups in critical incident data, nor was there a significant
correlation between ADHD symptoms, incidents and seclusion data. This finding is inconsistent with that
reported previously for offenders detained in mental health and prison settings.20,107,137 The present study
included a high proportion of patients detained in high security (69%) where, due to stringent security
procedures and sanctions, a relatively low base rate of acting out behaviours are found. Furthermore,
it might be the case that for the individuals held within the high-security hospital, other mental health
disorders create a comparable degree of behavioural problems regardless of the underlying diagnosis.
Overall, the current study strengthens our understanding of the comorbidity and behavioural consequence
of ADHD in adult forensic mental health settings. An advantage of the current research is that it was
conducted in a naturalistic setting with patients who have complex presentations and high comorbidity.
Furthermore, objective clinical records were used to obtain functional outcomes and diagnostic status was
established by comprehensive clinical interviews rather than screening measures.
Strengths and weaknesses
The study is limited by its small sample size, which is partly due to the high rate of refusal (46%),
something that is difficult to avoid in the settings investigated. Hence, the sample may be biased as some
patients may have refused to participate in a lengthy clinical assessment (including the completion of
screening questionnaires) because of problems with attention span and other symptoms associated with
ADHD, such as irritability.94 Alternatively, those with ADHD symptoms might have been more interested in
taking part in the study. These considerations might have resulted in a non-representative sample, which
was underpowered to detect some of the impairments, such as critical incidents, in within-group analysis.
A further limitation is that we did not interview those individuals who screened negative for ADHD, so the
specificity of the screening tool in this population remains unknown. Despite these limitations, the use of
the DIVA diagnostic interview gives confidence in the finding of high rates of ADHD in the PD group.
DIVA is designed to establish the presence or absence of each of the 18 DSM-IV symptoms for ADHD
during both childhood and adulthood, in addition to the essential age at onset, situational pervasiveness,
symptom chronicity and impairment criteria. As such, it is expected to give lower prevalence rates than
the use of symptom rating scales alone. A potential limitation is the ability to accurately identify ADHD
symptoms retrospectively when relying on self-report data alone, although in the context of this study this
would lead to more conservative estimates of prevalence. Future studies would benefit from diagnostic
interviews for ADHD in a wider range of patients and further work to improve on effective screening tools
in forensic mental health populations.
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Conclusions
Findings from the current study indicate a high prevalence of undetected and untreated ADHD in
offenders with a primary diagnosis of PD, but not in patients with a diagnosis of SMI. Patients with both
PD and ADHD reported significantly greater functional impairments and spent longer periods in seclusion
than their non-ADHD peers. These individuals have complex needs with high rates of comorbid psychiatric
conditions such as substance misuse and entrenched antisocial attitudes and thinking styles, and specific
interventions are required for their rehabilitation.20,138–142
Key messages
There is a high prevalence of undetected and untreated ADHD in offenders in NHS forensic units with a
primary diagnosis of PD.
Offenders in NHS forensic units have significantly greater functional impairments and have spent longer periods
in seclusion than their non-ADHD peers.
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Chapter 12 Detailed analysis of the different
clinical setting: forensic psychiatry – ASD in prisoners
Background
The prevalence of ASD among prisoners is unknown although a recent study of screening tools reported
ASD to be uncommon in prisons.143 Hence, as so little is known about ASD in prisoners, we first carried
out a search of electronic databases and then carried out a pilot study on rates of ASD and ADHD in
‘vulnerable prisoners’ (VPs) in a local prison (Brixton).
Methods
Step 1: electronic database search
A search of electronic databases (including the Research Autism website, MEDLINE, PsycINFO, EMBASE
and PubMed) identified just four relevant articles that focused specifically on ASD in prisons. One was a
study in Scotland on the evaluation of a screening tool for ASD in prisons;143 another was on knowledge
of ASD among prison staff144 and one reported two case studies of prisoners with Asperger syndrome.145
These papers are included in the review below. The final article was a Swedish study that could not be
obtained in full text.146
Step 2: rates of ASD and ADHD
Having completed the search of available published data (see Step 1: electronic database search), our next
aim was to examine how many adults in a local prison have NDs such as ASD and/or ADHD and to
examine rates of associated ID and mental health problems in these individuals in a local prison (HMP
Brixton, a category C resettlement prison with capacity for up to 798 category C and D prisoners).
The following screening tools were used: ID, Learning Disability Screening Questionnaire; ASD, Autism
Spectrum Quotient; and ADHD, ARSR. Those screening positive were assessed further using the Quick Test
(ID) and the so-called ‘gold standard’ research diagnostic tools for ASD and ADHD [Autism Diagnostic
Observation Schedule – 2nd Edition/ADI-R (for ASD) and DIVA (ADHD)]. All prisoners screening positive for
ID, ASD or ADHD (and all control group participants) were further assessed for mental health diagnoses
using the Mini International Neuropsychiatric Interview, which covers 22 DSM-IV/ICD-10 diagnoses.
Results
Step 1
Literature reports on rates of ASD among prisoners
Given that there are an estimated 86,000 prisoners in the UK,147 it might be expected that up to 1000 of
these individuals have ASD (applying the 1% rate of ASD among the general population). However, there
is little evidence to support or dispute this assumption.148 A review carried out in 2004 found no studies on
the prevalence of ASD among prisoners.78 Since then, one study has attempted to develop a screening tool
for ASD among prisoners but was not able to ascertain prevalence.143 Despite this lack of evidence, it is
commonly hypothesised that people with ASD will be over-represented among offenders in general and
among prisoners.143,149 In fact, although there is evidence that people with ASD are over-represented
among high-security psychiatric settings, it is not at all clear whether or not the same is true among prison
populations.150 In many studies, ASD is included among a range of broad ‘learning difficulties’, but it is rare
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for data on those with ASD to be reported separately. For example, a study of those with an existing
diagnosis of intellectual disabilities or ASD found 19 prisoners in 16 prisons; however, the number of
these individuals who had ASD was not reported.78
Rates of ASD appear to vary according to the type of prison, country/geographical location and, as with
all estimates of prevalence, the way in which ASD is identified. It is generally agreed that there are likely
to be many individuals in prisons who have unrecognised ASD.78,143,144 Recognising and assessing ASD
in prisons78 identified several opportunities for the identification of ASD among prisoners: reception
assessment, routine health-care appointments, education assessments and psychological assessments that
assess suitability for offender programmes. However, these opportunities continue to be missed and there
does not appear to be any policy of routine screening for ASD in UK prisons. A lack of suitable assessment
tools is often cited as a reason for this.78 However, the methods recommended by the NICE guidelines for
autism in adults include the 10-item AQ – a self-rating scale that takes around 2 minutes to complete.53
The AQ has been tested in high-security psychiatric setting but not systematically in prisons.151
A study in Scotland attempted to screen for ASD using a newly developed screening tool completed by
prison officers.143 Of the 2458 prisoners screened, 4% exceeded the cut-off point for ASD. However,
further assessment using other evidence-based tools found that few participants met the criteria for ASD.
The specificity and sensitivity of the new tool were low (< 80%) and its routine use was not recommended.
Literature on difficulties experienced by people with ASD in prison
There are a range of the difficulties that may be expected in prison for individuals who have impairment of
social communication and issues of sensory over- or understimulation.143 These characteristics of ASD may
affect how an individual interacts with others; their responses may appear inappropriate, discourteous or
even confrontational to staff and other prisoners.144 People with ASD may find the prison environment
itself extremely challenging (noisy, brightly lit and enclosed). Potential consequences for people with ASD
include being locked in their cell for longer than other prisoners for their own safety;78 difficulty adjusting
to the transition from community to prison;152 and vulnerability to bullying or exploitation.144,150 Paterson’s
case studies153 of two young prisoners with Asperger syndrome explored the type of problems experienced
by individuals at different levels of the autism spectrum. The participants’ experiences were affected by
the family support they received, comorbid mental health problems, their level of social skills and the
characteristics of their ASD traits.
Literature on prison staff and prisoners with ASD
Evidence suggests that there is of a lack of awareness and knowledge of ASD and ADHD among prison
staff. This does not appear to be restricted to prison officers, but also applies to health and mental
health-care staff. A survey of staff in one UK prison found that 34% did not know what autism was and
51% did not know what Asperger syndrome was.144 Among this sample, which included both officers
and health-care staff, 32% did not know that an individual’s senses could be affected by ASD. Many staff
believe there are prisoners who have unidentified ASD; they also believe that prisons are not an appropriate
environment for these individuals and, furthermore, that prisons are not able to meet their needs.78
Step 2
As of 16 May 2013 we had approached 351 prisoners, and, of these, 221 were screened. Fifty-nine
participants (27%) were housed on the VPs wing. Mean age was 36 years, 41% were white British
(around 50% of prisoners in Brixton are from black and minority ethnic backgrounds) and before coming
into prison 52% were single, 11% homeless, 47% unemployed and 27% reported past or current mental
health problems. Eighty-one prisoners have screened positive for a ND (ASD, n = 39; ADHD, n = 60;
ID, n = 32). For the ND group we aim to have a full data set (follow-up diagnostic assessment and the
Mini International Neuropsychiatric Interview) on 70 participants. Currently this stands at 60 participants,
with eight being followed up.
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Overlap of neurodevelopmental disorders and demographic characteristics of prisoners
screening positive
Intellectual disabilities
Of those screening positive for ID (n = 32), 75% screened positive for ADHD, 47% positive for ASD and
84% screened positive for either ASD or ADHD. Sixteen (50%) were held on the VP wing, 77% were
white, 72% single, 36% homeless before prison and 91% unemployed.
ASD
Of those screening positive for ASD (n = 39), 59% screened positive for ADHD, 38% positive for ID and
67% screened positive for either ASD or ADHD. Eighteen (46%) were held on the VP wing, 75% were
white, 62% single, 16% homeless before prison and 75% unemployed.
ADHD
Of those screening positive for ADHD (n = 60), 40% screened positive for ID, 38% positive for ASD and
58% screened positive for either ASD or ADHD. Twenty three (38%) were held on the VP wing, 80%
were white, 61% single, 18% homeless before prison and 72% unemployed.
Those screened who met research diagnostic criteria
In total, 57 participants (70% of those screening positive for ND) met diagnostic criteria for ASD, ADHD or
ID. Of the 39 participants who screened positive for ASD, 12 (31%) met diagnostic criteria and of the
60 participants who screened positive for ADHD, 46 (77%) met diagnostic criteria.
Comorbidity
Our preliminary analysis suggests that adult prisoners with ASD and/or ADHD have extremely high rates of
associated mental health symptoms (Table 30).
Discussion
The available literature suggests that a considerable proportion of prisoners may have ASD (or ADHD). Our
findings support the suggestion that many so-called ‘vulnerable’ prisoners have a ND – including ASD and/or
ADHD – and of these nearly all have associated mental health symptoms. However, in most individuals, this
had not been diagnosed or treated. Our initial results also suggest that those with a ND are significantly
younger, more likely to be white, homeless and unemployed than participants without a ND. Furthermore,
our findings challenge predicted current rates of ASD in prisons (of 1%). However, the rates may differ by
level of security (category) or diversion system. Nevertheless, our results suggest that we need to improve the
recognition and treatment assessment of NDs, such as ASD and ADHD, across the Criminal Justice System.
TABLE 30 Comorbidity between ASD and/or ADHD and associated mental health symptoms
ND
Associated symptom (%)
Past or
current major
depressive
episode
Current
MDE
Social
phobia OCD PTSD
Alcohol
dependence
Drug
dependence
Antisocial
PD
Psychotic
disorder
ADHD 81 46 39 13 19 24 32 68 6
ID 71 41 41 13 6 24 20 40 0
ASD 88 47 44 19 12 19 14 56 0
MDE, major depressive episode; PTSD, post-traumatic stress disorder.
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Unfortunately, however, there is currently a lack of access to specialist services and interventions for prisoners
diagnosed with ASD and/or ADHD. Furthermore, existing mainstream programmes are not being adapted to
meet their needs, with many individuals deemed ineligible because of their developmental and behavioural
problems. Indeed, research on and the provision of mental health care in prisons tends to focus on those
with a SMI.
Our work also suggests that there should be no room for therapeutic nihilism in treating ASD and/or
ADHD in prisons – and prisoners with ASD and/or ADHD should not be denied treatments offered to
others. For instance, psychosocial interventions, as described in relevant NICE guidelines,53,95 are suitable
for people with ASD and ADHD, but these are not currently being explored to them within prison settings.
This is also true for interventions such as Improving Access to Psychological Therapies services and/or
guided self-help critical time intervention. Missed opportunities for the assessment of ASD and ADHD
(and a failure to acknowledge their extent) hinder the ability of prisons to provide adequate care for
affected individuals.145 The development of provision for this unrecognised group of prisoners with lifelong
disabilities requires a coherent approach to planning of health care in prison to improve their long-term
health and social outcomes. These issues are further compounded by the current lack of evidence on which
to base the development of assessment and intervention services. Our results also suggest that multiagency
work across the Ministry of Justice/National Offenders Management Service, Department of Health and
Social Care, research organisations and voluntary sectors is required to (1) improve staff knowledge and
awareness of ASD and ADHD through training, (2) develop evidence-based screening tools and (3) test the
effectiveness of treatments. Unfortunately, however, treatment trials in prisons are difficult to run and to
our best knowledge none has been carried out in (either) ASD or ADHD. Hence, as a next step we obtained
proof of concept that trials for these disorders can be carried out in prison settings. This issue is addressed in
Chapter 21.
Key messages
ASD and ADHD are common in VPs, but are mostly unrecognised.
Prisoners with ASD or ADHD have very high levels of unrecognised additional mental health problems.
Multiagency work may help:
l improve forensic mental health and prison staff knowledge and awareness of ASD and ADHD
through training
l develop evidence-based screening tools for use in prisons.
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Chapter 13 The economic cost of ASD and ADHD
during the ‘transition’
Background
In the previous sections, we reported on the burden of ASD and ADHD as individuals transition from
adolescence into adulthood. We have investigated the impact on the affected individual and their carers;
and the rates that individuals with these disorders (and their associated mental health symptoms) were
identified and treated by clinical services in the community, in hospitals and in forensic/prison settings.
In brief, we found that, as they ‘transition’ into late adolescence and adulthood, most of the needs of
people with ASD/ADHD are met by their families (and not services). In addition, the burden on carers is
significantly increased by the presence of additional mental health symptoms in their offspring. We also
found that most individuals with ASD and/or ADHD in this age group are not in contact with clinical
services; an,d even if they are, it is unlikely that they (and their associated mental health symptoms) are
recognised or treated.
Given the need to use scarce (health-care) resources wisely, economics adds an important dimension to
these findings, that of cost. In particular, and in the knowledge that adolescence and transition to adult
services is often accompanied by reductions in support and treatment (as described above), our aim was
to identify both the costs of supporting young adults with ADHD or ASD and what might drive those costs.
Our reviews of the cost-related research literature pertaining to the support of young adults with ADHD
and ASD found little cost-related evidence either before this research programme started or over its
duration. Most of the existing studies come from the USA and simply examined the ‘cost of illness’ –
focusing on the costs of supporting children and young people with ADHD or ASD. Commonly, they used
billing databases or management information systems. Although there are lessons to be taken from such
studies, the very different health-care organisational and financing systems make it difficult to transfer
detailed findings between countries. In addition, the commonly used (narrow) focus on health care does
not allow estimates of the wider costs associated with the many areas where ADHD or ASD might be
expected to have an impact.
For instance, little is known about impacts (in either the USA or the UK) that are likely to be felt across
public sector health and social care services, youth and criminal justice services, the welfare benefits system
and/or family health and expenditure. Furthermore, as the young adult grows older, wider impacts are
likely to be seen, such as reduced employment prospects, lost productivity and problems with family and
other relationships, which in turn may generate needs for support.154
Other types of economic evaluation – such as cost-effectiveness studies – are very rarely found in child and
adolescent psychiatry, with only 14 economic evaluations that used primary data published since 2001
across this whole field (Beecham J, University of Kent; 2013). None of the prior studies investigated young
people at the point of transition to adult services and adulthood. Nonetheless, reviews of prior research
on medication in child psychiatry155,156 found some evidence to support the cost-effectiveness of ADHD
medication, albeit with concerns about the use of narrow cost and outcome measures, small sample sizes
and short time frames. By contrast there are no evaluations assessing the relative cost-effectiveness of
pharmacological interventions for individuals with ASD at any age, although there is some preliminary
evidence suggesting that early intervention applied behavioural analysis programmes are effective in very
young childhood157 and may reduce public sector costs.158
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Our main aim therefore was to estimate the costs of support for young adults at the point of transition
who have ADHD or ASD, and who were identified and treated for these conditions in childhood. The
questions that we addressed were the same for both patient groups:
l What health care and other services do these young adults now use?
l What are the associated costs to health care and other organisations of supporting these young adults?
l Do these costs change as young people age?
l Do support costs change as a consequence of transition to adult services and can reductions in any
particular cost domain (particular services or organisations) be identified?
l Is a young person’s transition to adult services linked to a change in the costs of treatment and support
over and above the loss of support they received while within school?
l To what extent do the young adults’ parents use services because of their child’s difficulties?
l Over and above age, what are the associations between cost and the young person’s characteristics,
needs and family circumstances?
Methods
These analyses are linked to the longer-term follow-up of children discussed previously (see Section 1).
To ensure we could add to the small body of evidence on the ‘what is’ scenario provided by the cost of
illness studies, we developed a project-specific version of the CSRI159 to be used in the data collection
interviews. Used in countless cost-related evaluations, this schedule allows data to be recorded across
all domains of support requirements: health and social care services, education and employment status,
youth/criminal justice services, etc. The CSRI uses a structured approach that retains sufficient flexibility
to ensure that questions about use of services and supports are tailored to the participants’ circumstances.
A major focus for these analyses was on (mental) health care, but the CSRI included questions about a
range of other supports and services so a comprehensive view could be obtained of service responses in
all the areas where ADHD or ASD many have an impact.
To convert the service use data into costs, unit costs for each type of service, treatment or support are
required. These were drawn from publicly available sources such as the annual Personal Social Services
Research Unit volume of nationally applicable costs160 and the NHS reference costs,161 as well as being
estimated specifically for this research using an equivalent methodology (see, for example, Beecham162).
Total costs of support were calculated by multiplying the frequency of use of each service by its unit cost.
The comprehensive approach to service use has the advantage of allowing costs data to be described
and analysed both as a total and in disaggregated form, highlighting the contribution of each agency
(e.g. the NHS, or local education authorities) to total support costs. Once costs per person have been
calculated over a retrospective period of 3 months, they would be explored using descriptive, bivariate
and multivariate analyses to address the research questions set out above.
Results
ADHD and transition
Our analyses were based on the follow-up interviews with young people aged 14–24 years and their
parents/partners who were recruited from the IMAGE research database through a childhood clinical
diagnoses of ADHD. Participants were included if they provided CSRI data at either wave 1 (n = 86) or
wave 2 (n = 79): 66 participants provided data at both waves. Data were also available from the CANDID,
the DIVA, the ADHD-specific BAARS-IV rating scale, the DAWBA, the CIS-R, the Zarit Burden Interview and
the AUDIT.
Additional questions, developed in the Social Policy Research Unit at the University of York, asked about
participants’ experiences of transition processes.163
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Our participants were aged, on average, 17 years; most were male and more than half were in full-time
education, although this figure had reduced by the wave 2 interviews (Table 31). Most remained living
with their parents and, at wave 1, 43% were taking ADHD medication. The young adults used a wide
variety of services, but, in most cases, few people used any one particular service.
The most common source of support in both waves was GPs, both for ADHD-specific problems (23% in
wave 1 and 15% in wave 2) and for other reasons (33% in both waves). Many participants had repeat
prescriptions (52% in wave 1 and 44% in wave 2). Use of specialist mental health services was sparse,
with the exception of psychiatrists in wave 1 (26%), but this had dropped to 15% of the sample by the
wave 2 interviews. In addition to these formal services, websites and helplines appear to play a fairly
important role in supporting young adults, with 19% in wave 1 and 13% in wave 2 reporting their use
in the 3 months prior to the interview.
The costs associated with service use and additional education supports (i.e. excluding the costs of
mainstream education) are shown in Table 32. In both waves, education was the highest contributor to
total costs, accounting for 46% at wave 1 and 34% at wave 2. Mental health services accounted for just
15% and 13% of costs, respectively. Although the average cost of primary care was similar in both waves,
the proportion it contributed to total costs was 16% in wave 2 compared with just 8% in wave 1. There
was a statistically significant reduction in total costs from wave 1 to wave 2 (£665 vs. £390), with
significant differences in the costs (subtotals) for hospital and for mental health-care services. Costs for
advice services and self-help supports were similar at each wave.
Our analyses of these data will explore what individual characteristics and needs are associated with these
costs at each wave and across both waves. We will also look in more detail at the group of young adults
who have transferred from children to adult services (n = 18) over the period; those who do and who do
not (n = 13, £0) receive any support; and those who do or do not use specialist mental health services.
These analyses will help address the questions identified in Background.
TABLE 31 Characteristics of the young adults with ADHD
Wave 1 (N= 86), mean (SD) Wave 2 (N= 79), mean (SD)
Age (years) 17.4 (2.27) 18.7 (2.45)
IQ 101.9 (15.44)
BAARS-IV checklist (sum) 4.2 (2.76) 3.7 (2.79)
Mood rating last month 17.4 (10.07) 13.2 (8.6)
Total number of needs (CANDID) 2.9 (2.4) 3.2 (2.92)
Total Zarit Burden Interview score 17.9 (9.28) 2.4 (2.80)
Male (n) 76 60
In full-time education (n) 48 33
Has a job (n) 30 34
Ethnicity white (n) 82 65
Marital status single (n) 80 70
Living with parents (n) 83 72
Drug use (n) 37 25
Medication use (n) 37 28
In trouble with police past year (n) 19 7
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ASD and transition
Young people aged 14–24 years with a diagnosis of ASD were recruited from CAMHS and adult clinics in
south London, voluntary organisations and research databases held at the IoP through their child’s childhood
clinical diagnosis of ASD. Data for 81 participants were available. As well as the CSRI, data were collected on
the CANDID, the AQ – Informant version, the DAWBA, the AUDIT and the Zarit Burden Interview.
The majority of participants were male and white British (85% each). At wave 1, ages ranged from 14 to
25 years, with an average of 17.9 years. Most participants had an International Classification of Diseases
(ICD) diagnosis (94%), with > 90% diagnosed as on the autistic spectrum (autism, Asperger syndrome).
On average, parents reported needs in nine of the CANDID domains, six of which parents considered to
be met needs.
Fifty six (69%) of these young adults were still in full-time education, with a further six in part-time
education (Table 33). Two-thirds had a statement of SEN. Additional support in school was common in
both waves 1 and 2, with around one in three young adults receiving individual help in class, some lessons
taught in smaller classes, support from the special educational needs co-ordinator, or additional meetings
with teachers.
The most commonly used service was the GP, seen by 36% of the sample in wave 1 and 35% in wave 2,
although by just 9% in each wave for ASD-related reasons. Repeat prescriptions were made for nearly half
the sample at both waves (47% and 46%, respectively). Use of mental health care was similar to the
proportion found among the ADHD sample: < 5% of participants used ASD-specific outpatient clinics,
therapists or counsellors; 27% had seen a psychiatrist (17% in wave 2); 17% had seen a psychologist
(10%); and 6% (2%) had seen a psychiatric nurse specialist. Fewer than 5% of the young adults used
community-based therapy services such as occupational or speech and language therapists, but social
workers were seen by 16% of participants and 21% had a keyworker.
The costs of support over 3 months are shown in Table 34; nearly half of total costs are absorbed by
additional supports provided by the education authorities with higher costs due to attendance at special
needs schools. A further one-fifth was accounted for by provision of social care services; higher costs here
are for one young adult spending time in a residential care unit and three who used respite care services.
Mental health services contributed just 5% to total costs in wave 1 and only slightly less in wave 2 (4%).
TABLE 32 Support costs for young adults with ADHD
Service category
Wave 1 (n= 86) Wave 2 (n= 79)
Average cost (£) (SD) Range (£) Average cost (£) (SD) Range (£)
Education 303 (1199) 0–10,207 133 (426) 0–2720
Hospitala 141 (347) 0–2132 56 (153) 0–755
Primary care 55 (55) 0–219 63 (67) 0–263
Mental healtha 103 (183) 0–945 50 (152) 0–823
Social work 10 (45) 0–344 44 (244) 0–1558
Community therapy 7 (55) 0–504 2 (11) 0–84
Advice services 14 (40) 0–228 16 (73) 0–587
Other services 32 (81) 0–452 26 (66) 0–270
Total costsa 665 (1283) 0–10,564 390 (594) 0–2907
a Significant difference in average cost between wave 1 and wave 2.
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Total average costs were lower in wave 2 than in wave 1 (£4557 vs. £2919), although there was a wide
range of costs at both periods; for a number of young adults, total costs were £0 indicating no services or
support were used. Mean costs for additional education, hospital services and social work/social care all
were lower in wave 2, although again showing wide ranges for each. The only significant difference
between wave 1 and wave 2 is mental health service costs (p = 0.02).
As with the ADHD sample, our analyses of these data will explore what individual characteristics and needs
are associated with these costs at each wave and across both waves. We will also look in more detail at
the group of young adults who have transferred from children to adult services over the period, those who
do and who do not receive any support, and those who do or do not use specialist mental health services.
These analyses will help address the questions identified in the earlier section (see Background).
TABLE 33 Use of additional support in school by young adults with ASD
Additional education support
Wave 1 Wave 2
n using service (%) n using service (%)
Individual tuition 8 (10) 5 (6)
Individual help in classes 31 (38) 25 (31)
Lessons in small classes 24 (30) 23 (28)
School nurse 6 (7) 7 (9)
Educational psychologist 7 (9) 3 (4)
Educational welfare officer 0 (0) 1 (1)
SENCO 30 (37) 21 (26)
Additional meetings with teacher 30 (37) 24 (30)
Connexions 1 (1) 2 (2)
SEN worker 1 (1) 0 (0)
Learning support assistant 1 (1) 1 (1)
SEN, special educational needs; SENCO, special educational needs co-ordinator.
TABLE 34 Costs of supporting young adults with ASD
Wave 1 Wave 2
Average cost (£) (SD) Range (£) Average cost (£) (SD) Range (£)
Additional education 2722 (5920) 0–45,511 1782 (3384) 0–20,657
Hospital services 583 (4145) 0–37,326 126 (397) 0–2946
Primary care 86 (105) 0–482 74 (90) 0–407
Mental health services 239 (531) 0–3761 130 (320) 0–2101
Social work and social care 838 (2408) 0–11,340 660 (2027) 0–11,492
Community therapy 18 (85) 0–672 58 (247) 0–1416
Advice/self-help 46 (177) 0–1440 72 (279) 0–1440
Other 26 (69) 0–339 17 (54) 0–226
Total costs 4557 (8117) 0–48,042 2919 (4231) 0–20,657
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Discussion
We carried out the first longitudinal study of the cost of ASD and ADHD as young people with ‘transition’
through adolescence and into young adulthood; and taking into account a wide range of potential service
consumption (including health, education and social services). We found that, overall, mean costs for both
disorders were mainly borne by education and social care agencies – with much less accounted for by
health. In addition, in both groups, mental health supports accounted for a relatively small proportion of the
total costs. Finally, as individuals with ADHD and ASD grew older, they continued to consume services, but
costs of education, hospital services and social work/social care all reduced for both disorder groups; and for
both disorders mental health service costs reduced significantly. The latter finding suggests that although
(as noted in prior chapters) individuals with ASD and ADHD continue to experience significant mental health
symptoms as they ‘transition’, their contact with treatment and support services reduces significantly.
Few other studies published over the period of our research programme focused on, or separately identified,
the age group we investigated (16–25 years). One US analysis showed the distribution of ADHD-related
treatment costs by age and found that, for males, > 90% were incurred for children up to age 15 years,
5% between ages 15 and 25 years and < 2% in young adults aged > 25 years.164 Given that two-thirds of
childhood ADHD cases persist into adulthood,101 this means that treatment drop-off among young adults
remains high, particularly as children transition out of children’s services (see also Young and colleagues165 and
Singh166). However, a recent review of the US literature on the cost of illness related to ADHD suggests that its
economic impact is around three times greater among affected adults than children and adolescents.167
For the UK, one recent study estimated the costs of health care (NHS), social care and education resources
associated with ADHD for a cohort of 143 young people aged between 12 and 18 years taking part in the
Cardiff Longitudinal ADHD Study, 5 years after their initial diagnosis.168 Over a 12-month period, average
costs were £5493 (median = £2330, 2010 prices), with estimated total costs for the UK of £670M. Snell
and colleagues,169 in their analysis of the British Child and Adolescent Mental Health Survey, found
observed mean costs for those with hyperkinetic disorders age 5–15 years to be lower, at £3108 per
annum. As with the Welsh study, this excluded any costs associated with the criminal justice system and
family-borne costs. Just two US studies of childhood ADHD have considered costs to the education sector,
and only one included youth justice costs.170 Notably, children and adolescents with ADHD tend to incur
higher medical care costs than their peers without ADHD,171,172 as well as greater other public sector costs
and out-of-pocket expenses.173 Additional problems may include other psychiatric disorders, substance
misuse, educational underachievement, difficulties with employment and relationships, and criminality.134
Each of these can lead to additional costs in (young) adulthood to the (mental) health and social care
budgets, welfare payments, as well as in lost productivity.
The economic literature on young adults with ASD is even sparser than that for ADHD. One recent study
attempting to estimate the costs of ASD in the UK found no nationally representative samples of children
or adults with ASD from which costs could be estimated.1,174 Costs were estimated for children (aged
0–17 years) and adults (aged ≥ 18 years) using a mixture of prevalence data, analysis of the Children in
Need surveys175 and by extracting data on individuals with ASD from ‘in-house’ studies of service use and
costs, or from large population psychiatric morbidity surveys. Although the analysis usefully identifies
resource use and cost differences between those with ID (higher costs) and those with high-functioning
ASD, the data were insufficient to disaggregate the costs in adulthood into different age groups. Only
costs attributable to ASD were included and covered all public sector services used by those with ASD and
their families, as well as out-of-pocket payments for services, family expenditure and lost employment
costs. Informal care time was excluded owing to lack of data. The average annual cost per child with ASD
was estimated at £25,400 per person and was £58,900 per adult (2005–6 prices).
Apart from one study based in Sweden,176 we have found no European studies and only one US study177
that estimated the full cost of supporting people with ASD. Ganz177 drew on the published literature on
use of services by children with ASD, to create a US prevalence-based cohort from which lifetime costs
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were calculated. The costs included all hospital and health-care services and equipment, child care, adult
care, respite care, home care and modifications, special education and supported employment (2003
prices, discounted to present value at 3%). The average age-specific per capita costs were (1) ages
13–17 years, US$285,082, (2) ages 18–22 years, US$248,446 and (3) ages 23–37 years, US$404,260.
As with ADHD, recent studies (mainly from the USA) have also found higher health-care costs for ASD than
for other diagnoses,178 or for children without ASD.179–181 In the 2003–4 US National Survey of Children’s
Health, parents of children with autism reported a significantly higher number of visits to all types of
physicians than did parents of children without autism.182 There is, however, evidence of a fall in the level of
support young people with ASD get once they leave school and should be supported by adult services.163,166,183
Thus, the body of evidence examining the costs of treatment and support for adolescents and young
adults with ADHD or ASD is small, often derived from less than ideal data and assumptions, and many
have a narrow focus on treatment (medication) or health care. Moreover, much of the literature is USA
based, where there are very different organisational and financial incentives at play. None of the existing
studies follow participants over the transition period, despite long-standing UK policy concerns such as the
National Service Frameworks for Children Young People and Maternity Services and for Mental Health,184,185
which specifically identified the importance of a planned and co-ordinated transition to adult services.
Although there is evidence to suggest that the transition to adult services for individuals with a range of
disabilities and health conditions is associated with reduced levels of support in England and Wales, the
published studies do not allow a full picture to be drawn of the intensity of support that adolescents with
ADHD or ASD receive, in which services the reductions in support occur pre or post transition, nor which
supports are used more commonly in young adulthood.
The current study can, therefore, inform the evidence base in a number of ways. Our study can clearly
show which services are and are not used, by what proportion of this population and by what age groups.
Although not all the details are reported here, as well as data on the use of health and social care, we
have data on specific education inputs and on young people’s involvement with youth and criminal justice
services. The former are more likely to be important for individuals with ASD and the latter for those with
ADHD, but both are sadly lacking in existing UK studies. One additional set of data may prove equally
revealing: the extent to which parents use services as a result of their child’s condition, for example
whether or not perceived carer burden translates into obtaining help for themselves from formal services.
The individual-level support costs can be calculated from these data on each individual’s use of treatment
and support services. In turn, these data enable us to identify which service providers bear the brunt of
responding to young people’s needs and how these might change as the adolescents grow older.
However, we also know very little about what drives treatment and support costs. Is it individuals with
greater condition-related symptoms and severity who receive and continue to receive support (as
summarised by costs)? Or is it their wider (met or unmet) needs? Or are there wider factors at play,
perhaps parental backgrounds or carer burden, leading to request additional support for their child? Or is
the level of treatment and support purely a matter of location – or chance? Addressing questions such as
these will add substantially to the evidence available to decision-makers and providers alike.
Key messages
The cost of ASD and ADHD is mainly borne by families, education and special care agencies.
Relatively low costs are borne by the NHS and especially low costs for mental health support.
Treatment and support costs reduce significantly with age – despite persistence of clinical symptoms.
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Section 3 Improving outcomes through better
diagnosis
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Chapter 14 An overview
In the previous two sections we saw that ASD and ADHD (and their associated mental health symptoms)are frequently unrecognised and untreated both in the community by GPs and by the specialist mental
health services we investigated. In addition, during the course of this programme, dramatic changes
occurred in recommendations for clinical diagnostic practice of ASD in DSM-V. These required urgent
clarification due to their potential impact on clinical services – as the effect of this change in young adults
was undetermined. Furthermore, breakthroughs were made in brain image analysis, but it was unknown if
these could be used to help categorise individuals with and without ASD or ADHD.
In this next section as a first step we:
l piloted the development of simple/accurate clinical diagnostic interviews for ASD that can be used in
community settings
l developed a tool to aid identification of associated mental health symptoms
l investigated the effect changes in DSM-V clinical diagnostic criteria would have in young adults with
ASD; and carried out a proof of concept study on the potential utility of brain imaging to help
categorise individuals with and without ASD/ADHD.
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Chapter 15 Improving diagnosis of ASD in the
community: tool development
Background
The NICE guidance highlights the increasing need for diagnostic services for children and young people
with ASD in the UK.186 It recommends that every autism diagnostic assessment includes ‘a developmental
history, focusing on developmental and behavioural features consistent with ICD-10 or DSM-IV criteria’ using
an ‘autism-specific tool’.186 Currently the best-established diagnostic tools for collecting an autism-specific
diagnostic history are the ADI-R; the Diagnostic Interview for Social Communication Disorders; and the
Developmental, Dimensional and Diagnostic Interview. These semistructured interviews are carried out by
highly trained clinical interviewers and take 2–3 hours to complete. Many community services have struggled
to adopt these instruments as part of the diagnostic protocol because of the level of expertise required, the
absence of trained staff and the time- and labour-intensive nature of the interview. Instead, they have
continued to rely on ‘routine clinical interview’, despite the low inter-rater reliability for clinical subtyping187,188
of this approach.
Hence there is a need for a simpler approach to diagnosis in community settings. Accordingly, we
examined the utility of the DAWBA as a diagnostic tool. We chose to pilot the adaption of the DAWBA
because it is an assessment tool that can be completed by the parent online, over the telephone or at
face-to-face interview with an interviewer. In addition, interviewers need minimal training and this can be
done by reviewing information and training materials provided online (URL: www.dawba.info).
The DAWBA has been designed to collect information sufficient to make various psychiatric diagnoses
according to ICD and Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. The pervasive
developmental disorders (PDDs) module, entitled ‘development of language, routines, play, and social
ability’ in the parent interview, gathers information required to diagnose ASDs.
Information from the PDD module is used in a computer algorithm to generate a probability of disorder
according to DSM and ICD criteria, ranging from < 0.1% to > 70% probability of meeting diagnostic
criteria for ASD. The DAWBA is relatively quick to complete compared with the ADI-R. For instance, the
PDD module takes about 20 minutes to complete and data entry is streamlined by online administration.
In addition, data entered online, along with the computer-generated probability, diagnosis and comments
made by the clinical rater, can be printed out in portable document format (PDF) for each case.
The overall aim of this pilot study, therefore, was to examine the effectiveness of the PDD module of the
DAWBA in identifying ASD in a community sample. Specific aims were to (1) compare the DAWBA with
the ADI-R as measures of autistic symptoms, (2) establish the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) for DAWBA diagnosis assigned by clinical rater and (3) examine
the improvement in detection of ASD by combining the DAWBA with an observational tool called the
Autism Diagnostic Observation Schedule – Generic (ADOS-G).
Methods
We examined the diagnostic utility of the DAWBA in a population-based sample of 169 twins, who were
screened to be at high or low risk for ASD. The sample was drawn from a large community-based twin
sample, the Twins Early Development Study (TEDS), which has been described in detail elsewhere.189
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This sample was utilised for a number of reasons. It was important to gain a sample of children and
adolescents with ASD who represented the full range of presentations of ASD. Samples ascertained from
clinics may be biased in various ways (e.g. children seen in tertiary or quaternary referral clinics are likely to
have more complex problems). Using a population-derived sample minimises these types of biases, while
also allowing the inclusion of those with subtle difficulties which had not previously been identified as ASD.
Children in TEDS were screened and assessed at multiple time points from age 2 years until adolescence,
maximising the chances of detecting all cases of ASD in the cohort. There is no evidence that the manifestation
of ASD is different in twins and singletons.190 The study was reviewed and approved by the Joint Schools
Research Ethics Sub-Committee for the IoP and the Florence Nightingale School of Nursing and Midwifery,
King’s College London. Parents of twins born from 1994 to 1996 in England and Wales were invited
to participate in TEDS and the resulting sample is representative of the UK in terms of maternal ethnicity
(93.5% white) and education (37.9% with A levels or higher, the equivalent of some college education
in the USA).
Selection and diagnostic assessment of ASD sample
Screening for ASD was carried out using the Social Communication Questionnaire (SCQ),191 the Childhood
Autism Spectrum Test (CAST)192 and additional questions about whether or not children had previously
been given an autism or Asperger syndrome diagnosis. In addition, some families also spontaneously
disclosed that one or both of their children was suspected of having ASD during data collection unrelated
to ASD. Data were collected via questionnaires mailed to parents when their children were aged 5–8 years
(SCQ), 8 years (CAST) and 9 years (questions about previous ASD diagnosis), and via telephone interview
when children were aged 7 years (questions about ASD diagnosis). A total of 14,797 families were invited
to complete questionnaires or a telephone interview and 8941 (60.4%) returned data at least once. This
sample was broadly representative of the UK population and of the TEDS cohort as a whole (maternal
ethnicity, 93.2% white; maternal education, 40.1% with A levels or higher).
Children were considered to be at risk of ASD if they met any of the following criteria:
l They scored ≥ 15 on the SCQ.
l They scored ≥ 15 on the CAST.
l Their parents had endorsed questionnaire items at ages 7, 8 or 9 years indicating that their child had
been given a diagnosis of ASD.
l Their parents had spontaneously indicated at other times that they were concerned that their child
might have ASD. Families where one or both children were considered to be at risk of ASD were then
invited to complete the ASD module of the DAWBA.
Families were then visited at home for further assessment. The ADI-R and the ADOS-G were carried out by
trained interviewers. Two interviewers assessed each family. One interviewer carried out the ADI-R for the
first twin, while the other interviewer carried out the ADOS-G. The interviewers then reversed roles for the
second twin so that the same interviewer did not carry out the ADI-R and the ADOS-G for the same child
and did not carry out either for both twins in a pair. A consensus diagnosis was assigned by the study
team after reviewing ADI-R and ADOS-G data and other relevant data, such as parent reports of previous
clinical diagnosis. Children were classified as ASD (i.e. met criteria for childhood autism, Asperger
syndrome, ‘other’ PDD) or unaffected. One hundred and twelve children with a diagnosis of ASD were
included in analyses (child sex, 83.0% male; maternal ethnicity, 96.4% white; maternal education, 50.4%
with A levels or higher).
Selection of comparison sample
The ‘at-risk’ sample consisted of children likely to have ASD and their co-twins, which included unaffected
co-twins. However, as unaffected co-twins were expected to be at higher risk of subthreshold autistic
traits,193 parents of twins considered to be low risk (score of < 12 on the CAST) were invited to complete
the DAWBA. These families were selected to be matched to the ‘at-risk’ group on sex, zygosity, age and
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socioeconomic status. Home visits were carried out with the families, during which parents completed the
family history interview and children were administered a battery of cognitive measures. Researchers also
completed an observation sheet for each child, which included observations about the child’s social
interaction with the researcher. Suspicion about ASD was raised for only one child in the control sample
and an ADI-R was completed with their mother. No further data were available for this child and so they
were excluded from analyses in which a consensus diagnosis was required.
Non-cases included 101 children who were unaffected co-twins of children with ASD and a further
68 children from the low-risk group. For analyses using ADI-R or ADOS-G data, non-cases included
unaffected co-twins (n = 101; child sex, 52.5% male; maternal ethnicity, 96.0% white; maternal
education, 52.0% with A levels or higher). For analyses using consensus diagnosis data, non-cases
included unaffected co-twins and low-risk twins (n = 169; child sex, 60.4% male; maternal ethnicity,
96.4% white; maternal education, 53.0% with A levels or higher).
Measures
Tools used to screen for and identify cases
Social Communication Questionnaire
The SCQ is a 40-item screening questionnaire that is completed by parents of children who are 4 years of
age or older. The content parallels that of the ADI-R and the SCQ has shown to be an effective way of
screening for PDDs.194 Parents who indicated that their child had social or communication difficulties
during data collection when children were aged 2–4 years were asked to complete the SCQ. A score of
≥ 15 was taken to indicate risk of ASD.
Childhood Autism Spectrum Test
The CAST195 is a 31-item questionnaire that is completed by parents. It was designed to be used in
mainstream, non-clinical samples to screen for ASD in primary school-aged children. All parents were
asked to complete the CAST when their children were 8 years of age. A score of ≥ 15 was taken to
indicate risk of ASD.
Autism Diagnostic Interview – Revised
The ADI-R is an extended semistructured interview designed to elicit sufficient information about
developmental history and current day-to-day behaviour to enable diagnosis of ASDs.196 A trained
interviewer carries out the interview with an informant, typically a parent, and the interview takes around
90–150 minutes to complete. A modified diagnostic algorithm based on criteria outlined by the Autism
Genetic Resource Exchange was used (URL: http://research.agre.org/program/diag.cfm), which, in addition
to the cut-off point for autism, had further cut-off points not quite autism and broad spectrum. Interviews
were recorded and consensus coded by the study team: an experienced child psychiatrist (PB) reviewed a
subset of cases, including ambiguous cases. A total algorithm score was generated by summing the scores
from algorithm items (excluding domain D), giving a quantitative measure of autistic symptoms.
Autism Diagnostic Observation Schedule – Generic
The ADOS-G is a semistructured assessment that provides opportunities to observe social and communication
behaviours relevant to diagnosis of ASDs.197 A trained assessor administers a series of structured and
semistructured tasks and interview questions to elicit a range of responses. It takes around 30–60 minutes to
administer. Modified diagnostic algorithms were used198 and children were classified as meeting criteria for
autism or ASD. A further category, broad spectrum, was defined as being up to 2 points below the cut-off
point for ASD. Assessments were videotaped and consensus coded by the study team: an experienced child
psychiatrist (PB) reviewed a subset of cases, including ambiguous cases.
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Tools used in protocol to be validated
Development and Well-Being Assessment
The module of the DAWBA designed to assess PDDs was administered by telephone interview or
completed online. Skip rules, an option available to shorten the interview if the answers to preliminary
questions do not indicate ASD, were not used, meaning that parents were asked all questions. Probability
bands were generated by computer algorithm, which placed children in one of six bands that ranged from
< 0.1% to > 70% probability of having a diagnosis of ASD. An experienced clinician (PB) rated each child,
using the probability band, the Social Aptitudes Scale (a measure of current social functioning which is
included in the PDD module of the DAWBA)199 score, and the answers to open-ended questions to assign
a diagnosis of autism, Asperger syndrome, or other PDD. Rating was carried out blind to diagnostic status
and other information gathered during the study. A continuous measure of autistic symptoms was
generated by summing scores from the answers to closed questions, giving a total impairment score
analogous to the ADI-R total algorithm score.
Statistical analysis
First, the DAWBA ASD module was compared with the ADI-R by examining the correlation between the
DAWBA total impairment score and ADI-R total algorithm score using Spearman’s r. The distribution of
scores for both measures was also compared in cases and non-cases.
Second, the optimal cut-off point for DAWBA probability bands in this sample was determined using
receiver operating characteristic (ROC) curve analysis and by examining the sensitivity, specificity, PPV, NPV
and overall percentage of children correctly classified at different cut-off points. The OR for cases versus
controls was used to determine if there was a significantly increased risk of ASD associated with probability
bands higher than the cut-off point. Robust standard errors, clustered by family, controlled for the
relatedness of twins in a pair.
Third, the sensitivity, specificity, PPV, NPV and overall percentage of children correctly classified using
diagnosis assigned by clinical rater were compared with the probability bands, to determine to what extent
prediction was improved by the clinical rater.
Finally, ADOS-G data were added to the DAWBA clinical rater diagnosis and the sensitivity, specificity, PPV,
NPV and overall percentage of children correctly classified were compared for children meeting criteria for
ASD on one or both measures.
Results
The sample included in analyses is described in Table 35.
One hundred and twelve children with a consensus diagnosis of ASD were included, the majority of whom
(83.0%) were male. Two non-ASD comparison groups (unaffected co-twins, n = 101; unaffected co-twins
and low-risk twins, n = 169) were included, and both had a significantly lower proportion of males than
the ASD group. The two comparison groups did not differ from the ASD group in terms of maternal
ethnicity or education. Furthermore, the comparison groups did not differ from each other in terms of
DAWBA ASD total impairment scores or Social Aptitudes Scale scores. Children were aged between 8 and
16 years when the DAWBA was completed, with the mean age being slightly higher in low-risk twins.
Performance of Development and Well-Being Assessment in comparison with the
Autism Diagnostic Interview – Revised
The distribution of continuous measures of ASD symptoms, the DAWBA ASD total impairment score
and the ADI-R algorithm total, were compared with each other in cases and non-cases. Figure 13 shows
that the distribution using the DAWBA mirrors that of the ADI-R. Both measures are positively skewed in
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non-cases, with the majority of children having low scores and roughly normally distributed in cases. There
is a strong correlation between the DAWBA ASD total impairment score and ADI-R algorithm score (in the
whole sample, r = 0.82, p < 0.001; in cases, r = 0.55, p < 0.001; and in non-cases, r = 0.64, p < 0.001).
Prediction of ASD by Development and Well-Being Assessment computer-generated
probability bands
Receiver operating characteristic curve analysis was used to determine how well DAWBA computer-generated
probability bands predicted consensus research diagnosis of ASD (Figure 14). The area under the ROC curve
was significant (0.90, 95% CI 0.87 to 0.94; p < 0.001) and the OR, corrected for relatedness of twins in each
pair, showed a threefold increase in the odds of an ASD diagnosis for each increasing probability band
(OR 3.39, 95% CI 2.60 to 4.42; p < 0.001).
Receiver operating characteristic curve
Classification statistics for probability bands are shown in Table 36. The optimal cut-off point in this sample
was low (3%) – taking those in this band or higher to be cases – with 86.1% of children correctly classified.
This achieved a good balance between sensitivity (0.88) and specificity (0.85). The PPV of 0.80 indicated
that 8 out of 10 children identified as cases at this cut-off point had a research diagnosis of ASD, whereas
2 out of 10 were false positives. The NPV of 0.91 showed that 9 out of 10 children identified as non-cases
were truly non-cases, whereas 1 in 10 identified as non-cases were cases of ASD that had been missed.
TABLE 35 Sample characteristics
Participant
information ASD Non-ASD (co-twins)
Non-ASD
(co-twins and low risk)
n 112 101 169
Child sex, % male 83.0 a52.5** a60.4**
Maternal ethnicity,
% white
96.4 a96.0 a96.4
Maternal education,
% with A level or
above
50.4 a52.0 a53.0
Child age in years,
mean (SD)
10.04 (1.58) 9.93 (1.37)a a11.55 (2.45)**
Mean (SD) 95% CI Mean (SD) 95% CI Mean (SD) 95% CI
DAWBA ASD total
impairment
30.65 (10.77) 28.64 to 32.67 9.02 (10.30) 6.99 to 11.05 8.67 (8.59) 7.37 to 9.98
SAS score 9.23 (6.54) 8.00 to 10.46 22.15 (7.79) 20.60 to 23.70 22.70 (7.17) 21.61 to 23.79
ADI-R algorithm total 39.18 (12.77) 36.79 to 41.57 10.59 (10.48) 8.53 to 12.66
ADOS severity score 6.91 (2.45) 6.15 to 7.07 2.31 (1.85) 1.94 to 2.67
**p < 0.001.
SAS, Social Aptitudes Scale.
a Each non-ASD group was compared with ASD group.
Notes
Non-ASD (co-twins): unaffected co-twins of those with ASD; comparison group with ADI-R and ADOS data. Non-ASD
(co-twins and low risk): unaffected co-twins and twins selected as being at lower risk of ASD (CAST score < 12); comparison
group with consensus diagnosis data. Comparison groups had very similar scores on demographic variables and ASD measures.
Adapted from McEwen et al.3 © 2016 McEwen et al.; licensee BioMed Central Ltd. This article is published under license to
BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Ability of DAWBA clinical rater-assigned diagnosis to predict ASD
The numbers of children rated as having autism or Asperger syndrome, other ASD, or not ASD by DAWBA
clinical rater are cross-tabulated with consensus research diagnosis of ASD in Table 37. The majority, 86.9%,
of children without a research diagnosis of ASD were correctly rated as non-cases by the DAWBA clinical rater.
Similarly, 85.7% of children with a research diagnosis of ASD were identified by the DAWBA clinical rater
as having an ASD diagnosis. Table 35 shows the classification statistics for cases defined as those with any
ASD diagnosis by DAWBA clinical rater, and for cases more narrowly defined as those with a diagnosis of
childhood autism or Asperger syndrome. Using the broader category of any ASD diagnosis, there was only
minimal improvement over computer probability bands in the overall percentage of children correctly
classified, from 86.1% to 86.4%, and minimal change in the sensitivity, specificity, PPV and NPV. Using
the narrower category of autism or Asperger syndrome, specificity improved to 0.98 and PPV to 0.95,
meaning that virtually all non-cases were correctly classified and there were very few false positives.
Conversely, sensitivity decreased to 0.54 and NPV to 0.76, meaning that only around half of the cases of
ASD were identified and less confidence was warranted by a negative result.
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FIGURE 13 Comparison of DAWBA and ADI-R. (a) Distribution of DAWBA ASD total impairment scores (cases n= 112);
(b) distribution of DAWBA ASD total impairment scores (non-cases n= 101); (c) ADI-R algorithm total scores (cases
n= 112); and (d) ADI-R algorithm total scores (non-cases n= 101). Adapted from McEwen et al.3 © 2016 McEwen
et al.; licensee BioMed Central Ltd. This article is published under license to BioMed Central Ltd. This is an Open
Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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FIGURE 14 Receiver operating characteristic curve of DAWBA computer-generated probability band predicting
consensus research diagnosis of ASD. Area under the curve = 0.90 (95% CI 0.87 to 0.94; p< 0.001). OR 3.39 (95% CI
2.60 to 4.42; p< 0.001) (robust standard error used, clustered by family to control for relatedness of twins in pairs).
Adapted from McEwen et al.3 © 2016 McEwen et al.; licensee BioMed Central Ltd. This article is published under
license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated.
TABLE 36 Classification statistics for DAWBA
DAWBA diagnosis Sensitivity Specificity PPV NPV Correctly classified, %
Positive if at this computer-generated probability band or higher
Very low (0.1) 1.00 0.00 0.40 – 40.0
Low (0.5) 0.94 0.79 0.74 0.95 84.6
Low (3) 0.88 0.85 0.80 0.91 86.1
Moderate (20) 0.69 0.90 0.83 0.81 81.8
50/50 0.38 0.97 0.89 0.70 73.2
High (80) 0.20 0.99 0.96 0.65 67.5
Positive if clinical rating of
Any ASD 0.86 0.87 0.82 0.90 86.4
Asperger syndrome or autism 0.54 0.98 0.95 0.76 73.9
Notes
Sensitivity, specificity, PPV and NPV for DAWBA computer-generated probability bands (upper section) and for diagnosis
assigned by DAWBA clinical rater (lower section).
Adapted from McEwen et al.3 © 2016 McEwen et al.; licensee BioMed Central Ltd. This article is published under license to
BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
TABLE 37 Cross-tabulation of DAWBA clinical rater-assigned diagnosis and consensus research diagnosis of ASD
Consensus diagnosis
DAWBA diagnosis (clinical rater)
Rated as not ASD Rated as ASD (other) Rated as Asperger syndrome/autism
Not ASD 146 19 3
ASD 16 35 61
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Does combining the DAWBA with the ADOS improve the classification of cases?
In practice, assessment of children suspected of having ASD should include both a detailed developmental
history and direct observation of the child using a tool such as the ADOS-G. Table 38 shows the classification
statistics when DAWBA clinical rater-assigned diagnosis was used in conjunction with ADOS-G diagnostic
status. Those with DAWBA and ADOS-G data were included (cases, n = 112; non-cases, n = 101; note that
this does not include the low-risk non-cases, see Table 37). Children who met criteria according to the
DAWBA and/or met criteria for ASD according to the ADOS were assumed to be positive for ASD, and this
diagnosis was compared with the research diagnosis of ASD. The DAWBA was used at both the broader
category of any ASD and the narrower category of autism and Asperger syndrome.
Results of this analysis are shown in Table 38. In summary:
l Using ADOS-G diagnosis in conjunction with a DAWBA diagnosis of any ASD increased the percentage
correctly classified.
l Using ADOS-G diagnosis in conjunction with the narrower DAWBA diagnosis of autism or Asperger
syndrome decreased the percentage correctly classified if cases were taken to be those positive on
DAWBA and ADOS-G, but increased it if cases were taken to be those positive on DAWBA or ADOS-G.
l When a positive result on either the DAWBA or the ADOS-G was used to define cases, sensitivity was
very high (nearly all cases were detected), but specificity was lower (some non-cases were incorrectly
flagged as having ASD), and the PPV showed that one out of five children identified as cases were
false positives.
l When cases were taken to be those with positive results for both DAWBA and ADOS-G, sensitivity was
lower (some cases were missed), but specificity was very high (very few non-cases were flagged as
ASD), and PPV was very high (there were very few false positives).
l Children negative on both the DAWBA and ADOS-G were very unlikely to have ASD.
TABLE 38 Classification statistics for DAWBA with ADOS
DAWBA clinical rater Sensitivity Specificity PPV NPV Correctly classified (%)
Positive if
DAWBA clinical rater classified as any ASD 0.86 0.79 0.82 0.83 82.5
AND ADOS-G +ve 0.74 0.95 0.94 0.77 84.0
OR ADOS-G +ve 0.98 0.69 0.78 0.97 84.4
DAWBA clinical rater classified as Asperger
syndrome/autism
0.54 0.97 0.95 0.66 74.5
AND ADOS-G +ve 0.49 0.99 0.98 0.63 72.6
OR ADOS-G +ve 0.92 0.82 0.85 0.90 87.3
+ve, positive.
Notes
Adapted from McEwen et al.3 © 2016 McEwen et al.; licensee BioMed Central Ltd. This article is published under license to
BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Sensitivity, specificity, PPV and NPV for diagnosis assigned by DAWBA clinical rater in
combination with ADOS-G diagnostic status (if met criteria for ASD or autism according to
revised algorithm198)
The level of confidence in positive results is conveyed in Figure 15, which shows the percentage of true
and false positives in cases identified through various combinations of DAWBA and ADOS-G results. For
example, although a DAWBA rating of any ASD resulted in around 80% true positives, the proportion of
true positives increased in those with a narrower DAWBA rating of Asperger syndrome or autism. The
proportion also increased in those who met both DAWBA and ADOS-G criteria for ASD, and was 98% in
those with a DAWBA rating of Asperger syndrome or autism and who met ADOS-G criteria for ASD.
The level of confidence in negative results can be seen in Figure 16, which shows the percentage of true
and false negatives using the DAWBA and ADOS-G. Nearly 20% of children rated as not having ASD using
the DAWBA were false negatives. However, this dropped to only 3% for children who did not meet either
DAWBA or ADOS-G criteria for ASD.
Discussion
We examined the utility of the DAWBA in (largely) straightforward cases in a general population sample.
Hence, these results are likely to be applicable to community settings. The DAWBA was used in a sample
that had been previously screened and that was considered to be at high risk of ASD. This means that the
classification statistics and inferences about confidence in positive and negative results will be applicable
only to other screened and high-risk samples. In practice, the DAWBA could be used after using an
age-appropriate screening tool, such as the CAST or SCQ.
The DAWBA showed good agreement with the ADI-R. Furthermore, the DAWBA predicted consensus diagnosis
with good sensitivity and specificity, and this was true using both computer-generated probability bands and
clinical rater-assigned diagnosis. Hence, we suggest that the DAWBA could replace the more complicated/
expensive ADI-R in assessing straightforward cases in community settings. This is likely to improve the reliability
of clinical diagnosis towards the so-called ‘gold standard’ research diagnostic instruments.
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FIGURE 15 Percentage of true and false positives for cases identified using DAWBA and ADOS-G. Adapted from
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Nonetheless, the performance and interpretability of results could be improved by using the DAWBA in
conjunction with the ADOS. The greatest confidence in positive results (high PPV) was warranted in cases
with a DAWBA rating of the narrower autism or Asperger syndrome diagnosis (regardless of ADOS-G
outcome) and in cases with a DAWBA rating of any ASD and who met ADOS-G criteria for ASD. The
greatest confidence in negative results (high NPV) was warranted in cases who did not receive a DAWBA
rating of ASD and who did not meet ADOS-G criteria for ASD.
The DAWBA may also offer other advantages in community settings, as it can be modified to include
modules that assess common co-occurring disorders such as ADHD, anxiety, depression and OCD. Our pilot
results suggest, therefore, that the DAWBA could be used as a ‘one-stop shop’ that (in one package) helps
information to be gathered about both ‘core symptoms’ and associated disorders, including the perspectives
of (more able) affected individuals, parents and teachers. Caution is needed, however, as the majority of
the current sample is likely to have consisted of fairly straightforward cases of ASD. The results are therefore
not necessarily applicable to more complex clinical samples of children with serious comorbid disorders
(e.g. ADHD). Hence, we suggest that the DAWBA should be tested in more complex samples (e.g. tertiary/
quaternary referral clinics) before any definitive recommendations can be made about its use in these settings.
Strengths and weaknesses
The strengths of this study include our sample being drawn from a large UK general population sample and
so our findings should be reasonably representative of the types of cases seen in community/first opinion
settings. The use of staged screening and assessment for ASD at multiple points through childhood and
adolescence should also have ensured that cases from across the autism spectrum were detected, including
those with more subtle difficulties that may not have been detected until late childhood.
However, our work also has limitations. For instance, the mothers in our sample had a higher level of education
than the UK average (≈50% vs. ≈40% with A level or above), and this may have resulted in better-quality data
(e.g. more detailed answers given to open questions). However, 50% of the mothers in our sample were of a
lower educational level so, despite the slight over-representation of more educated mothers, all educational
levels were included. It is therefore unlikely that this would have led to significant bias.
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FIGURE 16 Percentage of true and false negatives for cases identified using DAWBA and ADOS-G. Adapted from
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The use of a twin sample has the potential to introduce bias by (1) the relatedness of twins in each pair
inflating correlations and (2) contrast effects, whereby parents contrast twins with differing levels of
impairment and exaggerate the differences between them. We did control statistically for relatedness of
twins in pairs to try to reduce bias introduced by twin similarity. It remains possible that parent rating bias
could have exaggerated the difference between discordant pairs, increasing the contrast between affected
and unaffected twins. However, in the case of concordant pairs of which one is less severely affected than
the other, the less affected twin could be falsely rated by the parent as unaffected. Rater bias could,
therefore, result in an increase or decrease in the apparent accuracy of the DAWBA and it is not clear to
what extent, or in which direction, this could have acted on the results. However, the benefits of utilising
this longitudinal study of a nationally representative cohort, from which results can be generalised to
community health settings, are likely to outweigh the potential uncertainties in interpretation of twin data.
Although not necessarily a limitation, it is worth bearing in mind that, in many cases, the DAWBA was
administered using telephone interview by RAs. This could have improved the quality of data collection
beyond what might be expected if online administration had been used (e.g. interviewers may have asked
for clarification or provided guidance if parents had misinterpreted questions). This does not invalidate
the results, but it is possible that using an interviewer with some experience of ASD would result in
better-quality data than online administration. This needs to be tested as online tools are potentially
much more cost-effective than interviewers. Nonetheless, it is likely that some aspects of clinical interview
will still be required to be undertaken by trained clinicians to confirm diagnosis.
Conclusions
The DAWBA performed well in this sample and has the potential to be a useful tool in community settings,
where it could be used to collect a systematic developmental history and help to identify associated mental
health symptoms. The DAWBA should, however, be used in conjunction with a direct observational measure
(expert clinical observation or ideally a measure such as the ADOS-G). When both measures agree with each
other, there can be confidence in both positive and negative results. In cases where these measures are
discrepant, further assessment in more expert centres, using a tool such as the ADI-R, or through observation
of behaviour in school or with peers, could help to resolve issues.
The DAWBA will not necessarily perform similarly in other populations, such as more complex cases typical
of tertiary or quaternary referral services, and the DAWBA must be tested in these types of populations
before any definitive recommendations can be made. Moreover, we piloted this measure in children and
adolescents and we need to develop measures that may be more applicable to older populations and
examine the effect of recent changes in diagnostic practice. Hence, our next three projects focused on
adolescents/young adults and we aimed to (1) pilot a screening tool to help detect associated mental
health symptoms, (2) investigate the effect of recent changes in DSM-V and (3) develop proof of concept
for a novel brain imaging technique to aid in detecting ASD and ADHD.
Key messages
Current schedules for diagnosing ASD are time-consuming, require experts and are expensive.
By contrast the DAWBA can be completed online or by untrained staff over the telephone.
In community samples the DAWBA shows promise as an alternative diagnostic tool and has acceptable
sensitivity and specificity.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105

Chapter 16 Improving identification of associated
mental health symptoms: tool development
Background
As noted previously (see Sections 1 and 2), we and others found that rates of psychiatric comorbidity are
particularly high among individuals with ASD. The most prevalent psychiatric comorbidities associated with
ASD are anxiety disorders, depression and ADHD, with prevalence rates of approximately 41%, 37% and
28%, respectively.58,109,200 The presence of psychiatric comorbidity in ASD can cause significant functional
impairment to the affected individual201 and result in significant burden to their caregiver.57 Therefore,
recognising co-occurring conditions is a priority for GPs and specialist ASD services. Unfortunately,
comorbidity often goes unrecognised in ASD.202 To assist in the identification of service users with ASD,
clinicians need valid and reliable screening and assessment tools. Owing to the overlapping of symptoms
of ASD and certain psychiatric disorders,203 and given the difficulties ASD people have in introspection and
communicating their personal state,204 standard psychiatric screening tools may not be suitable for this
population. To this end, several instruments have been designed specifically for children with ASD, including
the Autism Comorbidity Interview201 and the Psychopathology in Autism Checklist.205 These instruments
have acceptable to good psychometric properties. However, they have not been studied across the autistic
spectrum and in the case of the Autism Comorbidity Interview, rely on clinically skilled interviewers and the
presence of an informant.201
The SDQ is one of the most widely used screening tools for psychopathology in children and adolescents
in the UK, as the it can be used to screen for psychopathologies that are most commonly found to be
comorbid in ASD (i.e. anxiety, ADHD and depression), and because the instrument is relatively brief and can
be administered to parents and youths. We considered it a good candidate to investigate its psychometric
properties in a group of adolescents and young adults with ASD. Hence, we tested the internal and external
validity (and temporal stability) of the SDQ in a sample of adolescents and adults with a diagnosis of ASD.
Methods
Sample
We included 145 families consisting of adolescents and adults with ASD and their parents. Families were
recruited through the patient’s clinical diagnosis of ASD from CAMHS, adult clinics, charities and research
databases that form part of our clinical research networks. Clinical diagnosis of autism was confirmed
using the ADI-R.27 When a parent was unavailable or unwilling to complete the ADI-R, the ADOS-G197
was used.
Measures
Strengths and Difficulties Questionnaire
The SDQ is a brief, 25-item questionnaire that can be administered as self-report, or to parents and teachers
of children and adolescents. Information about the SDQ is available online (URL: www.sdqinfo.com). It covers
common areas of emotional and behavioural difficulties and also asks whether or not the informant thinks
that the young person has a problem in these areas. It includes five subscales (emotional symptoms, conduct
problems, hyperactivity, peer problems and prosocial scales) and an impact score. Scores for each subscale
are classified as ‘normal’, ‘borderline’ or ‘abnormal’. Previously validated computerised algorithms were used
to predict psychiatric disorder by bringing together information on symptoms and impact from the SDQ
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completed by multiple informants. The algorithm makes separate predictions for three groups of disorders:
(1) conduct-oppositional disorders, (2) hyperactivity–inattention disorders and (3) anxiety–depressive disorder.
Each is predicted to be ‘unlikely’, ‘possible’ or ‘probable’. Predictions from these groups are combined to
generate a single prediction of the presence of any psychiatric disorder. For a prediction of probable
hyperactivity–inattention disorder it is essential to have evidence of pervasiveness through both parent and
teacher ratings. As only parent- and self-rated SDQ were available in this study, only unlikely or possible
predictions could result from these data.
Psychiatric diagnosis
As noted previously (see Chapter 15), DAWBA51 is a detailed computer-based psychiatric interview which
can be completed by parents and patients. Each section of the DAWBA uses skip rules, which start with
structured questions that cover the operationalised diagnostic criteria of the DSM-IV.206 A computer
algorithm uses the responses from both informants to generate probability bands for the presence of
particular psychiatric morbidity. A clinical rater then reviews all information and assigns a diagnosis for
each disorder. Where available, clinical notes were reviewed and the presence or absence of psychiatric
disorders was recorded. A patient was considered to be at high risk of particular clinical disorders if they
had been assigned a diagnosis by a DAWBA clinical rater, or if they had received a diagnosis in the clinic
where they were assessed.
Screening questionnaires
In addition to the DAWBA, we assessed the external validity of the SDQ against standard screening
questionnaires and diagnostic measures. Symptoms of ADHD were measured using the BAARS-IV.207
The BAARS-IV is a commonly used, validated 18-item rating scale of DSM-IV criteria for ADHD.
Anxiety and depression were measured by the relevant subscales of the Hospital Anxiety and Depression
Scale (HADS).208 The HADS is a commonly used, 14-item screening tool for anxiety and depression. It has
demonstrated excellent psychometric properties and is used routinely in clinical practice.
The Obsessive–Compulsive Inventory – Revised (OCI-R)209 was used to measure symptoms of OCD. The
OCI-R is an 18-item, self-report measure with excellent psychometric properties.209
Data analysis
Internal reliability was measured by examining the inter-rater reliability, construct validity and temporal
stability of the measure. Inter-rater reliability was tested by examining the correlation (Pearson’s r) of total
SDQ scores between parent and respondent. Construct validity was tested using multitrait–multimethod
analysis (MTMM). MTMMs are based on producing a correlation matrix of multiple traits (e.g. the subscales
of the SDQ) measured by multiple methods (e.g. parent and respondent). Construct validity is assessed
through comparisons across raters and across subscales. For example, correlations between parent and
respondent emotional subscale (a convergent correlation coefficient) would be expected to be higher than
between parent emotional and respondent hyperactivity subscales (a discriminant correlation coefficient).
Where poor convergent and discriminant correlations are observed, it is inferred that these subscales may
not be tapping into the same, distinct constructs across raters. MTMM was performed using Spearman’s
correlations calculated in SPSS for Windows version 20. We also present the Cronbach’s alpha for each
subscale according to each rater.
Temporal stability was tested by calculating the Pearson’s correlation between baseline and follow-up for
each SDQ subscale and the total SDQ score for each rater.
External validity was tested initially by examining the correlation (Spearman’s r) between SDQ subscale
scores and other measures of psychiatric disorder, namely DAWBA probability bands, clinical diagnosis
(coded as no, possible or definite diagnosis) and standard screening questionnaires. It was hypothesised
that SDQ emotional problems would be associated with measures of anxiety disorders, depression and
OCD, and that SDQ hyperactivity would be associated with measures of ADHD. Correlations were repeated,
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controlling for SDQ impact scores (partial r), to ensure that associations were not driven by severity of
symptoms (e.g. patients with more severe ASD symptoms being rated highly across SDQ subscales).
Parent- and self-rated SDQ emotional problems and hyperactivity subscales, coded into normal, borderline
and abnormal bands, were compared with risk of clinical disorder. Borderline and abnormal bands were
collapsed into one category and taken to indicate higher risk. Multi-informant predictive algorithms were
also used, with possible and probable categories collapsed for emotional disorders (probable category was
not available for hyperactivity, see Strengths and Difficulties Questionnaire). Risk of clinical disorder was
measured using DAWBA clinical rater-assigned diagnoses and evidence of diagnoses from clinical notes.
Sensitivity, specificity, PPV and NPV were calculated for each rater and for the predictive algorithm. The
overall percentage of individuals correctly classified and the OR was also calculated in each case.
Results
Inter-rater correlations
Pearson’s correlations between parent and respondent total SDQ scores were 0.418. This is comparable
with the 0.48 inter-rater correlation between parents and youth previously reported in a large-scale
epidemiological sample on the SDQ.210
Construct validity of the Strengths and Difficulties Questionnaire subscales
across informants
Table 39 presents a MTMM of the five hypothesised SDQ subscales. The Cronbach’s alpha coefficients
ranged between 0.484 and 0.810. The cross-method correlations of the same traits are shaded green; all
were significantly different from zero (p < 0.001) and in the moderate magnitude range (0.423–0.573).
In the majority of cases, the convergent correlations were significantly larger than the other correlation
coefficients in the same row or column (the discriminant correlations). However, there are some notable
exceptions. First, in both informant-rated pairs, the emotional problems subscale demonstrated poor
discriminant validity relative to peer problems and parent-rated behavioural problems (relevant cells are in
bold). Second, the youth-rated behavioural subscale did not show good discriminant validity relative to the
parent-reported hyperactivity subscale and the parent-rated behavioural subscale, which did not show
good discriminant validity relative to the youth-reported emotional subscale (relevant cells italicised).
The behavioural, emotional and peer problems subscales therefore demonstrate poor discriminant validity;
thus, these findings suggest that the five subscales do not tap into the same, distinct aspects of the youths
mental health problems across both informants. However, the three-factor (internalising–externalising–prosocial)
contrast provided much better convergent and discriminant validity. Furthermore, Cronbach’s alphas for
each subscale were higher on average in the three-factor model (Table 40).
Temporal stability
The SDQ was re-administered to parents and youths after an interval of ≈11 months (parents, n = 69;
youths, n = 35). The mean retest stability was 0.64. Stability did not differ by informant (parent = 0.62;
youth = 0.66) (Table 41).
External validity
Tables 42 and 43 show correlations between SDQ subscales and other measures of comorbid disorders
(DAWBA probability bands, clinical diagnosis and standard screening questionnaires). Both parent- and
self-report SDQ scores showed the predicted pattern of associations for emotional symptoms (correlating
with anxiety disorders, OCD and depression) and hyperactivity (correlating with ADHD). This was true even
when the effects of SDQ Impact scores were controlled (using partial correlations), suggesting that these
associations are not being driven by severity of problems regardless of domain.
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TABLE 39 Multitrait–multimethod analyses for the five hypothesised SDQ subscales
Parent Respondent
Emotional Peer problems Behavioural Hyperactivity Prosocial Emotional Peer problems Behavioural Hyperactivity Prosocial
Parent
Emotional α = 0.784
Peer problems 0.441 α = 0.550
Behavioural 0.358 0.341 α = 0.763
Hyperactivity 0.310 0.225 0.395 α= 0.779
Prosocial –0.144 –0.259 –0.447 –0.155 α = 0.810
Youth
Emotional 0.573 0.293 0.433 0.077 –0.055 α= 0.762
Peer problems 0.253 0.449 –0.058 –0.201 –0.123 0.573 α = –0.697
Behavioural –0.062 –0.009 0.423 0.319 –0.071 0.135 0.158 α= 0.484
Hyperactivity 0.180 0.046 0.149 0.560 –0.067 0.354 0.086 0.207 α= –0.775
Prosocial –0.018 –0.066 –0.098 –0.019 0.469 –0.154 –0.182 –0.226 –0.134 α = 0.734
Notes
The cross-method correlations of the same traits are shaded green.
Bold: emotional problems subscale demonstrates poor discriminant validity relative to peer and behavioural problems.
Italics: behavioural subscale demonstrates poor discriminant validity relative to parent-reported hyperactivity and behavioural subscales and emotional subscale.
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Parent- and self-rated SDQ emotional problems and hyperactivity subscales, coded into normal, borderline
and abnormal bands, were then compared with risk of clinical disorder.
Emotional disorder
Figure 17 shows ratings for SDQ emotional problems or disorder in those at high and low risk of clinical
diagnosis of any emotional disorder. For both parent- and self-rated emotional problems, more than half
of those rated as borderline or abnormal were at high risk of emotional disorder and the majority of those
rated as normal were at low risk of emotional disorder. Parents were more likely to give abnormal ratings,
resulting in more true and false positives, and patients were more likely to rate themselves as normal, resulting
in more true and false negatives.
Table 44 shows the sensitivity, specificity, PPV and NPV of each SDQ subscale in predicting risk of relevant
clinical disorders. Parent-rated emotional problems had high sensitivity (90% of cases would have been
detected), whereas only around half (55%) of cases would have been detected using self-ratings. The PPV
showed that 60–70% of cases identified were true positives and 30–40% were false positives. The NPV showed
that 60–75% of normal ratings reflected low risk of disorder, whereas 25–40% represented missed cases.
TABLE 40 Multitrait–multimethod analyses for the internalising, externalising and prosocial SDQ subscales
Parent Respondent
Internalising Externalising Prosocial Internalising Externalising Prosocial
Parent
Internalising α= 0.748
Externalising 0.402 α = 0.820
Prosocial –0.218 –0.326 α= 0.810
Youth
Internalising 0.525 –0.016 –0.100 α= 0.834
Externalising 0.060 0.525 –0.097 0.265 α = 0.797
Prosocial –0.024 –0.097 0.469 –0.189 –0.228 α = 0.734
Notes
Values in cells are Spearman’s correlations coefficients, except values in the diagonals, which are Cronbach’s alphas.
Cross-method correlations of same traits are presented in bold.
TABLE 41 Reliability coefficients for SDQ scores
SDQ scale
Time 1 × time 2 correlations
Parent (n= 69) Respondent (n= 35)
Emotional problems 0.547 0.644
Peer problems 0.583 0.724
Behavioural problems 0.695 0.642
Hyperactivity 0.704 0.546
Prosocial behaviour 0.620 0.687
Impact 0.602 0.611
Total difficulties 0.587 0.735
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TABLE 42 Correlations between parent SDQ and DAWBA probability bands, clinical diagnosis and questionnaires
Emotional Behavioural Hyperactivity Peer problems Prosocial
r Partial r r Partial r r Partial r r Partial r r Partial r
Anxiety
DAWBA GAD 0.73** 0.60** 0.30* 0.00 0.09 –0.20† 0.38** 0.08 –0.15 0.13
DAWBA specific phobia 0.49** 0.38** 0.16 –0.03 0.19 0.06 0.33** 0.18 –0.20† –0.07
DAWBA social phobia 0.54** 0.34** 0.31** 0.05 0.18 –0.06 0.44** 0.18 –0.26* –0.04
DAWBA panic disorder 0.48** 0.27* 0.22† –0.04 0.08 –0.16 0.35** 0.09 –0.18 0.04
DAWBA agoraphobia 0.53** 0.36** 0.18 –0.08 0.10 –0.12 0.21† –0.08 –0.23† –0.04
Clinical diagnosis 0.40** 0.37* –0.10 –0.22 0.01 –0.11 0.21 0.13 –0.14 –0.07
HADS anxiety 0.53* 0.54* –0.21 –0.35 –0.11 –0.21 –0.14 –0.33 0.14 0.16
OCD
DAWBA OCD 0.44** 0.29* 0.17 –0.05 0.18 0.01 0.31** 0.11 –0.22† –0.07
Clinical diagnosis 0.27† 0.41** –0.18 –0.13 –0.09 –0.02 –0.05 0.05 –0.00 –0.08
OCI-R 0.42† 0.31 0.23 0.07 0.24 0.10 0.07 –0.22 0.25 0.31
Depression
DAWBA depression 0.58** 0.40** 0.28* –0.00 0.21† –0.02 0.26* –0.08 –0.25* –0.02
Clinical diagnosis 0.10 0.20 –0.22 –0.17 0.03 0.13 –0.09 0.00 –0.10 –0.19
HADS depression 0.47* 0.36 –0.16 –0.47† –0.23 –0.51* 0.21 –0.06 –0.05 –0.00
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Emotional Behavioural Hyperactivity Peer problems Prosocial
r Partial r r Partial r r Partial r r Partial r r Partial r
ADHD
DAWBA ADHD 0.09 –0.25* 0.30* 0.07 0.77** 0.72** 0.09 –0.24* –0.25* –0.06
Clinical diagnosis –0.10 –0.28† 0.32* 0.24 0.50** 0.46** 0.26† 0.14 –0.10 0.01
BAARS-IV current inattentive (parent) 0.03 –0.29 0.51* 0.34 0.47* 0.30 0.54* 0.32 –0.07 –0.01
BAARS-IV current hyperactive/impulsive (parent) –0.13 –0.28 0.36 0.30 0.55* 0.53* 0.47* 0.46† 0.26 0.29
BAARS-IV current inattentive (self) –0.08 –0.33 0.39† 0.24 0.32 0.17 0.34 0.13 –0.21 –0.18
BAARS-IV current hyperactive/impulsive (self) –0.34 –0.56* 0.32 0.22 0.31 0.23 0.41† 0.34 0.28 0.33
*p< 0.05 (two-tailed); **p< 0.01 (two-tailed); †p< 0.10 (two-tailed).
Notes
Spearman’s rho and partial rho controlling for SDQ impact score.
Predicted associations in bold.
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TABLE 43 Correlations between self-report SDQ and DAWBA probability bands, clinical diagnosis and questionnaires
Emotional Behavioural Hyperactivity Peer problems Prosocial
r Partial r r Partial r r Partial r r Partial r r Partial r
Anxiety
DAWBA GAD 0.66** 0.52** 0.09 –0.08 0.34** 0.20† 0.33** 0.14 0.01 –0.06
DAWBA specific phobia 0.41** 0.27* 0.20† 0.11 0.32** 0.23† 0.26* 0.13 0.08 0.04
DAWBA social phobia 0.55** 0.36** 0.15 –0.00 0.26* 0.11 0.45** 0.29* –0.18 –0.28*
DAWBA panic disorder 0.40** 0.25* 0.10 –0.01 0.29* 0.19 0.20† 0.05 –0.04 –0.08
DAWBA agoraphobia 0.44** 0.36** 0.01 –0.09 0.26* 0.18 0.34** 0.24* –0.17 –0.22†
Clinical diagnosis 0.18 0.17 0.18 0.17 –0.02 –0.05 0.25† 0.26† –0.20 –0.20
HADS anxiety 0.24 0.15 –0.03 –0.06 –0.11 –0.12 0.10 –0.03 0.26 0.19
OCD
DAWBA OCD 0.49** 0.31** 0.24* 0.12 0.27* 0.14 0.35** 0.19 –0.10 –0.17
Clinical diagnosis 0.09 0.32* –0.01 0.03 –0.09 –0.04 0.14 0.37* –0.10 –0.10
OCI-R 0.52* 0.38 0.37 0.33 0.27 0.27 0.07 –0.28 0.31 0.14
Depression
DAWBA depression 0.53** 0.22† 0.19 –0.01 0.20† –0.03 0.43** 0.20† 0.09 0.02
Clinical diagnosis –0.03 0.18 –0.03 0.02 –0.10 –0.04 –0.07 0.10 –0.15 –0.15
HADS depression 0.35 0.33 –0.47* –0.50* –0.39† –0.40† 0.45† 0.49* 0.10 0.05
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Emotional Behavioural Hyperactivity Peer problems Prosocial
r Partial r r Partial r r Partial r r Partial r r Partial r
ADHD
DAWBA ADHD 0.15 0.05 0.23† 0.19 0.44** 0.41** –0.12 –0.23† –0.02 –0.04
Clinical diagnosis –0.03 0.16 0.08 0.13 0.42** 0.51** –0.29† –0.23 –0.17 –0.18
BAARS-IV current inattentive (parent) 0.12 0.08 0.17 0.15 0.30 0.30 0.19 0.17 0.29 0.29
BAARS-IV current hyperactive/impulsive (parent) 0.02 0.06 0.28 0.30 0.35 0.35 0.16 0.25 0.33 0.40
BAARS-IV current inattentive (self) 0.06 –0.06 0.24 0.22 0.45† 0.44† 0.11 –0.01 –0.03 –0.14
BAARS-IV current hyperactive/impulsive (self) 0.17 0.01 0.23 0.19 0.45† 0.45† 0.31 0.17 0.00 –0.17
*p< 0.05 (two-tailed); **p< 0.01 (two-tailed); †p< 0.10 (two-tailed).
Notes
Spearman’s rho and partial rho controlling for SDQ Impact score.
Predicted associations in bold.
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The odds of clinical disorder were significantly elevated in those identified using the SDQ, using parent or
self-ratings. The multi-informant predictive algorithm performed similarly to parent-rated SDQ, with only
slightly improved ability to correctly identify risk of clinical disorder.
Hyperactivity
A similar pattern was observed for SDQ hyperactivity. Figure 18 and Table 44 show that the majority
(60–65%) of those with borderline or abnormal ratings were at high risk of ADHD and the majority
(67–84%) of those with normal ratings were at low risk. ORs were significant for parent ratings, self-ratings
and multi-informant predictive algorithm. Parent ratings detected more cases (86%) than self-ratings (60%).
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FIGURE 17 Strengths and Difficulties Questionnaire emotional problems (parent and self-rated) and emotional
disorder (multi-informant predictive algorithm) scores in patients at high or low risk of clinical diagnosis of any
emotional disorder.
TABLE 44 Classification statistics for SDQ emotional problems and hyperactivity subscales
SDQ subscale Sensitivity Specificity PPV NPV % correctly classified OR 95% CI
Emotional problems
Parent 0.90 0.32 0.59 0.75 62 4.32 1.25 to 14.95
Self 0.55 0.70 0.67 0.59 62 2.89 1.13 to 7.40
Emotional disorder
Multi-informant 0.90 0.41 0.62 0.79 66 6.14 1.81 to 20.87
Hyperactivity
Parent 0.86 0.62 0.65 0.84 73 9.75 3.14 to 30.28
Self 0.60 0.67 0.60 0.67 64 3.00 1.18 to 7.62
Hyperactivity disorder
Multi-informant 0.86 0.64 0.67 0.84 74 10.80 3.46 to 33.70
Notes
SDQ emotional symptoms/disorder tested against risk of clinical diagnosis of any emotional disorder; SDQ hyperactivity/
hyperactivity disorder tested against risk of clinical diagnosis of any ADHD/hyperactivity disorder. Borderline/possible and
abnormal/probable ratings were collapsed and contrasted to normal/unlikely ratings.
n= 77.
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Discussion
The psychometric properties of the SDQ were assessed in a sample of adolescents and adults with an ASD.
The findings confirm that the SDQ is satisfactorily reliable and valid in this population.
We assessed the reliability of the SDQ by assessing inter-rater agreement, internal consistency and
temporal stability. Inter-rater agreement was satisfactory and comparable to the agreement reported in
other studies of non-ASD populations using the SDQ. The internal consistencies were reported for each
subscale of the five-factor model and the three-factor internalising-externalising model. Internal consistency
was generally satisfactory across all subscales. Test–retest reliability is usually measured by re-administering
the assessment after a brief interval of approximately 1–4 weeks. In the current study, retest was not
carried out until on average 12 months after initial assessment. Therefore, changes in the score may reflect
genuine alterations in the respondent’s psychological adjustment as well as from poor measurement
reliability. Nevertheless, we report a satisfactory lower bound for true test–retest reliability, which did not
seem to differ between rater.
Using a MTMM of the parent and respondent SDQ, we explored the construct validity of the subscales in
the two models. The convergent validity coefficients of 0.42–0.57 are higher than those previously
reported in a non-ASD sample. Within the five-factor model, we found poor discriminant validity between
the emotional subscale and the peer problems and behavioural subscales. The behavioural subscale also
showed poor discriminant validity relative to the hyperactivity subscale. Consequently, the labels given to
these four subscales (emotional, peer problems, behavioural and hyperactivity) may be misleading, as they
cannot be assumed to tap into distinct aspects of psychopathology. Interestingly, despite the association
between the behavioural subscale (a component of the externalising subscale in the three-factor model)
and the emotional subscale (a component of the internalising subscale), the three-factor model contrasts
provided much better discriminant validity.
Good external validity was demonstrated for the emotional problems and hyperactivity subscales.
SDQ emotional problems scores correlated with a variety of anxiety disorders, OCD and depression.
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FIGURE 18 Strengths and Difficulties Questionnaire hyperactivity (parent and self-rated) and hyperactivity disorder
(multi-informant predictive algorithm) scores in patients at high or low risk of clinical diagnosis of any type of
ADHD/hyperkinesis. NB. Probable band for multi-informant predictive algorithm requires evidence of pervasiveness
across settings from parent and teacher SDQ, which was not available in this sample.
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Similarly, SDQ hyperactivity scores correlated with ADHD. Emotional disorders and ADHD were measured
using a variety of methods – DAWBA, standard screening questionnaires and clinical diagnosis – suggesting
that the associations with the SDQ are robust and not entirely attributable to common method variance
(i.e. SDQ and other questionnaires being completed by the same rater). For example, parent SDQ emotional
problems correlated with HADS (anxiety), a self-report questionnaire and with diagnosis assigned by
clinician. There was some evidence that common method variance was a factor in hyperactivity: parent SDQ
correlated with parent- but not self-rated BAARS-IV scales, and self-rated SDQ correlated with self- but not
parent-rated BAARS-IV scales. However, both parent- and self-rated SDQ hyperactivity scores correlated
strongly with clinical diagnosis, a more objective measure of ADHD. Using SDQ bands validated in child
samples and taking borderline and abnormal scores to indicate risk of disorder, was a reasonably effective
way of identifying comorbid emotional disorders and ADHD, at least using parent-rated SDQ (around 90%
of cases were identified). Sensitivity was lower using self-rated SDQ (55–60% of cases identified), which
suggests that a significant proportion of adults with ASD under-report these difficulties. On this basis, it
would be advisable to seek a parent-rated SDQ, when possible, in order to detect the majority of cases of
comorbid emotional disorders and ADHD. However, it is important to note that around 4 in 10 cases
identified by parents were false positives. The SDQ should be used to identify those in need of further
assessment and should not be taken as confirmation of the presence of comorbidity.
The pattern of correlations suggests that the emotional and hyperactivity subscales are fairly specific to
these difficulties in adults with ASD: there was no association between SDQ emotional problems and
ADHD measures, or between SDQ hyperactivity and emotional disorders measures. Additionally, there
were few associations between other SDQ subscales and measures of emotional disorders or ADHD.
A notable exception was self-rated peer problems, which correlated with some measures of anxiety, OCD
and depression. It may be useful to use self-rated peer problems as an additional indicator of possible
emotional disorder, especially if a parent-rated SDQ is not available.
Using the multi-informant predictive algorithm did not markedly improve detection of comorbidities over
parent-rated SDQ. In this sample, there is little justification for combining parent- and self-rated SDQ and
impact scores using a statistical package. In practice, it may be sufficient, and indeed easier, to use a paper
version of the parent SDQ and the published subscale bands.
Key messages
Older adolescents and adults with ASD have a high prevalence of associated mental health symptoms.
Currently there are no instruments to help identify these comorbid conditions in adults with ASD.
We provide proof of concept that a modified form of the SDQ is an acceptable screening tool for comorbid
psychopathology. It can help identify individuals that require more in-depth assessment.
Strengths and weaknesses
The strengths of this study include our comparison of the SDQ with the some of the most widely used
screening tools for psychopathology in the UK (BAARS-IV, HADS and the OCI-R). In addition, we compared
the SDQ against clinical diagnoses assigned by chartered psychiatrists.
However, our work also has limitations. Our sample primarily consisted of high-functioning individuals,
which is not representative of ASD as a whole. For example, approximately 8% of our sample was
diagnosed with a LD, in comparison with an estimated prevalence of 56%.211 Thus, we can generalise our
findings only to higher-functioning adults with ASD.
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Data used to test external validity were limited in various ways. For example, it was clear from clinical notes
that, despite having evidence of comorbid emotional disorder or hyperactivity, some patients had not
received further assessment. This means that the absence of clinical diagnosis in these patients did not
necessarily reflect the absence of disorder. Furthermore, in some patients the time gap between
assessment with the SDQ and with other measures (screening questionnaires, clinical assessment) was
relatively long. Consequently, disagreement between the SDQ and other measures may have reflected
genuine change in mental state rather than poor performance of the SDQ. Despite these limitations of the
clinical data, a consistent pattern of significant associations emerged across measures. Indeed, it is possible
that these associations would have been stronger with better-quality data.
Conclusions
The SDQ appears to be a valid way to screen for comorbid anxiety disorders, depression and ADHD in
adults with ASD. We suggest that if the screen is used then adults with higher scores on the emotional
problems or hyperactivity subscale (using either the parent or self-report version of the SDQ) should be
offered further expert assessment. However, the SDQ may not perform similarly in other populations, such
as more complex cases or individuals with comorbid ID. Furthermore, it is possible that changes in the
diagnostic criteria for ASD (explored in the next study) may have implications for the performance of the
SDQ in the new diagnostic categories suggested in DSM-V. In our next work stream, we carried out an
initial investigation of the impact that changes in DSM-V have on diagnostic rates of ASD at the transition.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119

Chapter 17 Improving outcomes through better
diagnosis: the effects of changes in DSM-V on
clinical diagnosis
Introduction
Autism spectrum disorder is a ND with a prevalence currently estimated at 1 in 80 individuals.212 In recent
years there has been a rise in reported rates of ASD. The reason for this is unclear, but changes in diagnostic
practice are likely to have contributed.213 In addition, a formal diagnosis of an ASD is often used as a
‘gatekeeper’ for services and support. Therefore, changes in diagnostic practice may have important
implications – both for clinical prevalence rates and for an individual’s care options.
Autism spectrum disorder is diagnosed on the basis of three domains: (1) impaired social interaction,
(2) abnormal communication and (3) restricted and repetitive behaviours and interests. Using the current
diagnostic criteria in the ICD-10214 and the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR),206 ASD comes under the umbrella term of PDD. An individual may be
defined as having one of four diagnostic subtypes according to the range of symptoms and the presence/
absence of factors such as developmental language delay and ID (i.e. Asperger syndrome, childhood
autism/autistic disorder, atypical autism, PDD-unspecified). There are, however, problems with current
diagnostic algorithms. These include a lack of evidence for significant differences between ASD subtypes
(once IQ matched) in aetiology, neuropsychological profile, treatment or outcome and poor clinical agreement
when diagnosing.215 Hence, the Neurodevelopmental Disorders Workgroup, convened by the American
Psychiatric Association, has proposed a number of significant changes to the diagnostic criteria for ASD.216,217
These include collapsing previously distinct diagnostic subtypes into a single category of ASD, and reducing
the current ‘triad of impairments’ to two domains – by combining the social and communication impairment
criteria into a single set (as almost any example of communication is social and vice versa). Furthermore,
people who do not present with the full range of symptoms will no longer be eligible for an ASD diagnosis,
as there is no ‘atypical’ or ‘not otherwise specified’ category (as in ICD-10, DSM-IV). Instead, a new diagnostic
category called social communication disorder (SCD) has been proposed. This is defined as being outside
the autism spectrum, but will provide ‘diagnostic coverage’ for those individuals with symptoms in the
social-communication domain, but who have never displayed repetitive, restricted behaviours or interests.
The effect of the proposed changes on diagnostic outcomes has been investigated in children and
adolescents, with several studies reporting that the specificity of the proposed DSM-V criteria is good, but
sensitivity is relatively poor, when judged against current ICD-10 or DSM-IV-TR criteria.218–223 This highlights
a key concern of some, that the new criteria will fail to capture individuals currently receiving an ASD
diagnosis who are on the ‘broader spectrum’ according to DSM-IV-TR or ICD-10 criteria (e.g. PDD – not
otherwise specified). As a consequence, it is feared by some that these individuals will be denied access to
services. Reassuringly, however, a large study of children diagnosed within the PDD category according to
DSM-IV-TR suggested that sensitivity of DSM-V is very good (0.91), although sensitivity in this study was
much lower (0.53).224
The effect of the proposed changes for adults has received relatively little attention. This is of importance
because ASD is a lifelong condition; most people with ASD are adults and an increasing number of
individuals are presenting for first diagnosis in adulthood.225 Furthermore, diagnosis is particularly challenging
in this group because a developmental history is often unavailable and/or unreliable and presentation is
frequently complicated by additional mental health conditions.226 The only prior study that explored the
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agreement between current and proposed ASD criteria in adults included only individuals with (mostly
profound) ID living in residential centres;219 they reported that approximately one-third of the individuals
who met DSM-IV-TR criteria no longer met them using the draft DSM-V. This study was a valuable first step.
However, the majority of the ASD population does not have profound intellectual impairment227 and such
people are assessed within mental health or social/educational services. In addition, it is unknown what
proportion of individuals would qualify for the new, alternative diagnosis of SCD.
Our primary aim, therefore, was to investigate how diagnostic outcomes of the DSM-V algorithm differed
from both ICD-10 and the DSM-IV-TR when applied in a clinical health service; and to compare all three
algorithms to so-called ‘gold standard’ research diagnostic assessment tools (the ADI-R27 and ADOS-G197).
Our secondary aims were to investigate whether or not diagnostic outcomes were affected by participant
characteristics (age, sex, IQ, presence of additional mental health conditions), or alterations to the
formulation of the proposed algorithm. Specifically, we examined the impact of reducing the number of
criteria required for a formal diagnosis and also the treatment of criteria where the clinician was uncertain
or had insufficient information to code the item.
Method
Participants
Participants included 158 individuals consecutively assessed for an ASD diagnosis in a specialist national
tertiary ASD diagnostic clinic for adults between January and May 2011. The clinic is situated within the
South London and Maudsley NHS Foundation Trust. People are typically referred by their local family
physician/GP or consultant psychiatrist for a second opinion. In eight cases diagnosis was inconclusive due
to a history of acquired head injury or the presence of severe psychotic symptoms during assessment. Data
from these cases were excluded from the study. The remaining 150 participants were aged 18–65 years,
with a mean age of 31 years. There were 110 males (mean age 32 years) and 40 females (mean age
31 years). Seventy-three patients already had a diagnosis of a mental health condition, although only
seven of these had previously been diagnosed with ASD.
Clinical assessment
Assessment included a detailed psychiatric assessment using ICD-10 research diagnostic criteria and, when
possible (i.e. when parents were available, able and willing), an ADI-R. In the event that no parent was
available for the ADI-R, we asked the person seeking diagnosis to undergo the ADOS-G. In some cases
both assessment tools were required to gather enough relevant information. Seventy-one individuals were
assessed using the ADI-R, 62 were assessed with the ADOS-G and 17 were assessed using both the ADI-R
and the ADOS-G.
All information obtained was compiled by the multidisciplinary clinical team – a consultant psychiatrist, a
junior doctor and an ADI-R/ADOS-G administrator (nurse or psychologist) – who together decided whether
or not each criterion on the ICD-10 algorithm was fulfilled. If a patient met the full ICD-10 criteria (a total
of at least six symptoms must be present – either currently or by history – with at least two from the first
domain and one from each of the second and third domains) and the symptoms were noted before the age
of 3 years, they were diagnosed with childhood autism (if they exhibited a language delay) or Asperger
syndrome (if there was no evidence of a language delay). In line with ICD-10 guidelines, if a patient exhibited
some autistic symptoms but did not meet full ICD-10 diagnostic criteria they were diagnosed with PDD,
unspecified (PDD-unspecified), or atypical autism. For the purposes of this study these two subthreshold
diagnostic groups were collapsed into a single ‘PDD-unspecified’ group. In some cases, it was not possible
to decide confidently whether or not a symptom was present due to a lack of information, or because
information obtained from patient and parent was contradictory. In this event the criterion was coded as
‘unclear’ and the team made the clinical diagnostic decision based on the gestalt of the information received.
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Of the 150 consecutive assessments, 113 were diagnosed with an ASD using ICD-10 criteria. Of these,
28 participants were subtyped as having childhood autism, 48 Asperger syndrome and 37 PDD-unspecified.
Additional mental health conditions were also diagnosed in accordance with the ICD-10 (with the
exception of adult ADHD which, in keeping with UK guidelines, was assessed using DSM-IV-TR).
Supplementary self-report questionnaires were used to help inform the assessment of OCD, ADHD,
depression and anxiety. These were (respectively) the OCI-R,209 the Barkley Current and Childhood
Symptom Scales44 and the HADS.208
Where there was clinical suspicion that a participant might have ID (F70–73 in ICD-10) or a significant
lacuna in a neuropsychological function, they were referred for testing of general intellectual and executive
functioning. These participants (n = 35) were tested using the Wechsler Adult Intelligence Scale-III,228 which
revealed a mean performance IQ of 87 (SD 16, range 55–132) and a mean verbal IQ of 95 (SD 18, range
60–133). Mean full-scale IQ could not be calculated in 16 participants due to large discrepancies between
performance IQ and verbal IQ. In the remaining 19 participants mean full-scale IQ was 90 (SD 17, range
53–129) and only two participants had an IQ of < 70. The remaining 115 participants, not referred for
such testing, were estimated to be in the normal range of general intellectual function based on education
attainment, employment and informant report.
Procedure
For each participant the diagnostic outcome (ASD/not ASD; ICD-10 subtype of ASD; ADI-R and ADOS-G
scores; presence of additional mental health problems), was reviewed by the research team. Information
from the ICD-10 algorithm was used to determine whether or not each criterion on the proposed DSM-V
algorithm would be satisfied and this was supplemented by anonymised reports from the ADI-R, ADOS-G
and the psychiatric interview. Each criterion could be coded as ‘yes’, ‘no’ or ‘unclear’. A participant was
considered to meet criteria for ASD on the DSM-V only when all three criteria in ‘A’ and at least two out
of four criteria in ‘B’ were coded as ‘yes’, as suggested in the criteria last posted by the American
Psychiatric Association. If a participant did not meet criteria for ASD on the DSM-V it was determined
whether or not they would meet criteria for the alternative diagnosis of SCD (using last posted draft
criteria). Recoding was completed by pairs of researchers; and for 40 sets of participant data the recoding
was reviewed at consensus meetings with the whole team (10 researchers) to ensure agreement.
Data were also recoded to complete the DSM-IV-TR algorithm, on which participants could be diagnosed
as either ‘ASD’ (autistic disorder/Asperger syndrome) if they fulfilled at least six criteria, with at least two in
domain A and one from each of domains B and C, or ‘not ASD’.
Factors affecting agreement between ICD-10, DSM-IV-TR and DSM-V were also investigated. Participant
characteristics (age, sex, IQ, additional mental health conditions) were compared between ASD-positive
and ASD-negative groups. The effect of altering the DSM-V algorithm was examined in two ways: (1) by
relaxing the number of criterion required for diagnosis and (2) by considering criteria that were coded as
‘unclear’ as either met or not met. To examine the effect of relaxing the number of criteria required for
diagnosis we reduced the thresholds in criteria A (from three to two), or in criteria B (from two to one), or
both. To examine the effect of including or excluding the ‘unclear’ items we recoded the DSM-V algorithm
by considering ‘unclear’ items to be present. This was relevant because the DSM-V allows criteria to be
met by history and allowing or disallowing the ‘unclear’ criteria is likely to be crucial in many adult cases
where multiple informants are not available.
We hypothesised that (1) prevalence of childhood autism or Asperger syndrome diagnosed using ICD-10
criteria would be similar to that using DSM-IV-TR and DSM-V, (2) most participants diagnosed with ASD on
the ICD-10 but not the DSM-V would be diagnosed with SCD and (3) altering the DSM-V algorithm would
have significant effects on the rate of positive DSM-V ASD diagnosis.
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Results
Conclusions of initial diagnostic assessments
ICD-10 versus DSM-V
Of the 150 participants, 113 (75%) met criteria for an ASD according to the ICD-10 (childhood autism,
Asperger syndrome or PDD-unspecified). In contrast, however, according to the DSM-V, only 63 (42%)
met ASD criteria: this was a highly significant decline, χ2 = 35.57; p < 0.001. A further 21 (14%)
participants met DSM-V criteria for SCD. Overall, therefore, of those individuals positive for ASD on
ICD-10, 74% (84/113) met criteria for ASD or SCD on DSM-V. Nevertheless, the proportion of individuals
with no diagnosis at all (ASD or SCD) remained significantly higher when applying the DSM-V criteria
instead of ICD-10 (χ2 = 62.5; p < 0.001). None of the participants who was ASD negative using ICD-10
met diagnostic criteria for ASD (or SCD) according to the DSM-V, thus specificity of the DSM-V was 100%
(Table 45).
DSM-IV-TR versus DSM-V
The rate of ASD-positive diagnosis using DSM-V (42%) was also significantly lower than the rate of autistic
disorder or Asperger syndrome assessed using DSM-IV-TR (53%), χ2 > 82.5; p < 0.001. In addition, two
individuals were diagnosed with ASD on the DSM-V, but not with autistic disorder or Asperger syndrome
on the DSM-IV-TR; therefore, the specificity of the DSM-V according to the DSM-IV-TR was 0.97
(see Table 45).
Agreement with Autism Diagnostic Interview – Revised and Autism Diagnostic
Observation Schedule – Generic results
Agreement between diagnosis according to the ICD-10, DSM-IV-TR, DSM-V and outcomes of the ADI-R
and ADOS-G was calculated when this information was available. When measured against results of the
ADI-R, the sensitivity of the ICD-10 and the DSM-IV-TR was higher than the DSM-V (respectively, 0.97,
0.97 and 0.79; both McNemar’s p = 0.07), but their specificity was marginally lower. For the ADOS-G,
sensitivity was also higher on the ICD-10 and the DSM-IV-TR than on the DSM-V (respectively, 0.6, 0.7
and 0.5; McNemar’s p = 0.07/0.01) and specificity was very similar (Table 46).
Factors affecting agreement between ICD-10 and DSM-V
Participant characteristics: age, sex, intelligence quotient, diagnostic subtype and
additional mental health conditions
Among the participants who were ASD positive using the ICD-10, there were no differences with respect
to age, sex or IQ (where available) between those individuals who were ASD positive and those who were
ASD negative on the DSM-V.
TABLE 45 Outcome of initial assessment of 150 participants according to the ICD-10 and outcome of data recoded
according to DSM-IV-TR and DSM-V
Diagnostic assessment
Above/below ASD threshold, % (n)
Diagnosis of below ASD threshold
participants, % (n)
ASD full threshold Below ASD threshold PDD-unspecified or SCD No diagnosis
ICD-10 51 (76) 50 (74) 25 (37) 25 (37)
DSM-IV-TR 53 (80) 47 (70) n/a n/a
DSM-V 42 (63) 58 (87) 14 (21) 44 (66)
n/a, not applicable.
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There was, however, a significant difference in rate of DSM-V ASD-positive diagnosis between ICD-10
subtypes (χ2 = 31.58; p < 0.001). Significantly more participants diagnosed with ICD-10 childhood
autism or Asperger syndrome met DSM-V criteria for ASD than those in the PDD-unspecified group
(Table 47, column 1). The difference between ICD-10 defined childhood autism and Asperger syndrome
was not significant (χ2 = 1.64; p = 0.2).
TABLE 46 Percentage of participants in each diagnostic group scoring above and below threshold on ADI-R and
ADOS-G, and sensitivity and specificity of each diagnostic algorithm according to ADI-R/ADOS-G
Diagnostic assessment
ADI-R
below cut-off
score, % (n)a
ADI-R
above cut-off
score, % (n)a
ADOS-G
below cut-off
score, % (n)b
ADOS-G
above cut-off
score, % (n)b
ICD-10: below ASD threshold
(not ASD/PDD-unspecified)
96 (27) 4 (1) 75 (35) 25 (15)
ICD-10: ASD (Asperger
syndrome/childhood autism)
36 (17) 64 (30) 32 (12) 68 (25)
ICD-10 Sensitivity 0.97;c specificity 0.61 Sensitivity 0.63;c specificity 0.74
DSM-IV-TR: ASD negative 96 (27) 4 (1) 75 (36) 25 (12)
DSM-IV-TR: ASD positive 36 (17) 64 (30) 28 (11) 71 (28)
DSM-IV-TR Sensitivity 0.97;c specificity 0.61 Sensitivity 0.70;d specificity 0.77
DSM-V: ASD negative 83 (29) 17 (6) 64 (36) 36 (20)
DSM-V: ASD positive 38 (15) 63 (25) 36 (11) 65 (20)
DSM-V Sensitivity 0.81; specificity 0.66 Sensitivity 0.50; specificity 0.77
a ADI-R cut-off scores: social = 10; communication = 8; repetitive behaviours/interests = 3.
b ADOS-G cut-off scores: communication = 3; social interaction = 6; communication and social = 10.
c Difference between ICD-10/DSM-IV-TR and DSM-V: McNemar’s p< 0.1.
d Difference between ICD-10/DSM-IV-TR and DSM-V: McNemar’s p< 0.0.
TABLE 47 Percentage of participants who would be diagnosed with (A) ASD on DSM-V, (B) SCD on DSM-V or
(C) ASD on DSM-V if the number of criteria A required was reduced from three to two and/or the number of
criteria B required was reduced from two to one
ICD-10/DSM-IV-TR diagnosis
A B C
DSM-V ASD DSM-V SCD
DSM-V ASD:
relax A
DSM-V ASD:
relax B
DSM-V ASD:
relax A and B
ICD-10, % (n)
Not ASD (total n= 37) 0 0 0 0 0
ASD (total n= 113) 56 (63) 19 (21) 69 (78)a 70 (79)a 87 (98)a
Childhood autism (total n= 28) 82 (23) 11 (3) 86 (24) 93 (26) 96 (27)
Asperger syndrome (total n= 48) 69 (33) 15 (7) 83 (40)b 83 (40)b 98 (47)a
PDD-unspecified (total n = 37) 19 (7) 30 (11) 38 (14)b 35 (13)b 65 (24)a
DSM-IV-TR, % (n)
Not ASD (total n= 70) 3 (2) 13 (9) 14 (10)b 10 (7)b 27 (19)a
ASD (total n= 80) 77 (61) 15 (12) 85 (68)b 90 (72)a 99 (79)a
a Difference between full criteria and relaxed threshold: McNemar’s p< 0.001.
b Difference between full criteria and relaxed threshold: McNemar’s p< 0.05.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
With respect to additional mental health conditions, a significant difference was found only for OCD:
higher rates of OCD were found in the group that were ASD positive on the DSM-V than in the group that
were ASD positive only on the ICD-10 (χ2 = 4.58; p = 0.03; Figure 19).
Effects of relaxing the DSM-V algorithm
For the 113 participants who were ASD positive on the ICD-10, the sensitivity of the DSM-V increased
significantly (and specificity remained at 100%) when thresholds for criteria A or B, or both, were relaxed
(all χ2 > 20.0; p < 0.001) (see Table 47, column C).
For the 80 participants who were ASD positive on the DSM-IV-TR, the sensitivity of the DSM-V increased to
99% when thresholds A and B were both relaxed; however, specificity was significantly reduced.
Uncertainty on the DSM-V algorithm: ASD diagnostic outcome when criteria coded as
‘unclear’ were considered to be present
Of the participants diagnosed with ASD on the ICD-10, 74% received a diagnosis of ASD on the DSM-V
when criteria that were ‘unclear’ were treated as ‘yes’; this was a significant increase from 56% when
‘unclear’ was coded as ‘no’ (χ2 = 51.46; p < 0.001). Specificity remained at 100%.
Discussion
This is the first study to investigate how the DSM-V criteria for ASD might perform in a specialist clinical
health service diagnostic clinic for adults without significant ID – who form a large proportion of individuals
with ASD.
Our findings suggest that the specificity of the DSM-V criteria, as compared with the currently used ICD-10
and DSM-IV-TR criteria, is good. However, sensitivity is relatively poor. For instance, 44% of the participants
who received a diagnosis of an ASD according to ICD-10 did not meet DSM-V criteria. Similarly, 22% of the
individuals who met criteria for Asperger syndrome or autistic disorder on DSM-IV-TR would not qualify for a
DSM-V diagnosis of ASD. This is of concern, as these individuals, who have genuine difficulties and are most
likely on the ‘spectrum’, may not be able to access services available to the ASD population if the DSM-V is
used to define eligibility (i.e. if it is used as an ‘entry criterion’).
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The decline in sensitivity was highlighted when performance of each diagnostic algorithm was measured
against results of so-called ‘gold standard’ assessment tools. Both the ICD-10 and DSM-IV-TR had a 97%
chance of reporting a true ASD-positive diagnosis according to the outcome or the ADI-R; and this fell to
81% when using the DSM-V (a marginally significant decline). The chance of reporting a true negative,
however, was slightly better when using the DSM-V than when using current diagnostic algorithms.
Comparison with the ADOS-G revealed similar results, although there was a lower chance of true positives
across all algorithms. This is potentially problematic because poor agreement between different diagnostic
algorithms and research assessment tools may lead to confusion in both research and clinical settings;
revisions of the assessment tools may therefore be required for use in adult populations.
Given the evidence that a significant proportion of individuals currently considered on the autism spectrum
will not be included in the DSM-V ASD category, it is important to clarify what factors are associated with
the likelihood that an individual will meet the criteria. Encouragingly, there was no evidence of an effect of
age, sex or IQ on diagnostic outcome, suggesting that no particular demographic is more or less likely to
receive an ASD diagnosis. This runs counter to some concerns that higher-functioning children (those with
Asperger syndrome) are more likely to be missed by the proposed DSM-V criteria than lower-functioning
children (those with autistic disorder).221
In the current study, the difference in rate of DSM-V ASD-positive diagnosis between the ICD-10 subtypes
of childhood autism and Asperger syndrome was non-significant. This suggests that adults with an Asperger
syndrome diagnosis will be at no greater risk of missing out on an ASD diagnosis when using DSM-V than
adults with childhood autism, which perhaps supports the DSM-V proposal to combine these diagnoses into
a single category. However, the third ICD-10 subtype – PDD-unspecified – had a significantly lower rate of
ASD diagnosis using DSM-V than both of the other two diagnostic subtypes. This is not necessarily cause for
concern: people with a PDD-unspecified diagnosis did not actually meet full diagnostic criteria on the ICD-10
either; instead they showed significant ASD traits and were considered to be on the ‘spectrum’. What is
perhaps of concern is that one-quarter of people with an ICD-10 ASD diagnosis would not qualify for either
ASD or SCD on the DSM-V, and the majority of those affected were of the PDD-unspecified subtype. This is
the first study to report the proportion of people who would qualify for the new SCD diagnosis as currently
drafted, but our results suggest this alternative category, which was intended to provide diagnostic coverage
to many of those who will not qualify for the ASD diagnosis, may not solve the problem of the comparatively
poor sensitivity of the DSM-V relative to ICD-10.
The present data suggest that the sensitivity of the draft DSM-V criteria, compared at least with ICD-10
and DSM-IV-TR, can be improved. Several authors have suggested that increased sensitivity without
reduced specificity might be achieved by relaxing the proposed criteria.218,221,229 Our results supported this.
We found that relaxing thresholds in DSM-V for social communication and social interaction (criteria A),
and/or repetitive patterns of behaviour, interests and activities (criteria B), allowed the inclusion of almost
all people currently diagnosed with childhood autism or Asperger syndrome, and the majority of those with
PDD-unspecified, while maintaining specificity. Therefore, relaxing one criterion, or both criteria, is likely to
allow the inclusion of more people currently considered to have ASD using ICD-10 and DSM-IV-TR, without
weakening the boundaries between ASD and non-ASD. In addition, clear guidance on how to deal with
uncertainty in the DSM-V classification system will be particularly important; the latest drafts of the DSM-V
criteria allow criteria to be met by history or current state, which may help where information is missing or
uncertain. Rating criteria that were unclear as present versus absent had significant effects on the rates of
DSM-V ASD diagnosis.
Strengths and weaknesses
Although this is the first study to examine the draft DSM-V criteria in able adults with ASD, some limitations
should be noted. Like other studies comparing existing criteria with the DSM-V draft, we analysed existing
clinical notes and instruments that were used primarily for allocating current (ICD-10) diagnostic categories.
It remains to be seen whether or not using the DSM-V criteria in the clinic during assessment in a
prospective fashion would result in different findings. For example, sensory sensitivities are not part of
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current clinical criteria and might be more thoroughly assessed in future in clinics where DSM-V criteria are
adopted. Nonetheless, one potentially useful feature of the present study, in contrast to many others, is the
relatively large number of participants (25%) who were assessed for ASD but found to be negative using
current criteria. This allowed examination of specificity of the different diagnostic measures. Finally, it should
be noted, of course, that it remains unclear whether or not existing ICD-10 or DSM-IV-TR criteria should be
considered the ‘gold standard’ against which new criteria are compared; in the absence of biomarkers, the
exact definition of ASD and its boundaries remains a matter for debate.
Conclusions
The specificity of the DSM-V criteria, as compared with the currently used ICD-10 and DSM-IV-TR criteria,
is good but sensitivity is relatively low. This may be improved (without adversely affecting specificity) by
relaxing DSM-V criteria and by careful consideration of missing or uncertain symptom information.
Nonetheless, it is also important to determine whether or not clinical diagnosis can be aided by the use of
objective (non-interview-based) measures – for instance differences in brain anatomy. This was the focus of
our next study.
Key messages
Recent changes in DSM-V criteria have good specificity, but relatively low sensitivity compared with ICD-10.
Nearly half of young adults with an ASD do not meet DSM-V criteria, according to ICD-10.
If DSM-V is used to define eligibility for clinical services in the UK, many young adults will be excluded.
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Chapter 18 Improving diagnosis and identifying
associated mental health symptoms: can we use
recent advances in neuroimaging to help classify
ASD and ADHD?
Introduction
As noted in previous chapters, ASD is a highly heterogeneous neurodevelopmental condition with multiple
causes and courses, a wide range in symptom severity and many associated comorbid disorders (e.g. see
Amaral and colleagues230) – including ADHD. It has thus been suggested that ASD should be thought of
as ‘the autisms’ rather than a single autistic phenotype.231,232 This makes the diagnosis of ASD (and its
distinction from ADHD) complex. Moreover, it means that clinical trials (in both disorders) necessarily include
heterogeneous samples of individuals who may not share the same biological (or cognitive) deficits. This may
account for the failure of many clinical trials in ASD and ADHD. Hence, we need to be able to ‘fractionate’
clinical populations better in order to improve diagnostic accuracy and identify more homogeneous groups
for clinical trials. One potential way forward is to use recent advances (gained from neuroimaging) in our
understanding of the biology of both disorders.
For instance, there is increasing evidence that both ASD and ADHD are associated with abnormalities in
specific brain regions and neural systems.233–236 However, reports of region-specific differences in ASD (and
ADHD) are highly variable (reviewed in Toal and colleagues237 and Amaral and colleagues230). Such variable
findings may simply be explained by confounds such as clinical heterogeneity between studies or analytical
techniques. Alternatively, variability in findings may indicate that differences in brain anatomy in ASD
and ADHD are relatively subtle and spatially distributed, and are difficult to detect using mass-univariate
(i.e. voxel-wise) approaches. Finally, given the likely multiaetiology of ASD and ADHD, it is likely that their
neuroanatomy is not confined to a single morphological parameter but affects multiple cortical features.
There is already evidence to suggest that several aspects of cerebral morphology are different in people with
ASD and ADHD – including both volumetric (i.e. cortical thickness, regional area) and geometric features
(i.e. cortical shape)238,239 – and that different morphological features may have different neuropathological
and genetic underpinnings.240 So far, individual aspects of the cortex are generally explored in isolation
(i.e. in separate statistical models). Hence, it is not yet known (1) if they equally contribute to differentiating
individuals with ASD and ADHD from controls and (2) what the relationship between such multiple cortical
abnormalities in ASD is. In the present study, we therefore attempted to establish proof of concept that a
multiparameter classification approach employing a support vector machine (SVM) (see Mourão-Miranda
and colleagues,241 Davatzikos and colleagues242 and Kloppel and colleagues 243), to investigate brain anatomy
in adults with ASD and ADHD. Here, a variety of morphological features, including both volumetric and
geometric parameters, were used simultaneously to classify control and ASD/ADHD individuals.
We aimed to demonstrate that the neuroanatomical patterns discriminating individuals with autism and
ADHD from controls are truly multidimensional, comprising multiple and most likely independent cortical
features. If so, this may guide further exploration of the specific genetic and neuropathological
underpinnings of both disorders and provide proof of concept that these may be used to help classify
individuals with and without the disorders.
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Materials and methods
Participants
Twenty control adults were recruited locally by advertisement and 20 adults with ASD were recruited
through a clinical research programme at the Maudsley Hospital/IoP, London. All volunteers (Table 48)
gave informed consent (as approved by the IoP and Bethlem and Maudsley Hospital Trust REC), and had a
full-scale IQ of > 75 (WASI244).
All volunteers were right-handed males and were between 20 and 68 years of age. None had a history
of major psychiatric disorder or medical illness affecting brain function (e.g. psychosis or epilepsy). All
participants underwent a psychiatric interview and physical examination. Blood tests were used to exclude
biochemical, haematological or chromosomal abnormalities (including fragile X syndrome). All participants
with ASD were diagnosed with autism according to ICD-10 research criteria245 by a trained and qualified
clinician in our adult autism specialist clinic at the South London and Maudsley Hospital. The initial clinical
diagnosis was then confirmed using the ADI-R,27 whenever possible (i.e. where parents agreed to take
part, n = 17). In 3 out of the 20 included cases, ADI-R scores could not be obtained because informants
were unavailable. In these three cases, the clinical diagnosis was confirmed using the ADOS.196 Both ADI-R
and ADOS-G scores were available for two participants. All cases had to reach the ADOS-G or ADI-R
algorithm cut-off points in the three domains of impaired reciprocal social interaction, communication and
repetitive behaviours and stereotyped patterns, but we did allow failure to reach cut-off point in one of
the domains (by one point). Sixteen ASD individuals did not have a delay in development of phrase speech
at the age of 36 months (and so may be subtyped by some as having the autistic subtype of Asperger
syndrome); the remaining four individuals had a history of delayed phrase speech (and so may be subtyped
by some as having the autistic subtype of high-functioning autism). However, due to the small sample size
it was not possible to reliably investigate putative differences between people with HFA and Asperger
syndrome, and all subjects were analysed in a combined group of individuals with ASD.
TABLE 48 Subject demographics
Participant information ASD (n= 20) Controls (n= 20)
Age (years) 33 ± 11 (20–68) 36 ± 9 (20–49)
Full-scale IQ 103 ± 20 (76–141) 110 ± 13 (77–129)
Verbal IQ 102 ± 17 (78–133) 106 ± 14 (71–131)
Performance IQ* 98± 19 (77–138) 110 ± 14 (84–136)
ADI-R sociala 15± 4 –
ADI-R communicationa 10± 3 –
ADI-R repetitive behavioura 4± 2 –
ADOS-G totalb 10± 2 –
*p< 0.05.
a Information was unavailable for 3 out of 20 ASD subjects.
b Information was available for five ASD subjects; two cases had both ADOS-G and ADI-R.
Notes
Data expressed as mean± SD (range). There were no significant differences between subject groups in age and full-scale IQ
on p < 0.05 (two-tailed).
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Furthermore, we recruited a group of 19 individuals with ADHD from the adult ADHD services at the
Maudsley Hospital, London. This group served as a neurodevelopmental control group and was matched
to the ASD group in sex, age (mean 31 ± 8.5 years), full-scale IQ (mean 1.7 ± 6) and handedness. Of
these, eight individuals fulfilled the criteria for ADHD combined type and 11 for ADHD inattentive type.
The diagnosis of ADHD was made by a trained and qualified clinician based on a structured clinical
interview according to DSM-IV criteria. ADHD symptoms were also assessed using Barkley Current and
Childhood Symptoms Scales207 and the Wender Utah Rating Scale.246
Magnetic resonance imaging data acquisition
Magnetic resonance imaging (MRI) data were acquired using a 1.5-T GE Signa Neuro-optimized System
(General Electric Medical Systems, Milwaukee, WI, USA) fitted with 40 mT/m high-speed gradients at the
Maudsley Hospital, London. Whole-brain spoiled gradient recalled acquisition in the steady-state T1-weighted
series were collected in the coronal plane with repetition time= 13.8 months, echo time = 2.8 months,
yielding 124 contiguous 1.5-mm2 axial slices of 256 × 192 voxels with an in-plane resolution of 1 mm2. Similar
T1-weighted MRI scans were acquired for the ADHD group on a 1.5-T GE Signa Neuro-optimized System at
the Maudsley Hospital, London, using repetition time= 10.72 months, echo time = 4.86 months, yielding
146 contiguous 1.1-mm2 axial slices. A quadrature birdcage head coil was used for radiofrequency transmission
and reception. Foam padding and a forehead strap were used to limit head motion. All scans were visually
inspected by a radiologist to assess (1) image contrast, (2) movement artefacts and (3) the existence of clinical
abnormalities. Scans displaying low image quality or clinical abnormalities were excluded from this study.
Image processing
Cortical reconstruction and volumetric segmentation was performed with the FreeSurfer image analysis suite
(Laboratory for Computational Neuroimaging, Charlestown, MA, USA), which is documented and freely
available for download online [URL: http://surfer.nmr.mgh.harvard.edu/ (accessed 31 May 2018)]. The
technical details of these procedures are described in prior publications.247–254 Briefly, this processing includes
motion correction and averaging of multiple volumetric T1-weighted images (when more than one is
available), removal of non-brain tissue using a hybrid watershed/surface deformation procedure,249 automated
Talairach transformation, segmentation of the subcortical white matter and deep grey matter volumetric
structures (including hippocampus, amygdala, caudate, putamen, ventricles),251,252 intensity normalisation,
tessellation of the grey matter–white matter boundary, automated topology correction,255,256 and surface
deformation following intensity gradients to optimally place the grey/white and grey/cerebrospinal fluid
borders at the location where the greatest shift in intensity defines the transition to the other tissue class.247
Once the cortical models are complete, a number of deformable procedures can be performed for further data
processing and analysis, including surface inflation,247 registration to a spherical atlas (which utilised individual
cortical folding patterns to match cortical geometry across subjects248), parcellation of the cerebral cortex into
units based on gyral and sulcal structure253,257 and creation of a variety of surface-based data, including maps
of curvature and sulcal depth. This method uses both intensity and continuity information from the entire
three-dimensional magnetic resonance volume in segmentation and deformation procedures to produce
representations of cortical thickness, calculated as the closest distance from the grey/white boundary to the
grey/cerebral spinal fluid boundary at each vertex on the tessellated surface.250 The maps are created using
spatial intensity gradients across tissue classes and are therefore not simply reliant on absolute signal intensity.
The maps produced are not restricted to the voxel resolution of the original data, thus are capable of detecting
submillimetre differences between groups. Procedures for the measurement of cortical thickness have been
validated against histological analysis258 and manual measurements.259,260 FreeSurfer morphometric procedures
have been demonstrated to show good test–retest reliability across scanner manufacturers and across field
strengths.261 All reconstructed surfaces were visually inspected for gross anatomical topological defects. Brains
that did not reconstruct or showed geometric inaccuracies were excluded from the study.
A set of five morphometric parameters per vertex were used as input to the multimodal classifier. Three
parameters [1–3: average convexity or concavity, mean (radial) curvature and metric distortion] accounted
for geometric features at each cerebral vertex and two parameters (4–5: cortical thickness and surface
area, respectively), measured volumetric features.
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The average convexity or concavity was used for quantifying the primary folding pattern of a surface.
Convexity/concavity captures large-scale geometric features and is insensitive to noise in the form of small
wrinkles in a surface.248 At each vertex, convexity/concavity indicates the depth/height above the average
surface and measures sulcal depth or gyral height, respectively. Differences in sulcal depth have previously
been investigated as one important aspect of the cerebral geometry implicated in ASD238 and have been
suggested to reflect abnormal pattern of cortical connectivity. Mean (radial) curvature was used to assess
folding of the small secondary and tertiary folds in the surface. The selection of this feature was motivated
by early findings of polymicrogyria (i.e. excessive number of small convolutions on the surface of the brain)
in autism.262 These would not be captured by the average convexity measure reflecting large-scale
geometric features only. Metric distortion (i.e. Jacobian) indicating the degree of cortical folding was
calculated as degree of displacement and convolution of the cortical surface relative to the average
template.248,263 Although sulcal depth and radial curvature measure specific aspects of the cortical
geometry, metric distortion is a wider measure of the overall degree of cortical folding and thus captures
geometric distortions otherwise not specified. There is a large body of evidence to suggest that individuals
with ASD display abnormal patterns of cortical gyrification reflecting cerebral development and connectivity
(e.g. Levitt and colleagues239 and Hardan and colleagues264). Cortical thickness (see above) and pial area
(i.e. the area of a vertex on the grey matter surface, calculated as the average of the area of the triangles
touching that vertex) were used to quantify volumetric differences. Although these two features are
generally combined to measure regional brain volume, a recent study has shown that cortical thickness
and surface are influenced by distinct genetic mechanism240 and we therefore added as separate features
into the model. A summary of the set of parameters is displayed in Figure 20.
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FIGURE 20 Summary of the five morphometric parameters measured at each cerebral vertex. (a), Average
convexity; (b) cortical thickness; (c) pial area; (d) metric distortion (Jacobian); and (e) mean (radial) curvature.
g/w, grey/white. Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is
published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.
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These included average convexity, cortical thickness, pial area, metric distortion (Jacobian) and mean
(radial) curvature.
Group differences in intracranial volume, total brain volume and grey matter volume as estimated by
FreeSurfer were assessed using t-tests for independent samples prior to classification. There were no
significant differences between groups in any of these parameters at a level of p < 0.05 (Table 49). There
were also no significant differences in total brain volume between controls and individuals with ADHD, nor
between ASD and ADHD group on p < 0.05. Bartlett’s test for homogeneity of variances was used to
examine parameter variability across homologue regions in different hemispheres using a threshold of
p < 0.0014 (corrected for multiple comparisons).
Classification and support vector machine
A linear SVM was used to classify between patient and control group on the basis of their brain morphology.
SVM has previously been applied to MRI data241–243 and a detailed description can be found in Schoelkopf
and Smola265 and Burges.266 Briefly, SVM is a supervised multivariate classification method that treats each
image as a point in a high-dimensional space. If SVM is applied to images coming from different modalities,
as in the current study, the number of dimensions equals the number of voxels/vertices per image multiplied
by the number of modalities. Input data were then classified into two classes (e.g. individuals with ASD and
controls), by identifying a separating hyperplane or decision boundary. The algorithm is initially trained on a
subset of the data <x,c> to find a hyperplane that best separates the input space according to the class
labels c (e.g. –1 for patients, +1 for controls). Here, x represents the input data (i.e. feature vector). The
feature vector was generated by concatenating the five image modalities for each subject. Once the
decision function is learned from the training data, it can be used to predict the class of a new test example.
SVM267 is a maximum margin classifier, which identifies the optimal hyperplane by finding the hyperplane
with the maximum margin (i.e. maximal separation between classes). The margin is the distance from the
separating hyperplane to the closest training examples. The training examples that lie on the margin are
called support vectors. The hyperplane is defined by a weight vector and an offset. The weight vector is a
linear combination of the support vectors and is normal to the hyperplane. The linear kernel SVM used in
the present study allows direct extraction of the weight vector as an image (i.e. the SVM discrimination
map). A parameter C, that controls the trade-off between having zero training errors and allowing
misclassifications, was fixed at C = 1 for all cases (default value). The LIBSVM toolbox for MATLAB
(ACM Transactions on Intelligent Systems and Technology, Taiwan) was used to perform the classifications
[URL: www.csie.ntu.edu.tw/∼cjlin/libsvm/ (accessed 31 May 2018)].
TABLE 49 Between-group differences in overall brain volume and grey matter volume
ASD Control t(df= 38) p-value
ICV 1.67± 0.18 × 106 1.64± 0.21 × 106 –0.63 < 0.60
Total brain volume 9.74± 1.14 × 105 9.69± 0.76 × 105 –0.14 < 0.90
Total grey matter volume 4.89± 0.56 × 105 4.81± 0.41 × 105 –0.58 < 0.60
Grey matter volume right 2.45± 0.28 × 105 2.41± 0.20 × 105 –0.53 < 0.60
Grey matter volume left 2.44± 0.28 × 105 2.39 ± 0.21 × 105 –0.62 < 0.60
ICV, total intracranial volume.
Notes
Data expressed as mean± SD; all measures are in mm3.
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Discrimination maps
The weight vector has the same dimension as the feature vector and is normal to the hyperplane. It can be
thought of as a spatial representation of the decision boundary and thus represents a map of the most
discriminating regions. Here, the feature vector had n ×m dimensions, where n is the number of vertices
and m denotes the number of modalities (i.e. five). Given two groups (ASD vs. controls), with the labels +1
and –1, respectively, a positive value in the discrimination map (red/yellow colour scale) indicates relatively
higher parameter values in patients than in controls with respect to the hyperplane, and a negative weight
(blue/cyan colour scale) means relatively higher parameter values in controls than in patients with respect
to the hyperplane. As the classifier is multivariate by nature, the combination of all voxels as a whole is
identified as a global spatial pattern by which the groups differ (i.e. the discriminating pattern). To enable
visualisation of the discriminating pattern for each image modality, the weight vector was cut into its
constituent parts, which were then mapped back onto the average white matter surface. In the present
study we coloured all voxels that have values > 30% of the maximum value of the discrimination
map.241,268 This threshold, although ultimately arbitrary, eliminates noise components predominantly
(< 30%), thus enabling a better visualisation of the most discriminating regions (31–100%).
Intraregional morphometric profiles
To identify the relative contribution of specific parameters in discriminating between groups at different
locations on the cortical surface, we displayed so called intraregional morphometric profiles. These profiles
were derived by calculating the average weights of vertices within regions of interest (ROI) for the five
different parameters. ROIs were based on contiguous weight clusters from the overall discrimination maps.
The choice of the ROIs, although ultimately arbitrary, was motivated by (1) the relevance of a region to the
current literature (e.g. sulcal depth differences in intraparietal sulcus238) and (2) generally high parameter
weights for a specific morphometric feature (e.g. high weights for cortical thickness in medial temporal
sulcus). The ROI analysis aimed to illustrate that different regions can display distinct differences in one or
more parameters, rather than displaying the same pattern of feature weights. As all weights were scaled,
means and SDs are directly comparable across regions and parameters.
Cross-validation and permutation testing
The performance of the classifier was validated using the commonly used leave-two-out cross-validation
approach. This validation approach provides robust parameter estimates particularly for smaller samples.
In each trial observations from all but one subject from each group were used to train the classifier.
Subsequently, the class assignment of the test subjects was calculated during the test phase. This procedure
was repeated S = 20 times (where S is the number of subjects per group), each time leaving observations
from a different subject from each group out. The accuracy of the classifier was measured by the proportion
of observations that were correctly classified into patient or control group. We also quantified the sensitivity
and specificity of the classifier defined as:
sensitivity = TP / (TP + FN), (1)
specificity = TN / (TN + FP), (2)
where TP is the number of true positives (i.e. the number of patient images correctly classified); TN is the
number of true negatives (i.e. number of control images correctly classified); FP is the number of false
positives (i.e. number of controls images classified as patients); and FN is the number of false negatives
(i.e. number of patients images classified as controls).
Classifications were made, first, by including all five morphological modalities into the feature vector and,
second, on the basis of each individual parameter. Different classifiers were trained for each hemisphere.
This enabled us to assess the overall classification accuracies for individual parameters and hemispheres.
Classifier performance was evaluated using basic ROC graphs as well as permutation testing. Permutation
testing can be used to evaluate the probability of getting specificity and sensitivity values higher than the
ones obtained during the cross-validation procedure by chance. We permuted the labels 1000 times
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without replacement, each time randomly assigning patient and control labels to each image and repeated
the cross-validation procedure. We then counted the number of times the specificity and sensitivity for the
permuted labels were higher than the ones obtained for the real labels. Dividing this number by 1000 we
derived a p-value for the classification.
Finally, the established classifier was used to predict group membership of individuals with ADHD. To achieve
this, the classifier was first retrained using all ASD–control pairs to provide the best possible prediction model
for discriminating the two groups. This trained classifier was then applied to the multiparameter data from
the ADHD group and predictions for group membership for these subjects were derived.
To validate the binary classification of the subject groups on a quantitative level and to identify the degree
to which the classification is driven by autistic symptoms rather than confounds unrelated to autism, the test
margin for each subject coming from the all included classifier was correlated with the level of symptom
severity measured by the ADI-R subscales. A similar approach has previously been employed by Ecker et al.269
Results
Overall classifier performance
Classification accuracies as well as sensitivity and specificity for each classifier are listed in Table 50. On the
whole, strong hemispheric asymmetry was observed with regard to the overall classification accuracy.
The left hemisphere provided consistently higher and above chance prediction accuracies across all
TABLE 50 Results of SVM classification between ASD and control group using different brain morphometric
features in the left and right hemisphere
Morphometric feature Correctly classified (%) Sensitivity (%) Specificity (%) p-value
Left hemisphere
All parameters 85 90 80 0a
Cortical thickness 90 90 90 0a
Radial curvature 72.5 65 80 < 0.001
Average convexity 70 75 65 < 0.004
Metric distortion 80 80 80 0a
Pial area 77.5 70 85 0a
Right hemisphere
All parameters 65 60 70 < 0.03
Cortical thickness 60 65 55 < 0.01
Radial curvature 52.5 50 55 < 0.30
Average convexity 50 40 60 < 0.40
Metric distortion 57.5 45 70 < 0.06
Pial area 45 45 45 < 0.60
a p-values of zero indicates that not a single one of the 1000 permutations provided a better classification.
Notes
Correctly identified ASD cases were considered true positive.
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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morphometric parameters. Here, individuals with ASD were correctly assigned to the appropriate diagnostic
category in 85.0% of all cases when all parameters were considered simultaneously (Figure 21c). The
sensitivity of the multiparameter classification in the left hemisphere was 90.0% (i.e. if a volunteer had a
clinical diagnosis of ASD, the probability that this participant was correctly assigned to the ASD category
was 0.9). The specificity was 80.0%, meaning that 80.0% of the controls subjects were correctly classified
as controls. High classification accuracies were also obtained when individual morphological parameters
were considered. Figure 21a shows the receiver operator characteristics or ROC graph for the six classifiers
in the left hemisphere. In general, one point in ROC space is better than another if it is to the north-west
(true-positive rate is high, false-positive rate is low, or both), with the point (0,1) representing perfect
classification. Classifiers appearing on the left-hand side of the ROC graph, near the x-axis, may be
considered ‘conservative’ (i.e. make positive classifications only with strong evidence but often have low
true-positive rates), whereas classifiers on the upper right-hand side of the graph may be thought of as
‘liberal’ (i.e. make positive classifications with weak evidence so they classify nearly all positives correctly but
often have high false positives). The diagonal line y = x represents the strategy of randomly guessing a class.
Best discrimination was obtained when cortical thickness measures were used to classify between groups
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FIGURE 21 Receiver operating characteristic graphs for classifiers in the left hemisphere and right hemisphere.
(a) Left hemisphere; (b) right hemisphere; (c) classification plots for the left hemisphere; and (d) classification
plots for the right hemisphere. A, all parameters; B, cortical thickness; C, metric distortion/Jacobian; D, average
convexity; E, pial area; F, mean (radial) curvature. Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed
Central Ltd. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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with sensitivity and specificity values as high as 90.0%, followed by a classification on the basis of the metric
distortion parameter (sensitivity 80.0%, specificity 80.0%). The average convexity, pial area and mean
curvature displayed accuracies in the range of 70.0–80.0%. The classification p-value resulting from the
permutation test was very low across, as well as within, modalities (< 0.004). The probability of obtaining
specificity and sensitivity values higher than the ones obtained during cross-validation procedure by chance
is thus extremely low.
A very similar profile of parameter importance was observed in the right hemisphere – despite it having
generally lower classification accuracies. Here, individuals with ASD were correctly assigned to the
appropriate diagnostic category in 65.0% of all cases (sensitivity 60.0%, specificity 70.0%; p < 0.03),
when all parameters were considered simultaneously (see Figure 21a and d). As in the left hemisphere,
cortical thickness as well as metric distortion displayed the best classification performance, although only
cortical thickness measures reached statistical significance (p < 0.01). The discrepancy in overall classification
accuracy between the two hemispheres was not due to differences in parameter variability, as there were
no significant differences in parameter variance between homologous regions in different hemispheres
(calculated across the whole sample).
Thus, although all parameters provided statistically significant predictions in the left hemisphere, only the
full model and cortical thickness displayed significant predictions in the right hemisphere. Highest
classification accuracy (90.0%) might thus be obtained by using cortical thickness measures exclusively in
the left hemispheres. Correlation coefficients between ADI-R subscales and the test margin coming from
the combined model are listed in Table 51. The test margin in the left hemisphere was positively correlated
with the ADI-R scores for individuals with ASD in the social (r = 0.414; p < 0.05) and communication
domain (r = 0.62; p < 0.01). Therefore, individuals with higher values on these ADI-R subdomains are
located on the extreme right relative on the hyperplane, whereas the individuals with a lower level of
impairment are mostly located in close proximity to the hyperplane overall.
Classification of individuals with ADHD using the established ASD classifier
In order to establish the degree of clinical specificity of the discrimination algorithm to ASD, rather than to
NDs in general, the established classifier was used to predict group membership of individuals with ADHD.
To predict group membership, the model including all parameters was chosen as it provided best
classification accuracy in the right hemisphere and high accuracy in the left hemisphere. On the basis of
the neuroanatomical information available for the left hemisphere, 15 out of the 19 individuals with ADHD
were allocated to the control group (78.9%) and four individuals with ADHD were allocated to the ASD
group (21%). Using the right hemisphere, the classifier allocated cases with ADHD with approximately
equal frequencies (47% allocated to the ASD category; 52% allocated to the control category). The
classification plots for individuals with ADHD are shown in Figure 22 for both hemispheres.
TABLE 51 Correlation coefficients between ADI-R diagnostic criteria and weight vector for the model combining
all parameters
Diagnostic test (n= 17)
Left hemisphere Right hemisphere
r p-value r p-value
ADI-R social 0.414* < 0.04 –0.152 < 0.28
ADI-R communication 0.620** < 0.01 –0.074 < 0.38
ADI-R repetitive behaviour 0.161 < 0.26 –0.198 < 0.22
*p < 0.05 (one-tailed),**p< 0.01 (one-tailed).
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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FIGURE 22 Classification plots showing group allocation of individuals with ADHD (blue squares) in the (a) left and
(b) right hemisphere using the ASD classifier. Reproduced from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed
Central Ltd. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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Discrimination maps of ASD-specific abnormalities
The spatial maps of brain regions identified as outlined above are shown in Figure 23 and a summary
description can be found in Table 52. Each of these maps is a spatial representation of the SVM weight
vector, and although they do not directly quantify the information content of each region, each map forms
a spatially distributed pattern showing the relative contribution of each voxel to the decision function.
Although ‘knockout’ techniques may be used to directly quantify the information content of particular
regions, this approach may be hampered by substantial information redundancy across brain regions.
Nonetheless, the spatial distribution of the weight vector does provide information about which brain
regions contributed to classification and in this case is suggestive of a distributed pattern of relative deficit
or excess in ASD with respect to controls. We emphasise that due to the multivariate character of SVM
(i.e. it considers inter-regional correlations), each region in the discrimination maps should be interpreted in
the context of the entire discriminating pattern and should not be considered in isolation. Furthermore,
individual regions may display high classification weights for several reasons [e.g. there is a large difference
in volume between groups in that region, or the region is highly intercorrelated with other components of
the network (i.e. pattern)]. This is of particular relevance to ASD, as individuals with the disorder most likely
have abnormalities in the development of neural systems, in addition to differences in isolated regions.
Thus, it is important to highlight that individual network components are not necessarily different between
groups, but should be considered as constituent parts of a neuroanatomical network discriminating
between groups.
As can be seen in Figure 23, the five investigated parameters resulted in different spatially distributed
patterns of regions with highest contribution to the discrimination. Although cortical thickness provided
best classification accuracy and maximum weight values, differences between groups were observed in
both volumetric as well as geometric features.
Colour maps represent the weight vector on the basis of the five modality classification for cortical
thickness (see Figure 23a), average convexity (see Figure 23b), metric distortion (see Figure 23c) and pial
area (see Figure 23d). Weights for the mean (radial) curvature did not exceed the set threshold. Positive
weights (i.e. overall excess patters in ASD relative to controls) are displayed in red, negative weights
(i.e. overall deficit patterns in ASD relative to controls) are displayed in blue (see Figure 23).
Cortical thickness
In both hemispheres, the discriminative pattern for cortical thickness in ASD comprised regions in all four
lobes of the cortex (see Figure 23a). Regional details are summarised in Table 52. The ‘excess pattern’
(i.e. ASD > controls) comprised several temporal regions, including the right superior temporal sulcus
(STS, BA22), medial and superior temporal gyrus (BA21/BA22) as well as the parahippocampal gyrus (BA36),
fusiform gyrus (BA20) and enthorinal cortex. In addition, the excess pattern included the inferior/superior
parietal lobe (BA39), Brodmann area 18 of the occipital lobe, and the anterior and posterior cingulate gyrus.
Although the excess pattern comprised predominantly occipito-temporal regions, the pattern displaying a
relative thinning of the cortex in ASD versus controls (i.e. ‘deficit pattern’) included mainly frontal and
parietal regions such as the middle frontal gyrus (BA46), the medial/superior frontal gyrus (BA10) and
BA46 in the medial frontal gyrus. In addition, the deficit pattern contained the superior parietal cortex
(BA40/7) and in the anterior cingulate gyrus.
Surface area
Only a few surface area (see Figure 23d) differences were observed in relatively small clusters with
generally low weights. Details are summarised in Table 52.
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TABLE 52 Regions displaying high discrimination weights between ASD and control group for volumetric measures
Parameter Region Hemisphere x y z Weight of each cluster centroid
Cortical thickness
ASD> controls Lateral orbitofrontal R 27 22 –5 5.13
Supramarginal gyrus L –49 –45 35 4.37
Superior parietal R 20 –82 31 3.96
Inferior temporal L –53 –28 –22 4.53
Middle temporal L/R ± 48 –28 –7 6.66
Superior temporal gyrus L/R ± 53 –20 –1 5.85
Superior temporal sulcus R 51 –34 7 4.08
Parahippocampal gyrus L/R ± 31 –27 –16 3.27
Fusiform gyrus L/R –36 –28 –18 4.64
Entorhinal cortex L/R ± 21 –17 –23 3.87
Lateral occipital L/R ± 15 –98 6 6.92
Posterior cingulate gyrus L –7 –33 28 3.97
Anterior cingulate gyrus R –6 28 –7 –2.71
Precuneus L –11 –55 48 –3.82
ASD< controls Rostral middle frontal L/R ± 35 36 9 –5.60
Superior frontal L/R ± 12 61 7 –5.39
Caudal middle frontal L –40 20 36 –3.12
Pars opercularis L
Inferior parietal lobe R 41 –60 36 –3.95
Superior parietal lobe R 17 –64 50 –5.00
Precuneus R 13 –37 63 –3.18
Anterior cingulate gyrus R 6 30 –5 –3.18
Surface area
ASD> controls Precentral R 56 5 15 3.23
Orbitofrontal L –18 –96 –7 2.60
Supramarginal gyrus L –55 –40 36 3.45
Inferior parietal R 49 –50 12 4.57
Inferior temporal lobe L –45 –63 –1 2.69
Lateral occipital R 17 –95 14 2.54
ASD< controls Superior frontal R 15 39 7 –2.26
Rostral middle frontal R 35 36 8 –2.85
Paracentral R 10 –6 46 –2.20
Superior temporal L –51 5 13 –3.98
Pericalcarine fissure L –13 –76 7 –4.50
L, left hemisphere; R, right hemisphere.
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
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Regional geometric characteristics
Apart from volumetric differences, features describing regional geometric characteristics also displayed
high discrimination weights, which were summarised in Table 53. In both hemispheres, individuals with
ASD displayed a pattern of relative increase in sulcal depth (see Figure 23b) in the intraparietal sulcus as
well as in the superior frontal cortex. The discriminative pattern for cortical folding (see Figure 23c), as
indicated by the metric distortion (i.e. Jacobian), included mainly bilateral parietal regions such as the
inferior parietal lobe (BA39/40), and several regions of the right frontal lobe (e.g. supramarginal gyrus,
postcentral gyrus, orbitofrontal regions). In addition, the discriminative pattern in cortical folding comprised
the precuneus.
Morphometric profiles
The discrimination maps show that different morphometric parameters elicited different spatial patterns of
weights with some overlap between particular parameter pairs. The weights for individual parameters are
thus not uniform across the cortex, but vary from region to region (i.e. vertex to vertex). This can also be seen
on the basis of the morphometric profile for individual regions, which are displayed in Figures 24–27 and
listed in Table 54. These profiles visualise the mean parameter weights for individual features within ROI.
In the intraparietal sulcus for instance, high discrimination weights were observed for differences in sulcal
depth with lower weights for volumetric features such as cortical thickness or surface area (see Figure 24).
A similar profile was also seen in the inferior parietal lobe (BA39). Here, the weights for volumetric
parameters such as cortical thickness or surface area were very low in comparison with the weights
associated with the pattern of cortical folding (i.e. metric distortion) (see Figure 25).
(a)
(c) (d)
(b)
FIGURE 23 Discrimination maps for the five different morphometric features in the left and right hemispheres.
Colour maps represent the weight vector on the basis of the five modality classification for (a) cortical thickness;
(b) average convexity; (c) metric distortion; and (d) pial area. Weights for the mean (radial) curvature did not
exceed the set threshold. Positive weights (i.e. overall excess patters in ASD relative to controls) are displayed in red,
negative weights (i.e. overall deficit patterns in ASD relative to controls) are displayed in blue. Reproduced from
Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
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Other regions, however, displayed high weights for volumetric parameters exclusively. For instance, in the
temporal sulcus (BA21), high weights were observed for cortical thickness exclusively in the light of low
weights in all other parameters (see Figure 27). There were also regions with equally high weights in
volumetric as well as geometric features (e.g. the anterior cingulate gyrus). Here, cortical thickness as well
as local cortical folding displayed high parameter weights.
In summary, we observed a spatially distributed pattern of regions that can be used to differentiate individuals
with ASD from controls. Overall, highest weights were observed for measures of cortical thickness, followed
by geometric features such as sulcal depth and metric distortion, which were predominantly observed in
parietal regions. This suggests that both volumetric and geometric features play an important role in
distinguishing between ASD and control group. Finally, we demonstrated that the parameter weights for
individual cortical features were region dependent.
TABLE 53 Regions displaying high discriminative weights between ASD and control group for geometric measures
Parameter and region Hemisphere x y z Weight of each cluster centroid
Metric distortion: ASD > controls
Precentral gyrus L –50 –5 37 3.23
Rostral middle frontal L –44 24 28 3.27
Superior frontal gyrus R 14 40 14 2.51
Supramarginal gyrus L –51 –50 25 5.30
Postcentral gyrus L –60 –8 20 3.67
Posterior cingulate gyrus L –7 –28 29 3.50
Pericalcarine fissure L –17 –67 10 3.46
Lateral occipital gyrus R 28 –86 16 2.87
Inferior parietal lobe R 47 –45 37 4.90
Middle temporal gyrus R 53 –53 2 2.69
Paracentral gyrus R 8 –22 47 3.23
Lingual gyrus R 25 –55 2 2.50
Metric distortion: ASD < controls
Anterior cingulate L –6 34 0 –2.75
Postcentral gyrus R 30 –28 63 –3.98
Supramarginal gyrus R 59 –35 29 –3.75
Rostral middle frontal R 37 32 7 –4.27
Precentral gyrus R 42 –6 47 –3.59
L, left hemisphere; R, right hemisphere.
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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FIGURE 24 Visualisation of the morphometric abnormalities in the right intraparietal sulcus. (a) Colour maps
represent the weight vector score; (b) outlines of the cortical surface for ASD (red) and control (blue) group (this
main discriminating factor in this group was an increase in sulcal depth in ASDs relative to controls); (c) differences
in sulcal depth for this ROI are shown for both groups; and (d) morphometric profile for this region. Profiles were
derived by averaging the weight vector scores across vertices within this ROI and for the different morphometric
parameters. Weights were identified on the basis of the concatenated SVM model, thus showing the relative
contribution of parameters in this ROI. Reproduced from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central
Ltd. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.
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Discussion
Here, we used a multiparameter classification approach to characterise the complex and subtle grey matter
differences in adults with ASD and ADHD. SVM achieved good separation between groups and revealed
spatially distributed and largely non-overlapping patterns of regions with highest classification weights for
each of five morphological features. Our results confirm that the neuroanatomy of ASD and ADHD are
truly multidimensional, affecting multiple neural systems. The discriminating patterns detected using SVM
may help classify affected individuals.
There is good evidence to suggest that several aspects of cerebral morphology are implemented in ASD
and ADHD, including both volumetric and geometric features.238,239 However, these are normally explored
in isolation. Here, we aimed to establish a framework for multiparameter image classification to describe
differences in grey matter neuroanatomy in ASD and ADHD in multiple dimensions, and to explore the
predictive power of individual parameters for group membership. This was achieved using a multiparameter
classifier incorporating volumetric and geometric features at each cerebral vertex. In the left hemisphere,
SVM correctly classified 85% of all cases overall at a sensitivity and specificity as high as 90% and 80%,
respectively, using all five morphological features. This level of sensitivity compares well with behaviourally
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FIGURE 25 (a) Visualisation of the morphometric abnormalities in the left inferior parietal lobe (BA39); (b) outlines of
the cortical surface for ASD and control group; (c) differences in metric distortion for this ROI are shown for both
groups; and (d) morphometric profile. Reproduced from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative
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guided diagnostic tools, whose accuracies are on average around 80%. Naturally, one would expect lower
sensitivity values than the test used for defining the ‘autistic prototype’ itself (i.e. ADI-R). Thus, if a classifier
is trained on the basis of true positives identified by diagnostic tools, the maximal classification accuracy that
could be reached is only as good as the measurements used to identify true positives.
The significant predictive value of pattern classification approaches may have potential clinical applications.
Currently, both ASD and ADHD are diagnosed solely on the basis of behavioural criteria. The behavioural
diagnosis is, however, often time-consuming and can be problematic, particularly in adults. In addition,
different biological aetiologies might result in the same behavioural phenotype (the ‘autisms’232), which is
undetectable using behavioural measures alone. Thus, the existence of an ASD (or ADHD) biomarker such
as brain anatomy might be useful to facilitate and guide the behavioural diagnosis. This would, however,
require further extensive exploration in the clinical setting, particularly with regard to classifier specificity to
ASD or ADHD – rather than neurodevelopmental conditions in general.
To address the issue of clinical specificity, the established ASD classifier was used to classify individuals with
ADHD. Bilaterally, the ASD classifier did not allocate the majority of ADHD subjects to the ASD category.
This indicates that it does not perform equally well for other neurodevelopmental conditions and is more
specific to ASD. To further demonstrate that the classification is driven by autistic symptoms, the test
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FIGURE 26 (a) Morphometric abnormalities in the middle temporal sulcus; (b) visualisation of cortical thickness
measures within the middle temporal sulcus; (c) and (d) in this region, only cortical thickness discriminated between
ASD and control groups, for which individuals with ASD displayed an increase in thickness, relative to controls.
Reproduced from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under
license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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FIGURE 27 (a) Morphometric abnormalities in the posterior cingulate gyrus; (b) and (c) a combination of cortical
thickness and folding pattern lead to a high contribution to the classification in that region. Reproduced from
Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
TABLE 54 Mean discrimination weights within ROI for individual morphometric features
Region
Mean (weight)
Cortical
thickness
Mean
curvature Sulcal depth
Metric
distortion Surface area
Intraparietal sulcus (R) 0.97 0.16 4.63 1.51 2.38
Inferior parietal lobe (L) 1.51 0.23 0.99 4.96 0.88
Medial temporal sulcus (L) 5.66 0.07 0.17 0.48 0.62
Posterior cingulate gyrus (L) 3.83 0.09 0.78 3.79 0.20
L, left hemisphere; R, right hemisphere.
Adapted from Ecker et al.4 © 2010 Ecker et al.; licensee BioMed Central Ltd. This article is published under license to
BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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margins of individuals with ASD were correlated with measures of symptom severity.269 We found that
larger margins were associated with more severe impairments in the social and communication domain
of the ADI-R. The classifier therefore seems to utilise neuroanatomical information specifically related to
ASD rather than simply reflecting non-specific effects introduced by any kind of pathology. However, due
to a recent scanner upgrade, ADHD scans were acquired with different acquisition parameters, while
manufacturer, field strength and pulse sequence remained the same. FreeSurfer has been demonstrated
to show good test–retest reliability particularly within scanner manufacturer and field strength,261 but we
cannot exclude the possibility that systematic differences in regional contrast may have affected the ADHD
classification. Future research is thus needed to validate the ADHD findings on an independent sample.
The overall classification accuracy varied across hemispheres (79.0% left vs. 65.0% right) in the absence of
interhemispheric differences in parameter variability. Hemisphere laterality is an area, which remains relatively
unexplored in autism. Although our data suggest that the left hemisphere is better at discriminating between
groups (i.e. is more ‘abnormal’), it is unclear whether this discrepancy is due to quantitative differences in
parameters or to qualitative aspects of the discriminating patterns (i.e. additional regions). Furthermore, it is
also not possible to identify whether or not individuals with ASD or ADHD display a higher (lower) degree of
cortical asymmetry relative to controls. There is some evidence to suggest that individuals with ASD show a
lower degree of ‘leftward’ (i.e. left > right) cortical symmetry than controls,270 which may explain differences
in classification accuracy. There is also evidence to suggest that the left hemisphere is under tighter genetic
control than the right hemisphere,271 which may be of relevance to a highly heritable condition such as ASD.
However, a direct numerical comparison between hemispheres is needed to address this issue directly.
The classification accuracy varied not only across hemispheres, but also across morphometric parameters.
Bilaterally, cortical thickness provided the best classification accuracy and highest regional weights.
Differences in cortical thickness have been reported previously in ASD and ADHD for both increases272,273
as well as decreases,272,274 and in similar regions as reported here (i.e. parietal, temporal and frontal areas).
The overlap with previous studies indicates that these regions display high classification weights due to
a quantitative (i.e. ‘true’) difference rather than high intercorrelations with thickness measures in other
brain regions.
Certain geometric features such as average convexity and metric distortion provided above chance
classifications as well, particularly in parietal, temporal and frontal regions, and in areas of the cingulum.
Average convexity and metric distortion measure different aspects of cortical geometry (see Materials and
methods) and have previously been linked to ASD, as has sulcal depth.238 Such geometric features were
suggested to reflect abnormal patterns of cortical connectivity. There have also been reports of abnormal
patterns of gyrification262,264 and large-scale displacements of the major sulci.239 Thus, our study provides
further evidence to support the hypothesis that the ‘autistic brain’ is not just bigger or smaller but is also
abnormally shaped and that this is ‘separable’ from ADHD.
Strengths and weaknesses
Our findings should be interpreted in the context of a number of methodological limitations.
First, the classification algorithm is highly specific to the particular sample used for ‘training’ the classifier,
namely high-functioning adults with ASD. The advantage of this approach is that the classifier offers high
specificity with regard to this particular subject group, but is less specific to other cohorts on the spectrum.
Owing to the small sample size it was also not possible to reliably investigate differences between HFA and
Asperger syndrome. Evidence275 suggests that by adulthood these groups are largely indistinguishable at
the phenotypic level. However, the extent to which these groups differ at the level of brain anatomy is
unknown and may be worth investigating using SVM in the future. Second, 85% of ASD participants in
our sample were diagnosed using the ADI-R and 15% were diagnosed using the ADOS-G. As both
diagnostic tools measure autistic symptoms at different developmental stages, the classifier may be biased
towards individuals with an early diagnosis of ASD. Although it is not expected that classifier performance
on the basis of ADOS-G and ADI-R differ drastically, diagnostic heterogeneity may be a potential limitation.
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Finally, SVM is a multivariate technique and hence offers a limited degree of interpretability of specific
network components. Additional analysis such as ‘searchlight’ or ‘virtual lesions’ approaches276–278 may
therefore be combined with SVM in the future to establish the relative contribution of individual regions/
parameters to the overall classification performance.
Conclusions
Although classification values and specific patterns we report must be considered as preliminary, our study
offers a ‘proof of concept’ that brain imaging may help complement traditional interview-based techniques
to more accurately identify young adults with ASD and/or ADHD.
Key messages
ASD and ADHD are multidimensional and implicate multiple neural systems.
SVM achieves good separation between groups.
The discriminating patterns detected using SVM may help classify affected individuals.
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Section 4 Improving outcomes through
intervention
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Chapter 19 An overview
In the previous chapters, we saw that ASD and ADHD (and their associated mental health symptoms) arefrequently unrecognised and untreated – both in the community, by GPs, and by the specialist mental
health services we investigated. Therefore, as a next step, we piloted new methods to help identify
affected individuals based on clinical interview (and developed proof of concept for the potential utility
of biomarkers).
However, simply diagnosing affected individuals is not enough. They need to be offered appropriate
treatments based on their individual needs. This is true both in GP community settings and in mental
health services.
There are currently no highly effective pharmacological treatments for core symptoms in ASD, but there is
initial evidence that some associated symptoms may be modifiable by medication. However, we do not
know how medications are currently used in people with ASD. For instance, the current prescribing in the
UK by GPs of medication to people with ASD for associated symptoms is unknown. By contrast, in ADHD
there are effective treatments for core symptoms and prescribing practice by GPs in the NHS has been
extensively investigated. However, relatively little is known about how ADHD medications perform in
particular subgroups of individuals who are often excluded from classical clinical trials (e.g. those with ID or
prisoners). Finally, people increasingly wish to use cognitive–behavioural (as opposed to medication-based)
approaches. The evidence base for their use in these disorders is, however, sparse.
In summary, in order to improve clinical practice we need to understand how current treatments are used
across the UK and/or if they can be adapted (or better targeted) to be more effective (especially in people
who are often excluded). In addition, we need to improve staff knowledge and clinical practice.
Hence, our overall aims were to:
l improve understanding of the most commonly used pharmacological treatments in the community
through a survey of current prescribing by GPs across the UK to individuals with ASD
l initiate pilot studies on the effectiveness of ADHD treatments on both core and associated symptoms in
people with ID, and in prisoners
l provide proof of concept for the effectiveness of cognitive behavioural approaches in ASD
l pilot, and test, the effectiveness of electronic-based staff training from an expert centre to local services.
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Chapter 20 Pharmacological treatments
prescribed to people with ASD in UK primary
health care
Introduction
Individuals with ASD have a very high prevalence of comorbid mental health conditions, including ADHD,
LDs, oppositional defiance disorder or CD, emotional disorders, anxiety and other phobic disorders, and
chronic tic disorder.29,58,279 Hence, the development and optimisation of interventions (including behavioural
treatment, educational approaches and pharmacotherapy) to alleviate symptoms/impairments of those
with ASDs, so as to improve the quality of life of individuals and their families, is imperative.
Medication may be a helpful therapeutic intervention to manage disabling behavioural and/or mental
health symptoms in the autistic population; however, there are currently no practice guidelines.280 A
review concluded that although there is no standard medication for treating ASD, people are prescribed
a variety of psychotropic medications (and there is scant reliable research evidence supporting this practice
in adolescents and adults).281 In fact, some have suggested that in individuals with ASDs psychiatric
medications show decreased efficacy and result in more adverse effects, such as behavioural toxicity
with tricyclic antidepressants and social withdrawal and irritability with methylphenidate.282–284 This
creates uncertainty about the appropriateness of using existing pharmacological treatment(s) for
comorbid conditions, such as ADHD,280,285 and has led to recent work on drug effectiveness.54 Despite this
uncertainty, drug surveys and studies of health insurance claims databases conducted in the USA have
shown that over time more psychotropic drugs (and in particular antipsychotics, antidepressants and
stimulants) are being prescribed to children, young people and adults with ASD.286–290 For example, in
North Carolina between 1992–3 and 2001, psychotropic drug use rose significantly from 30.5% of
children and adults with autism to 45.2%. Furthermore, antidepressant use increased 3.5-fold (from 6.1%
in 1992–3 to 21.4% in 2001).286 There is also increasing evidence that the likelihood of an ASD person
being prescribed medication increases with age. For instance, one study reported that rates of psychotropic
drug use rose from 56% for 6- to 11-year-olds to 73% for 18- to 21-year-olds.288 This is of importance
because once an individual has been prescribed a psychotropic medication, they are (1) 11 times more
likely to remain on it than they would a non-psychotropic drug289 and (2) much more likely to be exposed
to (potentially hazardous) polypharmacy (e.g. some have reported that more than half of children and
youths with ASD who were prescribed psychotropic medication experienced this280,291).
Although there is limited evidence to guide psychotropic medication use in the ASD population, two drugs
have shown efficacy for the alleviation of behavioural symptoms in children and adolescents with autistic
disorder: risperidone (Risperdal®, Janssen-Cilag Ltd) 292,293 and aripiprazole (Abilify®; Otsuka Pharmaceuticals
Ltd, Slough, UK).294,295 In 2006, risperidone was approved by the Food and Drug Administration in the USA
for the treatment of irritability associated with autistic disorder in 5- to 16-year-olds; this includes aggression
and deliberate self-injuriousness. Aripiprazole was also approved by the Food and Drug Administration in
2009 after demonstrating efficacy in the same indication in 6- to 17-year-olds.294,295 An application for UK
approval was submitted but subsequently withdrawn by the licence holder of risperidone, Janssen-Cilag Ltd,
in 2006 after receiving an offer of conditional approval, but limiting its indication to the symptomatic
treatment of severe aggression and violence in children with autism.296 Safety monitoring through a treatment
registry formed part of the conditions due to concerns that risperidone could be misused as long-term
chemical control in children. In the UK, risperidone remains unlicensed for use in children with autism, but it is
approved for the treatment of persistent aggression in CD in children of subaverage intellectual functioning.
The reported side effects of antipsychotic drugs include significant weight gain and other metabolic effects
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such as hyperprolactinaemia and diabetes mellitus,297,298 movement disorders such as tardive dyskinesia,
tremor and dystonia,299,300 and life-threatening side effects such as rhabdomyolysis, neuroleptic malignant
syndrome and seizures have also been reported.301–303 However, little is known about the long-term safety
of antipsychotics and polypharmacy with other drug classes, especially in the autistic population. This is a
valid concern because of the early diagnosis of ASDs and the lifetime persistence of symptoms, which are
increasingly managed with psychotropic drugs.289
Studies have identified substantial support needs for ASD in terms of health, social care and educational
services,7,304 but to date we have very few data in the UK about the prescribing of pharmacological
treatment to young people with ASDs and associated neuropsychiatric comorbid disorders. Information
about prescribing practices and comorbidities is necessary for prioritising further research into the efficacy
and short- and long-term safety of psychotropic medications in this particular patient population. Hence,
we conducted an observational cohort study based on a primary care database to investigate the
pharmacological treatments used among a cohort of children, adolescents and young adults diagnosed
with ASD.
Method
Study design
A descriptive cohort study was conducted using THIN database to investigate the incidence and prevalence
of ASD diagnoses, psychotropic medication prescribing and neuropsychiatric-related comorbidities of
children, adolescents and young adults in UK primary care.
Data source
The Health Improvement Network contains anonymised computerised information systematically recorded
by GPs in the UK for patient management. The database provider collates and organises this information in
order for it to be used for research. In the UK, almost all patient care is managed by GPs in primary care,
who act as gatekeepers of the UK NHS. When required, GPs will refer patients to hospital consultants or
specialists in secondary care for diagnosis and initiation of treatment, and GPs usually continue to monitor
their patients and issue prescriptions. The diagnosis and management of ASDs and the initiation of drug
treatment for symptoms of ASDs (or comorbidities) is usually the responsibility of specialist teams and GPs
manage patients in primary care through shared care arrangements with these teams.
The Health Improvement Network covers approximately 5.7% of the UK population with 3.6 million active
patients from 464 general practices.305 The demographic distribution of THIN is broadly representative of
that of the UK; therefore, analysis of the clinical and prescribing data will provide information on trends
that is representative of national trends. This is particularly useful in evaluating treatment rates, rates of
specific diagnoses and changes in these rates.
The Health Improvement Network is a rich source of clinical primary care data and contains information
on patient demographics, prescriptions, diagnoses and referrals. Drugs are coded in the database using
Multilex® codes (First Databank; THIN). Diagnoses, symptoms and referrals are coded using Read Clinical
Terms, a comprehensive hierarchical system.306 The database has been previously used to study trends in
disease incidence and prescribing patterns in paediatric and adult populations.307–309 A previous study using
a similar UK primary care database (the former General Practice Research Database; GPRD), has validated
diagnoses of ASDs in GP records by expert review and by a computerised diagnostic algorithm of DSM-IV
symptoms ratings, showing they are appropriate for the identification of ASD cases.310 Practices who
contribute to THIN and/or GPRD use the same practice management software (Vision, In Practice Systems
Ltd, London, UK), so data from both databases are collected in a similar manner and structure. In fact, a
large proportion of practices contributing to THIN also contribute to GPRD (66%, 327/495 practices
in 2001–8).311
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Study population
The study population comprised all 5651 individuals in THIN who were children, adolescents and young
adults aged < 25 years who had a record of diagnosis of ASD in the study period between 1 January 1992
and 31 December 2009. The start date of each patient was defined as the latest of the following: the date
of the patient’s registration at the general practice; the date that the general practice began using the
Vision software (a clinical management system); the date that the practice was deemed to meet a key
quality indicator known as the acceptable mortality reporting.312 Patients were included if they had an
observation period of least 6 months available from their start date and were registered with the general
practice during the study period.
Prevalence of ASD
Patient records dated within 1 year after a patient’s start date (which may or may not be within the study
period), were screened to identify diagnoses of ASD. Any individual with an ASD diagnosis within 1 year of
the start date were considered affected with ASD (i.e. prevalent) unless they were aged < 2 years at the
time of the diagnosis. Autistic disorder can be diagnosed in children as young as 2 years of age, whereas
those with Asperger disorder and PDD (not otherwise specified) are frequently not reliably diagnosed until
4 or 5 years of age.313 Hence, patients with a record of ASD at ages < 2 years are likely to be incident with
ASD. Incident patients were defined as (1) those who have a first diagnosis of ASD following the first year
screening period; or (2) those with an ASD diagnosis when aged < 2 years during the screening period.
The index date for each patient was defined as the date of the first recorded diagnosis of ASD following
the patient’s start date. The annual prevalence of ASD was calculated by counting all patient incidents with
ASD in a particular year and all prevalent patients in active follow-up of that year divided by the total
number of individuals in the THIN mid-year population (MYP; i.e. those who remained registered on the
database on 1 July of that calendar year). The annual incidence of ASD was calculated by counting all
patients incident with ASD in a particular year divided by the total number of individuals in the THIN MYP.
Annual prevalence of ASD was calculated by age group defined as 0–5 years (young children), 6–12 years
(children), 13–17 years (adolescents) and 18–24 years (young adults).
Drug prescribing
Nine categories of drugs were defined (by MLM, ES and KG) as stimulants [methylphenidate, dexamfetamine
(Dexedrine®; Celltech Pharmaceuticals Ltd, Brussels, Belgium), atomoxetine]; antidepressants; antipsychotics;
antiepileptics/mood stabilisers; benzodiazepines; sleep medication [including melatonin (Circadin®; Temmler
Pharma GmbH & Co, Marburg, Germany)]; clonidine; beta-blockers; antiparkinsonism drugs which may be
co-prescribed with antipsychotics to counteract unwanted motor effects. The prescriptions for the study drugs
of each patient recorded on or after their index date were identified and the annual proportions of the ASD
cohort prescribed drug treatment were calculated by drug category and by individual drug (with 95% CIs).
Comorbidities
The clinical records of each patient recorded on or after their index date were screened for neuropsychiatric
comorbidities. Diagnostic codes (Read Codes) were categorised into 10 groups (by DGM, ES and MLM):
psychotic disorders (including schizophrenia and delusions); behavioural, conduct and PDs; mood disorders;
anxiety and phobias (including OCD); ADHD; suicidal behaviour and self-harm; anorexia and bulimia; tic
disorders; developmental difficulties and LDs; substance and alcohol misuse. The proportions of the cohort
with neuropsychiatric comorbidities were calculated.
Data management and analyses were performed using Stata® SE version 11.2 (StataCorp, College Station,
TX, USA).
The study protocol was granted approval by the Scientific Review Committee of Cegedim Strategic Data
Medical Research UK, the data providers of THIN.
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Results
Characteristics of the ASD cohort
There were 5651 patients aged < 25 years in the THIN database with at least one diagnosis record of ASD
during the study period: 83% were male (n = 4688). Table 55 provides details on the characteristics of the
study cohort. In 4541 patients who became incident with ASD during the study period, the mean age at
first recorded diagnosis was 9 years (SD 4.74 years); however, a bimodal distribution of age was observed,
with peak frequencies of first diagnoses recorded at 4 years and 8 years of age. First diagnoses of ASD
were recorded at a later age in females than in males.
Prevalence/incidence of ASD diagnoses
The overall prevalence of ASD diagnoses during the study period was 2.23 persons per 1000 MYP; the
highest prevalence was seen in children, with 3.87 children per 1000 MYP. In 2008, ASD prevalence for
young children was 2.06 per 1000 MYP, 8.89 per 1000 MYP in children, 6.64 per 1000 MYP in adolescents
(aged 13–17 years) and 2.44 per 1000 MYP in young adults (aged 18–24 years).
Figure 28 shows the prevalence of ASD in the cohort over the study period. The prevalence of ASD
increased 64.6-fold from 0.08 persons per 1000 MYP in 1992 (95% CI 0.05 to 0.12) to 5.04 persons per
1000 MYP in 2008 (95% CI 4.89 to 5.19). The increase was greater in males (77.1-fold) than in females
(36.8-fold). The incidence of ASD also rose in the same period by 23.7-fold, from 0.03 persons per 1000
MYP in 1992 (95% CI 0.01 to 0.05) to 0.67 persons per 1000 MYP in 2008 (95% CI 0.61 to 0.72).
The rise in incidence was greater in females (32.9-fold) than in males (23.1-fold).
TABLE 55 Characteristics of the patient cohort with ASD diagnoses
Cohort characteristic All Male Female
Number of subjects aged 0–24 years (%) with at least one diagnosis of ASD 5651 (100.0) 4688 (83.0) 963 (17.0)
Mean age (years) (SD) at first recorded diagnosis of ASD 9.3 (5.05) 9.2 (4.92) 10.1 (5.60)
Median age (years) (IQR) at first recorded diagnosis of ASD 8.4 (7.24) 8.2 (6.92) 9.1 (8.64)
ASD diagnoses
Total number of ASD diagnoses 8602 7205 1397
Mean number of ASD diagnoses per person (SD) 1.5 (1.25) 1.5 (1.27) 1.5 (1.10)
Median number of ASD diagnoses per person (IQR) 1.0 (1.00) 1.0 (1.00) 1.0 (1.00)
Prevalent/incident patients
Number of subjects prevalent with ASD (ASD diagnosis recorded within
1 year of entry into study)
1110 (19.6) 919 (19.6) 191 (19.8)
Number of subjects incident with ASD 4541 (80.4) 3769 (80.4) 772 (80.2)
Incident patients: mean age (years) (SD) at first recorded diagnosis of ASD 9.0 (4.74) 8.9 (4.61) 9.6 (5.29)
Incident patients: median age (years) (IQR) at first recorded diagnosis of ASD 8.1 (6.72) 8.0 (6.44) 8.5 (8.08)
Incident patients: mean number of ASD diagnoses per person (SD) 1.5 (1.33) 1.5 (1.34) 1.4 (1.28)
Prescribing
Total number of prescriptions prescribed post index date 158,285 122,587 35,698
Number of study drug prescriptions issued at any time post-index date 47,738 36,983 10,755
Total number of patients (%) prescribed at least one prescription for a
study drug
1619 (28.6) 1312 (28.0) 307 (31.9)
IQR, interquartile range.
Reproduced from Murray et al.6 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited. The table includes minor
formatting changes.
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Drug prescribing
There were a total of 1619 patients (28.7%, 95% CI 27.3% to 30.1%) in the cohort, who received
47,738 prescriptions for the study drugs; proportionally more females than males were prescribed these
drugs (see Table 55). In 2008, 33.8% of those prescribed psychotropic medications (305/902 patients)
were given prescriptions for two or more drugs. The three most commonly prescribed drug groups overall
(and in male patients) were sleep medication (9.7% overall, 95% CI 8.9% to 10.6%; 10.0% of males,
95% CI 9.1% to 10.9%), stimulants (7.9% overall, 95% CI 7.2% to 8.7%; 8.7% of males, 95% CI 7.8%
to 9.5%) and antipsychotics (7.3% overall, 95% CI 6.7% to 8.1%; 7.0% of males, 95% CI 6.3% to 7.8%).
For females they were antiepileptics/mood stabilisers (11.0%, 95% CI 9.0% to 13.3%), antidepressants
(9.0%, 95% CI 7.2% to 11.1%) and sleep medication (8.5%, 95% CI 6.8% to 10.6%). Clonidine and
beta-blockers were rarely prescribed; only 30 and 36 patients in the total cohort, respectively, were
prescribed these drugs. The five most commonly prescribed drugs were methylphenidate (7.1% of the ASD
cohort, 95% CI 6.4% to 7.8%), melatonin (5.7%, 95% CI 5.1% to 6.4%), risperidone (5.6%, 95% CI
5.0% to 6.3%), diazepam (3.2%, 95% CI 2.8% to 3.7%) and valproic acid (3.2%, 95% CI 2.8% to 3.7%).
Stimulants accounted for 23% (n = 10,981) of all psychotropic drug prescriptions issued to the cohort and
the average number of prescriptions per patient was 24.6. However, the drug group with the most
prescriptions was antiepileptics/mood stabilisers, with 33.2% of all prescriptions (n = 15,868; the mean
number of prescriptions per patient was 44.1) (Table 56).
The numbers of individuals with ASD diagnoses between 1992 and 1998 were relatively low (see Figure 28),
which made prescribing rates unstable. Consequently, Figure 29 shows the prescribing rates of the drug
groups from 1999 to 2008 only.
The proportion of the cohort prescribed stimulants rose by 4.7% between 1999 (1.5%, 95% CI 0.7% to
2.9%) and 2008 6.3%, 95% CI 5.6% to 7.0%) (see Figure 29a). Sleep medications also were prescribed
to 3.7% more young people during the same period [from 2.2% (95% CI 1.2% to 3.8%) in 1999 to
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TABLE 56 Prescribing details of cohort with ASD
Drug group
Number of
patients
prescribed (%)
Number of
prescriptions (%)
Mean
number of
prescriptions/
patient (SD)
Number of
males (%)
Number of
prescriptions
to males (%)
Mean number of
prescriptions/
male patient (SD)
Number of
females (%)
Number of
prescriptions
to females (%)
Mean
number of
prescriptions/
female
patient (SD)
Stimulants 446 (27.5) 10,981 (23.0) 24.6 (26.8) 406 (30.9) 10,159 (27.5) 25.0 (27.0) 40 (13.0) 822 (7.6) 20.6 (24.2)
Antidepressants 350 (21.6) 5183 (10.9) 14.8 (19.1) 263 (20.0) 3918 (10.6) 14.9 (19.8) 87 (28.3) 1265 (11.8) 14.5 (16.8)
Antipsychotics 415 (25.6) 7934 (16.6) 19.1 (24.3) 329 (25.1) 6105 (16.5) 18.6 (22.9) 86 (28.0) 1829 (17.0) 21.3 (29.0)
Antiepileptics and
mood stabilisers
360 (22.2) 15,868 (33.2) 44.1 (61.4) 254 (19.4) 10,651 (28.8) 41.9 (60.9) 106 (34.5) 5217 (48.5) 49.2 (62.5)
Benzodiazepines 275 (17.0) 1570 (3.3) 5.7 (12.2) 195 (14.9) 934 (2.5) 4.8 (11.6) 80 (26.1) 636 (5.9) 8.0 (13.3)
Clonidine 30 (1.9) 395 (0.8) 13.2 (15.2) 27 (2.1) 389 (1.1) 14.4 (15.6) 3 (1.0) 6 (0.1) 2.0 (1.0)
Sleep medication 550 (34.0) 4735 (9.9) 8.6 (13.1) 468 (35.7) 4027 (10.9) 8.6 (13.0) 82 (26.7) 708 (6.6) 8.6 (13.5)
Beta-blockers 36 (2.2) 312 (0.7) 8.7 (15.5) 28 (2.1) 249 (0.7) 8.9 (16.8) 8 (2.6) 63 (0.6) 7.9 (10.3)
Other 78 (4.8) 760 (1.6) 9.7 (15.5) 56 (4.3) 551 (1.5) 9.8 (16.9) 22 (7.2) 209 (1.9) 9.5 (11.5)
Antiparkinsonism
drugs
43 (2.7) 635 (1.3) 14.8 (19.1) 32 (2.4) 472 (1.3) 14.8 (20.8) 11 (3.6) 163 (1.5) 14.8 (13.8)
Any study drug 1619 (100.0) 47,738 (100.0) 29.5 (48.2) 1312 (100.0) 36,983 (100.0) 28.2 (45.0) 307 (100.0) 10,755 (100.0) 35.0 (59.7)
Reproduced from Murray et al.6 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The table includes minor formatting changes.
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5.9% (95% CI 5.2% to 6.6%) in 2008]. The prescribing of benzodiazepines, antipsychotics and
antiparkinsonism drugs remained stable (see Figure 29a and b), and a slight downwards trend in
antidepressant use was seen (see Figure 29c). There was a 1.8% decline in the proportion of patients
prescribed antiepileptic drugs between 1999 and 2008, from 6.1% (95% CI 4.3% to 8.4%) to 4.3%
(95% CI 3.7% to 4.9%) (see Figure 29c). Finally, prescribing rates (Figure 30) were relatively low in young
children/peak in young adolescents and reduce again in young adulthood.
Psychiatric comorbidities
There were 2062 patients (36.5%, 95% CI 34.9% to 38.1%) who had at least one record of a
neuropsychiatric comorbidity on or after their first recorded diagnosis of ASD on the database. The most
common neuropsychiatric comorbidities were developmental difficulties and LDs (12.6%, 95% CI 11.7%
to 13.6%), behavioural disorders, CDs and PDs (11.1%, 95% CI 10.3% to 12.0%), ADHD (7.5%, 95% CI
6.8% to 8.2%) and epilepsy (5.0%, 95% CI 4.4% to 5.6%) (Table 57). Of those with an ADHD diagnosis,
62.0% (n = 261) were prescribed a psychostimulant during the study period and 21.4% (n = 90) received
at least one prescription for a sleep medication. Furthermore, 41.5% (185/446) of those given at least
one psychostimulant prescription had no comorbidity of ADHD recorded during the period. Almost
three-quarters of patients (n = 210) with epilepsy recorded were prescribed an antiepileptic drug.
Discussion
To our knowledge this is the first naturalistic study of psychotropic drug prescribing and neuropsychiatric
comorbidities in a large nationally representative cohort of ASD patients in UK primary care. The database
has provided rich longitudinal data to enable us to characterise the shared care arrangements with
secondary care physicians.
We found that the incidence and prevalence of ASD increased substantially, by 23.7-fold and 64.6-fold,
respectively, between 1992 and 2008. These increases may be due to improved recognition and diagnosis
of ASD, broadened diagnostic criteria and increased awareness and acceptance of ASD by health-care
professionals and parents.54,314,315 The 2008 prevalence of ASD diagnoses in 6- to 12-year-olds in our
cohort (0.89%, 95% CI 0.85% to 0.93%) is comparable to that reported by Baird and colleagues314
(1.16%, 95% CI 0.90% to 1.42%) from their Special Needs and Autism Project sample and the estimate
of 1.57% (95% CI 0.9% to 2.46%) in a Cambridgeshire school-based population.315
Use of psychotropic drugs by British GPs (usually initiated by specialist physicians) is relatively conserative
compared with the practices of their American colleagues. Only 29% of our cohort (26% aged 0–21 years)
received psychotropic drug prescriptions in UK primary care. In contrast, Mandel and colleagues288 found
that 56% of Medicaid-enrolled youths with ASDs aged 0–21 years received at least one psychotropic drug
in 2001; likewise, in 2002, 57% of youths aged < 21 years enrolled to another US claims database
(MarketScan®, Truven Health Analytics, Michigan, MI, USA) were prescribed psychotropic drugs.287
Psychotropic drug prescribing practices will be strongly influenced by comorbidities associated with ASDs,
which may explain the large proportion of those prescribed psychotropic drugs who were given more than
one psychotropic drug (34% of prescribed patients in 2008). One-third of our cohort had at least one
neuropsychiatric comorbidity recorded in their primary care records following ASD diagnosis – the most
common being developmental difficulties and LDs, behavioural disorders, CDs and PDs, and ADHD.
Simonoff and colleagues58 found in their Special Needs and Autism Project cohort that 28.2% were
comorbid with ADHD, 30.0% had oppositional disorder or CD and 41.9% had anxiety or phobias; our
cohort had much lower proportions of these comorbidities. It is possible that there was under-recording as
specialist physicians may find it difficult to diagnose comorbid psychiatric disorders due to communication
impairment or cognitive problems in individuals.201 Alternatively, there may be nosological conventions
which exclude the diagnosis of certain symptoms as comorbid psychiatric disorders (e.g. symptoms of
hyperactivity and impulsiveness in autistic people may not be reported as ADHD).55,316 New diagnostic
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guidelines in DSM-V and almost certainly International Classification of Diseases, Eleventh Edition, will
remove the exclusion of making a diagnosis of ADHD in the context of ASD, which has been present.
Therefore, a large proportion of stimulant prescribing in our study is likely to be for the treatment of
comorbid ADHD or symptoms of hyperactivity,280,317 even though two-fifths of stimulant-prescribed patients
did not have an ADHD diagnosis recorded during the study period.
We found that individuals with ASD are much more likely than the UK general population to be prescribed
psychostimulants. For example, McCarthy and colleagues307 reported that 0.92% of children aged
6–12 years and and 0.74% of those aged 13–17 years in THIN were prescribed a stimulant drug in 2008.
However, 6.60% (of children aged 6–12) and 8.79% (of adolescents aged 13–17 years) of our cohort
received at least one prescription for methylphenidate, dexamfetamine or atomoxetine in the same year.
So compared with a child in the general population, a child with ASD is seven times more likely to be
prescribed a psychostimulant. For autistic adolescents, psychostimulant prescribing is almost 12 times
higher than that of the general population.
The increase in prescribing of stimulants over time may reflect the increasing recognition of comorbid
ADHD (and its persistence) in young people with ASDs. In addition, secondary care physicians may be
more willing to initiate (and GPs more willing to prescribe) methylphenidate following evidence that it is
effective in some autistic young people with ADHD.55 Two-thirds of the autistic population are reported as
having moderate sleep disturbances.318 However, < 10% of our cohort received sleep medications (< 5%
were prescribed benzodiazepines, some of which may be used to alleviate sleep problems); it is likely that
UK GPs consider prescribing pharmacological treatments only to patients with severe sleeping disorders.
It is interesting to note the rising trend of sleep medication prescribing. The trend may be due to
increased diagnosis of comorbid ADHD and/or the use of sleeping medications to counteract the effects
of stimulants on sleep. Prescribing for antipsychotics and antidepressants in the cohort was relatively
stable between 1999 and 2008, at the overall prescribing rates of 4.1% (95% CI 3.85% to 4.37%) and
3.3% (95% CI 3.03% to 3.49%), respectively. This differs from reported increases in antidepressant and
antipsychotic use in the US autistic population. Two drug surveys conducted in North Carolina in 1992–3
TABLE 57 Neuropsychiatric comorbidities of the cohort with ASD
Neuropsychiatric comorbidy All Male Female
ADHD 421 (7.5) 378 (8.1) 43 (4.5)
Anorexia and bulimia 47 (0.8) 30 (0.6) 17 (1.8)
Anxiety and phobias (including OCD) 251 (4.4) 192 (4.1) 59 (6.1)
Behavioural, conduct and PDs 628 (11.1) 505 (10.8) 123 (12.8)
Mood disorders 189 (3.3) 134 (2.9) 55 (5.7)
Epilepsy 283 (5.0) 209 (4.5) 74 (7.7)
Developmental difficulties and LDs 713 (12.6) 562 (12.0) 151 (15.7)
Psychotic disorders (including schizophrenia and delusions) 37 (0.7) 29 (0.6) 8 (0.8)
Substance and alcohol misuse 18 (0.3) 13 (0.3) 5 (0.5)
Suicidal behaviour and self-harm 63 (1.1) 45 (1.0) 18 (1.9)
Tic disorders 64 (1.1) 60 (1.3) 4 (0.4)
Unclassified neuropsychiatric disorders 287 (5.1) 227 (4.8) 60 (6.2)
Any neuropsychiatric comorbidity 2062 (36.5) 1669 (35.6) 393 (40.8)
Reproduced from Murray et al.6 This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited. The table includes minor formatting
changes.
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and 2001 revealed a significant 3.5-fold increase in the proportion of children and adults with autism who
were prescribed antidepressants.286 Williams and colleagues290 found that use of antipsychotics was high
(34% in 2008 vs. 7% of our cohort) in their study of Kentucky-based children with autism. This was
attributed to the greater use of atypical antipsychotics following the licensing of risperidone in the USA
for the treatment of irritability associated with autistic disorder.290 Although risperidone remains unlicensed
in the UK for this indication, we still found that one-fifth of the cohort who were prescribed psychotropic
drugs were given risperidone. Although the ratio of the cohort prescribed antipsychotics remained
relatively stable between 1999 and 2008, a high proportion of children and teenagers with ASD
are prescribed antipsychotics in comparison with the general British population. The prevalence of
antipsychotic prescribing in 0- to 18-year-olds was reported to be 0.08% in 2005,319 whereas in the
same age group in our cohort the prevalence was 2.98% (a 38.7-fold increased risk).
Antiparkinsonism drugs were prescribed to a very small proportion of patients (0.8% of ASD cohort,
n = 43), probably to mitigate extrapyramidal symptoms of antipsychotics, as has been reported elsewhere.289
Strengths and weaknesses
There may be some underestimation of prescribing as some patients may be treated in specialist centres
and THIN does not systematically record prescriptions generated in non-primary care health-care settings
(some information on drug treatment may be recorded in discharge summaries and hospital letters).
In addition, some GPs may not participate in shared care prescribing arrangements, especially of
psychotropic drugs in off-label use and controlled drugs such as the psychostimulants (e.g. methylphenidate
and dexamfetamine). The database does not record treatment compliance or dispensing of prescriptions.
There may be underestimation of neuropsychiatric comorbidities due to the censoring of patient records, or
incomplete transcription of clinical details from correspondence with specialist teams. Finally, prescriptions
are not directly linked to diagnoses in THIN, so we cannot definitely identify indications of use.
Further assessment of the efficacy and short- and long-term safety of psychotropic drugs for the treatment
of behavioural problems in this population is urgently required, as only two drugs so far (risperidone
and aripiprazole) have shown efficacy.293–295 More recently, optimal dosing of methylphenidate was
shown to be effective in reducing ADHD symptoms in about 40% of children with ID (including those
with ASDs), and the adverse effects profile was similar to that seen in typically developing children.54
Safety is an important consideration across all ages due to the lifetime persistence of symptoms and
impairment, polypharmacy of psychotropic medications and the difficulties some individuals may have in
communicating about adverse effects. More information on psychotropic drug use (and the appropriateness
of prescribing for comorbidities) in the ASD population across Europe would be beneficial to focus European
drug research activities and to inform clinical practice. In addition, there is a need to prioritise research of
the most commonly prescribed drugs in the autistic population: the antipsychotics (in particular risperidone
safety), the psychostimulants (especially efficacy and safety in those comorbid with ADHD) and sleep
medications.
Conclusions
The increase in prevalence of ASD diagnoses recorded in UK primary care between 1992 and 2008 may
be due to improved recognition of ASDs, widening diagnostic criteria and more awareness and acceptance
of the conditions. However, there is under-reporting of neuropsychiatric comorbidities in the British autistic
population following diagnosis of ASDs, possibly due to diagnostic exclusion or communication difficulties
in patients. Fewer than one-third of individuals with ASD receive at least one psychotropic drug prescription,
which are mostly for stimulants, antiepileptic drugs and mood stabilisers, and antipsychotics. Of those who
are prescribed psychotropic medication, one-fifth are treated with risperidone and at least one-third receive
more than one drug. Hence, further research into the appropriate use, efficacy and long-term safety of
antipsychotics and stimulants in the autistic population is warranted to support clinical practice for optimal
and safe treatment of ASDs and their comorbidities.
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Key messages
Psychotropic drugs were prescribed to 29% of the ASD cohort; the most prescribed drugs were sleep
medication, psychostimulants and antipsychotics.
Prescribing rates of psychostimulants and sleep medications are increasing over time.
Polypharmacy was seen in approximately equal to one-third of prescribed patients.
Prescribing levels are highest in young teenagers and lower in young adults.
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Chapter 21 Piloting pharmacology trials in
frequently excluded groups
Overview
In the previous chapter we established the current prescribing rates for ASD in the UK. We and others had
previously published similar data on ADHD outside this programme. Hence, we now had good knowledge
of current pharmacological treatments in both ASD and ADHD as used in general practice. However, the
effectiveness of current pharmacological treatments in specific subgroups of affected individuals (e.g. those
with ID and prisoners), and the effectiveness of CBT-based approaches, remained poorly understood. This
is due to lack of clinical trials; one contributing factor to the lack of trials in frequently excluded groups
such as these is that investigators typically face significant hurdles (e.g. ethical and practical).
Hence, in order to make the most rapid progress we ran two concurrent work streams to obtain pilot data/
proof of concept on the ability to run UK trials on effectiveness of interventions in ADHD and ASD. The
first focused on the effectiveness (or otherwise) of current pharmacological treatments for ADHD in people
typically excluded from trials (those with ID); and the second piloted a new CBT-based treatment approach
for OCD in ASD (discussed in Chapter 22).
Our first step was to pilot an open-label trial of atomoxetine for ADHD in young people with ID (see
Pharmacology step 1: atomoxetine trial for ADHD in people with intellectual disability). This was unsuccessful
and so resources were diverted to a proof of concept study in a prison setting (see Pharmacology step 2:
a pilot study on treating ADHD in prison).
Pharmacology step 1: atomoxetine trial for ADHD in people with
intellectual disability
The aim of this project was to obtain initial data about the efficacy and profile of common adverse effects
among youngsters with ADHD and ID (global LD) receiving atomoxetine as a second-line treatment.
Currently, there is a substantial evidence base for the treatment options among people who are of
average cognitive ability. Current guidelines recommend the first-line use of methylphenidate (often in a
sustained-release preparation), followed by atomoxetine if methylphenidate is unsuccessful, due either to
lack of efficacy or to dose limitation secondary to adverse effects.320 However, the evidence base does
not include young people with global LD, typically defined by an IQ of < 70, along with impairment in
adaptive functioning. Considering the latter group separately is important for two main reasons. First,
they are disproportionately likely to be affected with ADHD; our research,317 and that of others,321 showed
an 8- to 10-fold increase in the rates of ADHD. Second, there are good reasons to consider that the
evidence from cognitively average – ‘typically developing’ – young people may not directly extrapolate
to them. For instance, studies of methylphenidate indicate that it has a smaller effect size in people with
ID – about 0.5 compared with 0.9 in typically developing children.54 In addition, youngsters with ID have
considerably higher rates of adverse effects; much of this appears to be related to the increased rate of
ASD in people with ID.54 In some cases, this is simply greater sensitivity as demonstrated by higher rates of
common adverse effects; in others it is idiosyncratic effects. In addition, individuals with ID more commonly
have neurological and physical disorders, such as epilepsy or congenital heart disease, that may influence
the ability to use ADHD medication in therapeutic doses.
DOI: 10.3310/pgfar06020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2018 VOL. 6 NO. 2
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Murphy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
165
Hence, to address key scientific issues about the efficacy of stimulant treatment for ADHD, we undertook a
randomised controlled trial (RCT) of methylphenidate, funded by The Health Foundation.322 We reported
effect sizes of 0.3–0.52. Among parents of children receiving methylphenidate, 40% reported their child
to be ‘improved’ or better, compared with 7% on placebo. Nevertheless, despite these promising results,
many parents felt that their child had not made substantial improvement and a survey indicated that
they would welcome the opportunity to try an alternative treatment. At the time of application, the
evidence for atomoxetine came from studies with typically developing children or those with ASD; the
latter evidence base was one open-label trial of 16 children. Therefore, to extend the evidence base
of atomoxetine as a second-line intervention for youngsters with ADHD and ID, we undertook an
open-label trial of carefully titrated medication in which efficacy and common adverse effects were
systematically assessed. The trial included young individuals who had not shown an adequate response
to methylphenidate, either due to lack of efficacy of an adequate dose or because of dose limitations due
to adverse effects. We proposed to recruit affected individuals either from our previous trial, described
above, or from routine clinical practice.
What we did
The trial was set up with the involvement of the clinical trials unit at King’s College London. This involved
developing a trial protocol, which included genetic testing to determine whether or not genetic polymorphisms
were moderating response to atomoxetine. The trial protocol was reviewed by the Joint Clinical Trials Office
and the Medicines and Healthcare products Regulatory Agency. However, ethics approval was delayed for
several reasons. First, despite using a very similar set of measures that were approved in the previous trial,
the REC raised concerns about the inclusion of measures that characterised the sample either for purposes
of eligibility assessment or for broader description at the time of publication. We explained the need for
these data as part of good clinical practice. Second, we were asked to alter the method of recruitment into
the trial from two stages to one stage. In the previous trial we discovered that it was best to consent
participants and their families first to an assessment and then, if eligible, to the trial. Although families were
aware from the outset that they were being assessed for the trial, we discovered that the two-stage consent
process helped to highlight that they might not be eligible, as indeed only a minority were. However, we
were asked to change this and did so. We were also asked to give more prominence to certain possible
adverse effects, specifically suicidal ideation.
Following ethics approval, we began recruitment from our methylphenidate trial. Although a number
of parents had previously indicated an interest, recruitment was much lower than anticipated. There
were two main reasons for this. First, a number of the parents who had indicated at the end of the
methylphenidate trial that their child had not improved reported, when recontacted, that they thought
they were doing well on their present medication and did not want to change. Second, there was a
small group of parents who had not waited for the trial to obtain ethics approval and had gone to their
local clinician and requested a medication change. Over 1 year, we recruited 12 patients from our
methylphenidate trial and received no referrals from clinicians in the NHS, despite monthly e-mails and
regular visits to clinics. This reflected several issues. First, there was underidentification – diagnostic
overshadowing – of ADHD in people with ID generally (as we had previously noted in our methylphenidate
trial). Second, we were trying to identify a subgroup of a subgroup (i.e. those with ADHD and ID who had
not responded to medication). Although we were trying to recruit across the South Thames region, this
probably was not a large enough region. Hence, we contacted the Medicines for Children Network to
determine whether or not they could help with recruitment, but they were unable to take on the study.
The trial was therefore halted and we reallocated resources into a novel opportunity that arose only after
the programme started. Specifically, our NHS trust took over the provision of mental health services
to prisons for young people in 2012. This allowed us to build on our work in forensic populations (see
Chapter 16) and initiate a proof of concept study on the ability to undertake treatment trials for NDs in
prison settings (focusing first on ADHD; see Pharmacology step 2: a pilot study on treating ADHD in prison).
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What we learned from this failure and how it influenced practice
We learned a number of lessons from the study. First, although we had a robust trial protocol and
considerable experience of obtaining ethics approval to undertake clinical trials with the patient
population, we noted the considerable variation among RECs and learned that we could not assume that
they would have similar concerns. In small part, this reflected changes surrounding expectations in trial
conduct, but was largely due to different panel members’ views. However, this led to considerable time
delays. The need to approach several different local RECs in addition to a central REC (and despite central
ethics approval already been given) leads to very significant delays in clinical trials. For instance, we found
that there can be a poor understanding in many RECs about both children and adults with ID, with varying
views about the appropriateness of seeking assent (from minors), how to establish capacity in adults and
methods for managing consent when capacity is not present. We also learned that the absence of
systematic patient databases hinders their recruitment to research, including treatment trials from which
they might benefit.
The lessons learned in this research have been incorporated into other work. Specifically, the clinical and
research recommendations in the current NICE guidance on the management and support of children
with autism, just completing its consultation,323 have been influenced by this research. These guidelines
highlight the need for systematic assessment of children to identify co-occurring disorders such as ADHD,
which might be treatable in their own right.
Issues raised by this project and other experience of clinical trial among people with LD will be showcased
in a proposed editorial for the British Journal of Psychiatry as part of a special edition.
Pharmacology step 2: a pilot study on treating ADHD in prison
Background
Based on the finding of high rates of ADHD, and to a lesser extent ASD, within forensic adult mental
health services and adult prisons noted above (see Chapters 11 and 12), there is a need to evaluate rates
in prisons and the effectiveness of treatments for both disorders within these settings. We therefore
determined, as a first step, to ‘pump prime’ from this programme a pilot study of ADHD treatment in
young offenders.
Our rationale was that failure to recognise and treat ADHD most likely has a wide-reaching impact on
mental health and behaviour in forensic populations. Our previous work demonstrated that ADHD is
associated with high rates of incidents of verbal and physical aggression and other disruptive behaviours
in both forensic hospital services, as noted in our work above, and, as we previously published, in prisons.
For instance, we previously reported that ADHD accounted for a sixfold increase in such critical incidents
among prison inmates, even after controlling for antisocial PD.137 Furthermore, the symptoms of ADHD
are known to interfere with both educational and employment activities due to a combination of restless
overactivity and impulsivity, and the problems associated with inattention, forgetfulness and problems with
self-organisation.95,105 This suggests that ADHD itself may lead directly to some forms of disruptive
behaviour, potentially linked to difficulties with mood regulation (mood lability/volatile mood states/deficient
emotional self-regulation), that are strongly associated with ADHD in adults.130 Hence, we hypothesised that
untreated ADHD may explain a significant portion of aggressive behaviour in offenders.
Within forensic settings, the violent behaviour associated with ADHD significantly impacts on the quality of
life of the individual, but also on forensic services and society more widely as these individuals can be caught
up in the ‘revolving door’ of the criminal justice system. However, ADHD is a treatable condition with the
most recent NICE guidelines95 concluding that stimulant medication (methylphenidate or dexamfphetamine)
and atomoxetine provide cost-effective treatments for the control of ADHD symptoms in adults.
Nevertheless, as we found earlier (see above), ADHD often remains unrecognised and untreated, which
means that known effective treatments for ADHD (and potentially also for the co-occurring challenging
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behaviours) are not provided. The NICE guidelines for ADHD highlighted the extent of this unmet need and
the requirement to establish effective services for the diagnosis and treatment of ADHD in adults, to prevent
both immediate and longer-term impairments. Thus, we envisage that medical treatments used for ADHD
in the general population will be effective in reducing both the core symptom of ADHD and some of the
aggressive/antisocial behaviour and problems with engagement with educational activities associated with
ADHD in forensic populations. To date, however, these questions have not been investigated among young
offenders in the UK (although rates of ADHD will undoubtedly be high in this group), and there is very
limited guidance from international research.
Methods
We initiated an open-label pilot study of an extended release formulation of methylphenidate
(Concerta XL®, Janssen-Cilag Ltd) on aggression, in young male offenders with ADHD aged 18–30 years.
The primary outcome measure will be a change in disruptive behaviour as recorded in the prison records
(number of critical incidents). Secondary outcomes include measures of engagement with educational
activities reported by staff within the prison educational programme; measures of aggressive behaviour
collected using a behavioural report by prison and education programme staff; and the number of
recorded reports of disruptive behaviour reported by the educational programme staff.
Changes will be measured in the level of symptoms ADHD and emotional dysregulation, which previous
research has shown responds well to methylphenidate, with an average effect size of around 0.5.324 This will
include ratings of the DSM-IV ADHD items from the Conners’ Adult ADHD Rating Scales – Observer; and the
associated symptoms of ‘emotional dysregulation’ from the Wender–Reimherr Adult ADHD Scale.325
Further analyses will explicitly test the mediation hypothesis that change in symptoms of ADHD and
emotional dysregulation mediate changes in aggressive behaviour and engagement with educational
activities; and provide estimates of the extent of any mediation effects (partial or complete mediation of
the behavioural problems).
Dose escalation from 18 mg to a maximum of 90 mg is intended to maximise the effect of the medication
on ADHD symptom levels while limiting potential adverse effects. In addition, to evaluate the longer-term
outcomes associated with the use of Concerta XL in this population, the 12-week open-label trial will be
followed by a 6-month open-label trial with titration to an optimal dose based on clinician judgement.
The main hypotheses that will be tested are that:
l ADHD is found in high rates among young male offenders aged 18–30 years (the initial stages of the
project allow prevalence estimates for the disorder among the prison population to be estimated).
l Treating ADHD with Concerta XL will lead to reductions in aggressive behaviour within the
prison setting.
l Treating ADHD with Concerta XL will lead to increased engagement with educational activities within
the prison setting.
l Treatment with Concerta XL will lead to reductions in ADHD symptoms within the prison setting
(these changes will be similar in magnitude to those reported in previous clinical and prison populations
of adults with ADHD142,324).
l Treatment with Concerta XL will lead to reductions in symptoms of emotional dysregulation (these
changes will be similar in magnitude to those reported in previous clinical trials of the effects of
stimulants on symptoms of emotional dysregulation326).
l The ADHD symptoms and emotional dysregulation symptoms will show strong co-variation during the
treatment response.
l Change in symptoms of ADHD and emotional dysregulation will mediate changes in the measures of
aggression and engagement with educational activities.
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Study setting
This pilot work is taking place at HMP & YOI Isis, which is in the Belmarsh prison cluster. This is a relatively
new prison, which opened in 2010 and holds sentenced young male adults and category C offenders.
There are two house blocks with mixed single and double cells and the operational capacity was measured
at 480 in August 2010. HMP & YOI Isis has a broad-based curriculum for young sentenced prisoners and
available activities include mechanics, construction, bicycle repair, catering, broadcasting, job-related
studies and offending behaviour interventions. It therefore has a rehabilitation and resettlement emphasis
and all prisoners are offered a full-time occupation.
Progress to date
We have reviewed screening data on 592 prisoners and identified 129 prisoners who screen positive for
ADHD. We completed 71 full diagnostic assessments and confirmed a diagnosis of ADHD in 55 of these,
giving an overall prevalence rate just below 20%. This means that treatment for ADHD should be
considered in around one in five young adult male prisoners.
Recruitment into the treatment trial part of the programme has started, with 16 participants currently
entered into the pilot clinical trial. We have identified two main areas of impairment that can impact of risk
for repeat offending. First, there is a high rate of dysfunction with education and occupation that is linked
to the specific symptoms and impairments of ADHD: poor attention span and being easily distracted,
disorganised and forgetful. In addition, many individuals show motor overactivity and impulsive traits that
reduce their ability to function in the workplace. The second main area of difficulty is mood instability with
temper outbursts that can have a significant role to play in violent offending.
This pilot work is now being pursued as part of a Medical Research Council Efficacy and Mechanism
Evaluation-funded grant to Professor Philip Asherson (the principal investigator).
Key messages
Ethics governing research in vulnerable populations is complicated by considerable variation in local RECs.
The need to approach many local RECs in addition to one central REC slows research considerably.
It is possible to carry out treatment trials for NDs such as ADHD in prisons.
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Chapter 22 Piloting psychological approaches:
a pilot randomised controlled trial of
cognitive–behavioural therapy for comorbid
obsessive–compulsive disorder in high functioning ASD
Introduction
In prior chapters we audited – and initiated – pharmacological approaches. However, it is crucial to also
offer effective non-pharmacological treatment approaches. As a first step we targeted associated mental
health symptoms in ASD as the following:
l These are very common in this group.
l We already demonstrated in this programme (see Chapter 5), they very significantly add to the burden
experienced by both the affected individual and their carers.
l There is already substantial evidence for the effectiveness of these approaches in non-autistic populations.
We focused on anxiety disorders, as we found high rates as part of this programme and, likewise, high
rates have been reported by others, in both young people316 and adults.327,328 Rates of disorders in
childhood range from 11% to 84%, and a selective pattern of anxiety disorders, namely social anxiety,
OCD and specific phobias, has been reported.329,330
Childhood anxiety reduces social interactions, self-esteem and impoverishes social skills in typically
developing children,331 thereby exacerbating problems characteristic of ASD. Furthermore, behavioural
problems have been noted to be more likely to berelated to fears in children with ASD than in other groups.332
Comorbid OCD has been reported to occur in 30% of young people with ASD,328,333 and high rates of
OCD have also been reported in adults with ASD both with and without ID.334,335 OCD has considerable
impact on quality of life for both sufferers and carers and is listed in the World Health Organization’s top
20 leading causes of years lived with disability among individuals aged 15–44 years.336 OCD is a treatable
anxiety disorder with good evidence for the effectiveness of empirically based psychological treatments
such as CBT.337
There is emerging evidence that CBT may be effective in ameliorating distressing and debilitating anxiety in
people with ASD. Trials of group CBT interventions for anxiety symptoms330 and anxiety disorders338–340
adapted for children with ASD have reported promising results.
To date, most adult treatment studies of CBT in ASD have been confined to single case reports (e.g. its
effectiveness for depression341 and social anxiety disorder342). More recently, we reported343 preliminary
evidence from an uncontrolled pilot study of CBT for OCD in 24 adults with ASD and comorbid OCD. We
found that, of the 12 adults who received CBT for OCD, seven (58%) showed a good treatment response
in comparison with two (16%) in the treatment as usual (TAU) group, with a standardised effect size
(Cohen’s d) for CBT of 1.01. This is reasonably consistent with published treatment response rates for
behaviour therapy (59%) and CBT (67%) in adults with OCD without ASD.344
In summary, there is evidence of high rates of anxiety disorders, particularly comorbid OCD, in both young
people and adults with ASD. The results of both individual and group systematic psychological treatment
evaluations for anxiety disorders in children and adolescents with ASD have been promising, but to date
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none has been OCD specific. There is preliminary evidence that CBT may be more effective for OCD in
ASD than TAU, but this requires replication and comparison with other potentially effective approaches for
this group. Hence, the aims of the present study were to systematically evaluate CBT for OCD adapted for
people with ASD via a RCT comparing the new intervention with a plausible control treatment.
Methods
Participants
Seventy-five participants were recruited from specialist ASD clinics, specialist adult and paediatric OCD
clinics, and generic child and adult mental health services. Participants were individuals with a confirmed
diagnosis of an ASD, verbal IQ of > 70 and comorbid OCD, aged between 14 and 65 years. Participants
were excluded if they had current psychotic symptoms, a current episode of major depression, uncontrolled
epilepsy or current substance misuse. Participants were included only if psychiatric medication was stable in
the 6 weeks prior to study entry and if they had a baseline Yale–Brown Obsessive Compulsive Scale (YBOCS)
severity rating of > 16, typically used for inclusion in clinical trials.345 Diagnosis of ASD was confirmed using
the ADI-R. Diagnostic information was supplemented by the ADOS196 for all participants. The Mini
International Neuropsychiatric Interview 5.0 neuropsychiatric interview was used for assessment of other
comorbid psychiatric diagnoses and to confirm the presence of OCD.346
Delineating anxiety-based obsessions and compulsions from the repetitive routines and behaviours and
circumscribed interests characteristic of ASD was completed using the YBOCS Symptom Checklist and in
accordance with the procedures developed in an earlier phenomenological study,343 which were detailed
in the study manual. In brief, at the start of each clinical interview care was taken to ensure that the
participant was cognisant of the phenomena to be rated, that the discomfort and anxiety basis for each
potential obsessive–compulsive symptom was clearly established using visual tools if necessary. Eliciting of
symptoms was achieved if needed by enquiring about daily routines in total before gathering further
phenomenological information. Communication style and preferences of each individual were also taken
into account when administering the YBOCS. The presence of obsessions/compulsions was not recorded
unless the ego-dystonic basis for unwanted internal phenomena and a resistance to/recognition of the
excessive nature of compulsions could be established.
All participants read an information sheet and signed consent forms to take part in the study with
developmentally appropriate information and assent forms for participants aged 14–16 years.
The study was registered as a controlled trial (ISRCTN87114880) with ethics approval granted by the
local REC.
Study design
A manual outlining ASD-specific adaptations to standard CBT for OCD was developed on the basis of a
case note review of the pilot study,343 expert recommendations347,348 and the literature on cognitive and
neuropsychological function in ASD where deficits in emotion recognition and executive function are
reported. Standard CBT for OCD was adapted by:
l ensuring that the building blocks for treatment (i.e. understanding and differentiating emotions,
particularly anxiety, and making links between thoughts, feelings and behaviours) were in place
l if required, educational sessions about understanding and rating anxiety were provided before moving
on to present the rationale for treatment
l visual tools and concrete/special interest related analogies were used to convey psychological concepts
l a structured and therapist-directed approach to sessional and homework content.
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The CBT treatment was predominantly exposure and response prevention (ERP) based and this was conducted
in the usual hierarchal fashion both in sessions and as homework. Post hoc review of the treatment records
identified that an average of 10 (SD 5.4) ERP homework tasks were set and the compliance rate for ERP
homework tasks was 79%. Cognitive methods were also used to help individuals test out OCD and
anxiety-related beliefs if appropriate. Post hoc review identified that a mean of 2.7 (SD 3.2) sessions
contained some cognitive techniques in the CBT group.
The control or comparison treatment was specified as anxiety management (AM) to ensure that any treatment
effects were solely due to the adapted CBT for OCD, rather than therapist contact, psychoeducation about
anxiety or general anxiety reduction techniques. Furthermore, the general lack of access to psychological
treatment services for adults with ASD suggested that TAU or a no treatment condition would unfairly
advantage the experimental treatment and would not represent an adequate test of effectiveness.
The AM manual was developed for the present study by one of the authors (MF) and was based on
previous work.349,350 It comprised eight modules, which were adapted for ASD by including visual aids
or concrete examples. The modules included education about anxiety, diaphragmatic breathing and
practice, progressive muscle relaxation education and practice, education about mood, healthy habits
and problem-solving. The AM manual did not contain any of the ‘active’ ingredients considered important
in effective treatment of OCD (i.e. ERP or any cognitive strategies addressing OCD-related beliefs).
The treatments were matched for duration (up to 20 sessions) and amount of therapist contact
(approximately 1 hour per session). Treatment completers were defined as attending at least seven
sessions. Treatment duration was specified as up to 20 sessions as prior experience had suggested that a
longer assessment and orientation to therapy phase was necessary for some individuals with ASD. See
Appendix 1 for further details regarding the treatments.
The treating therapists were all clinical psychologists (n = 4), trained within a behavioural framework, who
had extensive experience in treating OCD in both young people and adults. All had received post-qualification
training in CBT for OCD, having attended workshops delivered by OCD specialists. All therapists delivered
both treatments on a randomly allocated basis. Three pilot cases (two young people and one adult with ASD)
were treated with the CBT manual prior to commencing the RCT for feasibility and user perspective purposes.
This also allowed the trial therapists to be trained in working more specifically with people with ASD and
OCD. As therapists who had worked in specialist OCD clinics, they had previous experience of working with
people with ASD. A consultant clinical psychologist with expertise in both adult and paediatric cases (DMC)
provided supervision for the CBT cases.
Randomisation procedure
Participants were randomised to the CBT or AM groups using a table of random numbers (1 : 1 ratio)
managed by an investigator who was part of the Trial Management Committee but not a treating therapist.
Review of the study protocol by the REC recommended that the ‘other’ treatment should be offered to
participants on completion of the first treatment. Thus, participants were informed via the study
information sheet that they could try the other treatment 1 month or more following completion of the
first treatment, if they wished.
Treatment fidelity and therapist allegiance
A random proportion of cases (20%) were audio-recorded to ensure treatment fidelity. All treatment
sessions were recorded and 20% of these recordings were then randomly selected and rated by an
independent therapist, blind to treatment condition and outside the clinical trial, as to whether the session
contained OCD-targeted interventions (such as ERP) or exploration of OCD-related beliefs. There was no
evidence of cross-contamination on the recordings (i.e. none of the AM sessions was recorded as
containing any elements of CBT for OCD).
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Outcome measurement
Symptom ratings were made by assessors blind to treatment group prior to commencing treatment (i.e. no
more than 4 weeks before the first treatment session), end of treatment (1 week after the final treatment
session), and at 1, 3, 6 and 12 months’ follow-up. Assessors were all trained clinicians experienced in
administering the YBOCS and interviewing people with ASD. In order to address the validity of the blinding
procedure, blind assessors were asked to complete a questionnaire at each assessment point noting which
they thought was the randomisation group and if this was (a) a random decision, (b) revealed by the
participant or (c) due to clinical improvement.351 Of the treatment completers, this section was not completed
in eight (20%) cases. None of the assessors was ‘unblinded’ to treatment group [i.e. cited (b) as the reason
for their choice of treatment group]. Blind assessors were accurate in their assignment of treatment group in
24 (60%) of cases. They described their choice as ‘random’ in 30 (75%) of cases. In 18 (45%) cases, clinical
improvement was also cited as a reason for group assignment.
Primary outcome
The YBOCS351 total severity rating was the primary outcome measure. In addition to the 10-item severity
scale, the insight item from the YBOCS (YBOCS item 11) was also included, with the interviewer being
asked to document ‘what is the worst thing that the patient worries will happen if she/he did not respond
to obsessive thoughts or urges to perform compulsions?’ and then rating the extent to which the patient is
certain that the feared consequence is reasonable and will actually occur ranging from 0, ‘certain that the
feared consequence will happen’, to 5, ‘certain that the feared consequence will not happen’.
A reduction of at least 25% on the YBOCS severity rating scale is considered to be a sensitive but not
specific measure of treatment response.352 A YBOCS total score of ≤ 12 for ≥ 1 week was used to define
remission,352 with remission lasting for ≥ 1 month being defined as recovery.
Secondary outcomes
A broad range of outcome measures, including the assessment of other anxiety disorders, were employed.
Clinical Global Impression
The CGI and Clinical Global Impression Improvement (CGI-I) rating scales.353
Dimensional Yale–Brown Obsessive–Compulsive Scale
The Dimensional Yale–Brown Obsessive–Compulsive Scale (D-YBOCS)354 is a semistructured interview to
ascertain the presence and severity of six symptom dimensions of OCD. Each symptom dimension is rated
for severity (0–15) with a global rating considering severity overall and global impairment (0–30).
Self-report (adult)
Measures comprised the OCI-R,209 Beck Depression Inventory,355 Beck Anxiety Inventory,356 Liebowitz Social
Anxiety Scale357 and the Work and Social Adjustment Scale (WSAS).358
Self-report (youth ages 14–18 years)
Measures comprised the OCI-R, Beck Depression Inventory – Youth,359 WSAS and the Spence Children’s
Anxiety Scale.360
Treatment satisfaction
All participants were asked to rate their satisfaction with the treatment they had received on an eight-point
visual analogue scale ranging from 0, ‘not at all satisfied’, to 8, ‘very much satisfied’.
Informant report (all participants)
A person who knew the participant well, such as parent, carer or spouse, was asked to complete the
Children’s Obsessive Compulsive Inventory – Parent Version361 at each measurement point. Severity scores
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can be obtained by summing up the item responses to give ‘compulsions impairment (0–24), obsessions
impairment (0–24) and total impairment (0–48)’. Informants were also asked to complete the Family
Accommodation Scale – Parent Report,362 where 13 items relating to the provision of reassurance,
modification of home routines, etc., are rated on a five-point scale with a possible maximum score of 52.
A total score of 13 is generally used as a cut-off point to indicate clinically meaningful accommodation of
OCD symptoms and this has been associated with treatment outcome in paediatric OCD.363
Correspondence
Correspondence between self-, clinician- and informant-administered measures of symptom content
and severity.
There were modest but significant correlations between self and informant reports of symptom severity
and clinician-administered pre-treatment measures. Furthermore, the subscales of the OCI-R were
associated with the relevant symptom dimensions on the D-YBOCS (Table 58).
Power analysis
Based on the data from the pilot study,343 a sample size calculation showed that in order to detect
statistically significant differences between the groups on the primary outcome measure (YBOCS total
severity rating) at alpha 5% and 80% power, 19 participants would be required for each randomisation
group. We recruited 23 participants in each group, allowing for four dropouts in each treatment arm.
Data analysis
Independent t-tests and chi-squared tests were used to consider any pre-treatment differences between
the groups on symptom measures and demographics.
An analysis of covariance was carried out on the primary outcome measure controlling for baseline
symptom severity to investigate any difference between the two groups at the end of treatment. Repeated
measures analyses of variance were used to detect pre–post treatment changes in the AM and CBT
groups. Effect sizes were calculated using Cohen’s d. All of the analyses were intention to treat and, where
outcome data were not available, pre-treatment scores were not carried forward.364
Results
Participant flow
Seventy-five people were referred to the study: eight (10.7%) were self-referrals, 24 (32%) were referred
from community mental health services, 21 (28%) were referred by specialist ASD services, 11 (14.7%)
were referred by specialist anxiety disorder clinics, 4four (5.3%) were referred by voluntary sector services
and referral information was missing for seven (9.4%). Seventeen (22.6%) of these 75 individuals did not
meet eligibility criteria for the study (Figure 31), two people were eligible but geography prevented
participation and 10 people did not consent to take part.
Twenty-three people were randomised to each of the two treatment groups (AM and CBT), with 20
treatment completers in each group.
Participants in the treatment groups were involved in the treatment arm of the study for equivalent periods
of time. The mean number of weeks between pre-treatment and end-of-treatment ratings was 23.74
(SD 10.37) in the AM group and 27.06 (SD 10.27) in the CBT group. The mode or most usual length of
treatment in weeks was 25.
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TABLE 58 Correlations of clinician, informant and self-report severity ratings of obsessive–compulsive symptoms
Rating
Informant
obsessions
severity
Informant
compulsions
severity
Informant
total
severity
Clinician
total
severity
Self-report
washing
Self-report
hoarding
Self-report
ordering
Self-report
obsessing
Self-report
neutralising
Clinician obsessions severity 0.481;a
p = 0.020;
n = 23
Clinician compulsions severity 0.276;a
p= 0.155;
n= 28
Clinician total severity 0.576;a
p= 0.001;
n= 28
Self-report total severity 0.482;a
p= 0.015;
n= 25
0.265;a
p= 0.108;
n= 38
Clinician contamination severity 0.468;a
p = 0.003;
n = 39
Clinician hoarding severity 0.394;a
p= 0.014;
n= 38
Clinician symmetry severity 0.374;a
p= 0.019;
n= 39
Clinician aggression obsessions severity 0.419;a
p= 0.01;
n= 37
0.462;a
p = 0.003;
n = 38
a Strength of correlation co-efficients.
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Demographics and clinical features
Independent-samples t-tests revealed no differences between the groups for the mean domain and total
scores on the ADOS-G, verbal IQ, age, or pre-treatment symptom scores (Table 59).
The treatment groups did not differ with respect to sex distribution (AM group, 69.6% male; CBT group,
82.6% male), or the proportion of those aged < 18 years [AM group, n = 6 (26.1%); CBT group, n = 3
(13%), youth protocol].
The groups did not differ significantly in respect of OCD symptom dimensions, with contamination
obsessions and related compulsions reported by 18 (78.2%) in the AM group and 20 (86.9%) in the CBT
group; aggressive/harm obsessions by 17 (73.9%) in the AM group and 14 (60.8%) in the CBT group;
sexual/religious obsessions by five (21.7%) in the AM group and nine (39.1%) in the CBT group; symmetry
obsessions by 16 (69.5%) of the AM and 15 (65.2%) of the CBT group; hoarding obsessions by nine
(39.1%) in the AM and 14 (60.8%) in the CBT group; and miscellaneous obsessions/compulsions endorsed
by 10 (43.3%) of the AM group and nine (39.1%) of the CBT group. The AM and CBT groups endorsed a
mean of 3.1 (SD 1.2) and 3.3 (SD 1.4) OCD symptom dimensions, respectively.
Number of sessions
The mean number of treatment sessions was marginally greater in the CBT (17.43, SD 4.3) than in the AM
condition (14.43, SD 5.3) (t = –2.022, df = 42, 95% CI –5.98 to –0.006; p = 0.05).
Analysed (n = 20)
Excluded from analysis (n = 3)
• Discontinued/lost to follow-up, n = 3 
Lost to follow-up (n = 1)
• Major depressive episode, n = 1
Discontinued intervention (n = 2)
Allocated to CBT for OCD (n = 23)
• Received allocated intervention,
n = 23
Discontinued intervention (n = 3)
• Depression, n = 1
• Withdrew assent, n = 1
• Reason unknown, n = 1
Allocated to anxiety management
(n = 23)
• Received allocated intervention,
n = 23
Analysed (n = 20)
Excluded from analysis, (n = 3)
• Discontinued intervention, n = 3
Analysis
Randomised
(n = 46)
1-month
follow-up
Attended, n = 17
Did not attend, n = 3
Crossed over to other treatment
after this point, n = 9
Attended, n = 18
Did not attend, n = 2
Crossed over to other treatment, n = 3
Entered follow-up, n = 17
Excluded (n = 29)
Not meeting inclusion criteria
• No OCD, n = 13
• Epilepsy, n = 1
• No ASD, n = 2
• Verbal IQ < 70, n = 1
Assessed for eligibility
(n = 75)
Allocation
Follow-up
FIGURE 31 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
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TABLE 59 Age, ADOS-G, verbal IQ and symptom measures at pre treatment
AM group,
mean (SD)
CBT group,
mean (SD) t-test (df) p-value
Age (years) 25.2 (13.5);
minimum = 14,
maximum = 65
28.6 (11.3);
minimum = 14,
maximum = 49
–0.93 (44) 1.00
ADOS-G communication and RSI total 9.9 (4.7) 10.7 (4.2) –0.49 (33) 0.621
WAIS-III/WISC-III verbal IQ 97.3 (15.2) 102.5 (16.7) –0.91 (30) 0.367
Clinician administered
YBOCS obsessions severity 12.4 (3.1) 11.6 (2.7) 0.90 (39) 0.370
YBOCS compulsions severity 12.9 (2.8) 13.2 (1.5) –0.47 (39) 0.638
YBOCS total severity 25.1 (5.2) 24.8 (3.7) 0.20 (39) 0.839
D-YBOCS global severity 20.4 (5.1) 20.6 (3.7) –0.15 (41) 0.880
CGI 4.2 (0.8) 4.1 (0.7) 0.35 (37) 0.725
Self-report
OCI-R
Checking subscale 5.8 (3.6) 6.4 (3.7) –0.37 (33) 0.708
Hoarding subscale 5.1 (3.6) 5.2 (3.6) –0.19 (33) 0.849
Neutralising subscale 2.8 (3.4) 3.3 (3.0) –0.58 (33) 0.566
Obsessing subscale 6.6 (3.6) 6.4 (4.0) 0.26 (32) 0.790
Ordering subscale 6.6 (3.2) 5.3 (4.4) 0.16 (34) 0.256
Washing subscale 4.3 (4.1) 3.8 (3.8) 0.16 (34) 0.869
OCI-R total 30.9 (13.7) 30.5 (15.9) 0.09 (34) 0.929
BDI 16.9 (12.0) 17.3 (13.5) –0.11 (38) 0.912
BAI 15.4 (10.9),
n = 15
16.2 (11.6),
n = 17
–0.19 (37) 0.725
SCAS total score 27.8 (4.7), n= 5 28.3 (20.3), n= 3 –0.05 (6) 0.955
LSAS total score 76.8 (26.1) 67.5 (33.5) 0.82 (26) 0.418
WSAS 18.5 (9.5) 18.8 (10.9) –0.069 (30) 0.946
Parental/carer report
CHOCI symptom total 14.7 (8.1) 14.4 (6.0) 0.11 (25) 0.908
CHOCI impairment total 28.9 (12.5) 27.9 (11.6) 0.21 (25) 0.832
FAS (n= 27) 24.1 (13.5) 27.3 (15.1) –0.58 (25) 0.562
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CHOCI, Children’s Obsessive Compulsive Inventory;
FAS, Family Accommodation Scale; LSAS, Liebowitz Social Anxiety Scale; RSI, reciprocal social interaction; SCAS, Spence
Children’s Anxiety Scale; WAIS-III, Wechsler Adult Intelligence Scale-III; WISC-III, Wechsler Intelligence Scale for Children-III.
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Treatment response (acute phase)
Table 60 shows, for blind clinical assessor, self and informant ratings, the means and SDs for each measure
pre and post treatment and at 1-month follow-up; per cent improvement change between pre and post
treatment and between pre treatment and the 1-month follow-up; and the mean difference, 95% CIs and
within-group effect sizes. In terms of missing data, YBOCS and D-YBOCS ratings were available for all
participants in both groups at the start of treatment, for 20 in the CBT group and 20 in the AM group
at the end of treatment and for 18 in the CBT and 17 in the AM group at 1-month follow-up. For the
self-report measures, the OCI-R was completed by 20, 17 and 17 in the CBT group and 19, 17 and 17 in
the AM group at the start, end and 1 month post treatment, respectively. There was a similar rate of
completion with the other self-report measures. The Informant measures were completed by 15, 14 and
11 in the CBT group and by 14, 11 and 9 in the AM group at the start and end of treatment and 1 month
post treatment, respectively.
Analysis of covariance, controlling for pre-treatment YBOCS severity ratings, detected no significant
differences between the treatment groups on the primary outcome measure (YBOCS total severity scores)
at end of treatment (F1,37 = 1.127; p = 0.295).
In the CBT group, univariate repeated measures ANOVAs established significant changes in YBOCS total
severity scores from pre treatment to end of treatment (F1,19 = 15.089; p = 0.001). In the AM group, there
were also significant changes in YBOCS total severity ratings from pre treatment to end of treatment
(F1,19 = 20.169; p < 0.0001).
Within-group treatment effect sizes on the YBOCS were large and could be considered clinically
meaningful in the CBT group (1.15) and medium in the AM group (0.6).
There were more treatment responders (i.e. had a > 25% reduction in YBOCS total severity ratings) in the
CBT group than in the AM group [9/20 (45%) vs. 5/20 (20%), respectively]. However, this difference in
response rate was not statistically significant (χ2 = 1.72, df = 1; p = 0.160). When a more stringent rating
of treatment response (i.e. a CGI ‘much or very much improved’ combined with a > 35% reduction in
YBOCS total severity ratings) was considered, 6 out of 20 (30%) in the CBT group achieved treatment
response, compared with 2 out of 20 (10%) in the AM group. Again, the groups did not differ significantly
in the proportion of treatment responders. The number participants classified as remitted cases (i.e. with a
YBOCS total severity rating of ≤ 12 1 week after treatment ended) was slightly higher in the CBT group
than in the AM group [5/20 (20%) vs. 3/20 (15%)], but the difference was not statistically significant.
Standardised effect sizes to further compare the two treatments were calculated for end of treatment
primary outcome ratings using Cohen’s d (mean CBT –mean AM/σpooled). Effect sizes were 0.4 for the
YBOCS total severity rating, 0.4 for YBOCS obsessions severity, 0.2 for YBOCS compulsions and 0.3 for
CGI, all indicating a small advantage for CBT over AM after.
Maintenance of treatment gains at long-term follow-up
Treatment satisfaction
There were no differences between the two treatment groups as to their reports of satisfaction with the
treatments they had received: AM group mean satisfaction score = 5.60 (SD 2.131); CBT group mean
satisfaction score = 4.9 (SD 2.3), t = 0.809 (df = 27); p = 0.425.
In the CBT group, there were significant changes in YBOCS total severity scores from pre treatment to
1-month follow-up (F1,17 = 10.530; p = 0.005), 3-month follow-up (n = 10, F1,9 = 11.602; p = 0.008),
6-month follow-up (n = 12, F1,11 = 10.823; p = 0.007) and 12-month follow-up (n = 11, F1,10 = 9.831;
p = 0.011). The stability of the change over time can be seen in Figure 32.
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TABLE 60 Pre and post treatment and 1-month follow-up clinician, self and informant ratings by group
Rating
Pre
treatment,
mean (SD)
Post
treatment,
mean (SD)
1-month
follow-up,
mean (SD)
Pre–post
difference,
mean (95% CI)
Pre 1-month
follow-up
difference,
mean (95% CI)
Pre–post %
improvement,
mean (SD)
Pre 1-month
follow-up %
improvement,
mean (SD)
Pre–post
effect
size
Pre 1-month
follow-up
effect size
CBT: clinician ratings
YBOCS
Total severity 24.8 (3.7) 17.8 (8.4) 18.7 (8.2) 7.0 (3.2 to 10.7) 5.8.(2 to 9.7) 27.8 (33.2) 23.5 (32.1) 1.078 0.958
Obsessions severity 11.7 (2.8) 8.7 (4.1) 8.5 (3.6) 2.9 (1.1 to 4.7) 3.1 (1.4 to 4.7) 24.0 (34.7) 25.2 (30.9) 0.854 0.922
Compulsions severity 13.1 (1.5) 9.0 (4.6) 9.7 (4.5) 4.0 (1.7 to 6.3) 3.2 (0.9 to 5.5) 29.7 (36.5) 23.9 (35.7) 1.198 1.013
CGI 4.2 (0.8) 3.3 (1.1) 3.5 (1.3) 0.9 (0.4 to 1.4) 0.8 (0.2 to 1.4) 21.4 (21.8) 19.6 (25.3) 0.935 0.648
D-YBOCS
Contamination 7.3 (4.1) 3.9 (3.8) 4.5 (3.8) 3.4 (1.4 to 5.3) 2.6 (0.8–4.5) 41.4 (48.6) 34.2 (41.3) 0.860 0.708
Hoarding 3.5 (3.9) 1.7 (2.8) 1.7 (2.8) 1.7 (0.2 to 3.3) 2.1 (0.3–3.9) 48.8 (55.7) 53.4 (49.5) 0.530 0.530
Symmetry 5.3 (4.5) 4.2 (4.6) 4.6 (4.4) 1.1 (–0.2 to 2.5) 1.2 (–0.3 to 2.8) 35.5 (47.1) 34.9 (48.0) 0.241 0.157
Aggression/harm 3.8 (4.3) 2.6 (4.0) 2.2 (3.5) 1.2 (–0.1 to 2.5) 1.8 (0.2 to 3.4) 29.9 (61.7) 65.7 (39.3) 0.288 0.408
Sexual/religious 2.0 (3.1) 1.2 (2.3) 1.3 (2.5) 0.8 (–0.2 to 1.8) 0.8 (–0.3 to 1.9) 37.3 (51.4) 34.7 (52.8) 0.293 0.248
Miscellaneous 3.2 (4.1) 1.4 (3.0) 1.6 (3.5) 1.8 (0.4 to 3.1) 1.7.(1 to 3.2) 60.6 (45.4) 58.5 (52.6) 0.501 0.419
Global total 20.7 (3.8) 15.5 (7.1) 15.8 (7.0) 5.2 (2.5 to 7.8) 5.0 (2.1 to 7.9) 26.7 (30.1) 25.4 (30.9) 0.913 0.870
CBT: self-ratings
OCI-R total 31.5 (12.7) 26.8 (15.3) 29.3 (12.9) 4.7 (–1.3 to 10.7) 1.3 (–6.9 to 9.7) 20.2 (45.8) –32.1 (97.4) 0.334 0.171
BDI 16.2 (13.8) 15.7 (16.5) 17.5 (15.1) –0.5 (–3.9 to 4.9) 2.0 (–2.9 to 6.9) 17.9 (58.3) 16.4 (39.1) 0.032 –0.089
BAI 16.4 (10.6) 14.0 (11.6) 13.6 (10.1) 2.3 (–0.8 to 5.5) 1.5 (–3.8 to 6.9) 14.1 (52.9) 26.5 (36.0) 0.215 0.270
LSAS total 74.7 (27.1) 67.8 (34.9) 66.2 (35.7) 6.9 (–9.8 to 23.7) –2.2 (–17.6 to 13) 7.0 (34.7) –20.3 (46.2.1) 0.220 0.268
SCAS total 28.3 (20.3) 49.0 (n= 1) 20.0 –28.9 –1.40
WSAS 19.0 (10.4) 22.4 (11.7) 14.1 (9.1) 3.4 (–7.8 to 1.0) 4.6 (–3.9 to 13.1) –24.4 (43.5) 8.4 (53.5) –0.307 0.501
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Rating
Pre
treatment,
mean (SD)
Post
treatment,
mean (SD)
1-month
follow-up,
mean (SD)
Pre–post
difference,
mean (95% CI)
Pre 1-month
follow-up
difference,
mean (95% CI)
Pre–post %
improvement,
mean (SD)
Pre 1-month
follow-up %
improvement,
mean (SD)
Pre–post
effect
size
Pre 1-month
follow-up
effect size
CBT: informant
CHOCI severity 30.3 (11.1) 25.8 (10.5) 28.8 (7.0) 4.5 (2.1 to 11.1) 2.7 (–7.5 to 13.0) 4.9 (41.1) –3.2 (41.2) 0.416 0.161
FAS 26.9 (15.2) 27.9 (15.0) 21.1 (9.3) –1 (–11 to 8.9) 6.3 (–5.8 to 18.4) –33.1 (90.1) 1.4 (71.3) –0.066 0.460
AM: clinician ratings
YBOCS
Total severity 25.1 (5.1) 20.8 (7.8) 20.7 (5.4) 4.7 (2.5 to 6.8) 3.8 (2.1 to 5.6) 20.3 (23.4) 16.2 (14.3) 0.652 0.837
Obsessions severity 12.4 (3.0) 10.5 (3.8) 11.9 (2.3) 2.0 (0.9 to 3.0) 2.2 (1.2 to 3.3) 17.6 (21.9) 19.7 (17.9) 0.554 0.187
Compulsions 12.9 (2.8) 10.3 (4.7) 10.8 (3.0) 2.7 (1.1 to 4.3) 1.9 (0.9 to 3.1) 22.5 (30.6) 13.1 (20.8) 0.672 0.723
CGI 4.2 (0.8) 3.7 (1.1) 3.7 (1.2) 0.5 (0.2 to 0.8) 0.6 (0.1 to 0.9) 13.9 (18.4) 14.9 (19.6) 0.519 0.490
D-YBOCS
Contamination 5.8 (4.3) 4.8 (4.8) 4.9 (4.4) 1.0 (–0.5 to 2.5) 0.8 (–0.6 to 2.2) 22.3 (69.6) 27.6 (45.0) 0.219 0.206
Hoarding 2.9 (3.8) 2.5 (3.6) 2.0 (3.4) 0.3 (–1.4 to 2.1) 0.8 (–1.4 to 3.1) 54.9 (36.0) 68.7 (39.2) 0.108 0.249
Symmetry 5.4 (4.3) 4.6 (3.9) 3.7 (3.7) 0.8 (–0.6 to 2.2) 2.0 (0.2 to 3.7) 21.8 (40.8) 43.1 (43.2) 0.194 0.423
Aggression/harm 6.5 (4.4) 5.3 (4.6) 4.5 (4.1) 1.2 (–0.1 to 2.6) 2.1 (0.27 to 3.9) 29.4 (37.7) 36.8 (41.7) 0.266 0.470
Sexual/religious 1.6 (3.4) 2.2 (4.2) 2.2 (4.2) –0.6 (–2.4 to 1.2) –1.0 (–2.8 to 0.8) 52.5 (55.0) 19.5 (14.7) –0.157 –0.157
Miscellaneous 3.3 (4.2) 1.6 (4.7) 1.1 (2.2) 1.6 (0.2 to 3.0) 1.9 (–0.2 to 3.9) 58.9 (46.8) 51.5 (50.8) 0.381 0.656
Global total 20.3 (4.7) 17.1 (7.5) 17 (5.9) 3.2 (1.1 to 5.2) 2.9 (1.3 to 4.5) 18.5 (27.1) 15.7 (14.9) 0.511 0.524
*p< 0.05; **p < 0.01; ***p< 0.001.
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CHOCI, Children’s Obsessive Compulsive Inventory; FAS, Family Accommodation Scale; LSAS, Liebowitz Social Anxiety Scale;
SCAS, Spence Children’s Anxiety Scale.
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Nine (39%) participants in the AM group, compared with three (13%) participants in the CBT group,
asked to ‘cross over’ or try the other treatment either at or after the 1-month follow-up point (χ2 = 4.05,
df = 1; p = 0.044).
Eight out of the nine participants originally randomised to AM who ‘crossed over’ to CBT completed the
second treatment and attended for symptom ratings (AM + CBT). One participant was not available for
end of treatment ratings despite completing the treatment. There was a significant effect of this second
treatment (F1,7 = 7.703; p = 0.027) on the primary outcome measure when the end of second treatment
scores were compared with those pre treatment. There was no change in YBOCS severity ratings for the
three participants who completed AM following CBT, although the individuals attended readily and
qualitatively commented that they found the treatment helpful in general stress management.
Secondary outcome measures
Although clinician ratings of CGI changed significantly between pre and post treatment (F = 29.1,
df = 1,34; p < 0.001), this did not vary by treatment group (F = 2.28, df = 1,34; p = 0.140). Figure 33
depicts the percentage of participants in each group rated as ‘much or very much improved’ and ‘minimally
improved, unchanged or worse’ on the CGI-I scale. On the basis of this dichotomous rating, the treatment
groups differ significantly in terms of the proportion of participants in each group rated as ‘much or very
much improved’ [CBT group, n = 11; AM group, n = 5 (χ2 = 3.886, df = 1); Fisher’s exact test p = 0.050].
Regarding self-report measures, neither of the groups showed significant differences between pre, post
and 1-month follow-up mean scores on any of the self-ratings (see Table 60). Informant ratings differed
significantly between pre and post treatment only for the AM group.
Moderating factors
Symptom severity
The five participants classified as treatment responders in the AM group had significantly lower YBOCS
severity ratings pre treatment (mean 21.20, SD 3.2) than with the non-responders in the AM group [mean
26.8, SD 4.8, t = 2.37 (df = 17), 95% CI 0.6 to 10.6; p = 0.029]. This was not the case in the CBT group,
in which responders and non-responders were equivalent with respect to symptom severity before starting
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FIGURE 32 Yale–Brown Obsessive Compulsive Scale total severity (pre and end of treatment, 1-month follow-up)
by treatment group and 3 (n= 10), 6 (n= 12) and 12 months (n= 11) follow-up for CBT group cross-over cases.
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treatment [CBT responder: mean 24.8, SD 3.2; CBT non-responder: mean 24.1, SD 4.4, t = –0.41
(df = 16); p = 0.687]. Similarly, treatment responders in the AM group had a significantly lower CGI rating
pre treatment than non-responders [AM responders: mean 3.2, SD 0.5; AM non-responders: mean 4.5,
SD 0.6, t = 3.56 (df = 15), 95% CI 0.5 to 2.0; p = 0.003]. The AM responders did not differ in terms of
number of obsessive–compulsive symptoms from non-responders.
Age
Age was not significantly associated with treatment outcome. The main outcome analysis was also
repeated excluding those participants who entered the youth protocol (age 14–16 years), and this did not
affect the pattern of results.
Other variables
Other variables purported to be of interest as potential moderators of treatment, including verbal IQ,
ADOS-G scores and performance on executive function measures, were investigated in terms of their
association with treatment response (i.e. the percentage change in total YBOCS severity scores). None of
these factors showed any association. However, the group categorised as treatment responders (i.e. > 25%
reduction in YBOCS ratings) differed significantly from non-responders on the Family Accommodation Scale
(FAS) at baseline [mean treatment responder: FAS score 18.22, SD 15.91; mean treatment non-responder:
FAS score 29.53, SD 12.30; t = 2.015 (df = 24), 95% CI of the difference –0.275 to 22.89; p = 0.055]. The
treatment responder and non-responder groups did not differ on the FAS at the end of treatment. There
was a wide range of scores on the FAS in the treatment response group at baseline and this reduced by the
end of treatment, suggesting that family factors may have changed over the course of treatment.
In terms of insight as ascertained by the YBOCS, 33 participants (71.7% of the total) could identify a
specific feared consequence if they did not respond to the obsessive thoughts or compulsive urges.
Certainty about the feared consequences differed post treatment according to treatment response at the
trend level [responder: mean rating 1.00 (SD 1.15); non-responder: mean rating 1.95 (SD 1.07); t = 2.00
(df = 26); p = 0.056], indicating that non-responders tended to have worse insight scores.
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FIGURE 33 Percentage of participants rated as ‘minimally improved, unchanged or worse’ and ‘much or very much
improved’ on the CGI-I scale by treatment group.
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Discussion
This is the first clinical trial to provide evidence for the effectiveness of CBT for comorbid OCD in young
people and adults with ASD. The effect of CBT treatment in the present study was comparable with
clinical trials of OCD in people without ASD, where aggregated effect sizes of 1.12 and 1.45 have been
reported from meta-analyses of CBT trials in adult364 and paediatric365 OCD studies, respectively.
Importantly, the treatment gains were sustained over a 12-month follow-up period.
Unexpectedly, AM, a plausible control treatment, was also effective in bringing about a reduction in OCD
symptoms in people with ASD, particularly those with milder symptoms. It was not possible to separate the
two treatment groups at the end of treatment in terms of symptom severity, although there were twice as
many responders in the CBTgroup than in the AM group. Comparison between the effect sizes of the two
treatments afforded some small advantage for ERP-based CBT over AM.
This advantage for CBT was greater for ratings of obsessions. In an earlier uncontrolled pilot study,343 in
which CBT was compared with TAU, we noted an overall advantage for CBT, with a significant change in
obsessions severity ratings but not compulsions. It is possible that measurement issues and in particular
difficulties in disentangling ASD-preferred routines and stereotyped behaviours from anxiety-based
compulsions has a role to play here. Alternatively, unwanted intrusive thoughts/images/impulses may be
associated with greater distress and thus motivation for treatment than compulsive rituals where a
preference for routine and sameness in ASD may infer greater tolerance of these symptoms. Furthermore,
outcome for adults with ASD is known to be poor with low levels of employment and independent living.
In the absence of full occupation, compulsive rituals may not present with a high level of daily interference.
Significantly more patients in the AM group requested crossover to the CBT group than did CBT patients
to the AM group after the 1-month follow-up, indicating that the AM treatment, although receiving
similar satisfaction ratings, was not perceived as being as potentially useful as the ERP-based treatment.
The eight patients who crossed over from AM to CBT and provided data at the 1-month follow-up point
achieved statistically significant reductions in OCD severity, whereas those who crossed over from CBT to
AM (n = 3) did not improve.
Setting aside the not inconsequential issues of sample size and statistical power (discussed below), it is
worth considering why AM might have performed relatively well in people with ASD and comorbid OCD,
particularly those with mild symptoms.
First, this is not an unprecedented finding. For example, Whittal and colleagues,366 in a study investigating
cognitive therapy for obsessions, found that stress management (a credible control treatment) was also
helpful in reducing obsessions with equivalent pre–post effect sizes for both treatments on the primary
outcome measure. Unexpectedly, changes in OCD-related cognitions and threat appraisals occurred in the
control group. In an internet-based trial of self-help for panic and phobias,350 a similar AM control group
did as well as the exposure therapy group on some outcome measures. In an ASD-specific study of group
treatment for anxiety in children, a social recreational programme was found to have a similar effect on
anxiety symptoms as CBT.367 Thus, under certain circumstances, non-specific interventions can lead to
clinically significant improvements in disorder-specific measures. In the current trial, it is important to note
that patients who responded to the control treatment had significantly less severe OCD.
Second, it is important to consider that OCD is not the only commonly occurring anxiety disorder in ASD.
There is evidence that processing and identification of emotions may be impaired in this group368 and the
AM intervention in the present study (with its focus on education about anxiety and teaching of relaxation
techniques) may have made anxiety a more predictable and manageable emotion for some individuals.
Risk factors for anxiety disorders, such as increased intolerance of uncertainty and anxiety sensitivity, may
be elevated in people with ASD, who have a preference for routine and sameness, and this may represent
a pathway to OCD. Increasing an individual’s capacity to manage the emotional consequences brought
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about by uncertainty and anxiety may thus bring about a reduction in OCD symptoms. Furthermore, the
non-specifics of therapy may be more potent in a group who can be socially isolated and lack support.
The majority of clinical trials in people with ASD have to date employed a wait list or TAU comparison
condition. However, a RCT evaluating CBT for anxiety compared with a social recreational programme
in young people with ASD had similar difficulties to the present study in significantly separating the
treatments in terms of their effects on anxiety.367
There were no therapist effects in terms of numbers of treatment responders. Prior to their work on the
present study, the majority of the therapists had gained some experience of working with people with
ASD as part of generic anxiety/OCD clinic work. Only one of the therapists had previously worked in an
ASD-specific service. Thus, the results should be generalisable to clinicians and psychological therapists
trained in treating OCD.
Self-report of OCD and other anxiety symptoms were correlated with clinician and informant ratings pre
treatment but not at follow-up, suggesting that they were not sensitive to change. Nonetheless, it is of
benefit to know that self-report measures can be used as an assessment tool to accurately assess the
content of anxiety-related problems in young people and adults with ASD and this is consistent with
findings from other studies.369 It is also important to note that many of the participants in the study had
good insight into their OCD and that obsessive–compulsive-related beliefs were prevalent.
There was some indication that family factors (family accommodation) were associated with treatment
outcome in the present study, and this is consistent with findings of other anxiety intervention studies in
ASD330 and outcome in general paediatric OCD treatment studies.363 Group and individual psychological
interventions for anxiety disorders in this group should then seek the engagement of relevant caregiving/
supportive individuals in treatment.
Strengths and weaknesses
Although the study was well powered to detect within-group changes in symptom severity, it may have
lacked statistical power to detect a difference between the two treatment groups. The power calculation
was based on an earlier pilot study where treatment was compared with no-treatment.343 As discussed
above, the AM intervention clearly had some modest effect, particularly in individuals with mild OCD
symptoms. This indicates that larger sample sizes will be needed to detect a statistically significant
difference between the groups. The results of the current trial will be useful to help more accurate power
calculations for future trials. However, the main message of the current study is that standard CBT for
OCD can be successfully adapted for ASD participants who are traditionally perceived as difficult to treat.
The disproportionately high number of participants who endorsed hoarding symptoms in the CBT (60%)
compared with the AM (40%) groups may also have contributed to the lack of clearly significant
differences between the groups because hoarding symptoms are usually considered difficult to treat with
conventional CBT for OCD.370 Given the current proposals to separate hoarding from OCD in DSM-V,371
future treatment studies would probably benefit from excluding any severe hoarding individuals from
their samples.
The wide ranges of age and symptom severity may have had an impact on the findings. Rounsaville and
colleagues372 recommend reducing therapist and participant heterogeneity and choosing narrow parameters
with which to define the treatment setting, participants and therapists in order to optimise the power
available in a small pilot trial. However, we felt that, as a proof of concept trial, it would be important to
recruit a wide range of individuals.
The lack of follow-up information on the AM group is a weakness imposed by our design, as it was
unethical to withhold the evidence-based treatment (CBT) for longer than the 1-month follow-up and
these patients had to be offered the option of a crossover. A further limitation was the absence of detailed
information about homework compliance and its association with treatment response.
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Not everyone did well as a result of treatment. A proportion of participants in both groups (15% AM and
10% CBT) were rated as minimally or much worse at 1-month follow-up on the Beck Depression
Inventory, one of the secondary outcome measures. In addition to the lack of longer-term follow-up
previously mentioned in the AM group, just over 50% of the treatment completers in the CBT group
remained in follow-up for 12 months. It is possible that those lost to follow-up may also have deteriorated
during that period and thus the positive effects of the intervention may have been limited to just those
who stayed in the study.
This study may be best considered as a feasibility pilot study. Ideally, randomisation should be carried out
by somebody entirely independent of the trials team. In this study participants were randomised to the
CBT or AM groups using a table of random numbers (1 : 1 ratio) managed by an investigator who was part
of the Trial Management Committee, but they were not part of the team delivering therapies, were blind
to individuals and not involved in data analysis.
Conclusions
Psychological treatments for OCD can be successfully adapted for comorbid ASD and OCD. Our results
suggest that further development of this intervention is required, together with testing in a larger sample
that better represents the whole spectrum of people with ASD.
Key messages
Both AM and CBT are effective in treating comorbid OCD in young people and adults with ASD.
More people responded to CBT than AM and it may have some advantage for treating obsessions.
The treatments are well accepted by affected individuals.
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Chapter 23 Piloting trials to improve knowledge:
a pilot study of web-based learning and clinical
supervision from expert centres to local clinical teams
working with ADHD and ASD
Introduction
An essential component in delivering effective treatments (and needs-led services) is that clinical teams
need to both accurately identify individuals with ASD/ADHD and diagnose their associated mental health
symptoms. They also need to communicate their findings to the affected individuals and their carers
(where relevant). Put simply, there is little point developing new treatments in research settings if these are
not applied by clinical services. However, as part of this programme (see Sections 1 and 2), we found that
clinical services frequently failed to recognise and treat affected individuals (and especially young adults).
Given a number of recent inquiries,373 the need to improve patient care and increase standards particularly
for more vulnerable groups is a high priority for health providers. There has been an increase in education
programmes to train health professionals over the last 10 years.374 However, these have not always
translated to highly specialist areas including the care of people with ADHD and ASD.
In current supervising practice in medicine there is very little empirical data to inform the structure and
approaches to be used in supporting the implementation of national guidelines.375 In addition, there is little
understanding of the factors that are key to the successful implementation of clinical supervision in the
development of new competencies for senior practitioners responsible for implementing national guidelines.
For instance the National Strategy for Adults with Autism titled Fulfilling and Rewarding Lives: The Strategy for
Adults with Autism in England376 is committed to increasing understanding and awareness across all public
sector services. Teaching resources such as e-learning modules were developed with the Royal College of
Psychiatrists and British Psychological Society to increase knowledge and diagnostic skills in ASD and to
improve care for people with ASD with complex presentations such as those requiring mental health care.
However, to support professionals across different types of health-care settings in their development of local
services, there was a need for professionals developing ASD services to access established experts in regional
or tertiary services. Similarly, NICE produced guidelines in 2008 on the diagnosis and management of
ADHD in children, young people and adults, which again required opportunities for professionals to develop
skills and expertise over time in the development of services for adults with ADHD.95 Hence, as part of this
programme we helped launch the UK Adult ADHD Network in 2009 following the publication of national
guidelines to support training among mental health professionals working with ADHD (URL: www.ukaan.org).
Therefore, the importance of supervision in developing skills following on from these national strategies
and guidelines was essential for the ongoing development of services for adults with ASD or ADHD. Prior to
those national initiatives there were a small number of experts working in national services and so the task of
offering supervision across the UK can only be achieved on a scale through the use of technology near to the
professional’s place of work and practice.
Hence, the aims of this study were to carry out a scoping exercise and:
l examine if clinical supervision using web-based learning technology can bring about an improvement in
participant’s knowledge and clinical assessment, management and diagnosis of ASD and ADHD.
l evaluate participants’ experience of web-based learning to deliver clinical supervision for the ADHD
and ASD.
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Methods
Participants were recruited through a series of 1-day training workshops organised across England. These
covered either the assessment or management of ASD and or ADHD in adults.
This study uses a simple randomised comparison of online supervision with no online supervision, to
evaluate the effectiveness of web-based learning to deliver clinical supervision relating to the recognition,
diagnosis and management of ADHD and ASD. The study is divided into two, with both the ADHD and
ASD studies incorporating a separate series of three web-based supervision seminars facilitated by clinical
and academic experts.
The ADHD study consisted of 13 participants (seven were randomised to the web-based online supervision
and six to the control group), whereas 15 participants took part in the ASD study (with six randomised to
the supervision group and nine to the control group). Prior to the start of the supervision process (time 1),
each participant underwent an assessment of knowledge, skills and attitudes, which was repeated at the
end of the study (time 2).
Participants for the ADHD web-based seminars were all psychiatrists, with the majority working in general
adult psychiatry and seeing between 11 and 50 ADHD cases per year. Participants for ASD web-based
seminars were multidisciplinary and included psychiatrists (53%), psychologists (33%) and others such
as speech and language therapists. Forty per cent worked in adult mental health services, 33% worked
in ID services and 20% worked in designated ASD services with 20% working in forensic services. Over
two-thirds of the group had undertaken at least 1–10 diagnostic assessments with a remaining one-third
completing ≥ 11 assessments.
For both studies prior to the start of the supervision process (time 1), each participant underwent an
assessment of knowledge, skills and attitudes, which was repeated at the end of the study (time 2).
The pre-study assessment at time 1 consisted of multiple-choice questions (MCQs) to test knowledge,
an attitude questionnaire (see Appendix 2) and a clinical assessment through a serious of case studies of
increasing complexity using videos. All participants (both intervention and control groups) completed the
MCQs, clinical skills assessment and attitude questionnaire at time 1 and completed the MCQs clinical skills
assessment and attitudes questionnaire at time 2 following the three web-based supervision workshops.
The clinical skills assessment for both the ADHD and ASD studies followed three people who had traits
of the disorders, but where it was also unclear whether or not they met diagnostic criteria. Background
information was given to accompany the series of video clips for each case. Participants were asked a
series of questions to elicit their clinical opinion based on their observation of the video and background
information. The vignettes portrayed situations of increasing complexity relating to the assessment,
diagnosis and management of ADHD and ASD.
Web-based clinical supervision
The three web-based supervision workshops on ADHD and ASD were hosted on the WebEx system
(Cisco Systems, San Jose, CA, USA). To access these, each participant in the intervention arm logged into a
secure online site through the King’s College London server.
Description of ADHD web-based supervision
The three ADHD supervision sessions were held over a 4-week period in July 2012. Seven participants were
invited to attend and all were able to complete at least two out of the three sessions. Each session was
attended by two experts (senior clinicians with experience of running a specialist adult ADHD service), in
addition to a chairperson. The participants were invited to submit anonymised clinical cases and vignettes
for discussion prior to supervision and over the course of the three sessions a total of 13 cases and clinical
scenarios were discussed, with six out of the seven participants presenting cases for discussion. The
sessions lasted from 1 hour to 1 hour 20 minutes. The WebEx system allowed experts and participants to
attend via a video link or telephone connection. For the three sessions, the two experts and chairperson
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attended by video link so participants were able to see and hear them. The participants (who also had this
option) largely attended via a telephone connection.
A wide variety of clinical cases were brought for discussion, reflecting the range of clinical environments
that participants worked in. The experience of the participants ranged from clinicians just starting to see
adults with ADHD presenting to their service and had not yet undertaken assessments for ADHD, to
clinicians experienced in the management of ADHD in adults. In addition, there were clinicians with
expertise in subspecialties such as addictions and ID. Cases for discussion were divided between diagnostic
and management questions. There were a number of cases relating to the difficulty in diagnosing ADHD
in the presence of comorbidity, including mood disorder, PD and ID, as well as discussion involving the role
of rating scales in assessment and monitoring of progress and the use of neuropsychological assessment.
Questions about the management of ADHD included how to treatment refractory initial insomnia, how to
manage comorbid anxiety and the use of venlafaxine (Efexor®; Actavis, Parsippany-Troy Hills, NJ, USA) and
antipsychotics in ADHD.
The experts tended to lead discussion with factual information related to their practice, as well as current
guidance such as NICE guidelines (e.g. the use of antipsychotics is not recommended as an effective treatment
of ADHD). However, the group interaction was made richer by discussion between the participants who had
specific expertise (e.g. addictions), and were able to comment on variation in clinical experience in different
parts of the UK (e.g. the availability of CBT for ADHD) and the ability to make use of second- and third-line
treatment options for ADHD. Abridged versions of the ADHD case studies are provided in Appendix 2.
Description of ASD web-based supervision
The three ASD supervision sessions were held over a 3-week period in September 2012. Six participants
were invited to attend and all were able to complete at least two out of the three sessions. Each session
was attended by two experts (senior clinicians with experience of running specialist adult ASD services).
In addition, a chairperson with similar experience was present. It was agreed with participants that each
of them would submit anonymised clinical cases. These cases were distributed prior to the supervision
sessions so participants could familiarise themselves. This left an hour discussion for each case and the
opportunity for peer review. The sessions lasted from 1 hour 40 minutes to 2 hours 10 minutes. The mode
of attendance was the same as the ADHD study.
The six cases presented over the course of the three sessions were a mixture of people with ASD with
complex cases histories of comorbid mental health problems and offending and/or challenging behaviours
from a variety of community and inpatient services. Unlike the ADHD study, all participants had significant
experience in the management of adults with ASD. In addition, many had expertise in subspecialties such
as ID, general psychiatry and offender health care. There were a number of cases relating to the assessment
strategies, for example in forensic settings, corroborating evidence and what to consider when making
recommendations to courts. Abridged versions of the ASD case studies are also provided in Appendix 2.
Discussion during the supervision sessions was framed from the presented case studies with the peer and
expert opinion offered greatly enhanced by the wide range and extensive experience of the supervision
group. The format of supervision (for both the ADHD and ASD) allowed participants to present cases in a safe
environment and receive peer support, through suggestion and interrogation of the information provided.
Preliminary results and discussion
Can clinical supervision using web-based learning technology bring about an improvement in participant’s
knowledge and clinical assessment, management and diagnosis of ASD and ADHD?
Table 61 provides scoring for knowledge and clinical skills at time 1 and time 2 for both the ADHD and
ASD groups. The knowledge scores apply to the MCQs, whereas the clinical skills scores refer to answers
given by participants following scrutiny of three video vignettes. Neither study reached significance
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although modest increases were demonstrated for three of the four groups, with no change in knowledge
scores for the participants of the ASD supervision group.
Attitude questionnaire scores
In terms of attitudes, the ADHD clinicians showed slight improvement in scores between times 1 and 2
for both the control (41.8–42.5) and intervention groups (38.9–41.8). In the ASD study there was no
improvement in the attitude score of the control group (39.1) between times 1 and 2. The intervention
group showed a slight improvement in attitude score between times 1 and 2 (42.2–44.5).
Following the study, participants in the control group were more likely to say they did not have enough
support from colleagues to manage adults with ADHD and ASD than those in the supervision group.
Evaluation of participants’ experience of web-based learning to deliver clinical
supervision for the ADHD and ASD
ADHD
The feedback from participants during the supervision was generally positive regarding the content of
discussion and the opportunity to discuss cases with experts but also with colleagues working in different
areas. There was some frustration with the technology because at times it was difficult to hear other
participants due to background noise on the telephone connection and more than one participant talking
at once.
Five out the seven participants completed written feedback at the end of the three sessions. None of them
reported that they had used e-supervision before. All the respondents reported that online supervision
was more convenient than face-to-face supervision. The majority (four out of five) rated the experience
of e-supervision the same or better than face-to-face supervision with respect to skills learning and the
ability to improve clinical practice. However, participants were divided whether or not face-to-face
supervision or e-supervision allowed better connection with peers and supervisors (one reported that online
offered better connection to supervisors, two felt that face to face was better for connection to peers
and supervisors, and three felt that there was no difference between the mediums). With respect to the
practicality of receiving online supervision, all respondents were satisfied with their ability to access and
participate in the sessions.
With regard to the quality of supervision offered, the respondents agreed that the supervision met their
expectations, the approach was relevant, the time allocated was appropriate and their clinical practice was
supported. Only one respondent felt that the supervision was not suited to their level of knowledge and
expertise. All the respondents were satisfied with the expertise of the supervisors.
TABLE 61 Attention deficit hyperactivity disorder and ASD clinical and knowledge skills pre and post group
Participant group
n pre
and
post
Pre
knowledge
scores,
mean (SD)
Post
knowledge
scores,
mean (SD)
Change
in mean
scores
Pre clinical
skills scores,
mean (SD)
Post clinical
skills scores,
mean (SD)
Change
in mean
scores
ADHD control 6–4 10.7 (1.4) 10.8 (1.5) 1 12.3 (6.8) 13.5 (5.3) 2.3
ADHD supervision 7–6 10.4 (1.9) 10.7 (2.0) 1.7 11.9 (4.5) 13.3 (3.2) 1.5
ASD control 9–9 21.6 (2.6) 21.9 (1.7) 0.25 67.8 (12.8) 71.9 (9.3) 4.1
ASD supervision 6–6 22.8 (2.1) 22.8 (1.9) 0.33 70.8 (7.1) 75.8 (11.6) 5
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The particular strengths of the online supervision were described as ‘easy access . . . [and] able to relate
to others’, ‘panel of approachable clinicians maintained focus and application’, ‘not having to travel to
London [for supervision]’ and ‘it was very useful to be able to communication with experts and fellow
participants from a distance’. One respondent commented on the mix of participants, suggesting that
separating supervision for doctors and psychologists would help clinical applicability of advice and for this
reason they felt they were not sure they had learnt much from the sessions. Other participants reported
that the sessions ‘improved my confidence in managing more complex clinical presentation’ and ‘clarified
lots of assessment issues [so I] feel more confident’. All respondents reported that they would recommend
this supervision to a colleague.
ASD
Again, there were concerns about the quality of the technology used by participants to utilise the chosen
web-based system to its full potential. There were issues because of this, including difficulty in consistently
hearing each other. The majority of participants relied on a telephone connection as they could either not
access the internet adequately or did not have access to web cams. In terms of general feedback the
following comments were received: there was an issue with the information technology (IT) infrastructure
in some NHS and university facilities not being up to date (e.g. web cameras, software, sound cards).
The ASD supervision group benefited from a high level of expertise within the supervision group who
found it very useful to be able to communicate with experts and fellow participants from a distance.
The online assessments were also well received and a number of participants commented on the need
for similar future initiatives such as e-groups where clinicians could post questions and answers in their
own time and focus on material that is relevant to them. Only one person suggested the need for a
discipline-specific forum.
Future directions
The original intention was to offer training to more junior staff; however, the recruitment of senior
experienced staff may be an indication of the dearth of forums and peer support networks available for
experienced clinicians working on complex atypical presentations. The presence of senior people enhanced
the process and gave an opportunity to engage with other professionals not usually accessible because of
organisational and team boundaries. The expected increase in skills and knowledge that was anticipated
did not materialise, probably as a result of the entry level in terms of experience of the participants, but
each found it valuable and thought a similar type forum would be beneficial.
In terms of future development, there have been recent calls to scale up the use of telemedicine in
psychiatry and specifically in the area of ADHD in order to disseminate good practice and allow training
and consultation. Our findings suggest, however, that issues such as accessibility to technology required
for web-based learning may be a barrier to widespread implementation. This may also be a contributory
to the lack of published evidence for the effectiveness of telehealth for ADHD, despite calls for its use and
implementation of some services.377
This study has highlighted the need when implementing policy (and particularly for those conditions poorly
understood at national level) to focus not just on those starting to develop services but also on those who
are working to develop services in relative professional isolation. The use of web-based learning to support
those with people requiring secondary services with a high level of specialism require access to supervision
either through experts at tertiary centres or through peer-to-peer supervision. The main limiting factor at
the present time is accessibility to adequate and user-friendly forms of technology being widely available
across health-care and academic institutions. Finally, our study suggests the need for the development of a
peer-to-peer support structure and networks among experts outside the current organisational boundaries
and individual collaborations.
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Key messages
e-learning and training is difficult to achieve in NHS settings due to lack of IT support.
e-support was reported by participants to be useful.
However, e-support did not lead to marked improvement in knowledge (or shift attitudes) in clinical teams
about ASD or ADHD.
This may partially reflect quality issues secondary to IT difficulties.
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Section 5 Conclusions and research
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Chapter 24 Conclusions
Background
Both ASD and ADHD frequently persist into adolescence and young adulthood and there are more
teenagers and adults in the UK affected by ASD and/or ADHD than children. However, there are few
clinical services that support those with these disorders through adulthood. Research into the needs of
young adults with an ASD or ADHD (and their carers) is important in order to design effective care
programmes, but little is known about the service use and needs of these groups as they reach
adolescence and transition to adulthood.
Objectives
The objectives of our research were to determine:
l What are the needs of affected individuals and their carers, and are these met by health services?
l Are people with ADHD and ASD already in contact with clinical services recognised and treated by
the services?
l Can we improve the diagnosis of ADHD and ASD by clinical services?
l Can we improve the treatment of ADHD and ASD by clinical services?
Methods
We (1) interviewed > 180 affected individuals (and their families) with a confirmed diagnosis of ASD and/or
ADHD, (2) screened for ASD and ADHD in approximately 1600 patients currently in receipt of clinical services
in community medical (general practice) and mental health services (including general adult, forensic and
prison settings) and (3) surveyed GP prescribing to 5651 ASD individuals across the UK (as prescribing in
ADHD has already been reported). Finally, we tested the effectivness of (1) new ASD diagnostic interview
measures in 169 twins, 145 familes and 150 non-twins, (2) a MRI-based diagnostic aid in 40 ASD individuals,
(3) psycholgical treatements in 46 ASD individuals and (4) the feasability of e-learning in 28 clinicians.
Results
What are the needs of affected individuals and their carers, and from their perspective
are these met by health services?
Young people with ASD and ADHD have very significant needs as they transition through to adolescence
and young adulthood. A major contributor is the presence of associated mental health symptoms and/or
ongoing educational and other functional impairments related to the ‘core disorder’. For instance, most
young people with ASD suffered from additional mental health problems (e.g. depression and anxiety), and
most of those who had suffered from ADHD as children continued to display residual symptoms closely linked
to the disorder such as fatigue and feelings of irritability or anger. Effective treatments for these additional
mental health problems already exist and if used would be expected to reduce disease burden. However, the
additional/residual mental health problems in ASD and ADHD are mostly undiagnosed (and untreated) by
clinical services and so the needs of affected individuals are mostly met by their families. Furthermore, we
found that the largest determinant of service provision was age and not severity of symptoms (e.g. in ADHD
each 1-year increase in a young person’s age, reduced the odds of being seen by services by 38%). This leads
to a carer burden that is similar to looking after somebody with a traumatic brain injury or dementia.
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This part of our programme suggests that needs-led services are required which can identify individuals
with the ‘core symptoms’ of ASD and ADHD at the ‘transition’ and treat their residual symptoms and
associated conditions such anxiety and depression.
Are people with ADHD and ASD already in contact with clinical services recognised
and treated?
We found that many clinical services have a relatively high prevalence of people with ASD and ADHD, but
that these are mainly unrecognised. For instance, rates of ADHD within clinical services for SUD populations
are approximately fivefold higher than general population rates, and some (but not all) forensic populations
have significantly increased rates of both ADHD and ASD. Furthermore, these (unrecognised) individuals
were functionally more impaired, including a higher rate of suicide attempts and spending longer periods in
seclusion. These findings begged the question – if people with ASD and/or ADHD are not being recognised
by clinical services who is bearing the cost?
We found that, overall, costs for both disorders were mainly borne by education and social care agencies,
with much less accounted for by physical (and especially mental) health. Finally, as individuals with
ADHD and ASD grew older they continued to consume services, but costs of education, hospital services
and social work/social care all reduced (and for both disorders mental health service costs reduced very
significantly). This suggests that, although (as noted in other parts of our programme) individuals with ASD
and ADHD continue to experience significant symptoms as they ‘transition’, their contact with treatment
and support services reduces significantly.
This part of our programme revealed diagnostic unawareness of both ASD and ADHD in a variety of
clinical service settings; with the burden of care mostly falling on families and service costs for both
disorders mainly borne by education and social care agencies. This situation most likely reflects both
a paucity of instruments to aid case identification and lack of clinical staff knowledge.
Can we aid the diagnosis of ADHD and ASD by clinical services?
We took the pragmatic decision to adapt existing instruments (rather than developing completely new
ones). In addition, relatively easy-to-use instruments for screening/diagnosing ADHD already exist. Hence,
as a first step we focused on ASD by testing the utility of the DAWBA and SDQ for (respectively)
diagnosing the core disorder and for identifying associated mental health symptoms.
The DAWBA performed well in our study of children, and our initial results suggest that it has the potential
to be a useful tool in community settings. Our results also suggest, however, that the DAWBA should be
used in conjunction with a direct observational measure (expert clinical observation or ideally a measure
such as the ADOS-G). When both measures agree with each other there can be confidence in both
positive and negative results. In cases where these measures are discrepant then further assessment in
more expert centres, using a tool such as the ADI-R, or through observation of behaviour in school or with
peers could help to resolve issues. In addition, our initial results suggested that the SDQ is also a valid way
to screen for comorbid anxiety disorders, depression and ADHD in adults with ASD. However, it is possible
that changes in the diagnostic criteria for ASD may have implications for the performance of the SDQ in
the new diagnostic categories suggested in DSM-V.
In the next study, therefore, we explored the effect that changes to clinical diagnostic practice as
recommended in DSM-V would have on affected individuals. We found that DSM-V is a relatively
insensitive measure of ASD in young adults compared with alternatives that are currently used in the UK
(such as ICD-10). This is noteworthy, as ICD-10 is about to be revised, and if approaches adopted in
International Classification of Diseases, Eleventh Edition are similar to those now used in DSM-V, or if
DSM-V is adopted in the UK as a service ‘gatekeeper’, then many affected individuals with ASD will be
excluded from services. A natural corollary is that changes in clinical diagnostic practice (that may not
reflect the underlying pathology) may worsen the already high level of unmet meets in affected individuals
and carer burden.
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We therefore next determined if, in young adults, we could establish proof of concept that new advances
in brain imaging provide objective measures that may help categorise young adults with ASD and/or
ADHD. We used a multiparameter classification approach to characterise the complex and subtle grey
matter differences as measured using MRI in ASD and ADHD. SVM achieved good separation between
groups and revealed spatially distributed and largely non-overlapping patterns of regions with highest
classification weights for each of five morphological features. For instance, in the left hemisphere, SVM
correctly classified 85% of all cases overall at a sensitivity and specificity as high as 90% and 80%,
respectively, using all five morphological features. Our results provide proof of concept that that the
neuroanatomy of ASD and ADHD are truly multidimensional and that the discriminating patterns detected
using SVM may help classify affected individuals. The significant predictive value of pattern classification
approaches may have potential clinical applications. Currently, both ASD and ADHD are diagnosed solely
based on behavioural criteria. The behavioural diagnosis is, however, often time-consuming and can be
problematic, particularly in adults. In addition, different biological aetiologies might result in the same
behavioural phenotype, which is undetectable using behavioural measures alone. Thus, the existence of an
ASD (or ADHD) biomarker such as brain anatomy might be useful to facilitate the behavioural diagnosis.
This would, however, require further extensive exploration in the clinical setting.
In summary, this part of our programme provided interview-based tools to help diagnose the core disorder
and associated symptoms in ASD, and proof of concept for the potential utility of brain biomarkers to help
aid clinical classification of ASD and ADHD in young adults.
Can we improve the treatment of ADHD and ASD?
An essential step in improving treatments is to understand how current treatments are used. We focused
on pharmacological prescriptions to affected individuals by GPs across the UK, as these data (unlike the
use of psychological approaches) are available from an electronic source called THIN. We had previously
reported on prescriptions to young adults with ADHD, but there was no published information on ASD.
Hence, we carried out the first naturalistic study of psychotropic drug prescribing and neuropsychiatric
comorbidities in a large nationally representative cohort of ASD patients in UK primary care. We found that
there were 5651 patients aged < 25 years in the THIN database with at least one diagnostic record of ASD
during the study period. In other parts of this programme, we found very high rates of associated mental
health symptoms in ASD (e.g. depression and anxiety). However, relatively few individuals had been
diagnosed with these symptoms by their GPs and, although approximately one-third of individuals with
ASD received at least one psychotropic drug prescription, these were mostly for stimulants, antiepileptic
drugs and mood stabilisers, and antipsychotics. Of those who were prescribed psychotropic medication,
one-fifth were treated with the antipsychotic risperidone and at least one-third received more than one
drug. Furthermore, as people aged, prescribing rates for risperidone remained high (whereas others
decreased), suggesting that those adolescents and young adults who are prescribed antipsychotics are
(relatively) unlikely to be taken off them. Hence, further research into the appropriate use, efficacy and
long-term safety of antipsychotics and stimulants is warranted to support for optimal and safe treatment
of ASDs and their comorbidities. One likely contributing factor to the lack of trials in frequently excluded
groups such as these is that investigators typically face significant hurdles (e.g. ethical and practical).
Hence, in order to make the most rapid progress we ran two concurrent work streams to obtain pilot
data/proof of concept on the ability to run UK trials on effectiveness of interventions in ADHD and ASD.
The first focused on the effectiveness (or otherwise) of current pharmacological treatments for ADHD in
people typically excluded from trials (those with ID). The second piloted a new CBT-based treatment
approach for OCD in ASD. We were unable to complete the first trial in the time frame of this grant
(mainly due to delays inherent in obtaining approval from multiple ethical and regulatory authorities)
and so, given our findings on high rates of unrecognised disorder in forensic populations, we switched
resources into a prison study of ADHD treatment that is ongoing. However, it is crucial to also offer
effective non-pharmacological treatment approaches. The effect of CBT treatment in the present study was
comparable to clinical trials of OCD in people without ASD. Unexpectedly, however, AM training was also
effective in bringing about a reduction in OCD symptoms and particularly in those with milder symptoms.
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Hence, further work is required to determine if OCD symptoms in ASD are underpinned by anxiety to a
greater extent than in non ASD individuals. If this is the case then it will allow more people to be treated
(and at lower cost), as AM training can be provided more simply, and with a lower degree of staff
expertise, than CBT.
Finally, in order to improve outcomes we need to improve staff knowledge. However, e-learning and
training is difficult to achieve in NHS settings due to lack of IT support and it did not lead to marked
improvement in knowledge (or shift attitudes) in clinical teams.
In summary, we found that individuals with ASD and ADHD at the ‘transition’ have significant unmet
needs and a high carer burden. In addition, the needs of affected individuals are mostly not being met by
clinical services and a main determinant of service delivery was age (and not need). Furthermore, many
services (including GP, mental health and prisons) contain relatively large numbers of people with ASD and
ADHD that have not been recognised; and these individuals suffer from high levels of impairment. To help
this situation we provide proof of concept for the potential utility of new interview-based diagnostic/
screening tools, biomarkers and behavioural treatments.
Recommendations for future research
Based on our findings, and the limitations of our studies, we suggest that future work is required to
address the following:
l If we can reduce the burden of ASD and ADHD by targeting associated mental health symptoms. We
need to develop tools (and training) so that these are recognised and treated. In addition, we need to
test the effectiveness of treatments for mental health disorders that are currently used in the general
population – it is largely unknown if they are equally effective (or have similar rates of adverse events)
in people with ASD or ADHD.
l The need for quicker, easier and more reliable screening, diagnostic and predictive tools (including
perhaps biomarkers) that work in ‘real-world’ clinical settings.
l The barriers to providing lifelong services for what are lifelong disorders. We need to understand what
prevents provision of services that are based on need – and not age.
l The acceptability to affected individuals and their carers of putative new screening, diagnostic and
treatment approaches.
l The validity, reliability and acceptability of objective outcome markers for treatment interventions.
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Chapter 25 Impact
Capacity building
During this programme we endeavoured to develop capacity, increase and disseminate knowledge and
help initiate progress. Our outputs are summarised below.
Undergraduate progression
During the course of the grant, two placement students from the University of Surrey and the University of
Westminster and a summer work experience student worked on the project. All three individuals reported
thoroughly enjoying their experience and two have gone on to further education within related fields; one
is applying for a Masters in Child Mental Health to commence in 2014 at the IoP and the other has just
been accepted at University of East London to study for a Doctorate in Counselling Psychology. The
remaining student will return to university for his final year in September 2013. He wishes to pursue a
career in Clinical Psychology.
Career progress of individuals employed by the programme
We are happy to report significant career progress of our RAs. This includes:
l Tim Cadman (RA) has obtained a placement on a Clinical Psychology training programme (this is
extremely competitive in the UK).
l Hanna Eklund (RA) was awarded a Doctor of Philosophy (PhD) for her work.
l Dee Howley (RA) has trained as a paediatric research nurse and is now leading a European study on
infants at risk of ASD.
l Hannah Hayward (RA) is leading a study on ADHD and ASD in prison settings.
l James Findon (RA) has been awarded an extremely prestigious Medical Research Council PhD
training fellowship.
l Jenna Vyas (RA) has obtained a placement on a Clinical Psychology training programme (this is
extremely competitive in the UK).
l Helen Todman (affiliated Master of Science student) obtained a place on the accelerated promotion
scheme for NHS management.
l Eddie Chaplin (research nurse) has completed his PhD on ASD and ADHD in forensic settings
l two of our other RAs continued into further education: with Zoe Huntley in her final year of Clinical
Psychology training at University College London and Amy Hammon completing her Doctorate in
Counselling at the University of East London.
l Emma Woodhouse (RA) is currently working as a RA on a project examining Tuberous Sclerosis and
ASD led by Professor Patrick Bolton at the IoP; she is now a registered Member of the British
Association for Counselling & Psychotherapy.
l Karen Ashwood (RA) is currently a post-doctoral research worker at the IoP, working with Professor
Tony Charman to develop a clinical European Clinical Trials network for ASD; the project is part of
European Autism Interventions – a Multicentre Study for Developing New Medications, one of the
largest ever collaborations between academia and industry to develop new medications for ASD.
l Dr Fiona McEwen (RA) has secured Post-doctoral researcher/study co-ordinator position on a further
study at the IoP and is continuing in the field of NDs.
l Dr Catherine Ames (RA) subsequently completed her doctorate in clinical psychology and secured a
position as a clinical psychologist at the Maudsley Hospital, South London & Maudsley NHS
Foundation Trust.
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Student dissertations
A number of student dissertations (undergraduate, postgraduate taught and PhD dissertations) are listed in
Acknowledgements, Publications.
Conference presentations/keynote talks
A number of papers have been presented at conferences and these are listed in Acknowledgements,
Publications.
Peer-reviewed publications
A list of peer-reviewed publications is presented in Acknowledgements, Publications.
Books and training materials
Bonell S, et al.378: this book offers a unique inside line on the subject as each chapter is considered through
the eyes of a different person. This compilation of personal insights has been written by consultant
psychiatrists, nurses, a GP and service users. Although it is designed to inspire medical professionals to pay
more consideration to the needs of this vulnerable and often excluded group; it assumes no prior knowledge
and is distributed free on request or by download from URL: www.rcpsych.ac.uk/pdf/Neurodevelopmental
%20psychiatry%20-%20an%20introduction%20for%20medical%20students.pdf.
The following books and training materials have been published by Pavilion in Brighton. A number of
these resources are available on a per chapter or section basis on individual compact discs (CDs). For
further details of the content of these publications go to URL: www.pavpub.com/Common/SearchResult.
aspx?type=2&tax-1=224906&tax-2=226290.
Chaplin E, et al.379: this book provides a comprehensive introduction to working with people who have
autism spectrum conditions. The book addresses the needs of people with autism spectrum conditions
across the lifespan and across the range of intellectual functioning. Although the content is grounded in
evidence-based practice and recent research, the text is intended to be as practical as possible, offering
insight into the everyday lives of people with autism spectrum conditions and how staff can best
support them.
Chaplin E, et al.380: written by a range of contributors from multidisciplinary backgrounds, this accessible
resource provides background information and learning opportunities for all those working in forensic
services for people with LDs. The training material is organised into 12 modules, each supported by a
chapter in the accompanying handbook. The training can be provided as standalone modules or as a
comprehensive course and is designed to be delivered by trainers and/or clinicians who have experience in
providing forensic services to people with LDs.
Relationship with media
Newspapers and magazines
Articles about our research have been featured in Nature (London), Science, New Scientist, MRC News,
The Times, The Sunday Times, The Guardian,381 The Independent, Daily Telegraph, Sunday Telegraph,
Daily Express, Daily Mail,382 The Washington Post, The New York Times and in numerous different baby,
parenting and women’s magazines.
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Television and radio
The British Broadcasting Corporation (BBC) National TV News, Channel 4 National TV News, ITV National
News, CBS National News, Good Morning America, Sky TV News, The Discovery Channel, Al Jazeera and
numerous other local and international TV news programs.
The Breakthrough Appeal and the BBC Radio 4 Appeal.383
URL: www.bbc.co.uk/news/health-10929032.384
The work from this NIHR-funded programme that underpins the new grant was launched at a reception
hosted by Mrs Samantha Cameron at the Prime Minister’s residence (10 Downing Street) on 2 July 2013.
It also was selected for a BBC Radio 4 appeal.383
Awards for/recognition of work in the past 5 years
Our biomarker work (see Section 3) was winner of NHS Healthcare Innovation of the Year award
(NHS HEAL awards) 2010 and was voted Top 10 Scientific Finding 2010 – Autism Speaks (USA).385
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Appendix 1 Description of the treatments
Cognitive–behavioural therapy treatment
The duration of each session ranged from 41 to 74 minutes (mean session length = 60 minutes,
SD 7.5 minutes). Homework was set at every session, which included reading materials from the session,
completing OCD diaries and exposure tasks. The compliance rate for homework was 90%, although this
included even partial completion of the homework tasks. On average 10 (SD 5.4) ERP tasks were set as
homework throughout treatment and the compliance rate for these was 79%. The mean compliance rate
for other homework, such as reading materials and keeping records, was 89%. In terms of session content
and how the treatment was generally structured, a mean of 2.7 (range 1–6, SD 1.6) sessions comprised
anxiety education; OCD education was included in 3–13 sessions (mean 5.8, SD 2.9) sessions; ERP was
covered in up to 16 (mean 8.6, SD 5.3) sessions and a mean of 2.7 (SD 3.2) sessions included cognitive
intervention techniques. Relapse prevention took between 0 and 2 (mean 1, SD 0.7) sessions.
In terms of the frequency of using ASD-specific modifications, work with one participant incorporated the
use of their special interest to help convey concepts; therapists were noted on the record forms as needing
to be ‘more directive’ in sessions for 13 (68%) participants; six (32%) participants needed ‘rules’ to engage
with the structure of the sessions (e.g. how much time to spend talking on non-OCD topics); nine (47%)
participants’ sessions record forms had reference to concrete examples being needed; and use of visual
material to convey concepts was incorporated in 11 (58%) participants’ sessions. Nine (47%) participants
in the CBT group had direct involvement of parents/carers in sessions.
Anxiety management treatment
The duration of the sessions ranged from 28 to 71 (mean 57, SD 8.3) minutes. Homework was set at every
session, which included reading materials, practising techniques learnt in the sessions and keeping records.
The compliance rate for homework was 95%, which included even partial completion of the homework tasks.
With regard to content of the treatment, between one and eight sessions were focused on learning and
practising breathing exercises (mean 3.9, SD 1.8) and between 1 and 13 sessions included relaxation
practice (mean 5.5, SD 3.1). Sessions on mood ranged from 0 to 3 (mean 1.4, SD 0.82), 0–10 sessions
were on healthy habits (mean 3.9, SD 2.7) and 0–4 sessions were spent on problem-solving (mean 1.9,
SD 1.2).
In terms of modifying the AM treatment to make it suitable for people with ASD, there were no records
suggesting any participants had their special interests incorporated into the session. Therapists were noted
as being ‘more directive’ in sessions for five (25%) participants, one (5%) participant needed rules for the
sessions, six (30%) participants needed reference to concrete examples, nine (45%) participants needed
visual aids and six (30%) participants’ parents/carers were directly involved in sessions.
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Appendix 2 Cases presented during web-based
clinical supervision
Summary of case discussed during web-based clinical supervision on ADHD
Session 1 cases presented
Case 1
Mr A is a 23-year-old man with a history of contact with mental health services, including a history of
depression. His score on the Adult ADHD Self-Report Scale (version 1.1) suggested ADHD. This was the
first assessment the participant planned to undertake regarding ADHD and advice was requested about
how to identify ADHD as being distinct from symptoms, which may be associated with other mental illness.
Case 2
Mr B is a 28-year-old man with inattention, obsessionality, anger and regular cannabis use. He has a
history of low self-esteem and depression since his early teens. He was diagnosed with ADHD as a child
and treated with methylphenidate until age 15 years. He has a family history of ADHD. His score on the
Wender–Reimherr Adult ADHD Scale self-report questionnaire was suggestive of adult ADHD. He was
unable to tolerate Concerta XL® and treatment was changed to atomoxetine, which he was tolerating well.
The question was whether or not the group agreed with the current management of this case.
Case 3
Ms A is a 18-year-old woman with borderline ID and a background of childhood adversity, including
neglect presenting with impulsivity, sexually inappropriate behaviour, social difficulties and inattention.
Screening on Brown Attention-Deficit Disorder Scales were highly suggestive of ADHD and eight of nine
symptoms of inattention according to DSM-IV criteria. The question presented for supervision was the
overlap between global LD and specific inattention secondary to ADHD, and whether or not it is
appropriate to consider treatment for this patient.
Session 2 cases presented
Case 1
Ms B, a 34-year-old woman, presented with a diagnosis of bipolar affective disorder with a suggestion
of borderline personality traits presenting with recurrent self-harm and with a background of childhood
abuse. Use of antidepressant medication precipitated elevated mood enhancing impulsivity and substance
misuse. Previous treatment to manage mood symptoms was of limited value. Assessment for adult ADHD
met the criteria for inattentive subtype. The challenge was to separate whether this was just ADHD, or
comorbid bipolar affective disorder and personality aspects, and how to manage case.
Case 2
Mr C is a 22-year-old man with predominantly attentive problems from childhood, which appeared to be
masked by high intelligence. The case was complicated by an extensive psychiatric history with a diagnosis
of PD, the possibility of Asperger syndrome and possible paranoid PD. The question was whether or not
antipsychotics had a place in ADHD treatment.
Case 3
Ms C is a 32-year-old woman, living with her son, diagnosed with ADHD on the basis of her clinic
presentation and her high score on the Wender Utah Rating Scale. She rejected the diagnosis and asked
to be treated for anxiety and depression. She was struggling to cope day to day, particularly with marked
emotional dysregulation. There was a personal history and strong family history of alcohol dependence and
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substance misuse, marked anxiety at presentation. The participants wanted to discuss the treatment of
ADHD in the presence of marked anxiety.
Case 4
Case 4 presented the scenario of an assessment for an adult with suspected ADHD and asked what is the
role of neuropsychological testing.
Case 5
Case 5 presented the scenario of a young man with marked sleep problems in the context of ADHD and
asked what sleep management treatment options are available.
Session 3 cases presented
Case 1
Case 1 presented the scenario of an assessment and follow-up for an adult with suspected ADHD and
asked what is the role of rating scales.
Case 2
Mr D is a 31-year-old man seeking assessment for potential adult ADHD. On DIVA diagnostic assessment
he met criteria for ADHD combined subtype. Presentation complicated by comorbid Huntington’s disease.
He commenced a trial of treatment with non-stimulant ADHD medication, atomoxetine, due to concerns
about the effect of stimulants in comorbid Huntington’s disease and he appears to be improving. The
question was whether or not the group agreed with the current clinical management of this case.
Case 3
Case 3 presented the scenario of treating an adult with ADHD and asked what are the types of social
interventions (including skills training) for which there is an evidence base for to use in adult ADHD.
Case 4
Case 4 presented the scenario of treating an adult with ADHD and asked can patients when diagnosed
with ADHD take medication on a pro re nata (as needed) basis.
Case 5
Ms D is a 40-year-old woman, referred for assessment by her employer’s occupational health team after
presenting with severe anxiety, obsessionality and depression over the past 6 months. Following continuing
psychological therapy these symptoms improved. As she got better, other aspects of her presentation
emerged suggesting a diagnosis of ADHD. She was prescribed stimulant treatment, which she was unable
to tolerate due to side effects, and refused further treatment for ADHD. In the light of ongoing anxiety
and depression, venlafaxine was prescribed and a marked improvement in ADHD symptoms noted. The
participant was interested to know if others have had similar experience using the serotonin–noradrenaline
reuptake inhibitors.
Summary of case discussed during web-based clinical supervision on ASD
Session 1
Case 1
Mr A is a 35-year-old white British man referred by his probation officer for a psychological risk
assessment. He has pleaded guilty to one count of causing or inciting a minor to engage in sexual activity
and 10 counts of possessing and distributing indecent images. To date, Mr A had been interviewed on one
occasion with the plan to offer him one further appointment.
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Questions
Can Mr A’s difficulties be understood within the context of Asperger syndrome? Attachment disorder?
If Asperger syndrome is a possibility, how is it best to assess/measure this when time is limited?
If Asperger syndrome is contributing to Mr A’s difficulties, how might this guide sentencing (e.g. custody,
response to treatment)?
In this case can excessive viewing of online indecent images be an example of ‘preoccupation with one or
more stereotyped and restricted patterns of interest that is abnormal either in intensity or focus’?
Case 2
Mr P is a 41-year-old white British man who has had no involvement with services in childhood and
adolescence. He initially came to the attention of services when he was referred to a Community Mental
Health Team in 2003 with depression. His history is characterised by a number of brief contacts with
services and, although there were concerns from a number of agencies over his lifestyle and maladaptive
coping, he often failed to meet the eligibility criteria to mental health services. This was in spite of major
concerns over his vulnerability, which included living in his grandmother’s shed. Other concerns noted
included his lack of willingness to engagement while not thriving in his current environment has led to
concerns over his physical health. Mr P also has a number of rituals interfering with activities of daily living.
Questions
Where next? We have been trying to support Mr P in the community and allow him to develop. However,
he does not appear to be doing well. His physical health remains poor and he only really engages with
services as they bring his money.
What other input might be useful to this man?
What other approaches may work to engage Mr P? We have found no way of engaging him which
works consistently.
Session 2
Case 3
Ms X is a 25-year-old woman with a long-standing diagnosis of emotionally unstable PD who was
transferred from prison to a medium-secure unit on Sections 47 and 49 of the Mental Health Act 2007.135
This followed a conviction for simple arson. The unit to which she was admitted was populated by women
with PD diagnoses and the staff had considerable experience in working with this group. Ms X was noted
to be significantly different from her peers and did not respond to the unit’s treatment programme. Her
responsible clinician was of the opinion that she could have a comorbid diagnosis of ASD and asked for a
second opinion.
Questions
My question is about the inter-relationship between trauma and ASD – I would like people to share their
experience in formulating and managing these individuals as my service is receiving an increasing number
of women with features of ASD, emotionally unstable PD and a history of trauma.
Case 4
A 41-year-old white British man referred by his local community team for LDs to an inpatient service for
assessment and treatment under Section 37 of the Mental Health Act 2007.135 He pleaded guilty to the
indecent assault of the 2-year-old daughter of a neighbour, at a barbecue.
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Questions
How can Mr P’s difficulties best be understood? In particular, his ‘healing’: circumscribed interest or means
to gain access to vulnerable women?
What assessments should we be carrying out, given Mr P’s limited intellectual ability?
Session 3
Case 5
Mr G is a 20-year-old man with a diagnosis of ASD (diagnosis in childhood prior to 2006), mild/moderate
ID (various views on diagnosis from different assessors).
Questions
Given his family history – genetic testing (fragile X testing was carried out and was negative) – is there
a strong argument for array comparative genomic hybridisation? What is the current understanding
regarding different genetic associations with ASD?
What are the panel’s thoughts on most effective psychological and pharmacological approaches to
agitation and anxiety?
Given the suspicion of father having ASD, how would they approach the difficulties that this presents?
Should he be made aware of it?
Given Mr G’s dislike and suspicion of authority, how best to motivate him to engage with the service and
occupational/leisure recommendations?
Given the overlapping nature of psychology and speech and language therapy interventions, how can the
delivery of these be best organised?
Case study 6
Mr Z is a 24-year-old current inpatient who has moderate ID, ASD and bipolar affective disorder. He was born
by caesarean section for fetal distress. He has limited vocabulary and is echolalic, using the Treatment and
Education of Autistic and related Communication Handicapped Children (TEACCH) system to communicate
through single words. He was raised in London and went to a special school and respite care in a residential
placement. At both his school and respite centre, he displayed sexualised behaviour and used the toilet
inappropriately, often refusing to go or relieving himself in inappropriately places.
Questions
Are there any other diagnoses that can better explain Mr Z’s history and presentation?
If admitted to your unit, what investigations (if any) and management strategies would you employ?
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